US006673545B2

(12) **United States Patent**
Faris et al.

(10) **Patent No.: US 6,673,545 B2**
(45) **Date of Patent: Jan. 6, 2004**

(54) **PROSTATE CANCER MARKERS**

(75) Inventors: **Mary Faris**, Los Angeles, CA (US); **Christopher M. Turner**, Stanford, CA (US)

(73) Assignee: **Incyte Corporation**, Palo Alto, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/919,172**

(22) Filed: **Jul. 30, 2001**

(65) **Prior Publication Data**

US 2002/0119463 A1 Aug. 29, 2002

Related U.S. Application Data

(60) Provisional application No. 60/222,469, filed on Jul. 28, 2000.

(51) **Int. Cl.**[7] **C12Q 1/68**
(52) **U.S. Cl.** **435/6**; 435/7.1; 435/287.2; 536/23.1
(58) **Field of Search** 536/23.1; 435/6, 435/287.2, 7.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,968,784 A * 10/1999 Spinella et al. 435/91.1

FOREIGN PATENT DOCUMENTS

WO WO 0064479 11/2000 ..... 514/2

OTHER PUBLICATIONS

AF005258, GENBANK, Nov. 21, 1997.*
AF047855, GENBANK, Feb. 25, 1998.*
Gerhold et al., It's the genes! EST access to human genome content. 1996, BioEssays, vol. 18, No. 12, pp. 973–981.*
Wells et al., The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases. 1997, Journal of Leukocyte Biology, vol. 61, No. 5, pp. 545–550.*
Russell et al., Structural Features can be Unconserved in Proteins with Similar Folds. 1994, Journal of Molecular Biology, vol. 244, pp. 332–350.*
Lopez et al., Whole–genome sequence annotation: 'Going wrong with confidence.' 1999, Molecular Microbiology, vol. 32, pp. 881–891.*
Attwood, The Babel of Bioinformatics. 2000, Science, vol. 290, No. 5491, pp. 471–473.*
Lin, J., et al., "The Phosphatidylinositol 3'–kinase Pathway is a Dominant Growth Factor–Activated Cell Survival Pathway in LNCaP Human Prostate Carcinoma Cells", *Cancer Res*;59(12):2891–2897, (Jun. 15, 1999).
Putz T., et al., Epideral Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin–like Growth Factor I, and a Protein Kinase A Activator on the Mitogen–activated Protein Kinase Pathway in Prostate Cancer Cell Lines[1], Cancer Res 59: 227–233 (1999).
Gold, L.I., "The Role for Transforming Growth Factor–β (TGF–β)in Human Cancer", Crit Rev Oncog 10(4):303–360 (1999).
Chung T.D., et al., "Characterization of the Role of IL–6 in the Progression of Prostate Cancer", Prostate 38: 199–207 (1999).
Hubert, R.S., et al., "STEAP: A prostate–specific cell–surface antigen highly expressed in human prostate tumors", PNAS, vol. 96, No. 25, 14523–14528 (Dec. 7, 1999).

* cited by examiner

Primary Examiner—Ardin H. Marschel
Assistant Examiner—Carolyn L Smith
(74) *Attorney, Agent, or Firm*—Incyte Corporation

(57) **ABSTRACT**

The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to treat or to monitor the treatment of a subject with prostate cancer.

9 Claims, No Drawings

PROSTATE CANCER MARKERS

This application claims the benefit of Provisional Application No. 60/222,469, filed Jul. 28, 2000.

FIELD OF THE INVENTION

The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used entirely or in part to diagnose, to stage, to treat, or to monitor the progression or treatment of prostate cancer.

BACKGROUND OF THE INVENTION

Array technology can provide a simple way to explore the expression of a single polymorphic gene or the expression profile of a large number of related or unrelated genes. When the expression of a single gene is examined, arrays are employed to detect the expression of a specific gene or its variants. When an expression profile is examined, arrays provide a platform for examining which genes are tissue specific, carrying out housekeeping functions, parts of a signaling cascade, or specifically related to a particular genetic predisposition, condition, disease, or disorder.

The potential application of gene expression profiling is particularly relevant to improving diagnosis, prognosis, and treatment of disease. For example, both the levels and sequences expressed in tissues from subjects with prostate cancer may be compared with the levels and sequences expressed in normal tissue.

Prostate cancer is a common malignancy in men over the age of 50, and the incidence increases with age. In the U.S., there are approximately 132,000 newly diagnosed cases of prostate cancer and more than 33,000 deaths from the disorder each year.

Once cancer cells arise in the prostate, they are stimulated by testosterone to a more rapid growth. Thus, removal of the testes can indirectly reduce both rapid growth and metastasis of the cancer. Over 95 percent of prostatic cancers are adenocarcinomas which originate in the prostatic acini. The remaining 5 percent are divided between squamous cell and transitional cell carcinomas, both of which arise in the prostatic ducts or other parts of the prostate gland.

As with most cancers, prostate cancer develops through a multistage progression ultimately resulting in an aggressive, metastatic phenotype. The initial step in tumor progression involves the hyperproliferation of normal luminal and/or basal epithelial cells that become hyperplastic and evolve into early-stage tumors. The early-stage tumors are localized in the prostate but eventually may metastasize, particularly to the bone, brain or lung. About 80% of these tumors remain responsive to androgen treatment, an important hormone controlling the growth of prostate epithelial cells. However, in its most advanced state, cancer growth becomes androgen-independent and there is currently no known treatment for this condition.

A primary diagnostic marker for prostate cancer is prostate specific antigen (PSA). PSA is a tissue-specific serine protease almost exclusively produced by prostatic epithelial cells. The quantity of PSA correlates with the number and volume of the prostatic epithelial cells, and consequently, the levels of PSA are an excellent indicator of abnormal prostate growth. Men with prostate cancer exhibit an early linear increase in PSA levels followed by an exponential increase prior to diagnosis. However, since PSA levels are also influenced by factors such as inflammation, androgen and other growth factors, some scientists maintain that changes in PSA levels are not useful in detecting individual cases of prostate cancer.

Current areas of cancer research provide additional prospects for markers as well as potential therapeutic targets for prostate cancer. Several growth factors have been shown to play a critical role in tumor development, growth, and progression. The growth factors Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), and Tumor Growth Factor alpha (TGFα) are important in the growth of normal as well as hyperproliferative prostate epithelial cells, particularly at early stages of tumor development and progression, and affect signaling pathways in these cells in various ways (Lin J et al. (1999) Cancer Res. 59:2891–2897; Putz T et al. (1999) Cancer Res 59:227–233). The TGF-β family of growth factors are generally expressed at increased levels in human cancers and the high expression levels in many cases correlates with advanced stages of malignancy and poor survival (Gold L I (1999) Crit Rev Oncog 10:303–360). Finally, there are human cell lines representing both the androgen-dependent stage of prostate cancer (LNCap) as well as the androgen-independent, hormone refractory stage of the disease PC3 and DU-145) that have proved useful in studying gene expression patterns associated with the progression of prostate cancer, and the effects of cell treatments on these expressed genes (Chung T D (1999) Prostate 15:199–207).

The present invention provides for a composition comprising a plurality of cDNAs for use in detecting changes in expression of genes encoding proteins that are associated with prostate cancer. Such a composition can be employed for the diagnosis, prognosis or treatment of prostate cancer and related disorders correlated with differential gene expression. The present invention satisfies a need in the art in that it provides a set of differentially expressed genes which may be used entirely or in part to diagnose, to stage, to treat, or to monitor the progression or treatment of a subject with prostate cancer.

SUMMARY

The present invention provides a composition comprising a plurality of cDNAs and their complements which are differentially expressed in prostate adenocarcinomas and which are selected from SEQ ID NOs:1–1–3, 5, 6, 8, 10–15, 17–19, 21, 23–28, 30, 32, 34–36, 38, 40, 42–45, 47–50, 52, 53, 55, 56, 58–65, 67, 68, 70–73, 75, 76, 78–86, 88–90, 92–97, 99–101 as presented in the Sequence Listing. In one embodiment, each cDNA is differentially regulated in metastatic versus non-metastatic tissue samples, SEQ ID NOs:1–3, 5, 6, 8, 10–15, 17–19, 21, 23–28, 30, 32, 34–36, 38, 40, 42–45, 47–50, 52, 53, 55, 56, 58–65, 67, 68, 70–73, 75; in another embodiment, each cDNA is differentially regulated at all stages of the disease, SEQ ID NOs:76, 78–86, 88–90, 92–97, 99–101. In one aspect, the composition is immobilized on a substrate. In another aspect, the composition is used to diagnose the presence and stage of prostate cancer in a subject. The invention also provides proteins encoded by the cDNAs and which are selected from SEQ ID NOs:4, 7, 9, 16, 20, 22, 29, 31, 33, 37, 39, 41, 46, 51, 54, 57, 66, 69, 74, 77, 87, 91, 98 as presented in the Sequence Listing.

The invention also provides a high throughput method to detect differential expression of one or more of the cDNAs of the composition. The method comprises hybridizing the substrate comprising the composition with the nucleic acids of a sample, thereby forming one or more hybridization

complexes, detecting the hybridization complexes, and comparing the hybridization complexes with those of a standard, wherein differences in the size and signal intensity of each hybridization complex indicates differential expression of nucleic acids in the sample. In one aspect, the sample is from a subject with prostate cancer and differential expression determines an early, mid, and late stage of the disorder.

The invention further provides a high throughput method of screening a library or a plurality of molecules or compounds to identify a ligand. The method comprises combining the substrate comprising the composition with a library or a plurality of molecules or compounds under conditions to allow specific binding and detecting specific binding, thereby identifying a ligand. The library or a plurality of molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, transcription factors, repressors, and other regulatory proteins.

The invention still further provides an isolated cDNA encoding the protein comprising the amino acid sequence of SEQ ID NO:37. The invention also provides an isolated cDNA comprising SEQ ID NO:36 as presented in the Sequence Listing. The invention also provides a vector comprising the cDNA, a host cell comprising the vector, and a method for producing a protein comprising culturing the host cell under conditions for the expression of a protein and recovering the protein from the host cell culture. The invention additionally provides a method for purifying a ligand, the method comprising combining a cDNA of the invention with a sample under conditions which allow specific binding, recovering the bound cDNA, and separating the cDNA from the ligand, thereby obtaining purified ligand.

The present invention provides a purified protein encoded and produced by a cDNA of the invention. The invention also provides a high-throughput method for using a protein to screen a library or a plurality of molecules or compounds to identify a ligand. The method comprises combining the protein or a portion thereof with the library or a plurality of molecules or compounds under conditions to allow specific binding and detecting specific binding, thereby identifying a ligand which specifically binds the protein. A library or a plurality of molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, proteins, agonists, antagonists, antibodies or their fragments, immunoglobulins, inhibitors, drug compounds, and pharmaceutical agents. The invention further provides for using a protein to purify a ligand. The method comprises combining the protein or a portion thereof with a sample under conditions to allow specific binding, recovering the bound protein, and separating the protein from the ligand, thereby obtaining purified ligand. The invention still further provides a pharmaceutical composition comprising the protein. The invention yet still further provides a method for using the protein to produce an antibody. The method comprises immunizing an animal with the protein or an antigenically-effective epitope under conditions to elicit an antibody response, isolating animal antibodies, and screening the isolated antibodies with the protein to identify an antibody which specifically binds the protein. The invention yet still further provides a method for using the protein to purify antibodies which bind specifically to the protein.

DESCRIPTION OF THE SEQUENCE LISTING AND TABLES

The Sequence Listing is a compilation of cDNAs obtained by sequencing and extension of clone inserts. Each sequence is identified by a sequence identification number (SEQ ID NO) and by the template number (TEMPLATE ID) from which it was obtained.

Table 1 shows the differential expression of cDNAs of the present invention in metastatic versus non-metastatic prostate adenocarcinoma. Column 1 shows the Clone ID of each sequence represented on a microarray. Columns 2–6 show differential expression in adenocarcinomas derived from prostate tissue relative to primary prostate epithelium. Differential expression values are presented as log 2 (normal tissue/adenocarcinoma). Negative values represent an increase in expression. Column 7 shows the t-test statistic used to evaluate markers specific to metastatic versus non-metastatic prostate adenocarcinoma.

Table 2 shows the differential expression of cDNAs of the present invention in prostate adenocarcinoma versus normal prostate. Column 1 shows the Clone ID of each sequence represented on a microarray. Columns 2–6 show differential expression in adenocarcinomas derived from prostate tissue relative to primary prostate epithelium. Differential expression values are presented as log 2 (normal tissue/adenocarcinoma). Negative values represent an increase in expression.

Table 3 shows the region within a gene template of each cDNA encompassed by a clone identified in Tables 1 and 2. Columns 1 and 2 show the SEQ ID NO: and Template ID, respectively. Column 3 shows the Clone ID and columns 4 and 5 show the first residue (Start) and last residue (Stop) encompassed by the clone on the template.

Table 4 lists the functional annotation of the cDNAs of the present invention. Columns 1 and 2 show the SEQ ID NO and Template ID, respectively. Columns 3, 4, and 5 show the GenBank hit (GI Number), probability score (E-value), and functional annotation, respectivly, as determined by BLAST analysis (version 1.4 using default parameters; Altschul (1993) J Mol Evol 36: 290–300; Altschul et al. (1990) J Mol Biol 215:403–410) of the cDNA against GenBank (release 117; National Center for Biotechnology Information (NCBI), Bethesda Md.).

Table 5 shows Pfam annotations of the cDNAs of the present invention. Columns 1 and 2 show the SEQ ID NO and Template ID, respectively. Columns 3, 4, and 5 show the first residue (Start), last residue (Stop), and reading frame, respectively, for the segment of the cDNA identified by Pfam analysis. Columns 6, 7, and 8 show the PFAM Hit, PFAM Annotation, and E-value, respectively, corresponding to the polypeptide domain of the protein or encoded by the cDNA segment.

Table 6 shows signal peptide and transmembrane regions predicted within the cDNAs of the present invention. Columns 1 and 2 show the SEQ ID NO and Template ID, respectively. Columns 3, 4, and 5 show the first residue (Start), last residue (Stop), and reading frame, respectively, for a segment of the cDNA, and column 6 identifies the polypeptide encoded by the segment as either a signal peptide (SP) or transmembrane (TM) domain.

DESCRIPTION OF THE INVENTION

Definitions

"Array" refers to an ordered arrangement of at least two cDNAs on a substrate. At least one of the cDNAs represents a control or standard sequence, and the other, a cDNA of diagnostic interest. The arrangement of from about two to about 40,000 cDNAs on the substrate assures that the size and signal intensity of each labeled hybridization complex formed between a cDNA and a sample nucleic acid is individually distinguishable.

The "complement" of a nucleic acid molecule of the Sequence Listing refers to a cDNA which is completely complementary over the full length of the sequence and which will hybridize to the nucleic acid molecule under conditions of high stringency.

A "composition" comprises at least two sequences selected from the Sequence Listing. "cDNA" refers to a chain of nucleotides, an isolated polynucleotide, nucleic acid molecule, or any fragment or complement thereof. It may have originated recombinantly or synthetically, be double-stranded or single-stranded, coding and/or noncoding, an exon with or without an intron from a genomic DNA molecule, and purified or combined with carbohydrate, lipids, protein or inorganic elements or substances. Preferably, the cDNA is from about 4000 to about 5000 nucleotides.

The phrase "cDNA encoding a protein" refers to a nucleic acid sequence that closely aligns with sequences which encode conserved regions, motifs or domains that were identified by employing analyses well known in the art. These analyses include BLAST (Basic Local Alignment Search Tool; Altschul (1993) J Mol Evol 36: 290–300; Altschul et al. (1990) J Mol Biol 215:403–410) which provides identity within the conserved region. Brenner et al. (1998; Proc Natl Acad Sci 95:6073–6078) who analyzed BLAST for its ability to identify structural homologs by sequence identity found 30% identity is a reliable threshold for sequence alignments of at least 150 residues and 40% is a reasonable threshold for alignments of at least 70 residues (Brenner et al., page 6076, column 2).

"Derivative" refers to a cDNA or a protein that has been subjected to a chemical modification. Derivatization of a cDNA can involve substitution of a nontraditional base such as queosine or of an analog such as hypoxanthine. These substitutions are well known in the art. Derivatization of a protein involves the replacement of a hydrogen by an acetyl, acyl, alkyl, amino, formyl, or morpholino group. Derivative molecules retain the biological activities of the naturally occurring molecules but may confer advantages such as longer lifespan or enhanced activity.

"Differential expression" refers to an increased, upregulated or present, or decreased, downregulated or absent, gene expression as detected by the absence, presence, or at least two-fold changes in the amount of transcribed messenger RNA or translated protein in a sample.

"Disorder" refers to conditions, diseases or syndromes associated with prostate cancer.

"Fragment" refers to a chain of consecutive nucleotides from about 200 to about 700 base pairs in length. Fragments may be used in PCR or hybridization technologies to identify related nucleic acid molecules and in binding assays to screen for a ligand. Nucleic acids and their ligands identified in this manner are useful as therapeutics to regulate replication, transcription or translation.

A "hybridization complex" is formed between a cDNA and a nucleic acid of a sample when the purines of one molecule hydrogen bond with the pyrimidines of the complementary molecule, e.g., 5'-A-G-T-C-3' base pairs with 3'-T-C-A-G-5'. The degree of complementarity and the use of nucleotide analogs affect the efficiency and stringency of hybridization reactions.

"Ligand" refers to any agent, molecule, or compound which will bind specifically to a complementary site on a cDNA molecule or polynucleotide, or to an epitope or a protein. Such ligands stabilize or modulate the activity of polynucleotides or proteins and may be composed of inorganic or organic substances including nucleic acids, proteins, carbohydrates, fats, and lipids.

"Oligonucleotide" refers a single stranded molecule from about 18 to about 60 nucleotides in length which may be used in hybridization or amplification technologies or in regulation of replication, transcription or translation. Substantially equivalent terms are amplimer, primer, and oligomer.

"Portion" refers to any part of a protein used for any purpose; but especially, to an epitope for the screening of ligands or for the production of antibodies.

"Post-translational modification" of a protein can involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and the like. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cellular location, cell type, pH, enzymatic milieu, and the like.

"Probe" refers to a cDNA that hybridizes to at least one nucleic acid molecule in a sample. Where targets are single stranded, probes are complementary single strands. Probes can be labeled with reporter molecules for use in hybridization reactions including Southern, northern, in situ, dot blot, array, and like technologies or in screening assays.

"Protein" refers to a polypeptide or any portion thereof. A "portion" of a protein retains at least one biological or antigenic characteristic of a native protein. An "oligopeptide" is an amino acid sequence from about five residues to about 15 residues that is used as part of a fusion protein to produce an antibody.

"Purified" refers to any molecule or compound that is separated from its natural environment and is from about 60% free to about 90% free from other components with which it is naturally associated.

"Sample" is used in its broadest sense as containing nucleic acids, proteins, antibodies, and the like. A sample may comprise a bodily fluid; the soluble fraction of a cell preparation, or an aliquot of media in which cells were grown; a chromosome, an organelle, or membrane isolated or extracted from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue; a tissue print; a fingerprint, buccal cells, skin, or hair; and the like.

"Specific binding" refers to a special and precise interaction between two molecules which is dependent upon their structure, particularly their molecular side groups. For example, the intercalation of a regulatory protein into the major groove of a DNA molecule, the hydrogen bonding along the backbone between two single stranded nucleic acids, or the binding between an epitope of a protein and an agonist, antagonist, or antibody.

"Similarity" as applied to sequences, refers to the quantification (usually percentage) of nucleotide or residue matches between at least two sequences aligned using a standardized algorithm such as Smith-Waterman alignment (Smith and Waterman (1981) J Mol Biol 147:195–197) or BLAST2 (Altschul et al. (1997) Nucleic Acids Res 25:3389–3402). BLAST2 may be used in a standardized and reproducible way to insert gaps in one of the sequences in order to optimize alignment and to achieve a more meaningful comparison between them.

"Substrate" refers to any rigid or semi-rigid support to which cDNAs or proteins are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores.

"Variant" refers to molecules that are recognized variations of a cDNA or a protein encoded by the cDNA. Splice variants may be determined by BLAST score, wherein the score is at least 100, and most preferably at least 400. Allelic variants have a high percent identity to the cDNAs and may differ by about three bases per hundred bases. "Single nucleotide polymorphism" (SNP) refers to a change in a single base as a result of a substitution, insertion or deletion. The change may be conservative (purine for purine) or non-conservative (purine to pyrimidine) and may or may not result in a change in an encoded amino acid.

The Invention

The present invention provides for a composition comprising a plurality of cDNAs or their complements, SEQ ID NOs:1–3, 5, 6, 8, 10–15, 17–19, 21, 23–28, 30, 32, 34–36, 38, 40, 42–45, 47–50, 52, 53, 55, 56, 58–65, 67, 68, 70–73, 75, 76, 78–86, 88–90, 92–97, 99–101, which may be used on a substrate to diagnose, to stage, to treat or to monitor the progression or treatment of prostate cancer. These cDNAs represent known and novel genes differentially expressed in cells from non-metastatic and metastatic prostate tumors. The composition may be used in its entirety or in part, as subsets of cDNAs differentially regulated between non-metastatic and metastatic prostate cancer, SEQ ID NOs:1–3, 5, 6, 8, 10–15, 17–19, 21, 23–28, 30, 32, 34–36, 38, 40, 42–45, 47–50, 52, 53, 55, 56, 58–65, 67, 68, 70–73, 75, or of cDNAs differentially regulated at all stages of prostate cancer, SEQ ID NOs:76, 78–86, 88–90, 92–97, 99–101. SEQ ID NOs:24, 36, 47, 60, 82, 88, 89, 92, 93, and 95 represent novel cDNAs associated with prostate cancer. Since the novel cDNAs were identified solely by their differential expression, it is not essential to know a priori the name, structure, or function of the gene or it's encoded protein. The usefulness of the novel cDNAs exist in their immediate value as diagnostics for prostate cancer.

Table 1 shows the differential expression of cDNAs of the present invention in metastatic versus non-metastatic prostate adenocarcinoma. Column 1 shows the Clone ID of each sequence represented on a microarray. Columns 2–6 show the differential expression in adenocarcinomas derived from prostate tissue relative to primary prostate epithelium. Differential expression values are presented as log 2 of the absolute expression in normal prostate tissue÷the absolute expression in prostate adenocarcinoma. Negative values represent an increase in expression. Column 7 shows the t-test statistic used to evaluate markers specific to metastatic versus non-metastatic prostate adenocarcinoma. All of the cDNAs in Table 1 show significant differential regulation in metastatic cancer relative to non-metastatic cancer. Further, expression profiles between the metastatic cancer lines show a high degree of correlation (>0.48), as do the expression profiles between the non-metastatic lines (0.64). However, the expression profiles between the metastatic and non-metastatic lines show significantly less correlation (<0.3).

Table 2 shows the differential expression of cDNAs of the present invention in prostate adenocarcinoma versus normal prostate. Column 1 shows the Clone ID of each sequence represented on a microarray. Columns 2–6 show differential expression in adenocarcinomas derived from prostate tissue relative to primary prostate epithelium. Differential expression values are presented as log 2 (normal tissue÷adenocarcinoma). Negative values represent an increase in expression. The expression profile for the cDNAs identified in Table 2 show high correlation between all tumor lines (>0.5).

SEQ ID NO:36 is a novel sequence differentially regulated between metastatic and non-metastatic prostate tumors. SEQ ID NO:36 encodes SEQ ID NO:37 which is 193 amino acids in length.

The cDNAs of the invention define a differential expression pattern against which to compare the expression pattern of biopsied and/or in vitro treated tissues. Experimentally, differential expression of the cDNAs can be evaluated by methods including, but not limited to, differential display by spatial immobilization or by gel electrophoresis, genome mismatch scanning, representational discriminate analysis, clustering, transcript imaging and array technologies. These methods may be used alone or in combination.

The composition may be arranged on a substrate and hybridized with tumor tissues from subjects to identify those sequences which are differentially expressed in both prostate cancer and tumors derived from other tissues. This allows identification of those sequences of highest diagnostic and potential therapeutic value. In one embodiment, an additional set of cDNAs, such as cDNAs encoding signaling molecules, are arranged on the substrate with the composition. Such combinations may be useful in the elucidation of pathways which are affected in a particular cancer or to identify new, coexpressed, candidate, therapeutic molecules.

In another embodiment, the composition can be used for large scale genetic or gene expression analysis of a large number of novel, nucleic acid molecules. These samples are prepared by methods well known in the art and are from mammalian cells or tissues which are in a certain stage of development; have been treated with a known molecule or compound, such as a cytokine, growth factor, a drug, and the like; or have been extracted or biopsied from a mammal with a known or unknown condition, disorder, or disease before or after treatment. The sample nucleic acid molecules are hybridized to the composition for the purpose of defining a novel gene profile associated with that developmental stage, treatment, or disorder.

cDNAs and Their Uses

cDNAs can be prepared by a variety of synthetic or enzymatic methods well known in the art. cDNAs can be synthesized, in whole or in part, using chemical methods well known in the art (Caruthers et al. (1980) Nucleic Acids Symp. Ser. (7):215–233). Alternatively, cDNAs can be produced enzymatically or recombinantly, by in vitro or in vivo transcription.

Nucleotide analogs can be incorporated into cDNAs by methods well known in the art. The only requirement is that the incorporated analog must base pair with native purines or pyrimidines. For example, 2,6-diaminopurine can substitute for adenine and form stronger bonds with thymidine than those between adenine and thymidine. A weaker pair is formed when hypoxanthine is substituted for guanine and base pairs with cytosine. Additionally, cDNAs can include nucleotides that have been derivatized chemically or enzymatically.

cDNAs can be synthesized on a substrate. Synthesis on the surface of a substrate may be accomplished using a chemical coupling procedure and a piezoelectric printing apparatus as described by Baldeschweiler et al. (PCT publication WO95/251116). Alternatively, the cDNAs can be synthesized on a substrate surface using a self-addressable electronic device that controls when reagents are added as described by Heller et al. (U.S. Pat. No. 5,605,662). cDNAs

can be synthesized directly on a substrate by sequentially dispensing reagents for their synthesis on the substrate surface or by dispensing preformed DNA fragments to the substrate surface. Typical dispensers include a micropipette delivering solution to the substrate with a robotic system to control the position of the micropipette with respect to the substrate. There can be a multiplicity of dispensers so that reagents can be delivered to the reaction regions efficiently.

cDNAs can be immobilized on a substrate by covalent means such as by chemical bonding procedures or UV irradiation. In one method, a cDNA is bound to a glass surface which has been modified to contain epoxide or aldehyde groups. In another method, a cDNA is placed on a polylysine coated surface and UV cross-linked to it as described by Shalon et al. (WO95/35505). In yet another method, a cDNA is actively transported from a solution to a given position on a substrate by electrical means (Heller, supra). cDNAs do not have to be directly bound to the substrate, but rather can be bound to the substrate through a linker group. The linker groups are typically about 6 to 50 atoms long to provide exposure of the attached cDNA. Preferred linker groups include ethylene glycol oligomers, diamines, diacids and the like. Reactive groups on the substrate surface react with a terminal group of the linker to bind the linker to the substrate. The other terminus of the linker is then bound to the cDNA. Alternatively, polynucleotides, plasmids or cells can be arranged on a filter. In the latter case, cells are lysed, proteins and cellular components degraded, and the DNA is coupled to the filter by UV cross-linking.

The cDNAs may be used for a variety of purposes. For example, the composition of the invention may be used on an array. The array, in turn, can be used in high-throughput methods for detecting a related polynucleotide in a sample, screening a plurality of molecules or compounds to identify a ligand, diagnosing prostate cancer, or inhibiting or inactivating a therapeutically relevant gene related to the cDNA.

When the cDNAs of the invention are employed on a microarray, the cDNAs are arranged in an ordered fashion so that each cDNA is present at a specified location. Because the cDNAs are at specified locations on the substrate, the hybridization patterns and intensities, which together create a unique expression profile, can be interpreted in terms of expression levels of particular genes and can be correlated with a particular metabolic process, condition, disorder, disease, stage of disease, or treatment.

Hybridization

The cDNAs or fragments or complements thereof may be used in various hybridization technologies. The cDNAs may be labeled using a variety of reporter molecules by either PCR, recombinant, or enzymatic techniques. For example, a commercially available vector containing the cDNA is transcribed in the presence of an appropriate polymerase, such as T7 or SP6 polymerase, and at least one labeled nucleotide. Commercial kits are available for labeling and cleanup of such cDNAs. Radioactive (Amersham Pharmacia Biotech (APB), Piscataway N.J.), fluorescent (Operon Technologies, Alameda Calif.), and chemiluminescent labeling (Promega, Madison Wis.) are well known in the art.

A cDNA may represent the complete coding region of an mRNA or be designed or derived from unique regions of the mRNA or genomic molecule, an intron, a 3' untranslated region, or from a conserved motif. The cDNA is at least 18 contiguous nucleotides in length and is usually single stranded. Such a cDNA may be used under hybridization conditions that allow binding only to an identical sequence, a naturally occurring molecule encoding the same protein, or an allelic variant. Discovery of related human and mammalian sequences may also be accomplished using a pool of degenerate cDNAs and appropriate hybridization conditions. Generally, a cDNA for use in Southern or northern hybridizations may be from about 400 to about 6000 nucleotides long. Such cDNAs have high binding specificity in solution-based or substrate-based hybridizations. An oligonucleotide, a fragment of the cDNA, may be used to detect a polynucleotide in a sample using PCR.

The stringency of hybridization is determined by G+C content of the cDNA, salt concentration, and temperature. In particular, stringency is increased by reducing the concentration of salt or raising the hybridization temperature. In solutions used for some membrane based hybridizations, addition of an organic solvent such as formamide allows the reaction to occur at a lower temperature. Hybridization may be performed with buffers, such as 5×saline sodium citrate (SSC) with 1% sodium dodecyl sulfate (SDS) at 60° C., that permit the formation of a hybridization complex between nucleic acid sequences that contain some mismatches. Subsequent washes are performed with buffers such as 0.2×SSC with 0.1% SDS at either 45° C. (medium stringency) or 65°–68° C. (high stringency). At high stringency, hybridization complexes will remain stable only where the nucleic acid molecules are completely complementary. In some membrane-based hybridizations, preferably 35% or most preferably 50%, formamide may be added to the hybridization solution to reduce the temperature at which hybridization is performed. Background signals may be reduced by the use of detergents such as Sarkosyl or Triton X-100 (Sigma Aldrich, St. Louis Mo.) and a blocking agent such as denatured salmon sperm DNA. Selection of components and conditions for hybridization are well known to those skilled in the art and are reviewed in Ausubel et al. (1997, *Short Protocols in Molecular Biology,* John Wiley & Sons, New York N.Y., Units 2.8–2.11, 3.18–3.19 and 4–64.9).

Dot-blot, slot-blot, low density and high density arrays are prepared and analyzed using methods known in the art. cDNAs from about 18 consecutive nucleotides to about 5000 consecutive nucleotides in length are contemplated by the invention and used in array technologies. The preferred number of cDNAs on an array is at least about 100,000, a more preferred number is at least about 40,000, an even more preferred number is at least about 10,000, and a most preferred number is at least about 600 to about 800. The array may be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and SNPs. Such information may be used to determine gene function; to understand the genetic basis of a disorder; to diagnose a disorder; and to develop and monitor the activities of therapeutic agents being used to control or cure a disorder. (See, e.g., U.S. Pat. No. 5,474,796; WO95/11995; WO95/35505; U.S. Pat. No. 5,605,662; and U.S. Pat. No. 5,958,342.)

Screening and Purification Assays

A cDNA may be used to screen a library or a plurality of molecules or compounds for a ligand which specifically binds the cDNA. Ligands may be DNA molecules, RNA molecules, peptide nucleic acid molecules, peptides, proteins such as transcription factors, promoters, enhancers, repressors, and other proteins that regulate replication, transcription, or translation of the polynucleotide in the biological system. The assay involves combining the cDNA or a fragment thereof with the molecules or compounds under conditions that allow specific binding and detecting the bound cDNA to identify at least one ligand that specifically binds the cDNA.

In one embodiment, the cDNA may be incubated with a library of isolated and purified molecules or compounds and binding activity determined by methods such as a gel-retardation assay (U.S. Pat. No. 6,010,849) or a reticulocyte lysate transcriptional assay. In another embodiment, the cDNA may be incubated with nuclear extracts from biopsied and/or cultured cells and tissues. Specific binding between the cDNA and a molecule or compound in the nuclear extract is initially determined by gel shift assay. Protein binding may be confirmed by raising antibodies against the protein and adding the antibodies to the gel-retardation assay where specific binding will cause a supershift in the assay.

In another embodiment, the cDNA may be used to purify a molecule or compound using affinity chromatography methods well known in the art. In one embodiment, the cDNA is chemically reacted with cyanogen bromide groups on a polymeric resin or gel. Then a sample is passed over and reacts with or binds to the cDNA. The molecule or compound which is bound to the cDNA may be released from the cDNA by increasing the salt concentration of the flow-through medium and collected.

The cDNA may be used to purify a ligand from a sample. A method for using a cDNA to purify a ligand would involve combining the cDNA or a fragment thereof with a sample under conditions to allow specific binding, recovering the bound cDNA, and using an appropriate agent to separate the cDNA from the purified ligand.

Protein Production and Uses

The full length cDNAs or fragment thereof may be used to produce purified proteins using recombinant DNA technologies described herein and taught in Ausubel et al. (supra; Units 16.1–16.62). One of the advantages of producing proteins by these procedures is the ability to obtain highly-enriched sources of the proteins thereby simplifying purification procedures.

The proteins may contain amino acid substitutions, deletions or insertions made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Such substitutions may be conservative in nature when the substituted residue has structural or chemical properties similar to the original residue (e.g., replacement of leucine with isoleucine or valine) or they may be nonconservative when the replacement residue is radically different (e.g., a glycine replaced by a tryptophan). Computer programs included in LASERGENE software (DNASTAR, Madison Wis.), MACVECTOR software (Genetics Computer Group, Madison Wis.) and RasMol software (www.umass.edu/microbio/rasmol) may be used to help determine which and how many amino acid residues in a particular portion of the protein may be substituted, inserted, or deleted without abolishing biological or immunological activity.

Expression of Encoded Proteins

Expression of a particular cDNA may be accomplished by cloning the cDNA into a vector and transforming this vector into a host cell, The cloning vector used for the construction of cDNA libraries in the LIFESEQ databases may also be used for expression. Such vectors usually contain a promoter and a polylinker useful for cloning, priming, and transcription. An exemplary vector may also contain the promoter for β-galactosidase, an amino-terminal methionine and the subsequent seven amino acid residues of β-galactosidase. The vector may be transformed into competent *E. coli* cells. Induction of the isolated bacterial strain with isopropylthiogalactoside (IPTG) using standard methods will produce a fusion protein that contains an N terminal methionine, the first seven residues of β-galactosidase, about 15 residues of linker, and the protein encoded by the cDNA.

The cDNA may be shuttled into other vectors known to be useful for expression of protein in specific hosts. Oligonucleotides containing cloning sites and fragments of DNA sufficient to hybridize to stretches at both ends of the cDNA may be chemically synthesized by standard methods. These primers may then be used to amplify the desired fragments by PCR. The fragments may be digested with appropriate restriction enzymes under standard conditions and isolated using gel electrophoresis. Alternatively, similar fragments are produced by digestion of the cDNA with appropriate restriction enzymes and filled in with chemically synthesized oligonucleotides. Fragments of the coding sequence from more than one gene may be ligated together and expressed.

Signal sequences that dictate secretion of soluble proteins are particularly desirable as component parts of a recombinant sequence. For example, a chimeric protein may be expressed that includes one or more additional purification-facilitating domains. Such domains include, but are not limited to, metal-chelating domains that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex, Seattle Wash.). The inclusion of a cleavable-linker sequence such as ENTEROKINASEMAX (Invitrogen, San Diego Calif.) between the protein and the purification domain may also be used to recover the protein.

Suitable host cells may include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, plant cells such as *Nicotiana tabacum,* yeast cells such as *Saccharomyces cerevisiae,* and bacteria such as *E. coli.* For each of these cell systems, a useful vector may also include an origin of replication and one or two selectable markers to allow selection in bacteria as well as in a transformed eukaryotic host. Vectors for use in eukaryotic host cells may require the addition of 3' poly(A) tail if the cDNA lacks poly(A).

Additionally, the vector may contain promoters or enhancers that increase gene expression. Many promoters are known and used in the art. Most promoters are host specific and exemplary promoters includes SV40 promoters for CHO cells; T7 promoters for bacterial hosts; viral promoters and enhancers for plant cells; and PGH promoters for yeast. Adenoviral vectors with the rous sarcoma virus enhancer or retroviral vectors with long terminal repeat promoters may be used to drive protein expression in mammalian cell lines. Once homogeneous cultures of recombinant cells are obtained, large quantities of secreted soluble protein may be recovered from the conditioned medium and analyzed using chromatographic methods well known in the art. An alternative method for the production of large amounts of secreted protein involves the transformation of mammalian embryos and the recovery of the recombinant protein from milk produced by transgenic cows, goats, sheep, and the like.

In addition to recombinant production, proteins or portions thereof may be produced manually, using solid-phase techniques (Stewart et al. (1969) *Solid-Phase Peptide Synthesis,* W H Freeman, San Francisco Calif.; Merrifield (1963) J Am Chem Soc 5:2149–2154), or using machines such as the ABI 431A peptide synthesizer (Applied Biosystems, Foster City Calif.). Proteins produced by any of the above methods may be used as pharmaceutical compositions to treat disorders associated with null or inadequate expression of the genomic sequence.

Screening and Purification Assays

A protein or a portion thereof encoded by the cDNA may be used to screen a library or a plurality of molecules or compounds for a ligand with specific binding affinity or to purify a molecule or compound from a sample. The protein or portion thereof employed in such screening may be free in solution, affixed to an abiotic or biotic substrate, or located intracellularly. For example, viable or fixed prokaryotic host cells that are stably transformed with recombinant nucleic acids that have expressed and positioned a protein on their cell surface can be used in screening assays. The cells are screened against a library or a plurality of ligands and the specificity of binding or formation of complexes between the expressed protein and the ligand may be measured. The ligands may be DNA, RNA, or PNA molecules, agonists, antagonists, antibodies, immunoglobulins, inhibitors, peptides, pharmaceutical agents, proteins, drugs, or any other test molecule or compound that specifically binds the protein. An exemplary assay involves combining the mammalian protein or a portion thereof with the molecules or compounds under conditions that allow specific binding and detecting the bound protein to identify at least one ligand that specifically binds the protein.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding the protein specifically compete with a test compound capable of binding to the protein or oligopeptide or fragment thereof. One method for high throughput screening using very small assay volumes and very small amounts of test compound is described in U.S. Pat. No. 5,876,946. Molecules or compounds identified by screening may be used in a model system to evaluate their toxicity, diagnostic, or therapeutic potential.

The protein may be used to purify a ligand from a sample. A method for using a protein to purify a ligand would involve combining the protein or a portion thereof with a sample under conditions to allow specific binding, recovering the bound protein, and using an appropriate chaotropic agent to separate the protein from the purified ligand.

Production of Antibodies

A protein encoded by a cDNA of the invention may be used to produce specific antibodies. Antibodies may be produced using an oligopeptide or a portion of the protein with inherent immunological activity. Methods for producing antibodies include: 1) injecting an animal, usually goats, rabbits, or mice, with the protein, or an antigenically-effective portion or an oligopeptide thereof, to induce an immune response; 2) engineering hybridomas to produce monoclonal antibodies; 3) inducing in vivo production in the lymphocyte population; or 4) screening libraries of recombinant immunoglobulins. Recombinant immunoglobulins may be produced as taught in U.S. Pat. No. 4,816,567.

Antibodies produced using the proteins of the invention are useful for the diagnosis of prepathologic disorders as well as the diagnosis of chronic or acute diseases characterized by abnormalities in the expression, amount, or distribution of the protein. A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies specific for proteins are well known in the art. Immunoassays typically involve the formation of complexes between a protein and its specific binding molecule or compound and the measurement of complex formation. Immunoassays may employ a two-site, monoclonal-based assay that utilizes monoclonal antibodies reactive to two noninterfering epitopes on a specific protein or a competitive binding assay (Pound (1998) *Immunochemical Protocols,* Humana Press, Totowa N.J.).

Immunoassay procedures may be used to quantify expression of the protein in cell cultures, in subjects with a particular disorder or in model animal systems under various conditions. Increased or decreased production of proteins as monitored by immunoassay may contribute to knowledge of the cellular activities associated with developmental pathways, engineered conditions or diseases, or treatment efficacy. The quantity of a given protein in a given tissue may be determined by performing immunoassays on freeze-thawed detergent extracts of biological samples and comparing the slope of the binding curves to binding curves generated by purified protein.

Labeling of Molecules for Assay

A wide variety of reporter molecules and conjugation techniques are known by those skilled in the art and may be used in various cDNA, polynucleotide, protein, peptide or antibody assays. Synthesis of labeled molecules may be achieved using commercial kits for incorporation of a labeled nucleotide such as ^{32}P-dCTP, Cy3-dCTP or Cy5-dCTP or amino acid such as ^{35}S-methionine. Polynucleotides, cDNAs, proteins, or antibodies may be directly labeled with a reporter molecule by chemical conjugation to amines, thiols and other groups present in the molecules using reagents such as BIODIPY or FITC (Molecular Probes, Eugene Oreg.).

The proteins and antibodies may be labeled for purposes of assay by joining them, either covalently or noncovalently, with a reporter molecule that provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported in the scientific and patent literature including, but not limited to U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

Diagnostics

The cDNAs, or fragments thereof, may be used to detect and quantify differential gene expression; absence, presence, or excess expression of mRNAs; or to monitor mRNA levels during therapeutic intervention in subjects with prostate-related disorders including prostate cancer. These cDNAs can also be utilized as markers of treatment efficacy against prostate cancer over a period ranging from several days to months. The diagnostic assay may use hybridization or amplification technology to compare gene expression in a biological sample from a patient to standard samples in order to detect altered gene expression. Qualitative or quantitative methods for this comparison are well known in the art.

For example, the cDNA may be labeled by standard methods and added to a biological sample from a patient under conditions for hybridization complex formation. After an incubation period, the sample is washed and the amount of label (or signal) associated with hybridization complexes is quantified and compared with a standard value. If the amount of label in the patient sample is significantly altered in comparison to the standard value, then the presence of the associated condition, disease or disorder is indicated.

In order to provide a basis for the diagnosis of a condition, disease or disorder associated with gene expression, a normal or standard expression profile is established. This may be accomplished by combining a biological sample taken from normal subjects, either animal or human, with a probe under conditions for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained using normal subjects with values from an experiment in which a known amount of a substantially purified target sequence is used. Standard values obtained in this manner may be compared with values obtained from

samples from patients who are symptomatic for a particular condition, disease, or disorder. Deviation from standard values toward those associated with a particular condition is used to diagnose that condition.

Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies and in clinical trial or to monitor the treatment of an individual patient. Once the presence of a condition is established and a treatment protocol is initiated, diagnostic assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in a normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

Gene Expression Profiles

A gene expression profile comprises a plurality of cDNAs and a plurality of detectable hybridization complexes, wherein each complex is formed by hybridization of one or more probes to one or more complementary sequences in a sample. The cDNA composition of the invention is used as elements on a microarray to analyze gene expression profiles. In one embodiment, the microarray is used to monitor the progression of prostate cancer. Researchers can assess and catalog the differences in gene expression between healthy and diseased tissues or cells. By analyzing changes in patterns of gene expression, prostate cancer can be diagnosed at earlier stages before the patient is symptomatic. The invention can be used to formulate a prognosis and to design a treatment regimen. The invention can also be used to monitor the efficacy of treatment. For treatments with known side effects, the microarray is employed to improve the treatment regimen. A dosage is established that causes a change in genetic expression patterns indicative of successful treatment. Expression patterns associated with the onset of undesirable side effects are avoided. This approach may be more sensitive and rapid than waiting for the patient to show inadequate improvement, or to manifest side effects, before altering the course of treatment.

In another embodiment, animal models which mimic a human disease can be used to characterize expression profiles associated with a particular condition, disorder or disease; or treatment of the condition, disorder or disease. Novel treatment regimens may be tested in these animal models using microarrays to establish and then follow expression profiles over time. In addition, microarrays may be used with cell cultures or tissues removed from animal models to rapidly screen large numbers of candidate drug molecules, looking for ones that produce an expression profile similar to those of known therapeutic drugs, with the expectation that molecules with the same expression profile will likely have similar therapeutic effects. Thus, the invention provides the means to rapidly determine the molecular mode of action of a drug.

Assays Using Antibodies

Antibodies directed against epitopes on a protein encoded by a cDNA of the invention may be used in assays to quantify the amount of protein found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The antibodies may be used with or without modification, and labeled by joining them, either covalently or noncovalently, with a labeling moiety.

Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS). Such immunoassays typically involve the formation of complexes between the protein and its specific antibody and the measurement of such complexes. These and other assays are described in Pound (supra). The method may employ a two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes, or a competitive binding assay. (See, e.g., Coligan et al. (1997) *Current Protocols in Immunology,* Wiley-Interscience, New York N.Y.; Pound, supra)

Therapeutics

The cDNAs and fragments thereof can be used in gene therapy. cDNAs can be delivered ex vivo to target cells, such as cells of bone marrow. Once stable integration and transcription and or translation are confirmed, the bone marrow may be reintroduced into the subject. Expression of the protein encoded by the cDNA may correct a cancer associated with mutation of a normal sequence, reduction or loss of an endogenous target protein, or overepression of an endogenous or mutant protein. Alternatively, cDNAs may be delivered in vivo using vectors such as retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, and bacterial plasmids. Non-viral methods of gene delivery include cationic liposomes, polylysine conjugates, artificial viral envelopes, and direct injection of DNA (Anderson (1998) Nature 392:25–30; Dachs et al. (1997) Oncol Res 9:313–325; Chu et al. (1998) J Mol Med 76(34):184–192; Weiss et al. (1999) Cell Mol Life Sci 55(3):334–358; Agrawal (1996) *Antisense Therapeutics,* Humana Press, Totowa N.J.; and August et al. (1997) *Gene Therapy (Advances in Pharmacology, Vol.* 40), Academic Press, San Diego Calif.).

In addition, expression of a particular protein can be regulated through the specific binding of a fragment of a cDNA to a genomic sequence or an mRNA which encodes the protein or directs its transcription or translation. The cDNA can be modified or derivatized to any RNA-like or DNA-like material including peptide nucleic acids, branched nucleic acids, and the like. These sequences can be produced biologically by transforming an appropriate host cell with a vector containing the sequence of interest.

Molecules which regulate the activity of the cDNA or encoded protein are useful as therapeutics for prostate cancer. Such molecules include agonists which increase the expression or activity of the polynucleotide or encoded protein, respectively; or antagonists which decrease expression or activity of the polynucleotide or encoded protein, respectively. In one aspect, an antibody which specifically binds the protein may be used directly as an antagonist or indirectly as a delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express the protein.

Additionally, any of the proteins, or their ligands, or complementary nucleic acid sequences may be administered as pharmaceutical compositions or in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to affect the treatment or prevention of the conditions and disorders associated with an immune response. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Further, the therapeutic agents may be combined with pharmaceutically-acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration used by doctors and pharmacists may be

found in the latest edition of *Remington's Pharmaceutical Sciences* (Maack Publishing, Easton Pa.).

Model Systems

Animal models may be used as bioassays where they exhibit a phenotypic response similar to that of humans and where exposure conditions are relevant to human exposures. Mammals are the most common models, and most infectious agent, cancer, drug, and toxicity studies are performed on rodents such as rats or mice because of low cost, availability, lifespan, reproductive potential, and abundant reference literature. Inbred and outbred rodent strains provide a convenient model for investigation of the physiological consequences of underexpression or overexpression of genes of interest and for the development of methods for diagnosis and treatment of diseases. A mammal inbred to overexpress a particular gene (for example, secreted in milk) may also serve as a convenient source of the protein expressed by that gene.

Transgenic Animal Models

Transgenic rodents that overexpress or underexpress a gene of interest may be inbred and used to model human diseases or to test therapeutic or toxic agents. (See, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337.) In some cases, the introduced gene may be activated at a specific time in a specific tissue type during fetal or postnatal development. Expression of the transgene is monitored by analysis of phenotype, of tissue-specific mRNA expression, or of serum and tissue protein levels in transgenic animals before, during, and after challenge with experimental drug therapies.

Embryonic Stem Cells

Embryonic (ES) stem cells isolated from rodent embryos retain the potential to form embryonic tissues. When ES cells such as the mouse 129/SvJ cell line are placed in a blastocyst from the C57BL/6 mouse strain, they resume normal development and contribute to tissues of the live-born animal. ES cells are preferred for use in the creation of experimental knockout and knockin animals. The method for this process is well known in the art and the steps are: the cDNA is introduced into a vector, the vector is transformed into ES cells, transformed cells are identified and microinjected into mouse cell blastocysts, blastocysts are surgically transferred to pseudopregnant dams. The resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains.

Knockout Analysis

In gene knockout analysis, a region of a gene is enzymatically modified to include a non-natural intervening sequence such as the neomycin phosphotransferase gene (neo; Capecchi (1989) Science 244:1288–1292). The modified gene is transformed into cultured ES cells and integrates into the endogenous genome by homologous recombination. The inserted sequence disrupts transcription and translation of the endogenous gene.

Knockin Analysis

ES cells can be used to create knockin humanized animals or transgenic animal models of human diseases. With knockin technology, a region of a human gene is injected into animal ES cells, and the human sequence integrates into the animal cell genome. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on the progression and treatment of the analogous human condition.

As described herein, the uses of the cDNAs, provided in the Sequence Listing of this application, and their encoded proteins are exemplary of known techniques and are not intended to reflect any limitation on their use in any technique that would be known to the person of average skill in the art. Furthermore, the cDNAs provided in this application may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known to the person of ordinary skill in the art, e.g., the triplet genetic code, specific base pair interactions, and the like. Likewise, reference to a method may include combining more than one method for obtaining or assembling full length cDNA sequences that will be known to those skilled in the art. It is also to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES

I Construction of cDNA Libraries

RNA was purchased from Clontech Laboratories (Palo Alto Calif.) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL reagent (Life Technologies, Rockville Md.). The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either isopropanol or ethanol and sodium acetate, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly(A) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (Qiagen, Valencia Calif.), or an OLIGOTEX mRNA purification kit (Qiagen). Alternatively, poly(A) RNA was isolated directly from tissue lysates using other kits, including the POLY(A) PURE mRNA purification kit (Ambion, Austin Tex.).

In some cases, Stratagene (La Jolla Calif.) was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies) using the recommended procedures or similar methods known in the art. (See Ausubel, supra, Units 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300–1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (APB) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of the PBLUESCRIPT phagemid (Stratagene), PSPORT1 plasmid (Life Technologies), or PINCY plasmid (Incyte Pharmaceuticals). Recombinant plasmids were transformed into XL1-BLUE, XL1-BLUEMRF, or SOLR competent *E. coli* cells (Stratagene) or DH5α, DH10B, or ELECTROMAX DH10B competent *E. coli* cells (Life Technologies).

In some cases, libraries were superinfected with a 5×excess of the helper phage, M13K07, according to the method of Vieira et al. (1987, Methods Enzymol. 153:3–11) and normalized or subtracted using a methodology adapted from Soares (1994, Proc Natl Acad Sci 91:9228–9232),

Swaroop et al. (1991, Nucl Acids Res 19:1954), and Bonaldo et al. (1996, Genome Research 6:791–806). The modified Soares normalization procedure was utilized to reduce the repetitive cloning of highly expressed high abundance cDNAs while maintaining the overall sequence complexity of the library. Modification included significantly longer hybridization times which allowed for increased gene discovery rates by biasing the normalized libraries toward those infrequently expressed low-abundance cDNAs which are poorly represented in a standard transcript image (Soares et al., supra).

II Isolation and Sequencing of cDNA Clones

Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using one of the following: the Magic or WIZARD MINIPREPS DNA purification system (Promega); the AGTC MINIPREP purification kit (Edge BioSystems, Gaithersburg Md.); the QIAWELL 8, QIAWELL 8 Plus, or QIAWELL 8 Ultra plasmid purification systems, or the REAL PREP 96 plasmid purification kit (QIAGEN, Valencia Calif.). Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao (1994) Anal Biochem 216:1–14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (Applied Biosystems) or the DNA ENGINE thermal cycler (MJ Research, Watertown Mass.) in conjunction with the HYDRA microdispenser (Robbins Scientific, Sunnyvale Calif.) or the MICROLAB 2200 system (Hamilton, Reno Nev.). cDNA sequencing reactions were prepared using reagents provided by APB or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE cycle sequencing kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled cDNAs were carried out using the MEGABACE 1000 DNA sequencing system (APB); the ABI PRISM 373 or 377 sequencing systems (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, supra, Unit 7.7).

III Extension of cDNA Sequences

Nucleic acid sequences were extended using the cDNA clones and oligonucleotide primers. One primer was synthesized to initiate 5' extension of the known fragment, and the other, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed. Preferred libraries are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred because they will contain more sequences with the 5' and upstream regions of genes. A randomly primed library is particularly useful if an oligo d(T) library does not yield a full-length cDNA.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the DNA ENGINE thermal cycler (MJ Research). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+}, $(NH_4)_2SO_4$, and β-mercaptoethanol, Taq DNA polymerase (APB), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B (Incyte Pharmaceuticals): Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C. In the alternative, the parameters for primer pair T7 and SK+ (Stratagene) were as follows: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C.

The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN reagent (0.25% reagent in 1×TE, v/v; Molecular Probes) and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton Mass.) and allowing the DNA to bind to the reagent. The plate was scanned in a FLUOROSKAN II (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1% agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleic acids were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC18 vector (APB). For shotgun sequencing, the digested nucleic acids were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with AGARACE enzyme (Promega). Extended clones were religated using T4 DNA ligase (New England Biolabs, Beverly Mass.) into pUC18 vector (APB), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transformed into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37° C. in 384-well plates in LB/2×carbenicillin liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (APB) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA was quantified using PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions described above. Samples were diluted with 20% dimethylsulfoxide (DMSO; 1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT cycle sequencing kit (APB) or the ABI PRISM BIGDYE terminator cycle sequencing kit (Applied Biosystems).

IV Assembly and Analysis of Sequences

Component nucleotide sequences from chromatograms were subjected to PHRED analysis (Phil Green, University

of Washington, Seattle Wash.) and assigned a quality score. The sequences having at least a required quality score were subject to various pre-processing algorithms to eliminate low quality 3' ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. Sequences were screened using the BLOCK 2 program (Incyte Genomics), a motif analysis program based on sequence information contained in the SWISS-PROT and PROSITE databases (Bairoch et al. (1997) Nucleic Acids Res 25:217–221; Attwood et al. (1997) J Chem Inf Comput Sci 37:417–424).

Processed sequences were subjected to assembly procedures in which the sequences were assigned to bins, one sequence per bin. Sequences in each bin were assembled to produce consensus sequences, templates. Subsequent new sequences were added to existing bins using BLAST (Altschul (supra); Altschul et al. (supra); Karlin et al. (1988) Proc Natl Acad Sci 85:841–845), BLASTn (vers.1.4, WashU), and CROSSMATCH software (Phil Green, supra). Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using PHRAP (Phil Green, supra). Bins with several overlapping component sequences were assembled using DEEP PHRAP (Phil Green, supra).

Bins were compared against each other, and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subjected to analysis by STITCHER/EXON MAPPER algorithms which analyzed the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types, disease states, and the like. These resulting bins were subjected to several rounds of the above assembly procedures to generate the template sequences found in the LIFESEQ GOLD database (Incyte Genomics).

The assembled templates were annotated using the following procedure. Template sequences were analyzed using BLASTn (vers. 2.0, NCBI) versus GBpri (GenBank vers. 116). "Hits" were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value equal to or greater than 1×10^{-8}. (The "E-value" quantifies the statistical probability that a match between two sequences occurred by chance). The hits were subjected to frameshift FASTx versus GENPEPT (GenBank version 109). In this analysis, a homolog match was defined as having an E-value of 1×10^{-8}. The assembly method used above was described in U.S. Ser. No. 09/276,534, filed Mar. 25, 1999, and the LIFESEQ GOLD user manual (Incyte Genomics).

Following assembly, template sequences were subjected to motif, BLAST, Hidden Markov Model (HMM; Pearson and Lipman (1988) Proc Natl Acad Sci 85:2444–2448; Smith and Waterman (1981) J Mol Biol 147:195–197), and functional analyses, and categorized in protein hierarchies using methods described in U.S. Ser. No. 08/812,290, filed Mar. 6, 1997; U.S. Ser. No. 08/947,845, filed Oct. 9, 1997; U.S. Pat. No. 5,953,727; and U.S. Ser. No. 09/034,807, filed Mar. 4, 1998. Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, eukaryote, prokaryote, and human EST databases.

V Selection of Sequences, Microarray Preparation and Use

Incyte clones represent template sequences derived from the LIFESEQ GOLD assembled human sequence database (Incyte Genomics). In cases where more than one clone was available for a particular template, the 5'-most clone in the template was used on the microarray. The HUMAN GENOME GEM series 1–3 microarrays (Incyte Pharmaceuticals) contain 28,626 array elements which represent 10,068 annotated clusters and 18,558 unannotated clusters. Tables 1 and 2 show the GenBank annotations for SEQ ID NOs:1-x of this invention as produced by BLAST analysis.

To construct microarrays, cDNAs were amplified from bacterial cells using primers complementary to vector sequences flanking the cDNA insert. Thirty cycles of PCR increased the initial quantity of cDNAs from 1–2 ng to a final quantity greater than 5 μg. Amplified cDNAs were then purified using SEPHACRYL-400 columns (APB). Purified cDNAs were immobilized on polymer-coated glass slides. Glass microscope slides (Corning, Corning N.Y.) were cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides were etched in 4% hydrofluoric acid (VWR Scientific Products, West Chester Pa.), washed thoroughly in distilled water, and coated with 0.05% aminopropyl silane (Sigma Aldrich) in 95% ethanol. Coated slides were cured in a 110° C. oven. cDNAs were applied to the coated glass substrate using a procedure described in U.S. Pat. No. 5,807,522. One microliter of the cDNA at an average concentration of 100 ng/ul was loaded into the open capillary printing element by a high-speed robotic apparatus which then deposited about 5 nl of cDNA per slide.

Microarrays were UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene), and then washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites were blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (Tropix, Bedford Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.

VI Preparation of Samples

The following cell lines were obtained from American Type Culture Collection (Manassus Va.) and cultured in media according to the manufacturer's protocols: PZ-HPV-7 was derived from epithelial cells cultured from normal tissue from the peripheral zone of the prostate. CA-HPV-10 was derived from cells from a prostatic adenocarcinoma of Gleason Grade 4/4. Both PZ cells were transformed by transfection with human papillomavirus (HPV)-18, and express keratins 5 and 8 and the early region 6 oncoprotein of HPV. PZ-HPV-7 and CA-HPV-10 are negative for prostate specific antigen (PSA). DU-145 is a prostate carcinoma cell line isolated from a 69 year-old man with widespread metastatic disease. DU-145 was isolated from a brain metastasis and has no detectable hormone sensitivity. Further, DU-145 is negative for PSA: PC-3 is a prostate adenocarcinoma cell line isolated from a 62 year-old male with grade IV prostate adenocarcinoma metastasized to the bone. PC-3 cells exhibit low acid phosphatase and testosterone-5-alpha reductase activities; LNCaP is a prostate carcinoma cell line isolated from a lymph node biopsy of a 50 year-old male with metastatic prostate carcinoma. LNCaP cells are responsive to 5-alpha-dihydrotestosterone and express androgen receptors.

PrEC, a primary prostate epithelial cell line isolated from a normal donor, was obtained from Cambrex Bioscience Inc.

(Walkersville Md.) and cultured in media according to the manufacturer's protocols.

All cultures were maintained at 37° C. and 5% CO_2 for 3–5 passages.

Isolation and Labeling of Sample cDNAs

Cells were harvested when cultures were approximately 70% confluent and lysed in 1 ml of TRIZOL reagent (5×10^6 cells/ml; Life Technologies). The lysates were vortexed thoroughly and incubated at room temperature for 2–3 minutes and extracted with 0.5 ml chloroform. The extract was mixed, incubated at room temperature for 5 minutes, and centrifuged at 15,000 rpm for 15 minutes at 4° C. The aqueous layer was collected and an equal volume of isopropanol was added. Samples were mixed, incubated at room temperature for 10 minutes, and centrifuged at 15,000 rpm for 20 minutes at 4° C. The supernatant was removed and the RNA pellet was washed with 1 ml of 70% ethanol, centrifuged at 15,000 rpm at 4° C., and resuspended in RNase-free water. The concentration of the RNA was determined by measuring the optical density at 260 nm.

Poly(A) RNA was prepared using an OLIGOTEX mRNA kit (QIAGEN) with the following modifications: OLIGOTEX beads were washed in tubes instead of on spin columns, resuspended in elution buffer, and then loaded onto spin columns to recover mRNA. To obtain maximum yield, the mRNA was eluted twice.

Each poly(A) RNA sample was reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-d(T) primer (21 mer), 1×first strand buffer, 0.03 units/ul RNase inhibitor, 500 uM dATP, 500 uM dGTP, 500 uM dTTP, 40 uM dCTP, and 40 uM either dCTP-Cy3 or dCTP-Cy5 (APB). The reverse transcription reaction was performed in a 25 ml volume containing 200 ng poly(A) RNA using the GEMBRIGHT kit (Incyte Pharmaceuticals). Specific control poly (A) RNAs (YCFR06, YCFR45, YCFR67, YCFR85, YCFR43, YCFR22, YCFR23, YCFR25, YCFR44, YCFR26) were synthesized by in vitro transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, control mRNAs (YCFR06, YCFR45, YCFR67, and YCFR85) at 0.002 ng, 0.02 ng, 0.2 ng, and 2 ng were diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000, 1:1000, 1:100 (w/w) to sample mRNA, respectively. To sample differential expression patterns, control mRNAs (YCFR43, YCFR22, YCFR23, YCFR25, YCFR44, YCFR26) were diluted into reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 1:25, 25:1 (w/w) to sample mRNA. Reactions were incubated at 37° C. for 2 hr, treated with 2.5 ml of 0.5M sodium hydroxide, and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA.

cDNAs were purified using two successive CHROMA SPIN 30 gel filtration spin columns (Clontech). Cy3- and Cy5-labeled reaction samples were combined as follows: Aliquots of Cy3-labeled PrEC cDNA were individually mixed with Cy5 labeled cDNA from PZ-HPV-7, CA-HPV-10, DU-145, PC-3, and LNCaP cells. The mixtures were ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol, dried to completion using a SpeedVAC system (Savant Instruments, Holbrook N.Y.), and resuspended in 14 μl 5×SSC/0.2% SDS.

VII Hybridization and Detection

Hybridization reactions contained 9 μl of sample mixture containing 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5×SSC, 0.2% SDS hybridization buffer. The mixture was heated to 65° C. for 5 minutes and was aliquoted onto the microarray surface and covered with an 1.8 cm^2 coverslip. The microarrays were transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber was kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the microarrays was incubated for about 6.5 hours at 60° C. The microarrays were washed for 10 min at 45° C. in low stringency wash buffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45° C. in high stringency wash buffer (0.1×SSC), and dried.

Reporter-labeled hybridization complexes were detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light was focused on the microarray using a 20×microscope objective (Nikon, Melville N.Y.). The slide containing the microarray was placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm microarray used in the present example was scanned with a resolution of 20 micrometers.

In two separate scans, the mixed gas multiline laser excited the two fluorophores sequentially. Emitted light was split, based on wavelength, into two photomultiplier tube detectors (PMT R1477; Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the microarray and the photomultiplier tubes were used to filter the signals. The emission maxima of the fluorophores used were 565 nm for Cy3 and 650 nm for Cy5. Each microarray was typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus was capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans was calibrated using the signal intensity generated by a cDNA control species. Samples of the calibrating cDNA were separately labeled with the two fluorophores and identical amounts of each were added to the hybridization mixture. A specific location on the microarray contained a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000.

The output of the photomultiplier tube was digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Norwood, Mass.) installed in an IBM-compatible PC computer. The digitized data were displayed as an image where the signal intensity was mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data was also analyzed quantitatively. Where two different fluorophores were excited and measured simultaneously, the data were first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid was superimposed over the fluorescence signal image such that the signal from each spot was centered in each element of the grid. The fluorescence signal within each element was then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis was the GEMTOOLS gene expression analysis program (Incyte Pharmaceuticals). Significance was defined as signal to background ratio exceeding 2× and area hybridization exceeding 40%.

VIII Data Analysis and Results

Array elements that exhibited at least 2.5-fold change in expression at one or more time points, a signal intensity over

250 units, a signal-to-background ratio of at least 2.5, and an element spot size of at least 40% were identified as differentially expressed using the GEMTOOLS program (Incyte Genomics). Differential expression values were converted to log base 2 scale. Differential expression values were then compared between the cell lines to identify genes which discriminated between normal and cancerous and between non-metastatic and metastatic cancer. The student's t-test and Pearson correlation statistics were used to distinguish significant differences between the groups. The resulting cDNAs are shown in Tables 1 and 2. The cDNAs are identified by their Clone ID. Table 3 shows the sequence overlap between the clones identified in Tables 1 and 2 and gene templates. Columns 1–3 show the SEQ ID NO:, Template ID, and Clone ID, respectively. Columns 4 and 5 show the start and stop nucleotides for the clone on the template. Table 4 shows a GenBank homolog and description associated with at least a fragment of each Template ID. The descriptions were obtained using the sequences of the Sequence Listing and BLAST analysis. SEQ ID NOs:1–3, 5, 6, 8, 10–15, 17–19, 21, 23–28, 30, 32, 34–36, 38, 40, 42–45, 47–50, 52, 53, 55, 56, 58–65, 67, 68, 70–73, 75 are highly correlated with metastatic prostate cancer cells PC-3, LNCaP, and DU-145, and SEQ ID NOs:76, 78–86, 88–90, 92–97, 99–101 are differentially expressed at significant levels in all of the prostate cancer cell lines.

IX Other Hybridization Technologies and Analyses

Other hybridization technologies utilize a variety of substrates such as nylon membranes, capillary tubes, etc. Arranging cDNAs on polymer coated slides is described in Example V; sample cDNA preparation and hybridization and analysis using polymer coated slides is described in examples VI and VII, respectively.

cDNAs are applied to a membrane substrate by one of the following methods. A mixture of cDNAs is fractionated by gel electrophoresis and transferred to a nylon membrane by capillary transfer. Alternatively, the cDNAs are individually ligated to a vector and inserted into bacterial host cells to form a library. The cDNAs are then arranged on a substrate by one of the following methods. In the first method, bacterial cells containing individual clones are robotically picked and arranged on a nylon membrane. The membrane is placed on LB agar containing selective agent (carbenicillin, kanamycin, ampicillin, or chloramphenicol depending on the vector used) and incubated at 37° C. for 16 hr. The membrane is removed from the agar and consecutively placed colony side up in 10% SDS, denaturing solution (1.5 M NaCl, 0.5 M NaOH), neutralizing solution (1.5 M NaCl, 1 M Tris, pH 8.0), and twice in 2×SSC for 10 min each. The membrane is then UV irradiated in a STRATALINKER UV-crosslinker (Stratagene).

In the second method, cDNAs are amplified from bacterial vectors by thirty cycles of PCR using primers complementary to vector sequences flanking the insert. PCR amplification increases a starting concentration of 1–2 ng nucleic acid to a final quantity greater than 5 μg. Amplified nucleic acids from about 400 bp to about 5000 bp in length are purified using SEPHACRYL400 beads (APB). Purified nucleic acids are arranged on a nylon membrane manually or using a dot/slot blotting manifold and suction device and are immobilized by denaturation, neutralization, and UV irradiation as described above.

Hybridization probes derived from cDNAs of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA in membrane-based hybridizations. Probes are prepared by diluting the cDNAs to a concentration of 40–50 ng in 45 μl TE buffer, denaturing by heating to 100° C. for five min and briefly centrifuging. The denatured cDNA is then added to a REDIPRIME tube (APB), gently mixed until blue color is evenly distributed, and briefly centrifuged. Five microliters of [^{32}P]dCTP is added to the tube, and the contents are incubated at 37° C. for 10 min. The labeling reaction is stopped by adding 5 μl of 0.2M EDTA, and probe is purified from unincorporated nucleotides using a PROBEQUANT G-50 microcolumn (APB). The purified probe is heated to 100° C. for five min and then snap cooled for two min on ice.

Membranes are pre-hybridized in hybridization solution containing 1% Sarkosyl and 1×high phosphate buffer (0.5 M NaCl, 0.1 M Na_2HPO_4, 5 mM EDTA, pH 7) at 55° C. for two hr. The probe, diluted in 15 ml fresh hybridization solution, is then added to the membrane. The membrane is hybridized with the probe at 55° C. for 16 hr. Following hybridization, the membrane is washed for 15 min at 25° C. in 1 mM Tris (pH 8.0), 1% Sarkosyl, and four times for 15 min each at 25° C. in 1 mM Tris (pH 8.0). To detect hybridization complexes, XOMAT-AR film (Eastman Kodak, Rochester N.Y.) is exposed to the membrane overnight at −70° C., developed, and examined.

X Further Characterization of Differentially Expressed cDNAs and Proteins

Clones were blasted against the LIFESEQ Gold 5.1 database (Incyte Genomics) and an Incyte template and its sequence variants were chosen for each clone. The template and variant sequences were blasted against GenBank database to acquire annotation. The nucleotide sequences were translated into amino acid sequence which was blasted against the GenPept and other protein databases to acquire annotation and characterization, i.e., structural motifs.

Percent sequence identity can be determined electronically for two or more amino acid or nucleic acid sequences using the MEGALIGN program (DNASTAR). The percent identity between two amino acid sequences is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no homology between the two amino acid sequences are not included in determining percentage identity.

Sequences with conserved protein motifs may be searched using the BLOCKS search program. This program analyses sequence information contained in the Swiss-Prot and PROSITE databases and is useful for determining the classification of uncharacterized proteins translated from genomic or cDNA sequences (Bairoch et al.(supra); Attwood et al. (supra). PROSITE database is a useful source for identifying functional or structural domains that are not detected using motifs due to extreme sequence divergence. Using weight matrices, these domains are calibrated against the SWISS-PROT database to obtain a measure of the chance distribution of the matches.

The PRINTS database can be searched using the BLIMPS search program to obtain protein family "fingerprints". The PRINTS database complements the PROSITE database by exploiting groups of conserved motifs within sequence alignments to build characteristic signatures of different protein families. For both BLOCKS and PRINTS analyses, the cutoff scores for local similarity were: >1300=strong, 1000–1300=suggestive; for global similarity were: p<exp-3; and for strength (degree of correlation) were: >1300=strong, 1000–1300=weak.

X Expression of the Encoded Protein

Expression and purification of a protein encoded by a cDNA of the invention is achieved using bacterial or virus-

based expression systems. For expression in bacteria, cDNA is subcloned into a vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into bacterial hosts, such as BL21(DE3). Antibiotic resistant bacteria express the protein upon induction with IPTG. Expression in eukaryotic cells is achieved by infecting *Spodoptera frugiperda* (Sf9) insect cells with recombinant baculovirus, *Autographica californica* nuclear polyhedrosis virus. The polyhedrin gene of baculovirus is replaced with the cDNA by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of transcription.

For ease of purification, the protein is synthesized as a fusion protein with glutathione-S-transferase (GST; APB) or a similar alternative such as FLAG. The fusion protein is purified on immobilized glutathione under conditions that maintain protein activity and antigenicity. After purification, the GST moiety is proteolytically cleaved from the protein with thrombin. A fusion protein with FLAG, an 8-amino acid peptide, is purified using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak, Rochester N.Y.).

XI Production of Specific Antibodies

A denatured protein from a reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits following standard protocols. About 100 μg is used to immunize a mouse, while up to 1 mg is used to immunize a rabbit. The denatured protein is radioiodinated and incubated with murine B-cell hybridomas to screen for monoclonal antibodies. About 20 mg of protein is sufficient for labeling and screening several thousand clones.

In another approach, the amino acid sequence translated from a cDNA of the invention is analyzed using PROTEAN software (DNASTAR) to determine regions of high antigenicity, essentially antigenically-effective epitopes of the protein. The optimal sequences for immunization are usually at the C-terminus, the N-terminus, and those intervening, hydrophilic regions of the protein that are likely to be exposed to the external environment when the protein is in its natural conformation. Typically, oligopeptides about 15 residues in length are synthesized using an ABI 431 peptide synthesizer (Applied Biosystems) using Fmoc-chemistry and then coupled to keyhole limpet hemocyanin (KLH; Sigma Aldrich) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester. If necessary, a cysteine may be introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with radioiodinated protein to identify those fusions producing a monoclonal antibody specific for the protein. In a typical protocol, wells of 96 well plates (FAST, Becton-Dickinson, Palo Alto Calif.) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled protein at 1 mg/ml. Clones producing antibodies bind a quantity of labeled protein that is detectable above background.

Such clones are expanded and subjected to 2 cycles of cloning at 1 cell/3 wells. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A(APB). Monoclonal antibodies with affinities of at least 10^8 M^{-1}, preferably 10^9 to 10^{10} M^{-1} or stronger, are made by procedures well known in the art.

XII Purification of Naturally Occurring Protein Using Specific Antibodies

Naturally occurring or recombinant protein is substantially purified by immunoaffinity chromatography using antibodies specific for the protein. An immunoaffinity column is constructed by covalently coupling the antibody to CNBr-activated SEPHAROSE resin (APB). Media containing the protein is passed over the immunoaffinity column, and the column is washed using high ionic strength buffers in the presence of detergent to allow preferential absorbance of the protein. After coupling, the protein is eluted from the column using a buffer of pH 2–3 or a high concentration of urea or thiocyanate ion to disrupt antibody/protein binding, and the protein is collected.

XIII Screening Molecules for Specific Binding with the cDNA or Protein

The cDNA or fragments thereof and the protein or portions thereof are labeled with ^{32}P-dCTP, Cy3-dCTP, Cy5-dCTP (APB), or BIODIPY or FITC (Molecular Probes), respectively. Candidate molecules or compounds previously arranged on a substrate are incubated in the presence of labeled nucleic or amino acid. After incubation under conditions for either a cDNA or a protein, the substrate is washed, and any position on the substrate retaining label, which indicates specific binding or complex formation, is assayed. The binding molecule is identified by its arrayed position on the substrate. Data obtained using different concentrations of the nucleic acid or protein are used to calculate affinity between the labeled nucleic acid or protein and the bound molecule. High throughput screening using very small assay volumes and very small amounts of test compound is fully described in Burbaum et al. U.S. Pat. No. 5,876,946.

All patents and publications mentioned in the specification are incorporated herein by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

TABLE 1

Clone ID	PrEC, Untx/CA-HPV-10	PrEC, Untx/PZ-HPV-7	PrEC, Untx/DU145	PrEC, Untx/LNCaP	PrEC, Untx/PC3	t-test
3184882	−0.26	−0.41	−3.37	−3.80	−3.28	0.0007
3973887	−0.45	−0.47	−1.47	−1.59	−1.59	0.0010

TABLE 1-continued

Clone ID	PrEC, Untx/CA-HPV-10	PrEC, Untx/PZ-HPV-7	PrEC, Untx/DU145	PrEC, Untx/LNCaP	PrEC, Untx/PC3	t-test
557538	0.15	0.41	−3.61	−3.88	−3.73	0.0029
793403	−0.57	−0.58	−2.84	−2.73	−2.45	0.0031
423513	−0.61	−0.67	−1.72	−1.81	−1.52	0.0036
5497369	−0.53	−0.24	−2.15	−2.62	−1.91	0.0054
3432534	−0.50	−0.61	−2.76	−3.45	−2.72	0.0072
1955573	0.12	−0.07	−1.27	−0.84	−1.32	0.0076
4029118	0.14	0.12	−1.32	−1.43	−1.00	0.0082
2723829	−0.58	−0.41	−1.45	−1.30	−1.17	0.0087
1628341	−0.39	−0.01	−2.07	−2.42	−1.68	0.0087
4513549	0.04	−0.19	−1.34	−1.78	−1.14	0.0091
1967556	−0.27	−0.39	−1.27	−1.80	−1.67	0.0095
2729629	−0.22	0.09	−1.32	−1.92	−1.27	0.0118
2701607	−0.62	−0.59	−2.23	−2.49	−1.88	0.0119
4933404	0.28	0.22	−1.05	−1.50	−0.95	0.0119
3616296	−0.59	−0.45	−1.23	−1.33	−0.97	0.0136
154371	0.08	0.40	−2.54	−2.91	−1.54	0.0154
3774181	−0.59	−0.55	−2.25	−3.28	−2.83	0.0172
1709387	−0.44	−0.74	−2.22	−2.42	−2.12	0.0184
351981	−0.21	−0.22	−1.08	−0.98	−1.41	0.0186
2057510	−0.68	−0.23	−3.49	−3.82	−3.77	0.0192
1324789	−0.38	−0.42	−1.67	−2.32	−1.66	0.0199
3120070	−1.03	−0.70	−2.60	−2.71	−2.40	0.0203
2833609	−0.19	0.07	−0.98	−1.90	−1.55	0.0221
3431481	−0.30	−0.21	−1.65	−2.39	−1.57	0.0222
4557506	−0.40	−0.08	−1.20	−1.81	−1.14	0.0233
1597810	−0.30	−0.55	−1.59	−2.31	−1.46	0.0237
2962788	−1.09	−1.13	−3.13	−4.19	−3.04	0.0240
3120209	−0.79	−0.60		−1.52	−1.74	0.0247
1800609	−0.33	−0.61	−1.68	−1.31	−1.47	0.0247
3384548	0.02	−0.07	−0.89	−1.42	−0.85	0.0250
2056584	−0.18	−0.21	−1.23	−1.81	−1.17	0.0268
3096030	−0.66	−0.85		−2.07	−1.79	0.0291
2505801	−0.01	0.11	−1.21	−1.88	−0.98	0.0300
3658143	0.07	−0.35	−1.64	−1.56	−0.98	0.0306
3384076	−0.25	−0.26	−1.43	−2.13	−1.32	0.0327
2058209	−0.34	−0.01	−1.46	−1.24	−0.80	0.0329
509758	−0.31	−0.39	−2.19	−2.24	−1.30	0.0341
1723319	−0.57	−0.71	−2.41	−3.45	−2.12	0.0343
2198951	−0.24	−0.26	−0.86	−1.32	−0.88	0.0359
4365223	−0.20	−0.15	−1.10	−1.97	−1.35	0.0372
1437565	−0.40	−0.31	−1.19	−1.93	−1.26	0.0381
3837686	0.01	0.27	−0.68	−1.36	−0.57	0.0387
36406	−0.78	−0.05	−2.26	−3.01	−1.93	0.0403
1217764	−0.49	0.18	−2.16	−2.48	−1.21	0.0412
2059420	−0.29	−0.41	−0.80	−1.31	−1.45	0.0425
1805911	−0.22	−0.16	−1.52	−2.32	−1.23	0.0429
461367	0.19	0.18	−1.00	−1.66	−0.71	0.0429
4089868	0.27	0.28	−0.46	−0.92	−1.35	0.0437
1549141	−0.48	−0.80	−1.18	−1.65	−1.58	0.0456
4571104	−0.88	−0.57	−1.69	−1.22	−2.00	0.0464
552594	−0.21	−0.49	−1.27	−1.84	−0.94	0.0475
2834343	−0.11	0.02	−0.94	−2.02	−1.21	0.0493

TABLE 2

Clone ID	PrEC, Untx/CA-HPV-10	PrEC, Untx/PZ-HPV-7	PrEC, Untx/DU145	PrEC, Untx/LNCaP	PrEC, Untx/PC3
1518310	−1.74	−1.27	−2.60	−2.97	−2.50
2823767	−1.70	−1.92	−1.72	−1.54	−1.34
2241825	−1.66	−1.49	−1.98	−1.55	−1.44
5033671	−1.33	−1.44	−1.53	−2.59	−1.62
44913	−1.30	−1.30	−1.11	−2.21	−2.29
4549259	−1.29	−1.36	−1.35	−1.68	−1.12
319075	−1.29	−1.37	−1.08	−2.26	−2.15
2520894	−1.27	−1.43	−1.50	−1.15	−1.04
4107861	−1.27	−2.03	−2.20	−2.67	−2.13
3172265	−1.67	−1.48		−1.74	−1.86
4402555	−1.43	−1.24		−1.52	−1.11
2495131	−1.40	−1.01	−1.26	−3.32	−0.95
3158828	−1.37	−1.19		−1.59	−1.31
5266015	−1.25	−1.31		−1.56	−1.26
4978708	−1.24	−1.42	−1.20	−1.63	−0.54
3069190	−1.21	−1.33		−1.67	−1.37
64073	−1.15	−1.09	−0.91	−2.04	−2.18
172023	1.01	1.29	2.11	0.98	1.59
3068978	−1.32	−1.13		0.00	−1.94
2060823	−1.08	−1.35	−1.38	−0.93	−0.95

TABLE 3

SEQ ID NO:	Template ID	Clone ID	Start	Stop
1	1382961.3	3184882	1080	1401
2	1382961.5	3184882	1	518
3	2852561CB1	3973887	1	1934
5	335942.2	557538	−4	354
6	2483854CB1	557538	21	1677
8	1454852CB1	793403	54	1564
10	353005.1	423513	1	309
11	378497.1	5497369	1	176
12	994684.9	3432534	2312	2868
13	995610.1	1955573	2345	2804
14	417119.1	4029118	1	427
15	3615080CB1	2723829	563	4670
17	331749.3	1628341	264	748
18	979243.1	4513549	299	1245
19	3189059CB1	1967556	192	1981
21	1650519CB1	2729629	5	1448
23	474630.4	2701607	1610	2083
24	093496.1	4933404	319	455
25	1231633.4	3616296	7	58
26	988891.1	154371	987	1538
27	988891.15	154371	1	363
28	3774181CB1	3774181	37	7081
30	1709387CB1	1709387	34	1742
32	1709118CB1	351981	45	1437
34	008513.49	2057510	1721	2258
35	047568.1	1324789	1	493
36	3120070CB1	3120070	43	2028
38	1303785CB1	2833609	3251	4766
40	1798379CB1	3431481	3	2711
42	350650.1	4557506	1	663
43	474630.24	1597810	443	809
44	108089.1	2962788	1	295
45	3346307CB1	3120209	13	1756
47	200143.25	1800609	234	679
48	001929.1	3384548	12	432
48	001929.1	3384076	797	1744
49	1088524.8	2056584	1218	1900
50	632664CB1	3096030	67	1181
52	457372.17	2505801	527	824
53	2993696CB1	3658143	17	2556
55	331106.6	2058209	4948	5465
56	1256895CB1	509758	530	3000
58	474630.29	1723319	3978	4495
59	1256295.18	2198951	497	1314
60	444096.1	4365223	632	1383
60	444096.1	1805911	1	1387
61	008942.10	1437565	4357	4498
62	008942.9	1437565	1320	1602
63	1252415.1	3837686	2794	2872
64	1399366.20	36406	5046	5265
65	3732868CB1	1217764	1	961
67	1137894.1	2059420	1947	2552
68	1418671CB1	461367	1	1529
70	464689.64	4089868	4741	5350
71	053959.1	1549141	1	56
72	1384594.1	4571104	1	580
73	021667CB1	552594	778	3348
75	224855.4	2834343	3902	5287
76	1518310CB1	1518310	45	2323

TABLE 3-continued

SEQ ID NO:	Template ID	Clone ID	Start	Stop
78	098533.1	2823767	1	445
79	410785.1	2241825	4507	4882
80	1089210.1	5033671	34	1152
81	333453.6	44913	1	202
82	365070.1	4549259	123	698
83	365070.3	4549259	393	841
84	413921.2	319075	3140	3637
85	336615.1	2520894	1088	1325
86	2733282CB1	4107861	1	3156
88	399161.1	3172265	473	1121
89	339638.1	4402555	1	687
90	697785CB1	2495131	233	770
92	399785.1	3158828	199	627
93	002455.1	5266015	668	1133
94	1382920.38	4978708	49	565
95	334749.1	3069190	74	634
96	041764.1	64073	319	579
97	2700132CB1	172023	208	10640
99	211881.1	3068978	1	548
100	409895.2	2060823	1224	1458
101	1422432CB1	2060823	1	860

TABLE 4

SEQ ID NO:	Template ID	GB Number	E-value	Annotation
1	1382961.3	g186704	0	Human 50 kDa type I epidermal keratin gene, complete cds.
2	1382961.5	g186704	2.00E − 86	Human 50 kDa type I epidermal keratin gene, complete cds.
3	2852561CB1	g5926733	0	Human mRNA for 4F2 heavy chain, complete cds.
4	2852561CD1	g5926733	0	Human mRNA for 4F2 heavy chain, complete cds.
5	335942.2	g33794	0	Human mRNA for interleukin-1 precursor (pre IL-1).
6	2483854CB1	g33794	0	Human mRNA for interleukin-1 precursor (pre IL-1).
7	2483854CD1	g33794	0	Human mRNA for interleukin-1 precursor (pre IL-1).
8	1454852CB1	g34074	0	Human mRNA for keratin-related protein.
9	1454852CD1	g34074	0	Human mRNA for keratin-related protein.
10	353005.1	g183063	0	Human glia-derived nexin (GDN) mRNA, 5' end.
11	378497.1	g2627428	7.00E − 36	Human laminin alpha 3b chain mRNA, partial cds.
12	994684.9	g186697	0	Human keratin type II (58 kD) mRNA, complete cds.
13	995610.1	g34815	0	Human mRNA encoding the c-myc oncogene.
14	417119.1	g33788	0	Human gene for prointerleukin 1 beta.
15	3615080CB1	g2429078	0	Human mRNA for Laminin-5 beta3 chain, complete cds.
16	3615080CD1	g2429078	0	Human mRNA for Laminin-5 beta3 chain, complete cds.
17	331749.3	g453368	0	Human maspin mRNA, complete cds.
18	979243.1	g212752	4.00E − 61	tensin
19	3189059CB1	g3242792	0	Human herpesvirus entry protein C (HVEC) mRNA, complete cds.
20	3189059CD1	g3242792	0	Human herpesvirus entry protein C (HVEC) mRNA, complete cds.
21	1650519CB1	g3483777	0	Human full length insert cDNA clone ZD79H11.
22	1650519CD1	g3483777	0	Human full length insert cDNA clone ZD79H11.
23	474630.4	g33956	0	Human mRNA for integrin beta-4 subunit.
24	093496.1	g338320	4.00E − 12	Human osyeonectin gene, exon 7.
25	1231633.4	g189265	5.00F-87	Human novel gene mRNA, complete cds.
26	988891.1	g186268	0	Human monocyte interleukin I (IL-1) mRNA, complete cds.
27	988891.15	g186268	0	Human monocyte interleukin I (IL-1) mRNA, complete cds.
28	3774181CB1	g179522	0	Human bullous pemphigoid antigen (BPAG1) mRNA, complete cds.
29	3774181CD1	g179522	0	Human bullous pemphigoid antigen (BPAG1) mRNA, complete cds.
30	1709387CB1	g34070	0	Human mRNA for cytokeratin 15.
31	1709387CD1	g34070	0	Human mRNA for cytokeratin 15.
32	1709118CB1	g178037	0	Human alpha-cardiac actin gene, exon 6 and 3' flank.
33	1709118CD1	g178037	0	Human alpha-cardiac actin gene, exon 6 and 3' flank.
34	008513.49	g908802	0	Human keratin 6 isoform K6e (KRT6E) mRNA, complete cds.
35	047568.1	g184056	0	Human histatin 3 (HIS2) gene exons 3–5, complete cds.
36	3120070CB1	g7582391	1.00F-60	p53 apoptosis-associated target
37	3120070CD1	g7582391	1.00F-60	p53 apoptosis-associated target
38	1303785CB1	g34387	0	Human mRNA for lipocortin.
39	1303785CD1	g34387	0	Human mRNA for lipocortin.
40	1798379CB1	g181401	0	Human epidermal cytokeratin 2 mRNA, complete cds.
41	1798379CD1	g181401	0	Human epidermal cytokeratin 2 mRNA, complete cds.
42	350650.1	g7020235	0	Human cDNA FLJ20261 fis, clone COLF7630.
43	474630.24	g2270919	0	Human beta4-integrin (ITGB4) gene, exons 31, 32, 33 and 34
44	108089.1	g747615	7.00E − 68	Human laminin S B3 chain (LAMB3) gene, exons 2–3.

TABLE 4-continued

SEQ ID NO:	Template ID	GB Number	E-value	Annotation
45	3346307CB1	g7020644	0	Human cDNA FLJ20500 fis, clone KAT09159.
46	3346307CD1	g7020644	0	Human cDNA FLJ20500 fis, clone KAT09159.
47	200143.25	g897916	1.00E − 47	Human 11kd protein mRNA, complete cds.
48	001929.1	g908779	0	keratin type II
49	1088524.8	g7453533	0	Human hepatic angiopoietin-related protein (ANGPTL2) mRNA, complete cds.
50	632664CB1	g7658294	0	Human transmembrane protein BRI mRNA, complete cds.
51	632664CD1	g7658294	0	Human transmembrane protein BRI mRNA, complete cds.
52	457372.17	g7959902	0	Human PRO2446 mRNA, complete cds.
53	2993696CB1	g1143491	0	Human mRNA for BiP protein.
54	2993696CD1	g1143491	0	Human mRNA for BiP protein.
55	331106.6	g33943	0	Human mRNA for integrin alpha 6.
56	1256895CB1	g2618612	0	Human mRNA for prion protein, complete cds.
57	1256895CD1	g2618612	0	Human mRNA for prion protein, complete cds.
58	474630.29	g33910	0	Human mRNA for integrin beta(4) subunit.
59	1256295.18	g182939	0	Human growth arrest and DNA-damage-inducible protein (gadd45) mRNA, complete cds.
60	444096.1	g34073	1.00E − 85	cytokeratin 4 (408 AA)
61	008942.10	g4426639	0	Human L-type amino acid transporter subunit LAT1 mRNA, complete cds.
62	008942.9	g5926731	0	Human mRNA for L-type amino acid transporter 1, complete cds.
63	1252415.1	g178083	0	Human adenylyl cyclase-associated protein (CAP) mRNA, complete cds.
64	1399366.20	g37464	0	Human mRNA for thrombospondin.
65	3732868CB1	g182852	0	Human GOS2 gene, 5' flank and cds.
66	3732868CD1	g182852	0	Human GOS2 gene, 5' flank and cds.
67	1137894.1	g2072389	0	Human zinc finger transcriptional regulator (COS24) gene, complete cds.
68	1418671CB1	g6984179	0	Human pleckstrin 2 mRNA, complete cds.
69	1418671CD1	g6984179	0	Human pleckstrin 2 mRNA, complete cds.
70	464689.64	g7415720	0	Human Sed mRNA for stearoyl-CoA desaturase, complete cds.
71	053959.1	g340012	3.00E − 13	Human tristetraproline (TTP) mRNA, complete cds.
72	1384594.1	g7020744	7.00E − 14	Human cDNA FLJ20557 fis, clone KAT11869.
73	021667CB1	g6580834	0	Human colon Kruppel-like factor (CKLF) mRNA, complete cds.
74	021667CD1	g6580834	0	Human colon Kruppel-like factor (CKLF) mRNA, complete cds.
75	224855.4	g1378108	0	Human lymphocyte specific interferon regulatory factor/ interferon regulatory factor 4 (LSIRF/IRF4) mRNA
76	1518310CB1	g4481752	0	Human connexin 26 (GJB2) mRNA, complete cds.
77	1518310CD1	g4481752	0	Human connexin 26 (GJB2) mRNA, complete cds.
78	098533.1	g2898163	4.00E − 52	Human microtubule-associated protein tau (tau) gene, exon 0.
79	410785.1	g187133	0	Human liver glucose transporter-like protein (GLUT2), complete cds.
80	1089210.1	g544761	0	chlordecone reductase {clone HAKRa} [Human liver, mRNA, 1167 nt].
81	333453.6	g2072424	5.00E − 65	Human non-lens beta gamma-crystallin like protein (AIM1) mRNA, partial cds.
82	365070.1			Incyte Unique
83	365070.3	g3550345	4.00E − 34	cellular repressor of E1A-stimulated genes CREG
84	413921.2	g474303	0	Human mRNA for Tec protein-tyrosine kinase, complete cds.
85	336615.1	g2072161	0	Human tubby related protein 1 (TULP1) mRNA, complete cds.
86	2733282CB1	g4887600	0	Human mRNA for chloride channel protein, complete cds.
87	2733282CD1	g4887600	0	Human mRNA for chloride channel protein, complete cds.
88	399161.1	g337708	2.00E − 37	Human U1 small nuclear RNA gene, clone HSD4, complete cds.
89	339638.1			Incyte Unique
90	697785CB1	g187109	0	Human 14 kd lectin mRNA, complete cds.
91	697785CD1	g187109	0	Human 14 kd lectin mRNA, complete cds.
92	399785.1			Incyte Unique
93	002455.1	g2708709	2.00E − 13	Wiskott-Aldrich Syndrome protein homolog
94	1382920.38	g31347	0	Human pseudogene for apoferritin H (clone 133)
95	334749.1			Incyte Unique
96	041764.1	g4589563	0	Human mRNA for KIAA0960 protein, partial cds.
97	2700132CB1	g415818	0	Human mki67a mRNA (long type) for antigen of monoclonal antibody Ki-67.

TABLE 4-continued

SEQ ID NO:	Template ID	GB Number	E-value	Annotation
98	2700132CD1	g415818	0	Human mki67a mRNA (long type) for antigen of monoclonal antibody Ki-67.
99	211881.1	g340088	7.00E − 15	Human small nuclear rna pseudogene (clone pul-1) and flanks.
100	409895.2	g36177	0	Human mRNA for calcium-binding protein S100P.

TABLE 4-continued

SEQ ID NO:	Template ID	GB Number	E-value	Annotation
101	1422432CB1	g36177	0	Human mRNA for calcium-binding protein S100P.
102	1422432CD1	g36177	0	Human mRNA for calcium-binding protein S100P.

TABLE 5

SEQ ID NO:	Template ID	Start	Stop	Frame	PFAM Hit	PFAM Annotaion	E-value
1	1382961.3	413	1348	forward 2	filament	Intermediate filament proteins	2.30E − 184
2	1382961.5	266	1036	forward 2	filament	Intermediate filament proteins	1.40E − 114
4	2852561CD1	112	491		alpha-amylase	Alpha amylase	1.70E − 04
7	2483854CD1	136	270		interleukin-1	Interleukin-1	5.60E − 68
9	1454852CD1	83	394		filament	Intermediate filament proteins	2.50E − 175
10	353005.1	87	242	forward 3	serpin	Serpins (serine protease inhibitors)	2.50E − 14
12	994684.9	1870	2601	forward 1	filament	Intermediate filament proteins	1.60E − 128
12	994684.9	2628	2729	forward 3	filament	Intermediate filament proteins	4.50E − 20
12	994684.9	2534	2644	forward 2	filament	Intermediate filament proteins	2.10E − 07
13	995610.1	2235	2393	forward 3	HLH	Helix-loop-helix DNA-binding domain	2.40E − 24
13	995610.1	1260	2207	forward 3	Myc_N_term	Myc amino-terminal region	2.90E − 166
16	3615080CD1	379	428		laminin_EGF	Laminin EGF-like (Domains III and V)	9.50E − 18
16	3615080CD1	26	248		laminin_Nterm	Laminin N-terminal (Domain VI)	1.50E − 38
20	3189059CD1	263	319		ig	Immunoglobulin domain	2.50E − 06
22	1650519CD1	59	314		7tm_1	7 transmembrane receptor (rhodopsin family)	6.90E − 42
23	474630.4	4737	4991	forward 3	fn3	Fibronectin type III domain	1.80E − 25
23	474630.4	329	1192	forward 2	integrin_B	Integrins, beta chain	1.10E − 231
23	474630.4	1179	1571	forward 3	integrin_B	Integrins, beta chain	2.80E − 75
25	1231633.4	25	267	forward 1	Ribosomal_L10e	Ribosomal L10	7.40E − 24
26	988891.1	538	966	forward 1	interleukin-1	Interleukin-1	2.60E − 86
27	988891.15	133	300	forward 1	interleukin-1	Interleukin-1	2.50E − 25
29	3774181CD1	1953	1997		Plectin_repeat	Plectin repeat	1.10E − 19
31	1709387CD1	104	416		filament	Intermediate filament proteins	8.90E − 178
33	1709118CD1	3	377		actin	Actin	3.90E − 282
34	008513.49	542	1483	forward 2	filament	Intermediate filament proteins	7.00E − 170
39	1303785CD1	275	342		annexin	Annexin	1.20E − 40
41	1798379CD1	183	496		filament	Intermediate filament proteins	8.20E − 159
42	350650.1	5	232	forward 2	filament	Intermediate filament proteins	1.10E − 27
48	001929.1	373	1314	forward 1	filament	Intermediate filament proteins	1.60E − 119
49	1088524.8	775	1023	forward 1	fibrinogen_C	Fibrinogen beta and gamma chains, C-terminal globular domain	1.80E − 41
49	1088524.8	1175	1399	forward 2	fibrinogen_C	Fibrinogen beta and gamma chains, C-terminal globular domain	2.70E − 19
49	1088524.8	2596	3213	forward 1	ras	Ras family	6.50E − 107
54	2993696CD1	30	636		HSP70	Hsp70 protein	0.00E + 00
55	331106.6	1084	1266	forward 1	FG-GAP	FG-GAP repeat	3.50E − 17
55	331106.6	3259	3303	forward 1	integrin_A	Integrin alpha cytoplasmic region	2.90E − 04
57	1256895CD1	23	253		prion	Prion protein	6.30E − 203
58	474630.29	4527	4781	forward 3	fn3	Fibronectin type III domain	1.80E − 25
58	474630.29	264	1520	forward 3	integrin_B	Integrins, beta chain	6.3e − 317
60	444096.1	83	565	forward 2	filament	Intermediate filament proteins	2.20E − 61
60	444096.1	546	746	forward 3	filament	Intermediate filament proteins	2.40E − 29
61	008942.10	207	1514	forward 3	aa_permeases	Amino acid permease	2.30E − 06
63	1252415.1	682	2094	forward 1	CAP	CAP protein	0.00E + 00
64	1399366.20	2117	2236	forward 2	EGF	EGF-like domain	3.00E − 06
64	1399366.20	1484	1636	forward 2	tsp_1	Thrombospondin type 1 domain	1.60E − 24
64	1399366.20	1121	1285	forward 2	vwc	von Willebrand factor type C domain	2.50E − 23
67	1137894.1	1145	1234	forward 2	zf-CCCH	Zinc finger C-x8-C-x5-C-x3-H type (and similar)	3.80E − 16
69	1418671CD1	139	225		DEP	Domain found in Dishevelled, Egl-10, and Pleckstrin	2.00E − 10
69	1418671CD1	248	353		PH	PH domain	1.70E − 18
70	464689.64	608	1342	forward 2	Desaturase	Fatty acid desaturase	1.20E − 163
72	1384594.1	121	264	forward 1	KRAB	KRAB box	4.20E − 04
74	021667CD1	165	189		zf-C2H2	Zinc finger, C2H2 type	1.60E − 06
75	224855.4	175	516	forward 1	IRF	Interferon regulatory factor transcription factor	2.60E − 76
77	1518310CD1	1	213		connexin	Connexin	5.80E − 163
79	410785.1	72	1451	forward 3	sugar_tr	Sugar (and other) transporter	8.10E − 124
79	410785.1	410	1480	forward 2	sugar_tr	Sugar (and other) transporter	2.30E − 05
80	1089210.1	61	903	forward 1	aldo_ket_red	Aldo/keto reductase family	2.60E − 192

TABLE 5-continued

SEQ ID NO:	Template ID	Start	Stop	Frame	PFAM Hit	PFAM Annotaion	E-value
84	413921.2	464	574	forward 2	BTK	BTK motif	4.30E − 23
84	413921.2	140	460	forward 2	PH	PH domain	2.70E − 16
84	413921.2	1235	1975	forward 2	pkinase	Eukaryotic protein kinase domain	8.80E − 72
84	413921.2	866	1117	forward 2	SH2	Src homology domain 2	2.30E − 35
84	413921.2	671	838	forward 2	SH3	SH3 domain	1.30E − 19
85	336615.1	86	874	forward 2	Tub	Tub family	3.00E − 195
91	697785CD1	22	126		Gal-bind_lectin	Vertebrate galactoside-binding lectins	2.90E − 65
94	1382920.38	253	723	forward 1	ferritin	Ferritins	9.80E − 116
98	2700132CD1	27	91		FHA	FHA domain	4.30E − 21
100	409895.2	1198	1284	forward 1	efhand	EF hand	1.80E − 04
102	1422432CD1	53	81		efhand	EF hand	1.80E − 04
102	1422432CD1	4	47		S_100	S-100/ICaBP type calcium binding domain	2.70E − 21

TABLE 6

SEQ ID NO:	Template ID	Start	Stop	Frame	Domain
1	1382961.3	336	422	forward 3	SP
4	2852561CD1	79	106		SP
5	335942.2	127	213	forward 1	TM
10	353005.1	14	100	forward 2	SP
12	994684.9	101	190	forward 2	SP
12	994684.9	2354	2446	forward 2	SP
13	995610.1	40	117	forward 1	SP
20	3189059CD1	1	30		SP
22	1650519CD1	43	70		TM
23	474630.4	53	133	forward 2	SP
26	988891.1	1300	1377	forward 1	TM
34	008513.49	243	335	forward 3	SP
37	3120070CD1	79	105		TM
37	3120070CD1	1	31		SP
49	1088524.8	1884	2000	forward 3	SP
49	1088524.8	232	321	forward 1	SP
49	1088524.8	1938	2015	forward 3	TM
55	331106.6	857	943	forward 2	SP

TABLE 6-continued

SEQ ID NO:	Template ID	Start	Stop	Frame	Domain
58	474630.29	2277	2369	forward 3	SP
58	474630.29	156	236	forward 3	SP
59	1256295.18	1242	1328	forward 3	TM
64	1399366.20	210	299	forward 3	SP
64	1399366.20	3746	3826	forward 2	SP
67	1137894.1	1459	1536	forward 1	SP
75	224855.4	2804	2890	forward 2	SP
75	224855.4	3845	3922	forward 2	TM
79	410785.1	1057	1143	forward 1	SP
79	410785.1	1385	1471	forward 2	TM
79	410785.1	2099	2185	forward 2	TM
79	410785.1	4757	4840	forward 2	TM
79	410785.1	4710	4787	forward 3	TM
83	365070.3	43	135	forward 1	SP
87	2733282CD1	900	926		TM
99	211881.1	651	731	forward 3	TM

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 102

<210> SEQ ID NO 1
<211> LENGTH: 1645
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1382961.3

<400> SEQUENCE: 1

cctttccaat ttacccgagc accttctctt cactcagcca actgctcgct cgctcacctc 60

cctcctctgc accatgacta cctgcagccg ccagttcacc tcctccagct ccatgaaggg 120

ctcctgcggc atcgggggcg gcatcggggg cggctccagc cgcatctcct ccgtcctggc 180

cggagggtcc tgccgcgccc ccagcaccta cgggggcggc ctgtctgtct catcctcccg 240

cttctcctct gggggagcct atgggttggg gggcggctat ggcggtggct tcagcagcag 300

aaccagcagc tttggtagtg gctttggggg aggatatggt ggtggccttg gtgctggctt 360

gggtggtggc tttggtggtg gctttgctgg tggtgatggg cttctggtgg gcagtgagaa 420

-continued

ggtgaccatg cagaacctca acgaccgcct ggcctcctac ctggacaagg tgcgtgctct 480

ggaggaggcc aacgccgacc tggaagtgaa gatccgtgac tggtaccaga ggcagcggcc 540

tgctgagatc aaagactaca gtccctactt caagaccatt gaggacctga ggaacaagat 600

tctcacagcc acagtggaca atgccaatgt ccttctgcag attgacaatg cccgtctggc 660

cgcggatgac ttccgcacca agtatgagac agagttgaac ctgcgcatga gtgtggaagc 720

cgacatcaat ggcctgcgca gggtgctgga cgaactgacc ctggccagag ctgacctgga 780

gatgcagatt gagagcctga aggaggagct ggcctacctg aagaagaacc acgaggagga 840

gatgaatgcc ctgagaggcc aggtgggtgg agatgtcaat gtggagatgg acgctgcacc 900

tggcgtggac ctgagccgca ttctgaacga gatgcgtgac cagtatgaga agatggcaga 960

gaagaaccgc aaggatgccg aggaatggtt cttcaccaag acagaggagc tgaaccgcga 1020

ggtggccacc aacagcgagc tggtgcagag cggcaagagc gagatctcgg agctccggcg 1080

caccatgcag aacctggaga ttgagctgca gtcccagctc agcatgaaag catccctgga 1140

gaacagcctg gaggagacca aaggtcgcta ctgcatgcag ctggcccaga tccaggagat 1200

gattggcagc gtggaggagc agctggccca gctccgctgc gagatggagc agcagaacca 1260

ggagtacaag atcctgctgg acgtgaagac gcggctggag caggagatcg ccacctaccg 1320

ccgcctgctg gagggcgagg acgcccacct ctcctcctcc cagttctcct ctggatcgca 1380

gtcatccaga gatgtgacct cctccagccg ccaaatccgc accaaggtca tggatgtgca 1440

cgatggcaag gtggtgtcca cccacgagca ggtccttcgc accaagaact gaggctgccc 1500

agccccgctc aggcctagga ggccccccgt gtggacacag atcccactgg aagatccccc 1560

ctcctgccca agcacttcac agctggaccc tgcttcaccc tcacccccctc ctggcaatca 1620

atacagcttc attatctgag ttgca 1645

<210> SEQ ID NO 2
<211> LENGTH: 1051
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1382961.5

<400> SEQUENCE: 2

agcaaatgcc ttctccctgc atgctccctg caaggcctcc tcgctatctc cacacacctg 60

actcatccca ttttacagga gcagttgatc ccaggaagag cattggagcc tccagcaggg 120

gctgttgggg cctgtctgag gagataggat gcgtcaggca gccccagaca cgatcacatt 180

cctctcaaca tgcctgccgg gccgggtatc catcccctgc agcagcaggc ttcctctacg 240

tggatgttaa aggcccattc agttcatgga gagctagcag gtgcgtgctc tggaggaggc 300

caacgccgac ctggaagtga agatccgtga ctggtaccag aggcagcggc ctgctgagat 360

caaagactac agtccctact tcaagaccat tgaggacctg aggaacaaga ttctcacagc 420

cacagtggac aatgccaatg tccttctgca gattgacaat gcccgtctgg ccgcggatga 480

cttccgcacc aagtatgaga cagagttgaa cctgcgcatg agtgtggaag ccgaccatca 540

atggcctgcg cagggtgctg gacgaactga cctggccaga gctgacctgg agatgcagat 600

tgagagcctg aaggaggagc tggcctacct gaagaagaac cacgaggagg agatgaatgc 660

cctgagaggc caggtgggtg gagatgtcaa tgtggagatg gacgctgcac ctggcgtgga 720

cctgagccgc attctgaacg agatgcgtga ccagtatgag aagatggcag agaagaaccg 780

-continued

caaggatgcc gaggaatggt tcttcaccaa gacagaggag ctgaaccgcg aggtggccac 840

caacagcgag ctggtgcaga gcggcaagag cgagatctcg gagctccggc gcaccatgca 900

gaacctggag atgattggca gcgtggagga gcagctggcc cagctccgct gcgagatgga 960

gcagcagaac caggagtaca agatcctgct ggacgtgaag acgcggctgg agcaggagat 1020

cgccacctac cgccgcctgc tggagggcga g 1051

<210> SEQ ID NO 3
<211> LENGTH: 1930
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2852561CB1

<400> SEQUENCE: 3

ccttaagggg cgggccgggg cggggctccg ctgcccttc ccagaggccg cgcctgctgc 60

tgagcagatg cagtagccga aactgcgcgg aggcacagag gccggggaga gcgttctggg 120

tccgagggtc caggtagggg ttgagccacc atctgaccgc aagctgcgtc gtgtcgccgg 180

ttctgcaggc accatgagcc aggacaccga ggtggatatg aaggaggtgg agctgaatga 240

gttagagccc gagaagcagc cgatgaacgc ggcgtctggg gcggccatgt ccctggcggg 300

agccgagaag aatggtctgg tgaagatcaa ggtggcggaa gacgaggcgg aggcggcagc 360

cgcggctaag ttcacgggcc tgtccaagga ggagctgctg aaggtggcag gcagccccgg 420

ctgggtacgc acccgctggg cactgctgct gctcttctgg ctcggctggc tcggcatgct 480

tgctggtgcc gtggtcataa tcgtgcgagc gccgcgttgt cgcgagctac cggcgcagaa 540

gtggtggcac acgggcgccc tctaccgcat cggcgacctt caggccttcc agggccacgg 600

cgcgggcaac ctggcgggtc tgaaggggcg tctcgattac ctgagctctc tgaaggtgaa 660

gggccttgtg ctgggtccaa ttcacaagaa ccagaaggat gatgtcgctc agactgactt 720

gctgcagatc gaccccaatt ttggctccaa ggaagatttt gacagtctct tgcaatcggc 780

taaaaaaaag agcatccgtg tcattctgga ccttactccc aactaccggg gtgagaactc 840

gtggttctcc actcaggttg acactgtggc caccaaggtg aaggatgctc tggagttttg 900

gctgcaagct ggcgtggatg ggttccaggt tcgggacata gagaatctga aggatgcatc 960

ctcattcttg gctgagtggc aaaatatcac caagggcttc agtgaagaca ggctcttgat 1020

tgcggggact aactcctccg accttcagca gatcctgagc ctactcgaat ccaacaaaga 1080

cttgctgttg actagctcat acctgtctga ttctggttct actggggagc atacaaaatc 1140

cctagtcaca cagtatttga atgccactgg caatcgctgg tgcagctgga gtttgtctca 1200

ggcaaggctc ctgacttcct tcttgccggc tcaacttctc cgactctacc agctgatgct 1260

cttcaccctg ccagggaccc ctgttttcag ctacggggat gagattggcc tggatgcagc 1320

tgcccttcct ggacagccta tggaggctcc agtcatgctg tgggatgagt ccagcttccc 1380

tgacatccca ggggctgtaa gtgccaacat gactgtgaag ggccagagtg aagaccctgg 1440

ctccctcctt tccttgttcc ggcggctgag tgaccagcgg agtaaggagc gctccctact 1500

gcatggggac ttccacgcgt tctccgctgg gcctggactc ttctcctata tccgccactg 1560

ggaccagaat gagcgttttc tggtagtgct taactttggg gatgtgggcc tctcggctgg 1620

actgcaggcc tccgacctgc ctgccagcgc cagcctgcca gccaaggctg acctcctgct 1680

cagcacccag ccaggccgtg aggagggctc ccctcttgag ctggaacgcc tgaaactgga 1740

-continued

gcctcacgaa gggctgctgc tccgcttccc ctacgcggcc tgacttcagc ctgacatgga 1800

cccactaccc ttctcctttc cttcccaggc cctttggctt ctgatttttc tctttttaa 1860

aaacaaacaa acaaactgtt gcagattatg agtgaacccc caaataggtg tttctgcctt 1920

caaataagaa 1930

<210> SEQ ID NO 4
<211> LENGTH: 529
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2852561CD1

<400> SEQUENCE: 4

Met Ser Gln Asp Thr Glu Val Asp Met Lys Glu Val Glu Leu Asn
1 5 10 15

Glu Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala
20 25 30

Ala Met Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys Ile
35 40 45

Lys Val Ala Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Lys Phe
50 55 60

Thr Gly Leu Ser Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro
65 70 75

Gly Trp Val Arg Thr Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu
80 85 90

Gly Trp Leu Gly Met Leu Ala Gly Ala Val Val Ile Ile Val Arg
95 100 105

Ala Pro Arg Cys Arg Glu Leu Pro Ala Gln Lys Trp Trp His Thr
110 115 120

Gly Ala Leu Tyr Arg Ile Gly Asp Leu Gln Ala Phe Gln Gly His
125 130 135

Gly Ala Gly Asn Leu Ala Gly Leu Lys Gly Arg Leu Asp Tyr Leu
140 145 150

Ser Ser Leu Lys Val Lys Gly Leu Val Leu Gly Pro Ile His Lys
155 160 165

Asn Gln Lys Asp Asp Val Ala Gln Thr Asp Leu Leu Gln Ile Asp
170 175 180

Pro Asn Phe Gly Ser Lys Glu Asp Phe Asp Ser Leu Leu Gln Ser
185 190 195

Ala Lys Lys Lys Ser Ile Arg Val Ile Leu Asp Leu Thr Pro Asn
200 205 210

Tyr Arg Gly Glu Asn Ser Trp Phe Ser Thr Gln Val Asp Thr Val
215 220 225

Ala Thr Lys Val Lys Asp Ala Leu Glu Phe Trp Leu Gln Ala Gly
230 235 240

Val Asp Gly Phe Gln Val Arg Asp Ile Glu Asn Leu Lys Asp Ala
245 250 255

Ser Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe Ser
260 265 270

Glu Asp Arg Leu Leu Ile Ala Gly Thr Asn Ser Ser Asp Leu Gln
275 280 285

Gln Ile Leu Ser Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu Thr
290 295 300

-continued

Ser Ser Tyr Leu Ser Asp Ser Gly Ser Thr Gly Glu His Thr Lys
305 310 315

Ser Leu Val Thr Gln Tyr Leu Asn Ala Thr Gly Asn Arg Trp Cys
320 325 330

Ser Trp Ser Leu Ser Gln Ala Arg Leu Leu Thr Ser Phe Leu Pro
335 340 345

Ala Gln Leu Leu Arg Leu Tyr Gln Leu Met Leu Phe Thr Leu Pro
350 355 360

Gly Thr Pro Val Phe Ser Tyr Gly Asp Glu Ile Gly Leu Asp Ala
365 370 375

Ala Ala Leu Pro Gly Gln Pro Met Glu Ala Pro Val Met Leu Trp
380 385 390

Asp Glu Ser Ser Phe Pro Asp Ile Pro Gly Ala Val Ser Ala Asn
395 400 405

Met Thr Val Lys Gly Gln Ser Glu Asp Pro Gly Ser Leu Leu Ser
410 415 420

Leu Phe Arg Arg Leu Ser Asp Gln Arg Ser Lys Glu Arg Ser Leu
425 430 435

Leu His Gly Asp Phe His Ala Phe Ser Ala Gly Pro Gly Leu Phe
440 445 450

Ser Tyr Ile Arg His Trp Asp Gln Asn Glu Arg Phe Leu Val Val
455 460 465

Leu Asn Phe Gly Asp Val Gly Leu Ser Ala Gly Leu Gln Ala Ser
470 475 480

Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys Ala Asp Leu Leu
485 490 495

Leu Ser Thr Gln Pro Gly Arg Glu Glu Gly Ser Pro Leu Glu Leu
500 505 510

Glu Arg Leu Lys Leu Glu Pro His Glu Gly Leu Leu Leu Arg Phe
515 520 525

Pro Tyr Ala Ala

<210> SEQ ID NO 5
<211> LENGTH: 664
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 335942.2

<400> SEQUENCE: 5

ccaaaatgga gggaataata cctaagcctt cctgccgcaa cagtttttta tgctaatcag 60

ggaggtcatt ttggtaaaat acttcttgaa gccgagcctc aagatgaagg caaagcacga 120

aatgttattt tttaattatt atttatatat gtatttataa atatatttaa gataattata 180

atatactata tttatgggaa ccccttcatc ctctgagtgt gaccaggcat cctccacaat 240

agcagacagt gttttctggg ataagtaagt ttgatttcat taatacaggg cattttggtc 300

caagttgtgc ttatcccata gccaggaaac tctgcattct agtacttggg agacctgtaa 360

tcatataata aatgtacatt aattaccttg agccagtaat tggtccgatc tttgactctt 420

ttgccattaa acttacctgg gcattcttgt ttcaattcca cctgcaatca agtcctacaa 480

gctaaaatta gatgaactca actttgacaa ccatgagacc actgttatca aaactttctt 540

ttctggaatg taatcaatgt ttcttctagg ttctaaaaat tgtgatcaga ccataatgtt 600

acattattat caacaatagt gattgataga gtgttatcag tcataactaa ataaagcttg 660

-continued

caac 664

<210> SEQ ID NO 6
<211> LENGTH: 1667
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2483854CB1
<400> SEQUENCE: 6

gtcatttcat tggcgtttga gtcagcaaag aagtcaagat ggccaaagtt ccagacatgt 60

ttgaagacct gaagaactgt tacagtgaaa atgaagaaga cagttcctcc attgatcatc 120

tgtctctgaa tcagaaatcc ttctatcatg taagctatgg cccactccat gaaggctgca 180

tggatcaatc tgtgtctctg agtatctctg aaacctctaa aacatccaag cttaccttca 240

aggagagcat ggtggtagta gcaaccaacg ggaaggttct gaagaagaga cggttgagtt 300

taagccaatc catcactgat gatgacctgg aggccatcgc caatgactca gaggaagaaa 360

tcatcaagcc taggtcagca ccttttagct tcctgagcaa tgtgaaatac aactttatga 420

ggatcatcaa atacgaattc atcctgaatg acgccctcaa tcaaagtata attcgagcca 480

atgatcagta cctcacggct gctgcattac ataatctgga tgaagcagtg aaatttgaca 540

tgggtgctta taagtcatca aaggatgatg ctaaaattac cgtgattcta agaatctcaa 600

aaactcaatt gtatgtgact gcccaagatg aagaccaacc agtgctgctg aaggagatgc 660

ctgagatacc caaaaccatc acaggtagtg agaccaacct cctcttcttc tgggaaactc 720

acggcactaa gaactatttc acatcagttg cccatccaaa cttgtttatt gccacaaagc 780

aagactactg ggtgtgcttg gcaggggggc caccctctat cactgacttt cagatactgg 840

aaaaccaggc gtaggtctgg agtctcactt gtctcacttg tgcagtgttg acagttcata 900

tgtaccatgt acatgaagaa gctaaatcct ttactgttag tcatttgctg agcatgtact 960

gagccttgta attctaaatg aatgtttaca ctctttgtaa gagtggaacc aacactaaca 1020

tataatgttg ttatttaaag aacaccctat attttgcata gtaccaatca ttttaattat 1080

tattcttcat aacaatttta ggaggaccag agctactgac tatggctacc aaaaagactc 1140

tacccatatt acagatgggc aaattaaggc ataagaaaac taagaaatat gcacaatagc 1200

agttgaaaca agaagccaca gacctaggat ttcatgattt catttcaact gtttgccttc 1260

tacttttaag ttgctgatga actcttaatc aaatagcata agtttctggg acctcagttt 1320

tatcattttc aaaatggagg gaataatacc taagccttcc tgccgcaaca gtttttttatg 1380

ctaatcaggg agggcatttt ggtaaaatac ttcttgaagc cgagcctcaa gatgaaggca 1440

aagcacgaaa tgttattttt taattattat ttatatatgt atttataaat atatttcaga 1500

taattataat atacctatat tgatgggaac ccttcatcct ctgaggtgtg accagggcat 1560

cctccacaat tagccgacag tggtttcctg gggataggta aggtttggtt tccattaata 1620

ccagggcatt ttgggtccaa gttgtgctta atcccataag ccaggga 1667

<210> SEQ ID NO 7
<211> LENGTH: 271
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2483854CD1

-continued

<400> SEQUENCE: 7

Met Ala Lys Val Pro Asp Met Phe Glu Asp Leu Lys Asn Cys Tyr
1 5 10 15

Ser Glu Asn Glu Glu Asp Ser Ser Ser Ile Asp His Leu Ser Leu
20 25 30

Asn Gln Lys Ser Phe Tyr His Val Ser Tyr Gly Pro Leu His Glu
35 40 45

Gly Cys Met Asp Gln Ser Val Ser Leu Ser Ile Ser Glu Thr Ser
50 55 60

Lys Thr Ser Lys Leu Thr Phe Lys Glu Ser Met Val Val Val Ala
65 70 75

Thr Asn Gly Lys Val Leu Lys Lys Arg Arg Leu Ser Leu Ser Gln
80 85 90

Ser Ile Thr Asp Asp Asp Leu Glu Ala Ile Ala Asn Asp Ser Glu
95 100 105

Glu Glu Ile Ile Lys Pro Arg Ser Ala Pro Phe Ser Phe Leu Ser
110 115 120

Asn Val Lys Tyr Asn Phe Met Arg Ile Ile Lys Tyr Glu Phe Ile
125 130 135

Leu Asn Asp Ala Leu Asn Gln Ser Ile Ile Arg Ala Asn Asp Gln
140 145 150

Tyr Leu Thr Ala Ala Ala Leu His Asn Leu Asp Glu Ala Val Lys
155 160 165

Phe Asp Met Gly Ala Tyr Lys Ser Ser Lys Asp Asp Ala Lys Ile
170 175 180

Thr Val Ile Leu Arg Ile Ser Lys Thr Gln Leu Tyr Val Thr Ala
185 190 195

Gln Asp Glu Asp Gln Pro Val Leu Leu Lys Glu Met Pro Glu Ile
200 205 210

Pro Lys Thr Ile Thr Gly Ser Glu Thr Asn Leu Leu Phe Phe Trp
215 220 225

Glu Thr His Gly Thr Lys Asn Tyr Phe Thr Ser Val Ala His Pro
230 235 240

Asn Leu Phe Ile Ala Thr Lys Gln Asp Tyr Trp Val Cys Leu Ala
245 250 255

Gly Gly Pro Pro Ser Ile Thr Asp Phe Gln Ile Leu Glu Asn Gln
260 265 270

Ala

<210> SEQ ID NO 8
<211> LENGTH: 1511
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1454852CB1

<400> SEQUENCE: 8

cccctctcct ccccagccct tctcctgtgt gcctgcctcc tgctgccctc accatgacca 60

cctccatccg ccagttcacc tcctccagct ccatcaaggg ctcctccggc ctgggggggcg 120

gctcgtcccg cacctcctgc cggctgtctg gcggcctggg tgccggctcc tgcaggctgg 180

gatctgctgg cggcctgggc agcaccctcg ggggtagcag ctactccagc tgctacagct 240

ttggctctgg tggtggctat ggcagcagct ttgggggtgt tgatgggctg ctggctggag 300

-continued

gtgagaaggc caccatgcag aacctcaatg accgcctggc ctcctacctg gacaaggtgc 360

gtgccctgga ggaggccaac actgagctgg aggtgaagat ccgtgactgg taccagaggc 420

aggccccggg gcccgcccgt gactacagcc agtactacag gacaattgag gagctgcaga 480

acaagatcct cacagccacc gtggacaatg ccaacatcct gctacagatt gacaatgccc 540

gtctggctgc tgatgacttc cgcaccaagt ttgagacaga gcaggccctg cgcctgagtg 600

tggaggccga catcaatggc ctgcgcaggg tgctggatga gctgaccctg gccagagccg 660

acctggagat gcagattgag aacctcaagg aggagctggc ctacctgaag aagaaccacg 720

aggaggagat gaacgccctg cgaggccagg tgggtggtga gatcaatgtg gagatggacg 780

ctgccccagg cgtggacctg agccgcatcc tcaacgagat gcgtgaccag tatgagaaga 840

tggcagagaa gaaccgcaag gatgccgagg attggttctt cagcaagaca gaggaactga 900

accgcgaggt ggccaccaac agtgagctgg tgcagagtgg caagagtgag atctcggagc 960

tccggcgcac catgcaggcc ttggagatag agctgcagtc ccagctcagc atgaaagcat 1020

ccctggaggg caacctggcg gagacagaga accgctactg cgtgcagctg tcccagatcc 1080

aggggctgat tggcagcgtg gaggagcagc tggcccagct tcgctgcgag atggagcagc 1140

agaaccagga atacaaaatc ctgctggatg tgaagacgcg gctggagcag gagattgcca 1200

cctaccgccg cctgctggag ggagaggatg cccacctgac tcagtacaag aaagaaccgg 1260

tgaccacccg tcaggtgcgt accattgtgg aagaggtcca ggatggcaag gtcatctcct 1320

cccgcgagca ggtccaccag accacccgct gaggactcag ctaccccggc cggccaccca 1380

ggaggcaggg aggcagccgc cccatctgcc ccacagtctc cggcctctcc agcctcagcc 1440

ccctgcttca gtcccttccc catgcttcct tgcctgatga caataaagct tgttgactca 1500

gctaaaaaaa a 1511

<210> SEQ ID NO 9
<211> LENGTH: 432
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1454852CD1

<400> SEQUENCE: 9

Met Thr Thr Ser Ile Arg Gln Phe Thr Ser Ser Ser Ser Ile Lys
1 5 10 15

Gly Ser Ser Gly Leu Gly Gly Gly Ser Ser Arg Thr Ser Cys Arg
20 25 30

Leu Ser Gly Gly Leu Gly Ala Gly Ser Cys Arg Leu Gly Ser Ala
35 40 45

Gly Gly Leu Gly Ser Thr Leu Gly Gly Ser Ser Tyr Ser Ser Cys
50 55 60

Tyr Ser Phe Gly Ser Gly Gly Gly Tyr Gly Ser Ser Phe Gly Gly
65 70 75

Val Asp Gly Leu Leu Ala Gly Gly Glu Lys Ala Thr Met Gln Asn
80 85 90

Leu Asn Asp Arg Leu Ala Ser Tyr Leu Asp Lys Val Arg Ala Leu
95 100 105

Glu Glu Ala Asn Thr Glu Leu Glu Val Lys Ile Arg Asp Trp Tyr
110 115 120

Gln Arg Gln Ala Pro Gly Pro Ala Arg Asp Tyr Ser Gln Tyr Tyr
125 130 135

-continued

```
Arg Thr Ile Glu Glu Leu Gln Asn Lys Ile Leu Thr Ala Thr Val
                140                 145                 150

Asp Asn Ala Asn Ile Leu Leu Gln Ile Asp Asn Ala Arg Leu Ala
                155                 160                 165

Ala Asp Asp Phe Arg Thr Lys Phe Glu Thr Glu Gln Ala Leu Arg
                170                 175                 180

Leu Ser Val Glu Ala Asp Ile Asn Gly Leu Arg Arg Val Leu Asp
                185                 190                 195

Glu Leu Thr Leu Ala Arg Ala Asp Leu Glu Met Gln Ile Glu Asn
                200                 205                 210

Leu Lys Glu Glu Leu Ala Tyr Leu Lys Lys Asn His Glu Glu Glu
                215                 220                 225

Met Asn Ala Leu Arg Gly Gln Val Gly Gly Glu Ile Asn Val Glu
                230                 235                 240

Met Asp Ala Ala Pro Gly Val Asp Leu Ser Arg Ile Leu Asn Glu
                245                 250                 255

Met Arg Asp Gln Tyr Glu Lys Met Ala Glu Lys Asn Arg Lys Asp
                260                 265                 270

Ala Glu Asp Trp Phe Phe Ser Lys Thr Glu Glu Leu Asn Arg Glu
                275                 280                 285

Val Ala Thr Asn Ser Glu Leu Val Gln Ser Gly Lys Ser Glu Ile
                290                 295                 300

Ser Glu Leu Arg Arg Thr Met Gln Ala Leu Glu Ile Glu Leu Gln
                305                 310                 315

Ser Gln Leu Ser Met Lys Ala Ser Leu Glu Gly Asn Leu Ala Glu
                320                 325                 330

Thr Glu Asn Arg Tyr Cys Val Gln Leu Ser Gln Ile Gln Gly Leu
                335                 340                 345

Ile Gly Ser Val Glu Glu Gln Leu Ala Gln Leu Arg Cys Glu Met
                350                 355                 360

Glu Gln Gln Asn Gln Glu Tyr Lys Ile Leu Leu Asp Val Lys Thr
                365                 370                 375

Arg Leu Glu Gln Glu Ile Ala Thr Tyr Arg Arg Leu Leu Glu Gly
                380                 385                 390

Glu Asp Ala His Leu Thr Gln Tyr Lys Lys Glu Pro Val Thr Thr
                395                 400                 405

Arg Gln Val Arg Thr Ile Val Glu Glu Val Gln Asp Gly Lys Val
                410                 415                 420

Ile Ser Ser Arg Glu Gln Val His Gln Thr Thr Arg
                425                 430


<210> SEQ ID NO 10
<211> LENGTH: 309
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 353005.1
<221> NAME/KEY: unsure
<222> LOCATION: 6, 10, 18, 24-25, 67, 76, 83, 98, 159, 290
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 10

ggtggntggn accatggnac tgtnnatctc cccctcttcc tcttggcctc tgtggacggt     60

gcctttncat ctgctnccac ttnaatcctc tgtctctnga ggaactaggc tccaacacgg    120
```

-continued

ggatccaggt tttcaatcag attgtgaagt cgaggcctna tgacaacatc gtgatctctc 180

cccatgggat tgcgtcggtc ctggggatgc ttcagctggg ggcggacggc aggaccagaa 240

gcagctcgcc atggtgatga gatacggcgt aaatgatatg attgacaatn tgctgtcccc 300

agatcttat 309

<210> SEQ ID NO 11
<211> LENGTH: 176
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 378497.1
<221> NAME/KEY: unsure
<222> LOCATION: 18, 30, 35, 39, 44, 52, 87, 93, 108, 112, 114, 151, 166, 168, 170
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 11

gcccaacgtc atcgggcngc agtgcacccn ctgtncaana ggancactac gnattcccac 60

gctgcaaccg tgcagctgtg gtcggcncct ttntgaagag atgacggngc antnccggct 120

tcccttcccc gcacggtcag gccccagtgt naggtgtgtg agacanantn cattca 176

<210> SEQ ID NO 12
<211> LENGTH: 3544
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 994684.9

<400> SEQUENCE: 12

cagcgtcaaa tttgtctcca ccacctcctc ctcccggaag agcttcaaga gctaagaacc 60

tgctgcaagt cactgccttc caagtgcagc aacccagccc atggagattg cctcttctag 120

gcagttgctc aagccatgtt ttatcctttt ctggatagca tcatcgctga ggtcaaggcc 180

cagtatgagg agattgccaa ccgcagccgg acagaagccg agtcctggta tcagaccaag 240

tatgaggagc tgcagcagac agctggccgg catggcgatg acctccgcaa caccaagcat 300

gagatctctg agatgaaccg gatgatccag aggctgagag ccgagattga caatgtcaag 360

aaacagtgcg ccaatctgca gaacgccatt gcggatgccg agcagcgtgg ggagctggcc 420

ctcaaggatg ccaggaacaa gctggccgag ctggaggagg ccctgcagaa ggccaagcag 480

gacatggccc ggctgctgcg tgagtaccag gagctcatga acaccaagct ggccctggac 540

gtggagatcg ccacttaccg caagctgctg gagggcgagg aatgcagact cagtggagaa 600

ggagttggac cagtcaacat ctgtaagtag ctttgaacag acattaacaa cgacaataat 660

atgggatata tttagtgcca actcagaatt ctgctgtttc tagatccaaa cttttcccat 720

cccagcatat ggttatttat aataatacac ttagtaagtt gtgggtggtg gaggggaagg 780

acagattggg acaggaagca atgtggctta tgtctcatct cttaaagggt aagccatgca 840

tcctatgctt cttggaccct gtcccctgcc ttgtccctag tacctagctc cccccagtac 900

ctagctcctc ccctcagtac ctagctcccc tcagtaccta gctccctgta gtacctagct 960

cccctcagta cctagctcct ctcagtacct agcaccttgc ctcttacact cacccacttt 1020

tttagggacc ttaattaaat gacagttctt ccgggccttg tttgctactc tgtaaagggg 1080

gtccagtaga gtgctccaac accagcagat caaataaatg ggccatgcag gatcagcctg 1140

gcagatggtc tcactgagtc ctccctcctt tccctgcagc tgttgtcaca agcagtgttt 1200

-continued

cctctggata tggcagtggc agtggctatg gcggtggcct cggtggaggt cttggcggcg 1260

gcctcggtgg aggtcttgcc ggaggtagca gtggaagcta ctactccagc agcagtgggg 1320

gtgtcggcct aggtggtggg ctcagtgtgg ggggctctgg cttcagtgca agcagtggcc 1380

gagggctggg ggtgggcttt ggcagtggcg ggggtagcag ctccagcgtc aaatttgtct 1440

ccaccacctc ctcctcccgg aagagcttca agagctaaga acctgctgca agtcactgcc 1500

ttccaagtgc agcaacccag cccatggaga ttgcctcttc taggcagagt cagccttgcg 1560

ggtgcttgtg gagtgggtgg ctatggcagc cggagcctct acaacctggg gggctccaag 1620

aggatatcca tcagcactag tggtggcagc ttcaggaacc ggtttggtgc tggtgctgga 1680

ggcggctatg gctttggagg tggtgccggt agtggatttg gtttcggcgg tggagctggt 1740

ggtggctttg ggctcggtgg cggagctggc tttggaggtg gcttcggtgg ccctggcttt 1800

cctgtctgcc ctcctggagg tatccaagag gtcactgtca accagagtct cctgactccc 1860

ctcaacctgc aaatcgaccc cagcatccag agggtgagga ccgaggagcg cgagcagatc 1920

aagaccctca acaataagtt tgcctccttc atcgacaagg tgcggttcct ggagcagcag 1980

aacaaggttc tggaaacaaa gtggaccctg ctgcaggagc agggcaccaa gactgtgagg 2040

cagaacctgg agccgttgtt cgagcagtac atcaacaacc tcaggaggca gctggacagc 2100

atcgtggggg aacggggccg cctggactca gagctgagaa acatgcagga cctggtggaa 2160

gacttcaaga acaagtatga ggatgaaatc aacaagcgta ccactgctga gaatgagttt 2220

gtgatgctga agaaggatgt agatgctgcc tacatgaaca aggtggagct ggaggccaag 2280

gttgatgcac tgatggatga gattaacttc atgaagatgt tctttgatgc ggagctgtcc 2340

cagatgcaga cgcatgtctc tgacacctca gtggtcctct ccatggacaa caaccgcaac 2400

ctggacctgg atagcatcat cgctgaggtc aaggcccagt atgaggagat tgccaaccgc 2460

agccggaccg aagccgagtc ctggtatcag accaagtatg aggagctgca gcagacagct 2520

ggccggcatg gcgatgacct ccgcaacacc aagcatgaga tctctgagat gaaccggatg 2580

atccagaggc tgagagccga gattgacaat gtcaagaaac agtgcgccaa tctggcagaa 2640

cgccattgcg gatgccgagc agcgtgggga gctggccctc aaggatgcca ggaacaagct 2700

ggccgagctg gaggaggccc tgcagaaggc caagcaggac atgggcccgg ctgctgcgtg 2760

agtaccagga gctcatgaac accaagctgg ccctggacgt ggagatcgcc acttaccgca 2820

agctgctgga gggcgaggaa tgcagactca gtggagaagg agttggacca gtcaacatct 2880

ctgttgtcac aagcagtgtt tcctctggat atggcagtgg cagtggctat ggcggtggcc 2940

tcggtggagg tcttggcggc ggcctcggtg gaggtcttgc cggaggtagc agtggaagct 3000

actactccag cagcagtggg ggtgtcggcc taggtggtgg gctcagtgtg gggggctctg 3060

gcttcagtgc aagcagtggc cgagggctgg gggtgggctt tggcagtggc gggggtagca 3120

gctccagcgt caaatttgtc tccaccacct cctcctcccg gaagagcttc aagagctaag 3180

aacctgctgc aagtcactgc cttccaagtg cagcaaccca gcccatggag attgcctctt 3240

ctaggcagtt gctcaagcca tgttttatcc ttttctggag agtagtctag accaagccaa 3300

ttgcagaacc acattctttg gttcccagga gagccccatt cccagcccct ggtctcccgt 3360

gccgcagttc tatattctgc ttcaaatcag ccttcaggtt tcccacagca tggcccctgc 3420

tgacacgaga acccaaagtt ttcccaaatc taaatcatca aaacagaatc cccaccccaa 3480

tcccaaattt tgttttggtt ctaactacct ccagaatgtg ttcaataaaa tgcttttata 3540

-continued

ttat 3544

<210> SEQ ID NO 13
<211> LENGTH: 3000
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 995610.1

<400> SEQUENCE: 13

ggagtttatt cataacgcgc tctccaagta tacgtggcaa tgcgttgctg ggttatttta 60

atcattctag gcatcgtttt cctccttatg cctctatcat tcctccctat ctacactaac 120

atcccacgct ctgaacgcgc gcccattaat acccttcttt cctccactct ccctgggact 180

cttgatcaaa gcgcggccct ttccccagcc ttagcgaggc gccctgcagc ctggtacgcg 240

cgtggcgtgg cggtgggcgc gcagtgcgtt ctcggtgtgg agggcagctg ttccgcctgc 300

gatgatttat actcacagga caaggatgcg gtttgtcaaa cagtactgct acggaggagc 360

agcagagaaa gggagagggt ttgagaggga gcaaaagaaa atggtaggcg cgcgtagtta 420

attcatgcgg ctctcttact ctgtttacat cctagagcta gagtgctcgg ctgcccggct 480

gagtctcctc cccaccttcc ccaccctccc caccctcccc ataagcgccc tcccgggttc 540

ccaaagcaga gggcgtgggg gaaaagaaaa aagatcctct ctcgctaatc tccgcccacc 600

ggcccctttat aatgcgaggg tctggacggc tgaggacccc cgagctgtgc tgctcgcggc 660

cgccaccgcc gggccccggc cgtccctggc tcccctcctg cctcgagaag ggcagggctt 720

ctcagaggct tggcgggaaa aagaacggag ggagggatcg cgctgagtat aaaagccggt 780

tttcggggct ttatctaact cgctgtagta attccagcga gaggcagagg gagcgagcgg 840

gcggccggct agggtggaag agccgggcga gcagagctgc gctgcgggcg tcctgggaag 900

ggagatccgg agcgaatagg gggcttcgcc tctggcccag ccctcccgct gatcccccag 960

ccagcggtcc gcaacccttg ccgcatccac gaaactttgc ccatagcagc gggcgggcac 1020

tttgcactgg aacttacaac acccgagcaa ggacgcgact ctcccgacgc ggggaggcta 1080

ttctgcccat ttggggacac ttccccgccg ctgccaggac ccgcttctct gaaaggctct 1140

ccttgcagct gcttagacgc tggatttttt tcgggtagtg gaaaaccagc agcctcccgc 1200

gacgatgccc ctcaacgtta gcttcaccaa caggaactat gacctcgact acgactcggt 1260

gcagccgtat ttctactgcg acgaggagga gaacttctac cagcagcagc agcagagcga 1320

ggctgcagcc cccggcgccc agcgaggata tctggaagaa attcgagctg ctgcccaccc 1380

cgcccctgtc ccctagccgc cgctccgggc tctgctcgcc ctcctacgtt gcggtcacac 1440

ccttctccct tcggggagac aacgacggcg gtggcgggag cttctccacg gccgaccagc 1500

tggagatggt gaccgagctg ctgggaggag acatggtgaa ccagagtttc atctgcgacc 1560

cggacgacga gaccttcatc aaaaacatca tcatccagga ctgtatgtgg agcggcttct 1620

cggccgccgc caagctcgtc tcagagaagc tggcctccta ccaggctgcg cgcaaagaca 1680

gcggcagccc gaaccccgcc cgcggccaca gcgtctgctc cacctccagc ttgtacctgc 1740

aggatctgag cgccgccgcc tcagagtgca tcgacccctc ggtggtcttc ccctaccctc 1800

tcaacgacag cagctcgccc aagtcctgcg cctcgcaaga ctccagcgcc ttctctccgt 1860

cctcggattc tctgctctcc tcgacggagt cctccccgca gggcagcccc gagcccctgg 1920

tgctccatga ggagacaccg cccaccacca gcagcgactc tgaggaggaa caagaagatg 1980

-continued

aggaagaaat cgatgttgtt tctgtggaaa agaggcaggc tcctggcaaa aggtcagagt 2040

ctggatcacc ttctgctgga ggccacagca aacctcctca cagcccactg gtcctcaaga 2100

ggtgccacgt ctccacacat cagcacaact acgcagcgcc tccctccact cggaaggact 2160

atcctgctgc caagagggtc aagttggaca gtgtcagagt cctgagacag atcagcaaca 2220

accgaaaatg caccagcccc aggtcctcgg acaccgagga gaatgtcaag aggcgaacac 2280

acaacgtctt ggagcgccag aggaggaacg agctaaaacg gagctttttt gccctgcgtg 2340

accagatccc ggagttggaa aacaatgaaa aggcccccaa ggtagttatc cttaaaaaag 2400

ccacagcata catcctgtcc gtccaagcag aggagcaaaa gctcatttct gaagaggact 2460

tgttgcggaa acgacgagaa cagttgaaac acaaacttga acagctacgg aactcttgtg 2520

cgtaaggaaa agtaaggaaa acgattcctt ctaacagaaa tgtcctgagc aatcacctat 2580

gaacttgttt caaatgcatg atcaaatgca acctcacaac cttggctgag tcttgagact 2640

gaaagattta gccataatgt aaactgcctc aaattggact ttgggcataa aagaactttt 2700

ttatgcttac catcttttt ttttctttaa cagatttgta tttaagaatt gtttttaaaa 2760

aattttaaga tttacacaat gtttctctgt aaatattgcc attaaatgta aataacttta 2820

ataaaacgtt tatagcagtt acacagaatt tcaatcctag tatatagtac ctagtattat 2880

aggtactata aaccctaatt ttttttattt aagtacattt tgctttttaa agttgatttt 2940

tttctattgt ttttagaaaa aataaaataa ctggcaaata tatcattgag ccaaaaaaaa 3000

<210> SEQ ID NO 14
<211> LENGTH: 427
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 417119.1

<400> SEQUENCE: 14

aaaacaaaga aggctggaaa ccaaagcaat catctcttta gtggaaacta ttcttaaaga 60

agatcttgat ggctactgac atttgcaact ccctcactct ttctcagggg cctttcactt 120

acattgtcac cagaggttcg taacctccct gtgggctagt gttatgacca tcaccatttt 180

acctaagtag ctctgttgct cggccacagt gagcagtaat agacctgaag ctggaaccca 240

tgtctaatag tgtcaggtcc agtgttctta gccaccccac tcccagcttc atccctactg 300

gtgttgtcat cagactttga ccgtatatgc tcaggtgtcc tccaagaaat caaattttgc 360

cacctcgcct tcacgaggcc tgcccttctg gatttatacc taacaacatg tgctccacat 420

ttcagaa 427

<210> SEQ ID NO 15
<211> LENGTH: 4108
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3615080CB1

<400> SEQUENCE: 15

tgccagattc ctgagacccg cctgcggtgg ggctacaccc agccagggag tctccagagg 60

tgaggctgtt gtttaaaaac ctggagccgg gaggggagac ccccacattc aagaggagct 120

ttcaggcgat ctggagaaag aacggcagaa cacacagcaa ggaaaggtcc tttctgggga 180

tcaccccatt ggctgaagat gagaccattc ttcctcttgt gttttgccct gcctggcctc 240

-continued

ctgcatgccc aacaagcctg ctcccgtggg gcctgctatc cacctgttgg ggacctgctt 300

gttgggagga cccggtttct ccgagcttca tctacctgtg gactgaccaa gcctgagacc 360

tactgcaccc agtatggcga gtggcagatg aaatgctgca agtgtgactc caggcagcct 420

cacaactact acagtcaccg agtagagaat gtggcttcat cctccggccc catgcgctgg 480

tggcagtcac agaatgatgt gaaccctgtc tctctgcagc tggacctgga caggagattc 540

cagcttcaag aagtcatgat ggagttccag gggcccatgc ccgccggcat gctgattgag 600

cgctcctcag acttcggtaa gacctggcga gtgtaccagt acctggctgc cgactgcacc 660

tccaccttcc ctcgggtccg ccagggtcgg cctcagagct ggcaggatgt tcggtgccag 720

tccctgcctc agaggcctga tgcacgccta aatgggggga aggtccaact taaccttatg 780

gatttagtgt ctgggattcc agcaactcaa agtcaaaaaa ttcaagaggt gggggagatc 840

acaaacttga gagtcaattt caccaggctg gcccctgtgc cccaaagggg ctaccaccct 900

cccagcgcct actatgctgt gtcccagctc cgtctgcagg ggagctgctt ctgtcacggc 960

catgctgatc gctgcgcacc caagcctggg gcctctgcag gcccctccac cgctgtgcag 1020

gtccacgatg tctgtgtctg ccagcacaac actgccggcc caaattgtga gcgctgtgca 1080

cccttctaca acaaccggcc ctggagaccg gcggagggcc aggacgccca tgaatgccaa 1140

aggtgcgact gcaatgggca ctcagagaca tgtcactttg accccgctgt gtttgccgcc 1200

agccaggggg catatggagg tgtgtgtgac aattgccggg accacaccga aggcaagaac 1260

tgtgagcggt gtcagctgca ctatttccgg aaccggcgcc cgggagcttc cattcaggag 1320

acctgcatct cctgcgagtg tgatccggat ggggcagtgc caggggctcc ctgtgaccca 1380

gtgaccgggc agtgtgtgtg caaggagcat gtgcagggag agcgctgtga cctatgcaag 1440

ccgggcttca ctggactcac ctacgccaac ccgcagggct gccaccgctg tgactgcaac 1500

atcctggggt cccggaggga catgccgtgt gacgaggaga gtgggcgctg cctttgtctg 1560

cccaacgtgg tgggtcccaa atgtgaccag tgtgctccct accactggaa gctggccagt 1620

ggccagggct gtgaaccgtg tgcctgcgac ccgcacaact ccctcagccc acagtgcaac 1680

cagttcacag ggcagtgccc ctgtcgggaa ggctttggtg gcctgatgtg cagcgctgca 1740

gccatccgcc agtgtccaga ccggacctat ggagacgtgg ccacaggatg ccgagcctgt 1800

gactgtgatt tccggggaac agagggcccg ggctgcgaca aggcatcagg ccgctgcctc 1860

tgccgccctg gcttgaccgg gccccgctgt gaccagtgcc agcgaggcta ctgcaatcgc 1920

tacccggtgt gcgtggcctg ccacccttgc ttccagacct atgatgcgga cctccgggag 1980

caggccctgc gctttggtag actccgcaat gccaccgcca gcctgtggtc agggcctggg 2040

ctggaggacc gtggcctggc ctcccggatc ctagatgcaa agagtaagat tgagcagatc 2100

cgagcagttc tcagcagccc cgcagtcaca gagcaggagg tggctcaggt ggccagtgcc 2160

atcctctccc tcaggcgaac tctccagggc ctgcagctgg atctgccccc ggaggaggag 2220

acgttgtccc ttccgagaga cctggagagt cttgacagaa gcttcaatgg tctccttact 2280

atgtatcaga ggaagaggga gcagtttgaa aaaataagca gtgctgatcc ttcaggagcc 2340

ttccggatgc tgagcacagc ctacgagcag tcagcccagg ctgctcagca ggtctccgac 2400

agctcgcgcc ttttggacca gctcagggac agccggagag aggcagagag gctggtgcgg 2460

caggcgggag gaggaggagg caccggcagc cccaagcttg tggccctgag gctggagatg 2520

tcttcgttgc ctgacctgac acccaccttc aacaagctct gtggcaactc caggcagatg 2580

-continued

gcttgcaccc caatatcatg ccctggtgag ctatgtcccc aagacaatgg cacagcctgt 2640

ggctcccgct gcaggggtgt ccttcccagg gccggtgggg ccttcttgat ggcggggcag 2700

gtggctgagc agctgcgggg cttcaatgcc cagctccagc ggaccaggca gatgattagg 2760

gcagccgagg aatctgcctc acagattcaa tccagtgccc agcgcttgga gacccaggtg 2820

agcgccagcc gctcccagat ggaggaagat gtcagacgca cacggctcct aatccagcag 2880

gtccgggact tcctaacaga ccccgacact gatgcagcca ctatccagga ggtcagcgag 2940

gccgtgctgg ccctgtggct gcccacagac tcagatactg ttctgcagaa gatgaatgag 3000

atccaggcca ttgcagccag gctccccaac gtggacttgg tgctgtccca gaccaagcag 3060

gacattgcgc gtgcccgccg gttgcaggct gaggctgagg aagccaggag ccgagcccat 3120

gcagtggagg gccaggtgga agatgtggtt gggaacctgc ggcaggggac agtggcactg 3180

caggaagctc aggacaccat gcaaggcacc agccgctccc ttcggcttat ccaggacagg 3240

gttgctgagg ttcagcaggt actgcggcca gcagaaaagc tggtgacaag catgaccaag 3300

cagctgggtg acttctggac acggatggag gagctccgcc accaagcccg gcagcagggg 3360

gcagaggcag tccaggccca gcagcttgcg gaaggtgcca gcgagcaggc attgagtgcc 3420

caagagggat ttgagagaat aaaacaaaag tatgctgagt tgaaggaccg gttgggtcag 3480

agttccatgc tgggtgagca gggtgcccgg atccagagtg tgaagacaga ggcagaggag 3540

ctgtttgggg agaccatgga gatgatggac aggatgaaag acatggagtt ggagctgctg 3600

cggggcagcc aggccatcat gctgcgctca gcggacctga caggactgga gaagcgtgtg 3660

gagcagatcc gtgaccacat caatgggcgc gtgctctact atgccacctg caagtgatgc 3720

tacagcttcc agcccgttgc cccactcatc tgccgccttt gcttttggtt gggggcagat 3780

tgggttggaa tgctttccat ctccaggaga ctttcatgta gcctaaagta cagcctggac 3840

cacccctggt gtgtagctag taagattacc ctgagctgca gctgagcctg agccaatggg 3900

acagttacac ttgacagaca aagatggtgg agattggcat gccattgaaa ctaagagctc 3960

tcaagtcaag gaagctgggc tgggcagtat cccccgcctt tagttctcca ctggggagga 4020

atcctggacc aagcacaaaa acttaacaaa agtgatgtaa aaatgaaaag ccaaataaaa 4080

atctttggaa aagaaaaaaa aaaaaaaa 4108

<210> SEQ ID NO 16
<211> LENGTH: 1172
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3615080CD1

<400> SEQUENCE: 16

Met Arg Pro Phe Phe Leu Leu Cys Phe Ala Leu Pro Gly Leu Leu
1 5 10 15

His Ala Gln Gln Ala Cys Ser Arg Gly Ala Cys Tyr Pro Pro Val
20 25 30

Gly Asp Leu Leu Val Gly Arg Thr Arg Phe Leu Arg Ala Ser Ser
35 40 45

Thr Cys Gly Leu Thr Lys Pro Glu Thr Tyr Cys Thr Gln Tyr Gly
50 55 60

Glu Trp Gln Met Lys Cys Cys Lys Cys Asp Ser Arg Gln Pro His
65 70 75

Asn Tyr Tyr Ser His Arg Val Glu Asn Val Ala Ser Ser Ser Gly

-continued

```
                 80                  85                  90

Pro Met Arg Trp Trp Gln Ser Gln Asn Asp Val Asn Pro Val Ser
                 95                 100                 105

Leu Gln Leu Asp Leu Asp Arg Arg Phe Gln Leu Gln Glu Val Met
                110                 115                 120

Met Glu Phe Gln Gly Pro Met Pro Ala Gly Met Leu Ile Glu Arg
                125                 130                 135

Ser Ser Asp Phe Gly Lys Thr Trp Arg Val Tyr Gln Tyr Leu Ala
                140                 145                 150

Ala Asp Cys Thr Ser Thr Phe Pro Arg Val Arg Gln Gly Arg Pro
                155                 160                 165

Gln Ser Trp Gln Asp Val Arg Cys Gln Ser Leu Pro Gln Arg Pro
                170                 175                 180

Asp Ala Arg Leu Asn Gly Gly Lys Val Gln Leu Asn Leu Met Asp
                185                 190                 195

Leu Val Ser Gly Ile Pro Ala Thr Gln Ser Gln Lys Ile Gln Glu
                200                 205                 210

Val Gly Glu Ile Thr Asn Leu Arg Val Asn Phe Thr Arg Leu Ala
                215                 220                 225

Pro Val Pro Gln Arg Gly Tyr His Pro Pro Ser Ala Tyr Tyr Ala
                230                 235                 240

Val Ser Gln Leu Arg Leu Gln Gly Ser Cys Phe Cys His Gly His
                245                 250                 255

Ala Asp Arg Cys Ala Pro Lys Pro Gly Ala Ser Ala Gly Pro Ser
                260                 265                 270

Thr Ala Val Gln Val His Asp Val Cys Val Cys Gln His Asn Thr
                275                 280                 285

Ala Gly Pro Asn Cys Glu Arg Cys Ala Pro Phe Tyr Asn Asn Arg
                290                 295                 300

Pro Trp Arg Pro Ala Glu Gly Gln Asp Ala His Glu Cys Gln Arg
                305                 310                 315

Cys Asp Cys Asn Gly His Ser Glu Thr Cys His Phe Asp Pro Ala
                320                 325                 330

Val Phe Ala Ala Ser Gln Gly Ala Tyr Gly Gly Val Cys Asp Asn
                335                 340                 345

Cys Arg Asp His Thr Glu Gly Lys Asn Cys Glu Arg Cys Gln Leu
                350                 355                 360

His Tyr Phe Arg Asn Arg Arg Pro Gly Ala Ser Ile Gln Glu Thr
                365                 370                 375

Cys Ile Ser Cys Glu Cys Asp Pro Asp Gly Ala Val Pro Gly Ala
                380                 385                 390

Pro Cys Asp Pro Val Thr Gly Gln Cys Val Cys Lys Glu His Val
                395                 400                 405

Gln Gly Glu Arg Cys Asp Leu Cys Lys Pro Gly Phe Thr Gly Leu
                410                 415                 420

Thr Tyr Ala Asn Pro Gln Gly Cys His Arg Cys Asp Cys Asn Ile
                425                 430                 435

Leu Gly Ser Arg Arg Asp Met Pro Cys Asp Glu Glu Ser Gly Arg
                440                 445                 450

Cys Leu Cys Leu Pro Asn Val Val Gly Pro Lys Cys Asp Gln Cys
                455                 460                 465

Ala Pro Tyr His Trp Lys Leu Ala Ser Gly Gln Gly Cys Glu Pro
                470                 475                 480
```

-continued

```
Cys Ala Cys Asp Pro His Asn Ser Leu Ser Pro Gln Cys Asn Gln
                485                 490                 495

Phe Thr Gly Gln Cys Pro Cys Arg Glu Gly Phe Gly Gly Leu Met
                500                 505                 510

Cys Ser Ala Ala Ala Ile Arg Gln Cys Pro Asp Arg Thr Tyr Gly
                515                 520                 525

Asp Val Ala Thr Gly Cys Arg Ala Cys Asp Cys Asp Phe Arg Gly
                530                 535                 540

Thr Glu Gly Pro Gly Cys Asp Lys Ala Ser Gly Arg Cys Leu Cys
                545                 550                 555

Arg Pro Gly Leu Thr Gly Pro Arg Cys Asp Gln Cys Gln Arg Gly
                560                 565                 570

Tyr Cys Asn Arg Tyr Pro Val Cys Val Ala Cys His Pro Cys Phe
                575                 580                 585

Gln Thr Tyr Asp Ala Asp Leu Arg Glu Gln Ala Leu Arg Phe Gly
                590                 595                 600

Arg Leu Arg Asn Ala Thr Ala Ser Leu Trp Ser Gly Pro Gly Leu
                605                 610                 615

Glu Asp Arg Gly Leu Ala Ser Arg Ile Leu Asp Ala Lys Ser Lys
                620                 625                 630

Ile Glu Gln Ile Arg Ala Val Leu Ser Ser Pro Ala Val Thr Glu
                635                 640                 645

Gln Glu Val Ala Gln Val Ala Ser Ala Ile Leu Ser Leu Arg Arg
                650                 655                 660

Thr Leu Gln Gly Leu Gln Leu Asp Leu Pro Leu Glu Glu Glu Thr
                665                 670                 675

Leu Ser Leu Pro Arg Asp Leu Glu Ser Leu Asp Arg Ser Phe Asn
                680                 685                 690

Gly Leu Leu Thr Met Tyr Gln Arg Lys Arg Glu Gln Phe Glu Lys
                695                 700                 705

Ile Ser Ser Ala Asp Pro Ser Gly Ala Phe Arg Met Leu Ser Thr
                710                 715                 720

Ala Tyr Glu Gln Ser Ala Gln Ala Ala Gln Gln Val Ser Asp Ser
                725                 730                 735

Ser Arg Leu Leu Asp Gln Leu Arg Asp Ser Arg Arg Glu Ala Glu
                740                 745                 750

Arg Leu Val Arg Gln Ala Gly Gly Gly Gly Gly Thr Gly Ser Pro
                755                 760                 765

Lys Leu Val Ala Leu Arg Leu Glu Met Ser Ser Leu Pro Asp Leu
                770                 775                 780

Thr Pro Thr Phe Asn Lys Leu Cys Gly Asn Ser Arg Gln Met Ala
                785                 790                 795

Cys Thr Pro Ile Ser Cys Pro Gly Glu Leu Cys Pro Gln Asp Asn
                800                 805                 810

Gly Thr Ala Cys Gly Ser Arg Cys Arg Gly Val Leu Pro Arg Ala
                815                 820                 825

Gly Gly Ala Phe Leu Met Ala Gly Gln Val Ala Glu Gln Leu Arg
                830                 835                 840

Gly Phe Asn Ala Gln Leu Gln Arg Thr Arg Gln Met Ile Arg Ala
                845                 850                 855

Ala Glu Glu Ser Ala Ser Gln Ile Gln Ser Ser Ala Gln Arg Leu
                860                 865                 870
```

-continued

```
Glu Thr Gln Val Ser Ala Ser Arg Ser Gln Met Glu Glu Asp Val
                875                 880                 885

Arg Arg Thr Arg Leu Leu Ile Gln Gln Val Arg Asp Phe Leu Thr
                890                 895                 900

Asp Pro Asp Thr Asp Ala Ala Thr Ile Gln Glu Val Ser Glu Ala
                905                 910                 915

Val Leu Ala Leu Trp Leu Pro Thr Asp Ser Asp Thr Val Leu Gln
                920                 925                 930

Lys Met Asn Glu Ile Gln Ala Ile Ala Ala Arg Leu Pro Asn Val
                935                 940                 945

Asp Leu Val Leu Ser Gln Thr Lys Gln Asp Ile Ala Arg Ala Arg
                950                 955                 960

Arg Leu Gln Ala Glu Ala Glu Glu Ala Arg Ser Arg Ala His Ala
                965                 970                 975

Val Glu Gly Gln Val Glu Asp Val Val Gly Asn Leu Arg Gln Gly
                980                 985                 990

Thr Val Ala Leu Gln Glu Ala Gln Asp Thr Met Gln Gly Thr Ser
                995                1000                1005

Arg Ser Leu Arg Leu Ile Gln Asp Arg Val Ala Glu Val Gln Gln
               1010                1015                1020

Val Leu Arg Pro Ala Glu Lys Leu Val Thr Ser Met Thr Lys Gln
               1025                1030                1035

Leu Gly Asp Phe Trp Thr Arg Met Glu Glu Leu Arg His Gln Ala
               1040                1045                1050

Arg Gln Gln Gly Ala Glu Ala Val Gln Ala Gln Gln Leu Ala Glu
               1055                1060                1065

Gly Ala Ser Glu Gln Ala Leu Ser Ala Gln Glu Gly Phe Glu Arg
               1070                1075                1080

Ile Lys Gln Lys Tyr Ala Glu Leu Lys Asp Arg Leu Gly Gln Ser
               1085                1090                1095

Ser Met Leu Gly Glu Gln Gly Ala Arg Ile Gln Ser Val Lys Thr
               1100                1105                1110

Glu Ala Glu Glu Leu Phe Gly Glu Thr Met Glu Met Met Asp Arg
               1115                1120                1125

Met Lys Asp Met Glu Leu Glu Leu Leu Arg Gly Ser Gln Ala Ile
               1130                1135                1140

Met Leu Arg Ser Ala Asp Leu Thr Gly Leu Glu Lys Arg Val Glu
               1145                1150                1155

Gln Ile Arg Asp His Ile Asn Gly Arg Val Leu Tyr Tyr Ala Thr
               1160                1165                1170

Cys Lys
```

<210> SEQ ID NO 17
<211> LENGTH: 795
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 331749.3

<400> SEQUENCE: 17

```
attttacata cactgtatgt tatagaactt catggatcag atctggggca gcaccctata     60

aatcaccacc ttaatatgct gcaacaaaat gtagaatatt cagacaaaat ggatacataa    120

agactaagta gcccataagg ggtcaaattt tgctgccaaa tgcgtatgcc accaacttac    180
```

-continued

aaaaacactt cgttcgcaga gcttttcaga ttgtggaatg ttggataagg aattatagac 240

ctctagtagc tgaaatgcaa gaccccaaga ggaagttcag atcttaatat aaattcactt 300

tcatttttga tagctgtccc atctggtcat ttggttggca ctagactggt ggcaggggct 360

tctagctgac tcgcacaggg attctcacaa tagccgatat cagaatttgt gttgaaggaa 420

cttgtctctt catctaatat gatagcggga aaaggagagg aaactactgc ctttagaaaa 480

tataagtaaa gtgattaaag tgctcacgtt accttgacac atagtttttc agtctatggg 540

tttagttact ttagatggca agcatgtaac ttatattaat agtaatttgt aaagttggtt 600

ggataagcta tccatgttgc aggttcatgg attacttctc tataaaaaat atgtatttac 660

caaaaaattt tgtgacattc cttctcccat ctcttccttg acatgcattg taaataggtt 720

cttcttgttc tgagattcaa tattgaattt ctcctatgct attgacaata aaatattatt 780

gaactacaaa aaaaa 795

<210> SEQ ID NO 18
<211> LENGTH: 2538
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 979243.1
<221> NAME/KEY: unsure
<222> LOCATION: 1479-1784, 1933-2000, 2002
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 18

cgccaggaca tgcagcccac catgaagttc gtgatggaca catctaaata ctggtttaag 60

ccaaacatca cccgagagca agcaatcgag ctgctgagga aggaggagcc aggggctttg 120

tcataaggga cagctcttca taccgaggct ccttcggcct ggccctgaag gtgcaggagg 180

ttcccgcgtc tgctcagaat cgaccaggtg aggacagcaa tgacctcatc cgacacttcc 240

tcatcgagtc gtctgccaaa ggagtgcatc tcaaaggagc agatgaggag ccctactttg 300

aactgggagg tgcagatggg gcctcggact ctacagacag cccagcctcc tgccagaaga 360

aatctgcggg ctgccacacc ctgtacctga gctcagtgag cgtggagacc ctgactggag 420

ccctggccgt gcagaaagcc atctccacca cctttgagag ggacatcctc cccacgccca 480

ccgtggtcca cttcaaagtc acagagcagg gcatcactct gactgatgtc cagaggaagg 540

tgtttttccg gcgccattac ccactcacca ccctccgctt ctgtggtatg gaccctgagc 600

aacggaagtg gcagaagtac tgcaaaccct cctggatctt tgggtttgtg gccaagagcc 660

agacagagcc tcaggagaac gtatgccacc tctttgcgga gtatgacatg gtccagccag 720

cctcgcaggt catcggcctg gtgactgctc tgctgcagga cgcagaaagg atgtagggga 780

gagactgcct gtgcacctaa ccaacacctc caggggctcg ctaaggagcc cccctccacc 840

ccctgaatgg gtgtggcttg tggccatatt gacagaccaa tctatgggac taggggggatt 900

ggcatcaagt tgacaccctt gaacctgcta tggccttcag cagtcaccat catccagacc 960

ccccgggcct cagtttcctc aatcatagaa gaagaccaat agacaagatc agctgttctt 1020

agatgctggt gggcatttga acatgctcct ccatgattct gaagcatgca cacctctgaa 1080

gacccctgca tgaaaataac ctccaaggac cctctgaccc catcgacctg ggccctgccc 1140

acacaacagt ctgagcaaga gacctgcagc ccctgtttcg tggcagacag caggtgcctg 1200

gcggtgaccc acggggctcc tggcttgcag ctggtgatgg tcaagaactg actacaaaac 1260

aggaatggat agactctatt tccttccata tctgttcctc tgttcctttt cccactttct 1320

-continued

gggtggcttt ttgggtccac ccagccagga tgctgcaggc caagctgggt gtggtattta 1380

gggcagctca gcaggggaa cttgtcccca tggtcagagg agacccagct gtcctgcacc 1440

cccttgcaga tgagtatcac cccatctttt ctttccacnn nnnnnnnnn nnnnnnnnn 1500

nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn 1560

nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn 1620

nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn 1680

nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn 1740

nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnccattc cttgataggc 1800

gagtattcca aagctggtat cgtagctgcc ctaatgttgc atattaggcg gcgggggcag 1860

agataagggc catctctctg tgattctgcc tcagctcctg tcttgctgag ccctccccca 1920

acccacgctc cannnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1980

nnnnnnnnnn nnnnnnnnnn gnccctctac tgctatgtgg cttcaaccag cctcacagcc 2040

acacggggga agcagagagt caagaatgca aagaggccgc ttccctaaga ggcttggagg 2100

agctgggctc tatcccacac ccacccccac cccaccccca cccagcctcc agaagctgga 2160

accatttctc ccgcaggcct gagttcctaa ggaaaccacc ctaccggggt ggaagggagg 2220

gtcagggaag aaacccactc ttgctctacg aggagcaagt gcctgccccc tcccagcagc 2280

cagccctgcc aaagttgcat tatctttggc caaggctggg cctgacggtt atgatttcag 2340

ccctgggcct gcaggagagg ctgagaccag cccacccagc cagtggtcga gcactgcccc 2400

gccgccaaag tctgcagaat gtgagatgag gttctcaagg tcacaggccc cagtcccagc 2460

ctgggggctg gcagaggccc ccatatactc tgctacagct cctatcatga aaaataaaat 2520

gtttgtcttt gcaaaaca 2538

<210> SEQ ID NO 19
<211> LENGTH: 1730
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3189059CB1

<400> SEQUENCE: 19

gcggccgcgc ggtatcccac ccagcccacc ccgccccggc cgacggctga cagctgacct 60

ggatccttcg agcgcccgcc gaccgccagc gatcttccct catcttccgg gctggtttct 120

gctgcgcgag gagcgtgccc tcgccgcccc tctcgccgga cccccggccc ccgatggctc 180

ggatggggct tgcgggcgcc gctggacgct ggtggggact cgctctcggc ttgaccgcat 240

tcttcctccc aggcgtccac tcccaggtgg tccaggtgaa cgactccatg tatggcttca 300

tcggcacaga cgtggttctg cactgcagct ttgccaaccc gcttcccagc gtgaagatca 360

cccaggtcac atggcagaag tccaccaatg gctccaagca gaacgtggcc atctacaacc 420

catccatggg cgtgtccgtg ctggctccct accgcgagcg tgtggaattc ctgcggccct 480

ccttcaccga tggcactatc cgcctctccc gcctggagct ggaggatgag ggtgtctaca 540

tctgcgagtt tgctaccttc cctacgggca atcgagaaag ccagctcaat ctcacggtga 600

tggccaaacc caccaattgg atagagggta cccaggcagt gcttcgagcc aagaaggggc 660

aggatgacaa ggtcctggtg gccacctgca cctcagccaa tgggaagcct cccagtgtgg 720

tatcctggga aactcggtta aaaggtgagg ccagagtacc aggagactcc ggaaccccaa 780

-continued

tggcaccagt gacggtcatc agccgctacc gcctggtgcc cagcagggaa gcccaccagc 840

agtccttggc ctgcatcgtc aactaccaca tggaccgctt caaggaaagc ctcactctca 900

acgtgcagta tgagcctgag gtaaccattg aggggtttga tggcaactgg tacctgcagc 960

ggatggacgt gaagctcacc tgcaaagctg atgctaaccc cccagccact gagtaccact 1020

ggaccacgct aaatggctct ctccccaagg gtgtggaggc ccagaacaga accctcttct 1080

tcaagggacc catcaactac agcctggcag ggacctacat ctgtgaggcc accaacccca 1140

tcggtacacg ctcaggccag gtggaggtca atatcacaga attcccctac accccgtctc 1200

ctcccgaaca tgggcggcgc gccgggccgg tgcccacggc catcattggg ggcgtggcgg 1260

ggagcatcct gctggtgttg attgtggtcg gcgggatcgt ggtcgccctg cgtcggcgcc 1320

ggcacacctt caagggtgac tacagcacca agaagcacgt gtatggcaac ggctacagca 1380

aggcaggcat cccccagcac cacccaccaa tggcacagaa cctgcagtac cccgacgact 1440

cagacgacga gaagaaggcc ggcccactgg gtggaagcag ctatgaggag gaggaggagg 1500

aggaggaggg cggtggaggg ggcgagcgca aggtgggcgg cccccacccc aaatatgacg 1560

aggacgccaa gcggccctac ttcaccgtgg atgaggccga ggcccgtcag gacggctacg 1620

gggaccggac tctgggctac cagtacgacc ctgagcagct ggacttggct gagaacatgg 1680

tttctcagaa cgacgggtct ttcatttcca agaaggagtg gtacgtgtag 1730

<210> SEQ ID NO 20
<211> LENGTH: 518
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3189059CD1

<400> SEQUENCE: 20

Met Ala Arg Met Gly Leu Ala Gly Ala Ala Gly Arg Trp Trp Gly
1 5 10 15

Leu Ala Leu Gly Leu Thr Ala Phe Phe Leu Pro Gly Val His Ser
20 25 30

Gln Val Val Gln Val Asn Asp Ser Met Tyr Gly Phe Ile Gly Thr
35 40 45

Asp Val Val Leu His Cys Ser Phe Ala Asn Pro Leu Pro Ser Val
50 55 60

Lys Ile Thr Gln Val Thr Trp Gln Lys Ser Thr Asn Gly Ser Lys
65 70 75

Gln Asn Val Ala Ile Tyr Asn Pro Ser Met Gly Val Ser Val Leu
80 85 90

Ala Pro Tyr Arg Glu Arg Val Glu Phe Leu Arg Pro Ser Phe Thr
95 100 105

Asp Gly Thr Ile Arg Leu Ser Arg Leu Glu Leu Glu Asp Glu Gly
110 115 120

Val Tyr Ile Cys Glu Phe Ala Thr Phe Pro Thr Gly Asn Arg Glu
125 130 135

Ser Gln Leu Asn Leu Thr Val Met Ala Lys Pro Thr Asn Trp Ile
140 145 150

Glu Gly Thr Gln Ala Val Leu Arg Ala Lys Lys Gly Gln Asp Asp
155 160 165

Lys Val Leu Val Ala Thr Cys Thr Ser Ala Asn Gly Lys Pro Pro
170 175 180

-continued

```
Ser Val Val Ser Trp Glu Thr Arg Leu Lys Gly Glu Ala Arg Val
                185                 190                 195

Pro Gly Asp Ser Gly Thr Pro Met Ala Pro Val Thr Val Ile Ser
                200                 205                 210

Arg Tyr Arg Leu Val Pro Ser Arg Glu Ala His Gln Gln Ser Leu
                215                 220                 225

Ala Cys Ile Val Asn Tyr His Met Asp Arg Phe Lys Glu Ser Leu
                230                 235                 240

Thr Leu Asn Val Gln Tyr Glu Pro Glu Val Thr Ile Glu Gly Phe
                245                 250                 255

Asp Gly Asn Trp Tyr Leu Gln Arg Met Asp Val Lys Leu Thr Cys
                260                 265                 270

Lys Ala Asp Ala Asn Pro Pro Ala Thr Glu Tyr His Trp Thr Thr
                275                 280                 285

Leu Asn Gly Ser Leu Pro Lys Gly Val Glu Ala Gln Asn Arg Thr
                290                 295                 300

Leu Phe Phe Lys Gly Pro Ile Asn Tyr Ser Leu Ala Gly Thr Tyr
                305                 310                 315

Ile Cys Glu Ala Thr Asn Pro Ile Gly Thr Arg Ser Gly Gln Val
                320                 325                 330

Glu Val Asn Ile Thr Glu Phe Pro Tyr Thr Pro Ser Pro Pro Glu
                335                 340                 345

His Gly Arg Arg Ala Gly Pro Val Pro Thr Ala Ile Ile Gly Gly
                350                 355                 360

Val Ala Gly Ser Ile Leu Leu Val Leu Ile Val Val Gly Gly Ile
                365                 370                 375

Val Val Ala Leu Arg Arg Arg Arg His Thr Phe Lys Gly Asp Tyr
                380                 385                 390

Ser Thr Lys Lys His Val Tyr Gly Asn Gly Tyr Ser Lys Ala Gly
                395                 400                 405

Ile Pro Gln His His Pro Pro Met Ala Gln Asn Leu Gln Tyr Pro
                410                 415                 420

Asp Asp Ser Asp Asp Glu Lys Lys Ala Gly Pro Leu Gly Gly Ser
                425                 430                 435

Ser Tyr Glu Glu Glu Glu Glu Glu Glu Glu Gly Gly Gly Gly Gly
                440                 445                 450

Glu Arg Lys Val Gly Gly Pro His Pro Lys Tyr Asp Glu Asp Ala
                455                 460                 465

Lys Arg Pro Tyr Phe Thr Val Asp Glu Ala Glu Ala Arg Gln Asp
                470                 475                 480

Gly Tyr Gly Asp Arg Thr Leu Gly Tyr Gln Tyr Asp Pro Glu Gln
                485                 490                 495

Leu Asp Leu Ala Glu Asn Met Val Ser Gln Asn Asp Gly Ser Phe
                500                 505                 510

Ile Ser Lys Lys Glu Trp Tyr Val
                515


<210> SEQ ID NO 21
<211> LENGTH: 1444
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1650519CB1
```

-continued

<400> SEQUENCE: 21

ggagaatttg aaagggtgcc ccaaaggaca atctctaaag gggtaagggg gatacctacc 60

ttgtctggta ggggagatgt ttcgttttca tgctttacca gaaaatccac ttccctgccg 120

accttagttt caaagcttat tcttaattag agacaagaaa cctgtttcaa cttgaagaca 180

ccgtatgagg tgaatggaca gccagccacc acaatgaaag aaatcaaacc aggaataacc 240

tatgctgaac ccacgcctca atcgtcccca agtgtttcct gacacgcatc tttgcttaca 300

gtgcatcaca actgaagaat ggggttcaac ttgacgcttg caaaattacc aaataacgag 360

ctgcacggcc aagagagtca caattcaggc aacaggagcg acgggccagg aaagaacacc 420

acccttcaca atgaatttga cacaattgtc ttgccggtgc tttatctcat tatatttgtg 480

gcaagcatct tgctgaatgg tttagcagtg tggatcttct tccacattag gaataaaacc 540

agcttcatat tctatctcaa aaacatagtg gttgcagacc tcataatgac gctgacattt 600

ccatttcgaa tagtccatga tgcaggattt ggaccttggt acttcaagtt tattctctgc 660

agatacactt cagttttgtt ttatgcaaac atgtatactt ccatcgtgtt ccttgggctg 720

ataagcattg atcgctatct gaaggtggtc aagccatttg gggactctcg gatgtacagc 780

ataaccttca cgaaggtttt atctgtttgt gtttgggtga tcatggctgt tttgtctttg 840

ccaaacatca tcctgacaaa tggtcagcca acagaggaca atatccatga ctgctcaaaa 900

cttaaaagtc ctttgggggt caaatggcat acggcagtca cctatgtgaa cagctgcttg 960

tttgtggccg tgctggtgat tctgatcgga tgttacatag ccatatccag gtacatccac 1020

aaatccagca ggcaattcat aagtcagtca agccgaaagc gaaaacataa ccagagcatc 1080

agggttgttg tggctgtgta ttttacctgc tttctaccat atcacttgtg cagaatgcct 1140

tctactttta gtcacttaga caggctttta gatgaatctg cacaaaaaat cctatattac 1200

tgcaaagaaa ttacactttt cttgtctgcg tgtaatgttt gcctggatcc aataatttac 1260

tttttcatgt gtaggtcatt ttcaagatgg ctgttcaaaa aatcaaatat cagacccagg 1320

agtgaaagca tcagatcact gcaaagtgtg agaagatcgg aagttcgcat atattatgat 1380

tacactgatg tgtaggcctt ttattgtttg ttggaatcga tatgtacaaa gtgtaataca 1440

tcag 1444

<210> SEQ ID NO 22
<211> LENGTH: 358
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1650519CD1

<400> SEQUENCE: 22

Met Gly Phe Asn Leu Thr Leu Ala Lys Leu Pro Asn Asn Glu Leu
1 5 10 15

His Gly Gln Glu Ser His Asn Ser Gly Asn Arg Ser Asp Gly Pro
20 25 30

Gly Lys Asn Thr Thr Leu His Asn Glu Phe Asp Thr Ile Val Leu
35 40 45

Pro Val Leu Tyr Leu Ile Ile Phe Val Ala Ser Ile Leu Leu Asn
50 55 60

Gly Leu Ala Val Trp Ile Phe Phe His Ile Arg Asn Lys Thr Ser
65 70 75

Phe Ile Phe Tyr Leu Lys Asn Ile Val Val Ala Asp Leu Ile Met

-continued

```
                 80                  85                  90

Thr Leu Thr Phe Pro Phe Arg Ile Val His Asp Ala Gly Phe Gly
                 95                 100                 105

Pro Trp Tyr Phe Lys Phe Ile Leu Cys Arg Tyr Thr Ser Val Leu
                110                 115                 120

Phe Tyr Ala Asn Met Tyr Thr Ser Ile Val Phe Leu Gly Leu Ile
                125                 130                 135

Ser Ile Asp Arg Tyr Leu Lys Val Val Lys Pro Phe Gly Asp Ser
                140                 145                 150

Arg Met Tyr Ser Ile Thr Phe Thr Lys Val Leu Ser Val Cys Val
                155                 160                 165

Trp Val Ile Met Ala Val Leu Ser Leu Pro Asn Ile Ile Leu Thr
                170                 175                 180

Asn Gly Gln Pro Thr Glu Asp Asn Ile His Asp Cys Ser Lys Leu
                185                 190                 195

Lys Ser Pro Leu Gly Val Lys Trp His Thr Ala Val Thr Tyr Val
                200                 205                 210

Asn Ser Cys Leu Phe Val Ala Val Leu Val Ile Leu Ile Gly Cys
                215                 220                 225

Tyr Ile Ala Ile Ser Arg Tyr Ile His Lys Ser Ser Arg Gln Phe
                230                 235                 240

Ile Ser Gln Ser Ser Arg Lys Arg Lys His Asn Gln Ser Ile Arg
                245                 250                 255

Val Val Val Ala Val Tyr Phe Thr Cys Phe Leu Pro Tyr His Leu
                260                 265                 270

Cys Arg Met Pro Ser Thr Phe Ser His Leu Asp Arg Leu Leu Asp
                275                 280                 285

Glu Ser Ala Gln Lys Ile Leu Tyr Tyr Cys Lys Glu Ile Thr Leu
                290                 295                 300

Phe Leu Ser Ala Cys Asn Val Cys Leu Asp Pro Ile Ile Tyr Phe
                305                 310                 315

Phe Met Cys Arg Ser Phe Ser Arg Trp Leu Phe Lys Lys Ser Asn
                320                 325                 330

Ile Arg Pro Arg Ser Glu Ser Ile Arg Ser Leu Gln Ser Val Arg
                335                 340                 345

Arg Ser Glu Val Arg Ile Tyr Tyr Asp Tyr Thr Asp Val
                350                 355


<210> SEQ ID NO 23
<211> LENGTH: 5933
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 474630.4
<221> NAME/KEY: unsure
<222> LOCATION: 2373-2407
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 23

caggacgggc gcacagcagc agccgaggct ggccgggaga gggaggaaga ggatggcagg     60

gccacgcccc agcccatggg ccaggctgct cctggcagcc ttgatcagcg tcagcctctc    120

tgggaccttg gcaactgacc actgcccacc ttcagggctg gaaaacttga ggctccaagc    180

tcttcagcct agagaagctt gagccctgac cacggggcct gagaatagga gcgaaggagg    240

ctgtgtctag aggaaagagg agacacccac ccaggactga ggcacccaga ggatgcactg    300
```

-continued

aggccccaga gcaaaccgct gcaagaaggc cccagtgaag agctgcacgg agtgtgtccg 360

tgtggataag gactgcgcct actgcacaga cgagatgttc agggaccggc gctgcaacac 420

ccaggcggag ctgctggccg cgggctgcca gcgggagagc atcgtggtca tggagagcag 480

cttccaaatc acagaggaga cccagattga caccaccctg cggcgcagcc agatgtcccc 540

ccaaggcctg cgggtccgtc tgcggcccgg tgaggagcgg cattttgagc tggaggtgtt 600

tgagccactg gagagccccg tggacctgta catcctcatg gacttctcca actccatgtc 660

cgatgatctg gacaacctca agaagatggg gcagaacctg gctcgggtcc tgagccagct 720

caccagcgac tacactattg gatttggcaa gtttgtggac aaagtcagcg tcccgcagac 780

ggacatgagg cctgagaagc tgaaggagcc ttggcccaac agtgaccccc ccttctcctt 840

caagaacgtc atcagcctga cagaagatgt ggatgagttc cggaataaac tgcagggaga 900

gcggatctca ggcaacctgg atgctcctga gggcggcttc gatgccatcc tgcagacagc 960

tgtgtgcacg agggacattg gctggcgccc ggacagcacc cacctgctgg tcttctccac 1020

cgagtcagcc ttccactatg aggctgatgg cgccaacgtg ctggctggca tcatgagccg 1080

caacgatgaa cggtgccacc tggacaccac gggcacctac acccagtaca ggacacagga 1140

ctacccgtcg gtgcccaccc tggtgcgcct gctcgccaag cacaacatca tccccatctt 1200

tgcttgtcac caactactcc tatagctact acgagaagct tcacacctat ttccctgtct 1260

cctcactggg ggtgctgcag gaggactcgt ccaacatcgt ggagctgctg gaggaggcct 1320

tcaatcggat ccgctccaac ctggacatcc gggccctaga cagcccccga ggccttcgga 1380

cagaggtcac ctccaagatg ttccagaaga cgaggactgg gtcctttcac atccggcggg 1440

gggaagtggg tatataccag gtgcagctgc gggcccttga gcacgtggat gggacgcacg 1500

tgtgccagct gccggaggac cagaagggca acatccatct gaaaccttcc ttctccgacg 1560

gcctcaagat ggacgcgggc atcatctgtg atgtgtgcac ctgcgagctg caaaaagagg 1620

tgcggtcagc tcgctgcagc ttcaacggag acttcgtgtg cggacagtgt gtgtgcagcg 1680

agggctggag tggccagacc tgcaactgct ccaccggctc tctgagtgac attcagccct 1740

gcctgcggga gggcgaggac aagccgtgct ccggccgtgg ggagtgccag tgcgggcact 1800

gtgtgtgcta cggcgaaggc cgctacgagg gtcagttctg cgagtatgac aacttccagt 1860

gtccccgcac ttccgggttc ctgtgcaatg accgaggacg ctgctccatg ggccagtgtg 1920

tgtgtgagcc tggttggaca ggcccaagct gtgactgtcc cctcagcaat gccacctgca 1980

tcgacagcaa tgggggcatc tgtaatggac gtggccactg tgagtgtggc cgctgccact 2040

gccaccagca gtcgctctac acggacacca tctgcgagat caactactcg gcgatccacc 2100

cgggcctctg cgaggaccta cgctcctgcg tgcagtgcca ggcgtggggc accggcgaga 2160

agaaggggcg cacgtgtgag gaatgcaact tcaaggtcaa gatggtggac gagcttaaga 2220

gagccgagga ggtggtggtg cgctgctcct tccgggacga ggatgacgac tgcacctaca 2280

gctacaccat ggaaggtgac ggcgcccctg ggcccaacag cactgtcctg gtgcacaaga 2340

agaaggactg ccctccgggc tccttctggt ggnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2400

nnnnnnnggc cctgctactg ctgctatgct ggaagtactg tgcctgctgc aaggcctgcc 2460

tggcacttct cccgtgctgc aaccgaggtc acatggtggg ctttaaggaa gaccactaca 2520

tgctgcggga gaacctgatg gcctctgacc acttggacac gcccatgctg cgcagcggga 2580

acctcaaggg ccgtgacgtg gtccgctgga aggtcaccaa caacatgcag cggcctggct 2640

-continued

```
ttgccactca tgccgccagc atcaacccca cagagctggt gccctacggg ctgtccttgc   2700

gcctggcccg cctttgcacc gagaacctgc tgaagcctga cactcgggag tgcgcccagc   2760

tgcgccagga ggtggaggag aacctgaacg aggtctacag gcagatctcc ggtgtacaca   2820

agctccagca gaccaagttc cggcagcagc ccaatgccgg gaaaaagcaa gaccacacca   2880

ttgtggacac agtgctgatg gcgccccgct cggccaagcc ggccctgctg aagcttacag   2940

agaagcaggt ggaacagagg gccttccacg acctcaaggt ggcccccggc tactacaccc   3000

tcactgcaga ccaggacgcc cggggcatgg tggagttcca ggagggcgtg gagctggtgg   3060

acgtacgggt gcccctcttt atccggcctg aggatgacga cgagaagcag ctgctggtgg   3120

aggccatcga cgtgcccgca ggcactgcca ccctcggccg ccgcctggta aacatcacca   3180

tcatcaagga gcaagccaga gacgtggtgt cctttgagca gcctgagttc tcggtcagcc   3240

gcggggacca ggtggcccgc atccctgtca tccggcgtgt cctggacggc gggaagtccc   3300

aggtctccta ccgcacacag gatggcaccg cgcagggcaa ccgggactac atccccgtgg   3360

agggtgagct gctgttccag cctggggagg cctggaaaga gctgcaggtg aagctcctgg   3420

agctgcaaga agttgactcc ctcctgcggg gccgccaggt ccgccgtttc cacgtccagc   3480

tcagcaaccc taagtttggg gcccacctgg gccagcccca ctccaccacc atcatcatca   3540

gggacccaga tgaactggac cggagcttca cgagtcagat gttgtcatca cagccacccc   3600

ctcacggcga cctgggcgcc ccgcagaacc ccaatgctaa ggccgctggg tccaggaaga   3660

tccatttcaa ctggctgccc ccttctggca agccaatggg gtacagggta aagtactgga   3720

ttcagggtga ctccgaatcc gaagcccacc tgctcgacag caaggtgccc tcagtggagc   3780

tcaccaacct gtacccgtat tgcgactatg agatgaaggt gtgcgcctac ggggctcagg   3840

gcgagggacc ctacagctcc ctggtgtcct gccgcaccca ccaggaagtg cccagcgagc   3900

cagggcgtct ggccttcaat gtcgtctcct ccacggtgac ccagctgagc tgggctgagc   3960

cggctgagac caacggtgag atcacagcct acgaggtctg ctatggcctg gtcaacgatg   4020

acaaccgacc tattgggccc atgaagaaag tgctggttga caaccctaag aaccggatgc   4080

tgcttattga gaaccttcgg gagtcccagc cctaccgcta cacggtgaag gcgcgcaacg   4140

gggccggctg ggggcctgag cgggaggcca tcatcaacct ggccacccag cccaagaggc   4200

ccatgtccat ccccatcatc cctgacatcc ctatcgtgga cgcccagagc ggggaggact   4260

acgacagctt ccttatgtac agcgatgacg ttctacgctc tccatcgggc agccagaggc   4320

ccagcgtctc cgatgacact gagcacctgg tgaatggccg gatggacttt gccttcccgg   4380

gcagcaccaa ctccctgcac aggatgacca cgaccagtgc tgctgcctat ggcacccacc   4440

tgagcccaca cgtgccccac cgcgtgctaa gcacatcctc caccctcaca cgggactaca   4500

actcactgac ccgctcagaa cactcacact cgaccacact gcccagggac tactccaccc   4560

tcacctccgt ctcctcccac ggcctccctc ccatctggga acacgggagg agcaggcttc   4620

cgctgtcctg ggccctgggg tcccggagtc gggctcagat gaaagggttc ccccccttcca   4680

ggggcccacg agactctata atcctggctg ggaggccagc agcgccctcc tggggcccag   4740

actctcgcct gactgctggt gtgcccgaca cgcccacccg cctggtgttc tctgccctgg   4800

ggcccacatc tctcagagtg agctggcagg agccgcggtg cgagcggccg ctgcagggct   4860

acagtgtgga gtaccagctg ctgaacggcg gtgagctgca tcggctcaac atccccaacc   4920

ctgcccagac ctcggtggtg gtggaagacc tcctgcccaa ccactcctac gtgttccgcg   4980

tgcgggccca gagccaggaa ggctggggcc gagagcgtga gggtgtcatc accattgaat   5040
```

-continued

cccaggtgca cccgcagagc ccactgtgtc ccctgccagg ctccgccttc actttgagca 5100

ctcccagtgc cccaggcccg ctggtgttca ctgccctgag cccagactcg ctgcagctga 5160

gctgggagcg gccacggagg cccaatgggg atatcgtcgg ctacctggtg acctgtgaga 5220

tggcccaagg aggagggcca gccaccgcat tccgggtgga tggagacagc cccgagagcc 5280

ggctgaccgt gccgggcctc agcgagaacg tgccctacaa gttcaaggtg caggccagga 5340

ccactgaggg cttcgggcca gagcgcgagg gcatcatcac catagagtcc caggatggag 5400

gacccttccc gcagctgggc agccgtgccg ggctcttcca gcacccgctg caaagcgagt 5460

acagcagcat caccaccacc cacaccagcg ccaccgagcc cttcctagtg gatgggccga 5520

ccctgggggc ccagcacctg gaggcaggcg gctccctcac ccggcatgtg acccaggagt 5580

ttgtgagccg gacactgacc accagcggaa cccttagcac ccacatggac caacagttct 5640

tccaaacttg accgcaccct gccccacccc cgccatgtcc cactaggcgt cctcccgact 5700

cctctcccgg agcctcctca gctactccat ccttgcaccc ctgggggccc agcccacccg 5760

catgcacaga gcaggggcta ggtgtctcct gggaggcatg aaggggggcaa ggtccgtcct 5820

ctgtgggccc aaacctattt gtaaccaaag agctgggagc agcacaagga cccagccttt 5880

gttctgcact taataaatgg ttttgctact gctaaaaaaa aaaaaaaagc ggc 5933

<210> SEQ ID NO 24
<211> LENGTH: 573
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 093496.1

<400> SEQUENCE: 24

aaaagaaaag gaaaagaaaa gtgtggactt ggatgaaatc ttcaggtcca acatttggga 60

ttctaagttc caaagaccag gttggaatca tttctaagaa ggttctggtg gttacacatt 120

cctggagtcc tctactcccc actccctgcc aagctgggcc tgtggataga tgtgatccct 180

cagcctccca gcttcaaaca cctgccaatg gttgacgtga acaacatggg ctcagtctca 240

gctaggatca cacccaaagc ccagcaccca gtaaggtgca ggagccatcc atttccctga 300

gcagagcaga ttaggctgag gaaagcagca gccatgcctt tgcacaatgc atttctaggg 360

cattcttccc acacataatc tcctctgctc attgtcctgt gaagaaactg tggcctggag 420

aggttgagcc actgtgccaa ggccaccaat gcaggtggta tgtgggtggg tgggggcctg 480

gggtggggag cacggcccag gcagggtctg tgctgaccgc ccttgtgttt ggaacctaga 540

catcccccct tgcctggatc tgagctgacc gaa 573

<210> SEQ ID NO 25
<211> LENGTH: 269
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1231633.4

<400> SEQUENCE: 25

accactgaag atcctggtgt cgccatgggc cgccgccccg cccgttgtta ccggtattgt 60

aagaacaagc cgtacccaaa gtctcgcttc tgccgaggtg tccctgccct ggaggctgcc 120

cgaatttgtg ccaataagta catggtaaaa agttgtggca aagatggctt ccatatccgg 180

-continued

gtgcggctcc acccttcca cgtcatccgc atcaacaaga tgttgtcctg tgctggggct 240

gacaggctcc aaacaggcat gcgaggtgc 269

<210> SEQ ID NO 26
<211> LENGTH: 1743
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 988891.1
<221> NAME/KEY: unsure
<222> LOCATION: 1562
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 26

ggtattcaac agagaaattt ctcagcctcc tacttctgct tttgaaagct ataaaaacag 60

cgagggagaa actggcagat accaaacctc ttcgaggcac aagggcacaa caggctgctc 120

tgggattctc ttcagccaat cttcattgct caagtgtctg aagcagccat ggcagaagta 180

cctgagctcg ccagtgaaat gatggcttat tacagtggca atgaggatga cttgttcttt 240

gaagctgatg gccctaaaca gatgaagtgc tccttccagg acctggacct ctgccctctg 300

gatggcggca tccagctacg aatctccgac caccactaca gcaagggctt caggcaggcc 360

gcgtcagttg ttgtggccat ggacaagctg aggaagatgc tggttccctg cccacagacc 420

ttccaggaga atgacctgag caccttcttt cccttcatct ttgaagaaga acctatcttc 480

ttcgacacat gggataacga ggcttatgtg cacgatgcac ctgtacgatc actgaactgc 540

acgctccggg actcacagca aaaaagcttg gtgatgtctg gtccatatga actgaaagct 600

ctccacctcc agggacagga tatggagcaa caagtggtgt tctccatgtc ctttgtacaa 660

ggagaagaaa gtaatgacaa aatacctgtg gccttgggcc tcaaggaaaa gaatctgtac 720

ctgtcctgcg tgttgaaaga tgataagccc actctacagc tggagagtgt agatcccaaa 780

aattacccaa agaagaagat ggaaaagcga tttgtcttca acaagataga aatcaataac 840

aagctggaat ttgagtctgc ccagttcccc aactggtaca tcagcacctc tcaagcagaa 900

aacatgcccg tcttcctggg agggaccaaa ggcggccagg atataactga cttcaccatg 960

caatttgtgt cttcctaaag agagctgtac ccagagagtc ctgtgctgaa tgtggactca 1020

atccctaggg ctggcagaaa gggaacagaa aggtttttga gtacggctat agcctggact 1080

ttcctgttgt ctacaccaat gcccaactgc ctgccttagg gtagtgctaa gaggatctcc 1140

tgtccatcag ccaggacagt cagctctctc ctttcagggc caatccccag ccctttttgtt 1200

gagccaggcc tctctcacct ctcctactca cttaaagccc gcctgacaga aaccacggcc 1260

acatttggtt ctaagaaacc ctctgtcatt cgctcccaca ttctgatgag caaccgcttc 1320

cctatttatt tatttatttg tttgtttgtt ttattcattg gtctaattta ttcaaagggg 1380

gcaagaagta gcagtgtctg taaaagagcc tagtttttaa tagctatgga atcaattcaa 1440

tttggactgg tgtgctctct ttaaatcaag tcctttaatt aagactgaaa atatataagc 1500

tcagattatt taaatgggaa tatttataaa tgagcaaata tcatactgtt caatggttct 1560

gngcttatat attttcagtc ttaattaaag gactggtgtg ctctctttaa atcaagtcct 1620

ttaattaaga ctgaaaatat ataagctcag attatttaaa tgggaatatt tataaatgag 1680

caaatatcat actgttcaat ggttcttcag tgaagtttat ttcagaaaaa aaaaaaaaag 1740

ggg 1743

-continued

<210> SEQ ID NO 27
<211> LENGTH: 391
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 988891.15
<221> NAME/KEY: unsure
<222> LOCATION: 14
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 27

attttgctag agantgttct aaaaccattg cactttactt acaactcctg tccggaaggt 60

gcgaggcaac aagtttttac agccttcaca gaggagtttc tggcagcacc tgtacgatca 120

ctgaactgca cgctccggga ctcacagcaa aaaagcttgg tgatgtctgg tccatatgaa 180

ctgaaagctc tccacctcca gggacaggat atggagcaac aagtggtgtt ctccatgtcc 240

tttgtacaag gagaagaaag taatgacaaa atacctgtgg ccttgggcct tcaaggaaaa 300

gaatctgtac ctgtcctgcg tgttgaaaga tggataaagc ccacttctac agctgggaga 360

gtgttaggat ccccaaaaaa atttacccca a 391

<210> SEQ ID NO 28
<211> LENGTH: 7045
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3774181CB1
<221> NAME/KEY: unsure
<222> LOCATION: 103, 6960
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 28

agtttgctcg gaattcggct cgagcagcac ataaaggaga acacagcgta tttcgagttt 60

ttcaatgatg ccaaagaagc tactgattac ttaaggaatc tanaagatgc cattcagcgg 120

aagtacagct gtgatagatc aagcagcatt cacaagctag aagaccttgt tcaggaatca 180

atggaagaga aagaagaact tctgcagtac aaaagcacta tagcaaacct aatgggaaaa 240

gcaaaaacaa taattcaact gaagccaagg aattctgact gtccactcaa aacttctatt 300

ccgatcaaag ctatctgtga ctacagacaa attgagataa ccatttacaa agacgatgaa 360

tgtgttttgg cgaataactc tcatcgtgct aaatggaagg tcattagtcc tactgggaat 420

gaggctatgg tcccatctgt gtgcttcacc gttcctccac caaacaaaga agcggtggac 480

cttgccaaca gaattgagca acagtatcag aatgtcctga ctctttggca tgagtctcac 540

ataaacatga agagtgtagt atcctggcat tatctcatca atgaaattga tagaattcga 600

gctagcaatg tggcttcaat aaagacaatg ctacctggtg aacatcagca agttctaagt 660

aatctacaat ctcgttttga agattttctg gaagatagcc aggaatccca agtcttttca 720

ggctcagata taacacaact ggaaaaggag gttaatgtat gtaagcagta ttatcaagaa 780

cttcttaaat ctgcagaaag agaggagcaa gaggaatcag tttataatct ctacatctct 840

gaagttcgaa acattagact tcggttagag aactgtgaag atcggctgat tagacagatt 900

cgaactcccc tggaaagaga tgatttgcat gaaagtgtgt tcagaatcac agaacaggag 960

aaactaaaga aagagctgga acgacttaaa gatgatttgg gaacaatcac aaataagtgt 1020

gaggagtttt tcagtcaagc agcagcctct tcatcagtcc ctaccctacg atcagagctt 1080

aatgtggtcc ttcagaacat gaaccaagtc tattctatgt cttccactta catagataag 1140

-continued

ttgaaaactg ttaacttggt gttaaaaaac actcaagctg cagaagccct cgtaaaactc 1200

tatgaaacta aactgtgtga agaagaagca gttatagctg acaagaataa tattgagaat 1260

ctaataagta ctttaaagca atggagatct gaagtagatg aaaagagaca ggtattccat 1320

gccttagagg atgagttgca gaaagctaaa gccatcagtg atgaaatgtt taaaacgtat 1380

aaagaacggg accttgattt tgactggcac aaagaaaaag cagatcaatt agttgaaagg 1440

tggcaaaatg ttcatgtgca gattgacaac aggttacggg acttagaggg cattggcaaa 1500

tcactgaagt actacagaga cacttaccat cctttagatg attggatcca gcaggttgaa 1560

actactcaga gaaagattca ggaaaatcag cctgaaaata gtaaaaccct agccacacag 1620

ttgaatcaac agaagatgct ggtgtccgaa atagaaatga aacagagcaa aatggacgag 1680

tgtcaaaaat atgcagaaca gtactcagct acagtgaagg actatgaatt acaaacaatg 1740

acctaccggg ccatggtaga ttcacaacaa aaatctccag tgaaacgccg aagaatgcag 1800

agttcagcag atctcattat tcaagagttc atggacctaa ggactcgata tactgccctg 1860

gtcactctca tgacacaata tattaaattt gctggtgatt cattgaagag gctggaagag 1920

gaggagatta aaaggtgtaa ggagacttct gaacatgggg catattcaga tctgcttcag 1980

cgtcagaagg caacagtgct tgagaatagc aaacttacag gaaagataag tgagttggaa 2040

agaatggtag ctgaactaaa gaaacaaaag tcccgagtag aggaagaact tccgaaggtc 2100

agggaggctg cagaaaatga attgagaaag cagcagagaa atgtagaaga tatctctctg 2160

cagaagataa gggctgaaag tgaagccaag cagtaccgca gggaacttga aaccattgtg 2220

agagagaagg aagccgctga aagagaactg gagcgggtga ggcagctcac catagaggcc 2280

gaggctaaaa gagctgccgt ggaagagaac ctcctgaatt ttcgcaatca gttggaggaa 2340

aacaccttta ccagacgaac actggaagat catcttaaaa gaaaagattt aagtctcaat 2400

gatttggagc aacaaaaaaa taaattaatg gaagaattaa gaagaaagag agacaatgag 2460

gaagaactct tgaagctgat aaagcagatg gaaaaagacc ttgcatttca gaaacaggta 2520

gcagagaaac agttgaaaga aaagcagaaa attgaattgg aagcaagaag aaaaataact 2580

gaaattcagt atacatgtag agaaaatgca ttgccagtgt gtccgatcac acaggctaca 2640

tcatgcaggg cagtaacggg tctccagcaa gaacatgaca agcagaaagc agaagaactc 2700

aaacagcagg tagatgaact aacagctgcc aatagaaagg ctgaacaaga catgagagag 2760

ctgacatatg aacttaatgc cctccagctt gaaaaaacgt catctgagga aaaggctcgt 2820

ttgctaaaag ataaactaga tgaaacaaat aatacactca gatgccttaa gttggagctg 2880

gaaaggaagg atcaggcgga gaaagggtat tctcaacaac tcagagagct tggtaggcaa 2940

ttgaatcaaa ccacaggtaa agctgaagaa gccatgcaag aagctagtga tctcaagaaa 3000

ataaagcgca attatcagtt agaattagaa tctcttaatc atgaaaaagg gaaactacaa 3060

agagaagtag acagaatcac aagggcacat gctgtagctg agaagaatat tcagcattta 3120

aattcacaaa ttcattcttt tcgagatgag aaagaattag aaagactaca aatctgccag 3180

agaaaatcag atcatctaaa agaacaattt gagaaaagcc atgagcagtt gcttcaaaat 3240

atcaaagctg aaaaagaaaa taatgataaa atccaaaggc tcaatgaaga attggagaaa 3300

agtaatgagt gtgcagagat gctaaaacaa aaagtagagg agcttactag gcagaataat 3360

gaaaccaaat taatgatgca gagaattcag gcagaatcag agaatatagt tttagagaaa 3420

caaactatcc agcaaagatg tgaagcactg aaaattcagg cagatggttt taaagatcag 3480

ctacgcagca caaatgaaca cttgcataaa cagacaaaaa cagagcagga ttttcaaaga 3540

-continued

aaaattaaat gcctagaaga agacctggcg aaaagtcaaa atttggtaag tgaatttaag 3600

caaaagtgtg accaacagaa cattatcatc cagaatacca agaaagaagt tagaaatctg 3660

aatgcggaac tgaatgcttc caaagaagag aagcgacgcg gggagcagaa agttcagcta 3720

caacaagctc aggtgcaaga gttaaataac aggttgaaaa aagtacaaga cgaattacac 3780

ttaaagacca tagaggagca gatgacccac agaaagatgg ttctgtttca ggaagaatct 3840

ggtaaattca aacaatcagc agaggagttt cggaagaaga tggaaaaatt aatggagtcc 3900

aaagtcatca ctgaaaatga tatttcaggc attaggcttg actttgtgtc tcttcaacaa 3960

gaaaactcta gagcccaaga aaatgctaag ctttgtgaaa caaacattaa agaacttgaa 4020

agacagcttc aacagtatcg tgaacaaatg cagcaagggc agcacatgga agcaaatcat 4080

taccaaaaat gtcagaaact tgaggatgag ctgatagccc agaagcgtga ggttgaaaac 4140

ctgaagcaaa aaatggacca acagatcaaa gagcatgaac atcaattagt tttgctccag 4200

tgtgaaattc aaaaaaagag cacagccaaa gactgtacct tcaaaccaga ttttgagatg 4260

acagtgaagg agtgccagca ctctggagag ctgtcctcta gaaacactgg acaccttcac 4320

ccaacaccca gatcccctct gttgagatgg actcaagaac cacagccatt ggaagagaag 4380

tggcagcatc gggttgttga acagataccc aaagaagtcc aattccagcc accaggggct 4440

ccactcgaga aagagaaaag ccagcagtgt tactctgagt acttttctca gacaagcacc 4500

gagttacaga taacttttga tgagacaaac cccattacaa gactgtctga aattgagaag 4560

ataagagacc aagccctgaa caattctaga ccacctgtta ggtatcaaga taacgcatgt 4620

gaaatggaac tggtgaaggt tttgacaccc ttagagatag ctaagaacaa gcagtatgat 4680

atgcatacag aagtcacaac attaaaacaa gaaaagaacc cagttcccag tgctgaagaa 4740

tggatgcttg aagggtgcag agcatctggt ggactcaaga aaggggattt ccttaagaag 4800

ggcttagaac cagagacctt ccagaacttt gatggtgatc atgcatgttc agtcagggat 4860

gatgaattta aattccaagg gcttaggcac actgtgactg ccaggcagtt ggtggaagct 4920

aagcttctgg acatgagaac aattgagcag ctgcgactcg gtcttaagac tgttgaagaa 4980

gttcagaaaa ctcttaacaa gtttctgacg aaagccacct caattgcagg gctttaccta 5040

gaatctacaa aagaaaagat ttcatttgcc tcagcggccg agagaatcat aatagacaaa 5100

atggtggctt tggcattttt agaagctcag gctgcaacag gttttataat tgatcccatt 5160

tcaggtcaga catattctgt tgaagatgca gttcttaaag gagttgttga ccccgaattc 5220

agaattaggc ttcttgaggc agagaaggca gctgtgggat attcttattc ttctaagaca 5280

ttgtcagtgt ttcaagctat ggaaaataga atgcttgaca gacaaaaagg taaacatatc 5340

ttggaagccc agattgccag tgggggtgtc attgaccctg tgagaggcat tcgtgttcct 5400

ccagaaattg ctctgcagca ggggttgttg aataatgcca tcttacagtt tttacatgag 5460

ccatccagca acacaagagt tttccctaat cccaataaca agcaagctct gtattactca 5520

gaattactgc gaatgtgtgt atttgatgta gagtcccaat gctttctgtt tccatttggg 5580

gagaggaaca tttccaatct caatgtcaag aaaacacata gaatttctgt agtagatact 5640

aaaacaggat cagaattgac cgtgtatgag gctttccaga gaaacctgat tgagaaaagt 5700

atatatcttg aactttcagg gcagcaatat cagtggaagg aagctatgtt ttttgaatcc 5760

tatgggcatt cttctcatat gctgactgat actaaaacag gattacactt caatattaat 5820

gaggctatag agcagggaac aattgacaaa gccttggtca aaaagtatca ggaaggcctc 5880

-continued

atcacactta cagaacttgc tgattctttg ctgagccggt tagtccccaa gaaagatttg 5940

cacagtcctg ttgcagggta ttggctgact gctagtgggg aaaggatctc tgtactaaaa 6000

gcctcccgta gaaatttggt tgatcggatt actgccctcc gatgccttga agcccaagtc 6060

agtacagggg gcataattga tcctcttact ggcaaaaagt accgggtggc cgaagctttg 6120

catagaggcc tggttgatga ggggtttgcc cagcagctgc gacagtgtga attagtaatc 6180

acagggattg gccatcccat cactaacaaa atgatgtcag tggtggaagc tgtgaatgca 6240

aatattataa ataaggaaat gggaatccga tgtttggaat ttcagtactt gacaggaggg 6300

ttgatagagc cacaggttca ctctcggtta tcaatagaag aggctctcca agtaggtatt 6360

atagatgtcc tcattgccac aaaactcaaa gatcaaaagt catatgtcag aaatataata 6420

tgccctcaga caaaaagaaa gttgacatat aaagaagcct tagaaaaagc tgattttgat 6480

ttccacacag gacttaaact gttagaagta tctgagcccc tgatgacagg aatttctagc 6540

ctctactatt cttcctaatg ggacatgttt aaataactgt gcaaggggtg atgcaggctg 6600

gttcatgcca ctttttcaga gtatgatgat atcggctaca tatgcagtct gtgaattatg 6660

taacatactc tatttcttga gggctgcaaa ttgctaagtg ctcaaaatag agtaagtttt 6720

aaattgaaaa ttacataaga tttaatgccc ttcaaatggt ttcatttagc cttgagaatg 6780

gttttttgaa acttggccac actaaaatgt ttttttttt ttacgtagaa tgtgggataa 6840

acttgatgaa ctccaagttc acagtgtcat ttcttcagaa ctccccttca ttgaatagtg 6900

atcatttatt aaatgataaa ttgcactcgc tgaaagagca cagtcatgag gcacctggan 6960

atccaagggg aaggtataaa ttccgttcca acggccttca ggtggcgtgt tttgggttgc 7020

ttccaaaatg gaaagttttg ccttt 7045

<210> SEQ ID NO 29
<211> LENGTH: 2125
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3774181CD1

<400> SEQUENCE: 29

Met Glu Glu Lys Glu Glu Leu Leu Gln Tyr Lys Ser Thr Ile Ala
1 5 10 15

Asn Leu Met Gly Lys Ala Lys Thr Ile Ile Gln Leu Lys Pro Arg
20 25 30

Asn Ser Asp Cys Pro Leu Lys Thr Ser Ile Pro Ile Lys Ala Ile
35 40 45

Cys Asp Tyr Arg Gln Ile Glu Ile Thr Ile Tyr Lys Asp Asp Glu
50 55 60

Cys Val Leu Ala Asn Asn Ser His Arg Ala Lys Trp Lys Val Ile
65 70 75

Ser Pro Thr Gly Asn Glu Ala Met Val Pro Ser Val Cys Phe Thr
80 85 90

Val Pro Pro Pro Asn Lys Glu Ala Val Asp Leu Ala Asn Arg Ile
95 100 105

Glu Gln Gln Tyr Gln Asn Val Leu Thr Leu Trp His Glu Ser His
110 115 120

Ile Asn Met Lys Ser Val Val Ser Trp His Tyr Leu Ile Asn Glu
125 130 135

Ile Asp Arg Ile Arg Ala Ser Asn Val Ala Ser Ile Lys Thr Met

-continued

```
                140                 145                 150

Leu Pro Gly Glu His Gln Gln Val Leu Ser Asn Leu Gln Ser Arg
                155                 160                 165

Phe Glu Asp Phe Leu Glu Asp Ser Gln Glu Ser Gln Val Phe Ser
                170                 175                 180

Gly Ser Asp Ile Thr Gln Leu Glu Lys Glu Val Asn Val Cys Lys
                185                 190                 195

Gln Tyr Tyr Gln Glu Leu Leu Lys Ser Ala Glu Arg Glu Glu Gln
                200                 205                 210

Glu Glu Ser Val Tyr Asn Leu Tyr Ile Ser Glu Val Arg Asn Ile
                215                 220                 225

Arg Leu Arg Leu Glu Asn Cys Glu Asp Arg Leu Ile Arg Gln Ile
                230                 235                 240

Arg Thr Pro Leu Glu Arg Asp Asp Leu His Glu Ser Val Phe Arg
                245                 250                 255

Ile Thr Glu Gln Glu Lys Leu Lys Lys Glu Leu Glu Arg Leu Lys
                260                 265                 270

Asp Asp Leu Gly Thr Ile Thr Asn Lys Cys Glu Glu Phe Phe Ser
                275                 280                 285

Gln Ala Ala Ala Ser Ser Ser Val Pro Thr Leu Arg Ser Glu Leu
                290                 295                 300

Asn Val Val Leu Gln Asn Met Asn Gln Val Tyr Ser Met Ser Ser
                305                 310                 315

Thr Tyr Ile Asp Lys Leu Lys Thr Val Asn Leu Val Leu Lys Asn
                320                 325                 330

Thr Gln Ala Ala Glu Ala Leu Val Lys Leu Tyr Glu Thr Lys Leu
                335                 340                 345

Cys Glu Glu Glu Ala Val Ile Ala Asp Lys Asn Asn Ile Glu Asn
                350                 355                 360

Leu Ile Ser Thr Leu Lys Gln Trp Arg Ser Glu Val Asp Glu Lys
                365                 370                 375

Arg Gln Val Phe His Ala Leu Glu Asp Glu Leu Gln Lys Ala Lys
                380                 385                 390

Ala Ile Ser Asp Glu Met Phe Lys Thr Tyr Lys Glu Arg Asp Leu
                395                 400                 405

Asp Phe Asp Trp His Lys Glu Lys Ala Asp Gln Leu Val Glu Arg
                410                 415                 420

Trp Gln Asn Val His Val Gln Ile Asp Asn Arg Leu Arg Asp Leu
                425                 430                 435

Glu Gly Ile Gly Lys Ser Leu Lys Tyr Tyr Arg Asp Thr Tyr His
                440                 445                 450

Pro Leu Asp Asp Trp Ile Gln Gln Val Glu Thr Thr Gln Arg Lys
                455                 460                 465

Ile Gln Glu Asn Gln Pro Glu Asn Ser Lys Thr Leu Ala Thr Gln
                470                 475                 480

Leu Asn Gln Gln Lys Met Leu Val Ser Glu Ile Glu Met Lys Gln
                485                 490                 495

Ser Lys Met Asp Glu Cys Gln Lys Tyr Ala Glu Gln Tyr Ser Ala
                500                 505                 510

Thr Val Lys Asp Tyr Glu Leu Gln Thr Met Thr Tyr Arg Ala Met
                515                 520                 525

Val Asp Ser Gln Gln Lys Ser Pro Val Lys Arg Arg Arg Met Gln
                530                 535                 540
```

-continued

```
Ser Ser Ala Asp Leu Ile Ile Gln Glu Phe Met Asp Leu Arg Thr
                545                 550                 555

Arg Tyr Thr Ala Leu Val Thr Leu Met Thr Gln Tyr Ile Lys Phe
                560                 565                 570

Ala Gly Asp Ser Leu Lys Arg Leu Glu Glu Glu Ile Lys Arg
                575                 580                 585

Cys Lys Glu Thr Ser Glu His Gly Ala Tyr Ser Asp Leu Leu Gln
                590                 595                 600

Arg Gln Lys Ala Thr Val Leu Glu Asn Ser Lys Leu Thr Gly Lys
                605                 610                 615

Ile Ser Glu Leu Glu Arg Met Val Ala Glu Leu Lys Lys Gln Lys
                620                 625                 630

Ser Arg Val Glu Glu Glu Leu Pro Lys Val Arg Glu Ala Ala Glu
                635                 640                 645

Asn Glu Leu Arg Lys Gln Gln Arg Asn Val Glu Asp Ile Ser Leu
                650                 655                 660

Gln Lys Ile Arg Ala Glu Ser Glu Ala Lys Gln Tyr Arg Arg Glu
                665                 670                 675

Leu Glu Thr Ile Val Arg Glu Lys Glu Ala Ala Glu Arg Glu Leu
                680                 685                 690

Glu Arg Val Arg Gln Leu Thr Ile Glu Ala Glu Ala Lys Arg Ala
                695                 700                 705

Ala Val Glu Glu Asn Leu Leu Asn Phe Arg Asn Gln Leu Glu Glu
                710                 715                 720

Asn Thr Phe Thr Arg Arg Thr Leu Glu Asp His Leu Lys Arg Lys
                725                 730                 735

Asp Leu Ser Leu Asn Asp Leu Glu Gln Gln Lys Asn Lys Leu Met
                740                 745                 750

Glu Glu Leu Arg Arg Lys Arg Asp Asn Glu Glu Glu Leu Leu Lys
                755                 760                 765

Leu Ile Lys Gln Met Glu Lys Asp Leu Ala Phe Gln Lys Gln Val
                770                 775                 780

Ala Glu Lys Gln Leu Lys Glu Lys Gln Lys Ile Glu Leu Glu Ala
                785                 790                 795

Arg Arg Lys Ile Thr Glu Ile Gln Tyr Thr Cys Arg Glu Asn Ala
                800                 805                 810

Leu Pro Val Cys Pro Ile Thr Gln Ala Thr Ser Cys Arg Ala Val
                815                 820                 825

Thr Gly Leu Gln Gln Glu His Asp Lys Gln Lys Ala Glu Glu Leu
                830                 835                 840

Lys Gln Gln Val Asp Glu Leu Thr Ala Ala Asn Arg Lys Ala Glu
                845                 850                 855

Gln Asp Met Arg Glu Leu Thr Tyr Glu Leu Asn Ala Leu Gln Leu
                860                 865                 870

Glu Lys Thr Ser Ser Glu Glu Lys Ala Arg Leu Leu Lys Asp Lys
                875                 880                 885

Leu Asp Glu Thr Asn Asn Thr Leu Arg Cys Leu Lys Leu Glu Leu
                890                 895                 900

Glu Arg Lys Asp Gln Ala Glu Lys Gly Tyr Ser Gln Gln Leu Arg
                905                 910                 915

Glu Leu Gly Arg Gln Leu Asn Gln Thr Thr Gly Lys Ala Glu Glu
                920                 925                 930
```

-continued

Ala Met Gln Glu Ala Ser Asp Leu Lys Lys Ile Lys Arg Asn Tyr
935 940 945

Gln Leu Glu Leu Glu Ser Leu Asn His Glu Lys Gly Lys Leu Gln
950 955 960

Arg Glu Val Asp Arg Ile Thr Arg Ala His Ala Val Ala Glu Lys
965 970 975

Asn Ile Gln His Leu Asn Ser Gln Ile His Ser Phe Arg Asp Glu
980 985 990

Lys Glu Leu Glu Arg Leu Gln Ile Cys Gln Arg Lys Ser Asp His
995 1000 1005

Leu Lys Glu Gln Phe Glu Lys Ser His Glu Gln Leu Leu Gln Asn
1010 1015 1020

Ile Lys Ala Glu Lys Glu Asn Asn Asp Lys Ile Gln Arg Leu Asn
1025 1030 1035

Glu Glu Leu Glu Lys Ser Asn Glu Cys Ala Glu Met Leu Lys Gln
1040 1045 1050

Lys Val Glu Glu Leu Thr Arg Gln Asn Asn Glu Thr Lys Leu Met
1055 1060 1065

Met Gln Arg Ile Gln Ala Glu Ser Glu Asn Ile Val Leu Glu Lys
1070 1075 1080

Gln Thr Ile Gln Gln Arg Cys Glu Ala Leu Lys Ile Gln Ala Asp
1085 1090 1095

Gly Phe Lys Asp Gln Leu Arg Ser Thr Asn Glu His Leu His Lys
1100 1105 1110

Gln Thr Lys Thr Glu Gln Asp Phe Gln Arg Lys Ile Lys Cys Leu
1115 1120 1125

Glu Glu Asp Leu Ala Lys Ser Gln Asn Leu Val Ser Glu Phe Lys
1130 1135 1140

Gln Lys Cys Asp Gln Gln Asn Ile Ile Ile Gln Asn Thr Lys Lys
1145 1150 1155

Glu Val Arg Asn Leu Asn Ala Glu Leu Asn Ala Ser Lys Glu Glu
1160 1165 1170

Lys Arg Arg Gly Glu Gln Lys Val Gln Leu Gln Gln Ala Gln Val
1175 1180 1185

Gln Glu Leu Asn Asn Arg Leu Lys Lys Val Gln Asp Glu Leu His
1190 1195 1200

Leu Lys Thr Ile Glu Glu Gln Met Thr His Arg Lys Met Val Leu
1205 1210 1215

Phe Gln Glu Glu Ser Gly Lys Phe Lys Gln Ser Ala Glu Glu Phe
1220 1225 1230

Arg Lys Lys Met Glu Lys Leu Met Glu Ser Lys Val Ile Thr Glu
1235 1240 1245

Asn Asp Ile Ser Gly Ile Arg Leu Asp Phe Val Ser Leu Gln Gln
1250 1255 1260

Glu Asn Ser Arg Ala Gln Glu Asn Ala Lys Leu Cys Glu Thr Asn
1265 1270 1275

Ile Lys Glu Leu Glu Arg Gln Leu Gln Gln Tyr Arg Glu Gln Met
1280 1285 1290

Gln Gln Gly Gln His Met Glu Ala Asn His Tyr Gln Lys Cys Gln
1295 1300 1305

Lys Leu Glu Asp Glu Leu Ile Ala Gln Lys Arg Glu Val Glu Asn
1310 1315 1320

Leu Lys Gln Lys Met Asp Gln Gln Ile Lys Glu His Glu His Gln

-continued

```
                1325                1330                1335

Leu Val Leu Leu Gln Cys Glu Ile Gln Lys Lys Ser Thr Ala Lys
                1340                1345                1350

Asp Cys Thr Phe Lys Pro Asp Phe Glu Met Thr Val Lys Glu Cys
                1355                1360                1365

Gln His Ser Gly Glu Leu Ser Ser Arg Asn Thr Gly His Leu His
                1370                1375                1380

Pro Thr Pro Arg Ser Pro Leu Leu Arg Trp Thr Gln Glu Pro Gln
                1385                1390                1395

Pro Leu Glu Glu Lys Trp Gln His Arg Val Val Glu Gln Ile Pro
                1400                1405                1410

Lys Glu Val Gln Phe Gln Pro Pro Gly Ala Pro Leu Glu Lys Glu
                1415                1420                1425

Lys Ser Gln Gln Cys Tyr Ser Glu Tyr Phe Ser Gln Thr Ser Thr
                1430                1435                1440

Glu Leu Gln Ile Thr Phe Asp Glu Thr Asn Pro Ile Thr Arg Leu
                1445                1450                1455

Ser Glu Ile Glu Lys Ile Arg Asp Gln Ala Leu Asn Asn Ser Arg
                1460                1465                1470

Pro Pro Val Arg Tyr Gln Asp Asn Ala Cys Glu Met Glu Leu Val
                1475                1480                1485

Lys Val Leu Thr Pro Leu Glu Ile Ala Lys Asn Lys Gln Tyr Asp
                1490                1495                1500

Met His Thr Glu Val Thr Thr Leu Lys Gln Glu Lys Asn Pro Val
                1505                1510                1515

Pro Ser Ala Glu Glu Trp Met Leu Glu Gly Cys Arg Ala Ser Gly
                1520                1525                1530

Gly Leu Lys Lys Gly Asp Phe Leu Lys Lys Gly Leu Glu Pro Glu
                1535                1540                1545

Thr Phe Gln Asn Phe Asp Gly Asp His Ala Cys Ser Val Arg Asp
                1550                1555                1560

Asp Glu Phe Lys Phe Gln Gly Leu Arg His Thr Val Thr Ala Arg
                1565                1570                1575

Gln Leu Val Glu Ala Lys Leu Leu Asp Met Arg Thr Ile Glu Gln
                1580                1585                1590

Leu Arg Leu Gly Leu Lys Thr Val Glu Glu Val Gln Lys Thr Leu
                1595                1600                1605

Asn Lys Phe Leu Thr Lys Ala Thr Ser Ile Ala Gly Leu Tyr Leu
                1610                1615                1620

Glu Ser Thr Lys Glu Lys Ile Ser Phe Ala Ser Ala Ala Glu Arg
                1625                1630                1635

Ile Ile Ile Asp Lys Met Val Ala Leu Ala Phe Leu Glu Ala Gln
                1640                1645                1650

Ala Ala Thr Gly Phe Ile Ile Asp Pro Ile Ser Gly Gln Thr Tyr
                1655                1660                1665

Ser Val Glu Asp Ala Val Leu Lys Gly Val Val Asp Pro Glu Phe
                1670                1675                1680

Arg Ile Arg Leu Leu Glu Ala Glu Lys Ala Ala Val Gly Tyr Ser
                1685                1690                1695

Tyr Ser Ser Lys Thr Leu Ser Val Phe Gln Ala Met Glu Asn Arg
                1700                1705                1710

Met Leu Asp Arg Gln Lys Gly Lys His Ile Leu Glu Ala Gln Ile
                1715                1720                1725
```

-continued

```
Ala Ser Gly Gly Val Ile Asp Pro Val Arg Gly Ile Arg Val Pro
               1730                1735                1740

Pro Glu Ile Ala Leu Gln Gln Gly Leu Leu Asn Asn Ala Ile Leu
               1745                1750                1755

Gln Phe Leu His Glu Pro Ser Ser Asn Thr Arg Val Phe Pro Asn
               1760                1765                1770

Pro Asn Asn Lys Gln Ala Leu Tyr Tyr Ser Glu Leu Leu Arg Met
               1775                1780                1785

Cys Val Phe Asp Val Glu Ser Gln Cys Phe Leu Phe Pro Phe Gly
               1790                1795                1800

Glu Arg Asn Ile Ser Asn Leu Asn Val Lys Lys Thr His Arg Ile
               1805                1810                1815

Ser Val Val Asp Thr Lys Thr Gly Ser Glu Leu Thr Val Tyr Glu
               1820                1825                1830

Ala Phe Gln Arg Asn Leu Ile Glu Lys Ser Ile Tyr Leu Glu Leu
               1835                1840                1845

Ser Gly Gln Gln Tyr Gln Trp Lys Glu Ala Met Phe Phe Glu Ser
               1850                1855                1860

Tyr Gly His Ser Ser His Met Leu Thr Asp Thr Lys Thr Gly Leu
               1865                1870                1875

His Phe Asn Ile Asn Glu Ala Ile Glu Gln Gly Thr Ile Asp Lys
               1880                1885                1890

Ala Leu Val Lys Lys Tyr Gln Glu Gly Leu Ile Thr Leu Thr Glu
               1895                1900                1905

Leu Ala Asp Ser Leu Leu Ser Arg Leu Val Pro Lys Lys Asp Leu
               1910                1915                1920

His Ser Pro Val Ala Gly Tyr Trp Leu Thr Ala Ser Gly Glu Arg
               1925                1930                1935

Ile Ser Val Leu Lys Ala Ser Arg Arg Asn Leu Val Asp Arg Ile
               1940                1945                1950

Thr Ala Leu Arg Cys Leu Glu Ala Gln Val Ser Thr Gly Gly Ile
               1955                1960                1965

Ile Asp Pro Leu Thr Gly Lys Lys Tyr Arg Val Ala Glu Ala Leu
               1970                1975                1980

His Arg Gly Leu Val Asp Glu Gly Phe Ala Gln Gln Leu Arg Gln
               1985                1990                1995

Cys Glu Leu Val Ile Thr Gly Ile Gly His Pro Ile Thr Asn Lys
               2000                2005                2010

Met Met Ser Val Val Glu Ala Val Asn Ala Asn Ile Ile Asn Lys
               2015                2020                2025

Glu Met Gly Ile Arg Cys Leu Glu Phe Gln Tyr Leu Thr Gly Gly
               2030                2035                2040

Leu Ile Glu Pro Gln Val His Ser Arg Leu Ser Ile Glu Glu Ala
               2045                2050                2055

Leu Gln Val Gly Ile Ile Asp Val Leu Ile Ala Thr Lys Leu Lys
               2060                2065                2070

Asp Gln Lys Ser Tyr Val Arg Asn Ile Ile Cys Pro Gln Thr Lys
               2075                2080                2085

Arg Lys Leu Thr Tyr Lys Glu Ala Leu Glu Lys Ala Asp Phe Asp
               2090                2095                2100

Phe His Thr Gly Leu Lys Leu Leu Glu Val Ser Glu Pro Leu Met
               2105                2110                2115
```

-continued

Thr Gly Ile Ser Ser Leu Tyr Tyr Ser Ser
2120 2125

<210> SEQ ID NO 30
<211> LENGTH: 1708
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1709387CB1
<400> SEQUENCE: 30

cctgccagca tctcttgggt ttgctgagaa ctcacgggct ccagctacct ggccatgacc 60

accacatttc tgcaaacttc ttcctccacc tttgggggtg gctcaacccg agggggttcc 120

ctcctggctg ggggaggtgg ctttggtggg gggagtctct ctgggggagg tggaagccga 180

agtatctcag cttcttctgc taggtttgtc tcttcagggt caggaggagg atatgggggt 240

ggcatgaggg tctgtggctt tggtggaggg gctggtagtg ttttcggtgg aggctttgga 300

gggggcgttg gtgggggttt tggtggtggc tttggtggtg gcgatggtgg tctcctctct 360

ggcaatgaga aaattaccat gcagaacctc aatgaccgcc tggcctccta cctggacaag 420

gtacgtgccc tggaggaggc caatgctgac ctggaggtga agatccatga ctggtaccag 480

aagcagaccc cagccagccc agaatgcgac tacagccaat acttcaagac cattgaagag 540

ctccgggaca agatcatggc caccaccatc gacaactccc gggtcatcct ggagatcgac 600

aatgccaggc tggctgcgga cgacttcagg ctcaagtatg agaatgagct ggccctgcgc 660

cagggcgttg aggctgacat caacggcttg cgccgagtcc tggatgagct gaccctggcc 720

aggactgacc tggagatgca gatcgagggc ctgaatgagg agctagccta cctgaagaag 780

aaccacgaag aggagatgaa ggagttcagc agccagctgg ccggccaggt caatgtggag 840

atggacgcag caccgggtgt ggacctgacc cgtgtgctgg cagagatgag ggagcagtac 900

gaggccatgg cggagaagaa ccgccgggat gtcgaggcct ggttcttcag caagactgag 960

gagctgaaca aagaggtggc ctccaacaca gaaatgatcc agaccagcaa gacggagatc 1020

acagacctga gacgcacgat gcaggagctg gagatcgagc tgcagtccca gctcagcatg 1080

aaagctgggc tggagaactc actggccgag acagagtgcc gctatgccac gcagctgcag 1140

cagatccagg ggctcattgg tggcctggag gcccagctga gtgagctccg atgcgagatg 1200

gaggctcaga accaggagta caagatgctg cttgacataa agacacggct ggagcaggag 1260

atcgctactt accgcagcct gctcgagggc caggatgcca agatggctgg cattggcatc 1320

agggaagcct cttcaggagg tggtggtagc agcagcaatt tccacatcaa tgtagaagag 1380

tcagtggatg gacaggtggt ttcttcccac aagagagaaa tctaagtgtc tattgcagga 1440

gaaacgtccc ttgccactcc ccactctcat caggccaagt ggaggactgg ccagagggcc 1500

tgcacatgca aactccagtc cctgccttca gagagctgaa aagggtccct cggtctttta 1560

tttcagggct ttgcatgcgc tctattcccc ctctgcctct ccccaccttc tttggagcaa 1620

ggagatgcag ctgtattgtg taacaagctc atttgtacag tgtctgttca tgtaataaag 1680

aattactttt ccttttgcaa aaaaaaaa 1708

<210> SEQ ID NO 31
<211> LENGTH: 456
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature

-continued

<223> OTHER INFORMATION: Incyte ID No: 1709387CD1

<400> SEQUENCE: 31

```
Met Thr Thr Thr Phe Leu Gln Thr Ser Ser Ser Thr Phe Gly Gly
  1               5                  10                  15

Gly Ser Thr Arg Gly Gly Ser Leu Leu Ala Gly Gly Gly Gly Phe
                20                  25                  30

Gly Gly Gly Ser Leu Ser Gly Gly Gly Gly Ser Arg Ser Ile Ser
                35                  40                  45

Ala Ser Ser Ala Arg Phe Val Ser Ser Gly Ser Gly Gly Gly Tyr
                50                  55                  60

Gly Gly Gly Met Arg Val Cys Gly Phe Gly Gly Gly Ala Gly Ser
                65                  70                  75

Val Phe Gly Gly Gly Phe Gly Gly Gly Val Gly Gly Gly Phe Gly
                80                  85                  90

Gly Gly Phe Gly Gly Gly Asp Gly Gly Leu Leu Ser Gly Asn Glu
                95                  100                 105

Lys Ile Thr Met Gln Asn Leu Asn Asp Arg Leu Ala Ser Tyr Leu
                110                 115                 120

Asp Lys Val Arg Ala Leu Glu Glu Ala Asn Ala Asp Leu Glu Val
                125                 130                 135

Lys Ile His Asp Trp Tyr Gln Lys Gln Thr Pro Ala Ser Pro Glu
                140                 145                 150

Cys Asp Tyr Ser Gln Tyr Phe Lys Thr Ile Glu Glu Leu Arg Asp
                155                 160                 165

Lys Ile Met Ala Thr Thr Ile Asp Asn Ser Arg Val Ile Leu Glu
                170                 175                 180

Ile Asp Asn Ala Arg Leu Ala Ala Asp Asp Phe Arg Leu Lys Tyr
                185                 190                 195

Glu Asn Glu Leu Ala Leu Arg Gln Gly Val Glu Ala Asp Ile Asn
                200                 205                 210

Gly Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr Asp
                215                 220                 225

Leu Glu Met Gln Ile Glu Gly Leu Asn Glu Glu Leu Ala Tyr Leu
                230                 235                 240

Lys Lys Asn His Glu Glu Glu Met Lys Glu Phe Ser Ser Gln Leu
                245                 250                 255

Ala Gly Gln Val Asn Val Glu Met Asp Ala Ala Pro Gly Val Asp
                260                 265                 270

Leu Thr Arg Val Leu Ala Glu Met Arg Glu Gln Tyr Glu Ala Met
                275                 280                 285

Ala Glu Lys Asn Arg Arg Asp Val Glu Ala Trp Phe Phe Ser Lys
                290                 295                 300

Thr Glu Glu Leu Asn Lys Glu Val Ala Ser Asn Thr Glu Met Ile
                305                 310                 315

Gln Thr Ser Lys Thr Glu Ile Thr Asp Leu Arg Arg Thr Met Gln
                320                 325                 330

Glu Leu Glu Ile Glu Leu Gln Ser Gln Leu Ser Met Lys Ala Gly
                335                 340                 345

Leu Glu Asn Ser Leu Ala Glu Thr Glu Cys Arg Tyr Ala Thr Gln
                350                 355                 360

Leu Gln Gln Ile Gln Gly Leu Ile Gly Gly Leu Glu Ala Gln Leu
                365                 370                 375
```

-continued

```
Ser Glu Leu Arg Cys Glu Met Glu Ala Gln Asn Gln Glu Tyr Lys
                380                 385                 390

Met Leu Leu Asp Ile Lys Thr Arg Leu Glu Gln Glu Ile Ala Thr
                395                 400                 405

Tyr Arg Ser Leu Leu Glu Gly Gln Asp Ala Lys Met Ala Gly Ile
                410                 415                 420

Gly Ile Arg Glu Ala Ser Ser Gly Gly Gly Gly Ser Ser Ser Asn
                425                 430                 435

Phe His Ile Asn Val Glu Glu Ser Val Asp Gly Gln Val Val Ser
                440                 445                 450

Ser His Lys Arg Glu Ile
                455
```

<210> SEQ ID NO 32
<211> LENGTH: 1393
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1709118CB1

<400> SEQUENCE: 32

```
ggacagggct ggagatcgag ttcccagttc gtgaaaagga aaacccccctg aagctgtgcc     60

aagatgtgtg acgacgagga gaccaccgcc ctggtgtgcg acaacggctc tgggctggtg    120

aaggccggct ttgcgggcga tgacgcgccc cgcgctgtct tcccgtccat cgtgggccgc    180

ccgcggcacc agggagttat ggtgggtatg ggtcagaagg actcctacgt aggtgatgaa    240

gcccagagca agagaggcat cctgaccctg aagtatccca tcgagcatgg tatcatcacc    300

aactgggacg acatggagaa gatctggcac cacaccttct acaatgagct ccgtgtggct    360

cccgaggagc accccaccct gctcacagag gccccgctga accccaaggc caaccgggag    420

aagatgactc agatcatgtt tgagaccttc aatgtccctg ccatgtacgt ggccatccag    480

gcagtgctat ccctgtatgc ttctggccgt accacaggca ttgttctgga ctctggggat    540

ggtgtaactc acaatgtccc catctatgag ggctacgctt tgccccatgc catcatgcgt    600

ctggttctgg ctggtcggga cctcactgac tacctcatga agatcctcac tgagcgtggc    660

tactcctttg tcaccactgc tgaacgtgaa attgtccgtg acattaaaga gaagctgtgc    720

tatgtcgccc tggattttga gaatgagatg gccacagctg cctcttcctc ctccctggag    780

aagagctatg aactgcctga tggccaagtc atcactattg gcaatgagcg cttccgctgt    840

cctgagacac tcttccagcc ctccttcatt ggtatggaat ctgctggcat ccatgaaaca    900

acttacaata gcatcatgaa gtgtgacatt gatatccgca aggacctgta tgccaacaat    960

gtcttatctg gaggcaccac tatgtaccct ggtattgctg atcgtatgca gaaggaaatc   1020

actgctctgg ctcctagcac catgaagatt aagattattg ctccccctga gcgtaaatac   1080

tctgtctgga ttgggggctc catcctggcc tctctgtcca ccttccagca aatgtggatt   1140

agcaagcaag agtacgatga ggcaggccca tccattgtcc accgcaaatg cttctaagat   1200

gccttctctc tccatctacc ttccagtcag gatgacggta ttatgcttct tggagtcttc   1260

caaaccacct tccctcatct ttcatcaatc attgtacagt ttgtttacac acgtgcaatt   1320

tgtttgtgct tctaatattt attgctttat aaataaacca gaccaggact tgcaacctaa   1380

aaaaaaaaaa aaa                                                      1393
```

<210> SEQ ID NO 33

-continued

<211> LENGTH: 377
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1709118CD1

<400> SEQUENCE: 33

Met Cys Asp Asp Glu Glu Thr Thr Ala Leu Val Cys Asp Asn Gly
1 5 10 15

Ser Gly Leu Val Lys Ala Gly Phe Ala Gly Asp Asp Ala Pro Arg
20 25 30

Ala Val Phe Pro Ser Ile Val Gly Arg Pro Arg His Gln Gly Val
35 40 45

Met Val Gly Met Gly Gln Lys Asp Ser Tyr Val Gly Asp Glu Ala
50 55 60

Gln Ser Lys Arg Gly Ile Leu Thr Leu Lys Tyr Pro Ile Glu His
65 70 75

Gly Ile Ile Thr Asn Trp Asp Asp Met Glu Lys Ile Trp His His
80 85 90

Thr Phe Tyr Asn Glu Leu Arg Val Ala Pro Glu Glu His Pro Thr
95 100 105

Leu Leu Thr Glu Ala Pro Leu Asn Pro Lys Ala Asn Arg Glu Lys
110 115 120

Met Thr Gln Ile Met Phe Glu Thr Phe Asn Val Pro Ala Met Tyr
125 130 135

Val Ala Ile Gln Ala Val Leu Ser Leu Tyr Ala Ser Gly Arg Thr
140 145 150

Thr Gly Ile Val Leu Asp Ser Gly Asp Gly Val Thr His Asn Val
155 160 165

Pro Ile Tyr Glu Gly Tyr Ala Leu Pro His Ala Ile Met Arg Leu
170 175 180

Val Leu Ala Gly Arg Asp Leu Thr Asp Tyr Leu Met Lys Ile Leu
185 190 195

Thr Glu Arg Gly Tyr Ser Phe Val Thr Thr Ala Glu Arg Glu Ile
200 205 210

Val Arg Asp Ile Lys Glu Lys Leu Cys Tyr Val Ala Leu Asp Phe
215 220 225

Glu Asn Glu Met Ala Thr Ala Ala Ser Ser Ser Ser Leu Glu Lys
230 235 240

Ser Tyr Glu Leu Pro Asp Gly Gln Val Ile Thr Ile Gly Asn Glu
245 250 255

Arg Phe Arg Cys Pro Glu Thr Leu Phe Gln Pro Ser Phe Ile Gly
260 265 270

Met Glu Ser Ala Gly Ile His Glu Thr Thr Tyr Asn Ser Ile Met
275 280 285

Lys Cys Asp Ile Asp Ile Arg Lys Asp Leu Tyr Ala Asn Asn Val
290 295 300

Leu Ser Gly Gly Thr Thr Met Tyr Pro Gly Ile Ala Asp Arg Met
305 310 315

Gln Lys Glu Ile Thr Ala Leu Ala Pro Ser Thr Met Lys Ile Lys
320 325 330

Ile Ile Ala Pro Pro Glu Arg Lys Tyr Ser Val Trp Ile Gly Gly
335 340 345

Ser Ile Leu Ala Ser Leu Ser Thr Phe Gln Gln Met Trp Ile Ser

-continued

350 355 360

Lys Gln Glu Tyr Asp Glu Ala Gly Pro Ser Ile Val His Arg Lys
365 370 375

Cys Phe

<210> SEQ ID NO 34
<211> LENGTH: 2310
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 008513.49
<221> NAME/KEY: unsure
<222> LOCATION: 2307
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 34

cttccctctc tcctccagcc tctcacactc tcctcagctc tctcatctcc tggaaccatg 60

gccagcacat ccaccaccat caggagccac agcagcagcc gccggggttt cagtgccaac 120

ttcagccagg ctcctgggg tcagccgctc tggcttcagc agcgtctccg tgtcccgctc 180

caggggcagt ggtggcctgg gtggtgcatg tggaggagct ggctttggca gccgcagtct 240

gtatggcctg gggggctcca agaggatctc cattggaggg ggcagctgtg ccatcagtgg 300

cggctatggc agcagagccg gaggcagcta tggctttggt ggcgccggga gtggatttgg 360

tttcggtggt ggagccggca ttggctttgg tctgggtggt ggagccggcc ttgctggtgg 420

ctttgggggc cctggcttcc ctgtgtgccc ccctggaggc atccaagagg tcaccgtcaa 480

ccagagtctc ctgactcccc tcaacctgca aatcgatccc accatccagc gggtgcgggc 540

cgaggagcgt gagcagatca agaccctcaa caacaagttt gcctccttca tcgacaaggt 600

gcggttcctg gagcagcaga acaaggttct ggaaacaaag tggaccctgc tgcaggagca 660

gggcaccaag actgtgaggc agaacctgga gccgttgttc gagcagtaca tcaacaacct 720

caggaggcag ctggacagca ttgtcgggga acggggccgc ctggactcag agctcagagg 780

catgcaggac ctggtggagg acttcaagaa caaatatgag gatgaaatca acaagcgcac 840

agcagcagag aatgaatttg tgactctgaa gaaggatgtg gatgctgcct acatgaacaa 900

ggttgaactg caagccaagg cagacactct cacagacgag atcaacttcc tgagagcctt 960

gtatgatgca gagctgtccc agatgcagac ccacatctca gacacatctg tggtgctgtc 1020

catggacaac aaccgcaacc tggacctgga cagcatcatc gctgaggtca aggcccaata 1080

tgaggagatt gctcagagaa gccgggctga ggctgagtcc tggtaccaga ccaagtacga 1140

ggagctgcag gtcacagcag gcagacatgg ggacgacctg cgcaacacca agcaggagat 1200

tgctgagatc aaccgcatga tccagaggct gagatctgag atcgaccacg tcaagaagca 1260

gtgcgccaac ctgcaggccg ccattgctga tgctgagcag cgtggggaga tggccctcaa 1320

ggatgccaag aacaagctgg aagggctgga ggatgccctg cagaaggcca agcaggacct 1380

ggcccggctg ctgaaggagt accaggagct gatgaatgtc aagctggccc tggacgtgga 1440

gatcgccacc taccgcaagc tgctggaggg tgaggagtgc aggctgaatg gcgaaggcgt 1500

tggacaagtc aacatctctg tggtgcagtc caccgtctcc agtggctatg gcggtgccag 1560

tggtgtcggc agtggcttag gcctgggtgg aggaagcagc tactcctatg gcagtggtct 1620

tggcgttgga ggtggcttca gttccagcag tggcagagcc attgggggtg gcctcagctc 1680

tgttggaggc ggcagttcca ccatcaagta caccaccacc tcctcctcca gcaggaagag 1740

-continued

ctataagcac taaagtgcgt ctgctagctc tcggtcccac agtcctcagg cccctctctg 1800

gctgcagagc cctctcctca ggttgccttt cctctcctgg cctccagtct cccctgctgt 1860

cccaggtaga gctgggtatg gatgcttagt gccctcactt cttctctctc tctctatacc 1920

atctgagcac ccattgctca ccatcagatc aacctctgat tttacatcat gatgtaatca 1980

ccactggagc ttcactgtta ctaaattatt aatttcttgc ctccagtgtt ctatctctga 2040

ggctgagcat tataagaaaa tgacctctgc tccttttcat tgcagaaaat tgccaggggc 2100

ttatttcaga acaacttcca cttactttcc actggctctc aaactctcta acttataagt 2160

gttgtgaacc cccacccagg cagtatccat gaaagcacaa gtgactagtc ctatgatgta 2220

caaagcctgt atctctgtga tgatttctgt gctcttcgct gtttgcaatt gctaaataaa 2280

gcagatttat aatacaaaaa aaaaaanggg 2310

<210> SEQ ID NO 35
<211> LENGTH: 493
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 047568.1

<400> SEQUENCE: 35

cttaacctta attttataag agacaaatac atgttataat aatacttaag ctctttatag 60

aatttgtagg gctattgaga gacattatag ggaagccctt gttctggaag gtgtatggtt 120

gtggccatgg gtttctctgc cactaaatct gtacctggtt gttatttgaa gttttctgtc 180

ctaaaatgta atctttggag aagctgcaca accgccatct gggaactcat gagaaattta 240

cgttttatgc ctaagtaact ctaatgagca atggctatag gaatgactaa taaaatatca 300

acaaggagat gggaattttc aaggaaatat gatatggtaa caatgtcctt tttagaaagt 360

catttttact tatctatatt cacagcataa aatgttccaa aatctatgaa atattaaata 420

ttatacttca aaataaagta atattttgga gataaaagag tactgttcta caattcaaaa 480

ttgaaatagt tca 493

<210> SEQ ID NO 36
<211> LENGTH: 1983
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3120070CB1

<400> SEQUENCE: 36

ggaaccgcct ccccgcggcc tcttcgcttt tgtggcggcg cccgcgctcg caggccactc 60

tctgctgtcg cccgtcccgc gcgctcctcc gacccgctcc gctccgctcc gctcggcccc 120

gcgccgcccg tcaacatgat ccgctgcggc ctggcctgcg agcgctgccg ctggatcctg 180

cccctgctcc tactcagcgc catcgccttc gacatcatcg cgctggccgg ccgcggctgg 240

ttgcagtcta gcgaccacgg ccagacgtcc tcgctgtggt ggaaatgctc ccaagagggc 300

ggcggcagcg ggtcctacga ggagggctgt cagagcctca tggagtacgc gtggggtaga 360

gcagcggctg ccatgctctt ctgtggcttc atcatcctgg tgatctgttt catcctctcc 420

ttcttcgccc tctgtggacc ccagatgctt gtcttcctga gagtgattgg aggtctcctt 480

gccttggctg ctgtgttcca gatcatctcc ctggtaattt accccgtgaa gtacacccag 540

accttcaccc ttcatgccaa ccctgctgtc acttacatct ataactgggc ctacggcttt 600

-continued

gggtgggcag ccacgattat cctgattggc tgtgccttct tcttctgctg cctccccaac 660

tacgaagatg accttctggg caatgccaag cccaggtact tctacacatc tgcctaactt 720

gggaatgaat gtgggagaaa atcgctgctg ctgagatgga ctccagaaga agaaactgtt 780

tctccaggcg actttgaacc catttttgg cagtgttcat attattaaac tagtcaaaaa 840

tgctaaaata atttgggaga aaatattttt taagtagtgt tatagtttca tgtttatctt 900

ttattatgtt ttgtgaagtt gtgtcttttc actaattacc tatactatgc caatatttcc 960

ttatatctat ccataacatt tatactacat ttgtaagaga atatgcacgt gaaacttaac 1020

actttataag gtaaaaatga ggtttccaag atttaataat ctgatcaagt tcttgttatt 1080

tccaaataga atggactcgg tctgttaagg gctaaggaga agaggaagat aaggttaaaa 1140

gttgttaatg accaaacatt ctaaaagaaa tgcaaaaaaa aagtttattt tcaagccttc 1200

gaactattta aggaaagcaa aatcatttcc taaatgcata tcatttgtga gaatttctca 1260

ttaatatcct gaatcattca tttcagctaa ggcttcatgt tgactcgata tgtcatctag 1320

gaaagtacta tttcatggtc caaacctgtt gccatagttg gtaaggcttt cctttaagtg 1380

tgaaatattt agatgaaatt ttctctttta aagttcttta tagggttagg gtgtgggaaa 1440

atgctatatt aataaatctg tagtgttttg tgtttatatg ttcagaacca gagtagactg 1500

gattgaaaga tggactgggt ctaatttatc atgactgata gatctggtta agttgtgtag 1560

taaagcatta gggtcattcc tgtcacaaaa gtgccactaa aacagcctca ggagaataaa 1620

tgacttgctt ttctaaatct caggtttatc tgggctctat catatagaca ggcttctgat 1680

agtttgcaac tgtaagcaga aacctacata tagttaaaat cctggtcttt cttggtaaac 1740

agattttaaa tgtctgatat aaaacatgcc acaggagaat tcggggattt gagtttctct 1800

gaatagcata tatatgatgc atcggatagg tcattatgat tttttaccat ttcgacttac 1860

ataatgaaaa ccaattcatt ttaaatatca gattattatt ttgtaagttg tggaaaaagc 1920

taattgtagt tttcattatg aagttttccc aataaaccag gtattctaaa cttgaaaaaa 1980

aaa 1983

<210> SEQ ID NO 37
<211> LENGTH: 193
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3120070CD1

<400> SEQUENCE: 37

Met Ile Arg Cys Gly Leu Ala Cys Glu Arg Cys Arg Trp Ile Leu
1 5 10 15

Pro Leu Leu Leu Leu Ser Ala Ile Ala Phe Asp Ile Ile Ala Leu
20 25 30

Ala Gly Arg Gly Trp Leu Gln Ser Ser Asp His Gly Gln Thr Ser
35 40 45

Ser Leu Trp Trp Lys Cys Ser Gln Glu Gly Gly Gly Ser Gly Ser
50 55 60

Tyr Glu Glu Gly Cys Gln Ser Leu Met Glu Tyr Ala Trp Gly Arg
65 70 75

Ala Ala Ala Ala Met Leu Phe Cys Gly Phe Ile Ile Leu Val Ile
80 85 90

Cys Phe Ile Leu Ser Phe Phe Ala Leu Cys Gly Pro Gln Met Leu

-continued

```
                 95                  100                 105

Val Phe Leu Arg Val Ile Gly Gly Leu Leu Ala Leu Ala Ala Val
                110                 115                 120

Phe Gln Ile Ile Ser Leu Val Ile Tyr Pro Val Lys Tyr Thr Gln
                125                 130                 135

Thr Phe Thr Leu His Ala Asn Pro Ala Val Thr Tyr Ile Tyr Asn
                140                 145                 150

Trp Ala Tyr Gly Phe Gly Trp Ala Ala Thr Ile Ile Leu Ile Gly
                155                 160                 165

Cys Ala Phe Phe Phe Cys Cys Leu Pro Asn Tyr Glu Asp Asp Leu
                170                 175                 180

Leu Gly Asn Ala Lys Pro Arg Tyr Phe Tyr Thr Ser Ala
                185                 190
```

<210> SEQ ID NO 38
<211> LENGTH: 1516
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1303785CB1
<221> NAME/KEY: unsure
<222> LOCATION: 1512
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 38

```
ctttgttttt ggacatagct gagccatgta cttcaaacag aaggcagcca attactaact     60

tctggttgct aggtgtggct tcctttaaaa tcctataaaa tcagaagccc aagtctccac    120

tgccagtgtg aaatcttcag agaagaattt ctctttagtt ctttgcaaga aggtagagat    180

aaagacactt tttcaaaaat ggcaatggta tcagaattcc tcaagcaggc ctggtttatt    240

gaaaatgaag agcaggaata tgttcaaact gtgaagtcat ccaaaggtgg tcccggatca    300

gcggtgagcc cctatcctac cttcaatcca tcctcggatg tcgctgcctt gcataaggcc    360

ataatggtta aaggtgtgga tgaagcaacc atcattgaca ttctaactaa gcgaaacaat    420

gcacagcgtc aacagatcaa agcagcatat ctccaggaaa caggaaagcc cctggatgaa    480

acactgaaga aagcccttac aggtcacctt gaggaggttg ttttagctct gctaaaaact    540

ccagcgcaat ttgatgctga tgaacttcgt gctgccatga agggccttgg aactgatgaa    600

gatactctaa ttgagatttt ggcatcaaga actaacaaag aaatcagaga cattaacagg    660

gtctacagag aggaactgaa gagagatctg gccaaagaca taacctcaga cacatctgga    720

gattttcgga acgctttgct ttctcttgct aagggtgacc gatctgagga ctttggtgtg    780

aatgaagact tggctgattc agatgccagg gccttgtatg aagcaggaga aaggagaaag    840

gggacagacg taaacgtgtt caataccatc cttaccacca gaagctatcc acaacttcgc    900

agagtgtttc agaaatacac caagtacagt aagcatgaca tgaacaaagt tctggacctg    960

gagttgaaag gtgacattga gaaatgcctc acagctatcg tgaagtgcgc cacaagcaaa   1020

ccagctttct ttgcagagaa gcttcatcaa gccatgaaag gtgttggaac tcgccataag   1080

gcattgatca ggattatggt ttcccgttct gaaattgaca tgaatgatat caaagcattc   1140

tatcagaaga tgtatggtat ctccctttgc caagccatcc tggatgaaac caaaggagag   1200

tatgagaaaa tcctggtggc tctttgtgga ggaaactaaa cattcccttg atggtctcaa   1260

gctatgatca gaagacttta attatatatt ttcatcctat aagcttaaat aggaaagttt   1320

cttcaacagg attacagtgt agctacctac atgctgaaaa atatagcctt taaatcattt   1380
```

-continued

ttatattata actctgtata atagagataa gtccattttt taaaaatgtt ttccccaaac 1440

cataaaaccc tatacaagtt gttctagtaa caatacatga gaaagatgtc tatgtagctg 1500

aaaataaaat gncgtc 1516

<210> SEQ ID NO 39
<211> LENGTH: 346
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1303785CD1

<400> SEQUENCE: 39

Met Ala Met Val Ser Glu Phe Leu Lys Gln Ala Trp Phe Ile Glu
1 5 10 15

Asn Glu Glu Gln Glu Tyr Val Gln Thr Val Lys Ser Ser Lys Gly
20 25 30

Gly Pro Gly Ser Ala Val Ser Pro Tyr Pro Thr Phe Asn Pro Ser
35 40 45

Ser Asp Val Ala Ala Leu His Lys Ala Ile Met Val Lys Gly Val
50 55 60

Asp Glu Ala Thr Ile Ile Asp Ile Leu Thr Lys Arg Asn Asn Ala
65 70 75

Gln Arg Gln Gln Ile Lys Ala Ala Tyr Leu Gln Glu Thr Gly Lys
80 85 90

Pro Leu Asp Glu Thr Leu Lys Lys Ala Leu Thr Gly His Leu Glu
95 100 105

Glu Val Val Leu Ala Leu Leu Lys Thr Pro Ala Gln Phe Asp Ala
110 115 120

Asp Glu Leu Arg Ala Ala Met Lys Gly Leu Gly Thr Asp Glu Asp
125 130 135

Thr Leu Ile Glu Ile Leu Ala Ser Arg Thr Asn Lys Glu Ile Arg
140 145 150

Asp Ile Asn Arg Val Tyr Arg Glu Glu Leu Lys Arg Asp Leu Ala
155 160 165

Lys Asp Ile Thr Ser Asp Thr Ser Gly Asp Phe Arg Asn Ala Leu
170 175 180

Leu Ser Leu Ala Lys Gly Asp Arg Ser Glu Asp Phe Gly Val Asn
185 190 195

Glu Asp Leu Ala Asp Ser Asp Ala Arg Ala Leu Tyr Glu Ala Gly
200 205 210

Glu Arg Arg Lys Gly Thr Asp Val Asn Val Phe Asn Thr Ile Leu
215 220 225

Thr Thr Arg Ser Tyr Pro Gln Leu Arg Arg Val Phe Gln Lys Tyr
230 235 240

Thr Lys Tyr Ser Lys His Asp Met Asn Lys Val Leu Asp Leu Glu
245 250 255

Leu Lys Gly Asp Ile Glu Lys Cys Leu Thr Ala Ile Val Lys Cys
260 265 270

Ala Thr Ser Lys Pro Ala Phe Phe Ala Glu Lys Leu His Gln Ala
275 280 285

Met Lys Gly Val Gly Thr Arg His Lys Ala Leu Ile Arg Ile Met
290 295 300

Val Ser Arg Ser Glu Ile Asp Met Asn Asp Ile Lys Ala Phe Tyr

-continued

305 310 315

Gln Lys Met Tyr Gly Ile Ser Leu Cys Gln Ala Ile Leu Asp Glu
320 325 330

Thr Lys Gly Glu Tyr Glu Lys Ile Leu Val Ala Leu Cys Gly Gly
335 340 345

Asn

<210> SEQ ID NO 40
<211> LENGTH: 2712
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1798379CB1

<400> SEQUENCE: 40

ccagccttga ctcttctcaa gagcctgtga ctttcctccc tggacaaagg catcatgagt 60

tgtcagatct cttgcaaatc tcgaggaaga ggaggaggtg gaggaggatt ccggggcttc 120

agcagcggct cagctgtggt gtctggtgga agccggagat caacttccag cttctcctgc 180

ttgagccgcc atggtggtgg tggtgggggc ttcggtggag gcggctttgg cagtcggagt 240

cttgttggcc ttggagggac caagagcatc tccattagtg tggctggagg aggtggtggc 300

tttggcgccg ctggtggatt tggtggcaga ggaggtggtt ttggaggcgg cagcggcttt 360

ggaggcggca gcggctttgg aggtggcagc ggcttcagtg gtggtggttt cggtggaggc 420

ggctttggtg gaggccgctt tggaggtttt gggggccctg gtggtgttgg aggtttaggg 480

ggtcctggtg gctttgggcc tggaggatac cctggtggca tccacgaagt ctctgtcaac 540

cagagcctcc tgcagcctct caacgtgaaa gttgacccag agatccagaa tgtgaaggcc 600

caagagcgtg agcagatcaa aactctcaac aacaaatttg cctccttcat tgacaaggtg 660

cggttcttgg agcagcagaa ccaggtgtta cagaccaaat gggagctgct acaacaaatg 720

aatgttggca cccgccccat caacctggag cccatcttcc aggggtatat cgacagcctc 780

aagagatatc tggatgggct cactgcagaa agaacatcac agaattcaga gctgaataac 840

atgcaggatc ttgtggagga ttataagaag aagtatgagg atgaaatcaa taagcgcaca 900

gctgctgaga atgattttgt gacgcttaaa aaggacgtgg acaatgccta catgataaag 960

gtggagttgc agtccaaggt ggacctgctg aaccaggaaa ttgagtttct gaaagttctc 1020

tatgatgcgg agatatccca gatacatcag agtgtcactg acaccaacgt catcctctcc 1080

atggacaaca gccgcaacct ggacttggat agcatcatcg ccgaggtcaa ggcccagtat 1140

gaggagatcg cccagaggag caaggaagaa gcggaggccc tgtaccacag caagtatgag 1200

gagctccagg tgactgtcgg gagacatgga gacagcctga aagagatcaa gatagagatc 1260

agcgagctga accgcgtgat ccagaggctg caggggaga tcgcacatgt gaagaagcag 1320

tgtaagaatg tgcaagatgc catcgcagat gccgagcagc gtggggagca tgccctcaag 1380

gatgccagga acaagttgaa tgacctggag gaggccctgc agcaggccaa ggaggacttg 1440

gcgcggctgc tgcgtgacta ccaggagctg atgaacgtga agctggccct agatgtggag 1500

atcgccacct accgcaaact gctggagggc gaggagtgca ggatgtctgg agacctcagc 1560

agcaatgtga ctgtgtctgt gacaagcagc accatttcat caaatgtggc atccaaggct 1620

gcctttggag gttctggagg tagagggtcc agttccggag gaggatacag ctctggaagc 1680

agcagttatg gctctggagg ccgacagtct ggctccagag gcggtagtgg aggaggaggt 1740

-continued

tctatctctg gaggaggata tggctctggc ggtggttctg gaggaagata cggatctggt 1800

ggtggctcta agggagggtc catctctgga ggaggatatg gctctggagg tggaaaacac 1860

agctctggag gtggctctag aggaggctcc agctctggag gaggatatgg ctctggaggt 1920

gggggttcta gctctgtaaa gggtagctca ggtgaagctt ttggttccag cgtgaccttc 1980

tcttttagat aaagatgagc ccccaccacc accgactctc ccaacccaga ctctcccact 2040

ccagaatgta gaagcctgtc tctgtacctc taactggcag caagttaaat ttttgtcatt 2100

tatctctgat ggcactttga gggaaaagaa tgtccacata cagtttttga aagatcttct 2160

ctccaaacca gttagttaga gccagtgacg cctctgtgtt ctggggcgga atctgtgctg 2220

tctaggtttg tgcttctagc catgcccatt cccgccccca ccatgcctct ttgcattgcc 2280

cattttccag atgtgtattc tgttgaggac ccaggcccat ccagggattt catctctaag 2340

cctggcagtg ctgggggggaa atgtgtttct gtgtatatag ctcctcttgt ccactctgct 2400

ttcggaagtg ctgtggtctg ggggtcttca taatataaac ctcatttggc aattcaaaaa 2460

aaaaaaaaag gggggccccc ccacttattt agggggttcc cgacctccaa attcgcgaac 2520

cagggaaaaa ccggtttccc ggtggaaaaa ttgtaacccg cacaaaattt ccccaaaaat 2580

attggccccg gaacctaaaa ggtaaaaact cgggggggccc aaagagtttg gcaaacccca 2640

ataatttggg tgggcacaag gcccgtttcc catgggggaa acttttgtgc cacggcttta 2700

ataataggcc cc 2712

<210> SEQ ID NO 41
<211> LENGTH: 645
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1798379CD1

<400> SEQUENCE: 41

Met Ser Cys Gln Ile Ser Cys Lys Ser Arg Gly Arg Gly Gly Gly
1 5 10 15

Gly Gly Gly Phe Arg Gly Phe Ser Ser Gly Ser Ala Val Val Ser
20 25 30

Gly Gly Ser Arg Arg Ser Thr Ser Ser Phe Ser Cys Leu Ser Arg
35 40 45

His Gly Gly Gly Gly Gly Gly Phe Gly Gly Gly Gly Phe Gly Ser
50 55 60

Arg Ser Leu Val Gly Leu Gly Gly Thr Lys Ser Ile Ser Ile Ser
65 70 75

Val Ala Gly Gly Gly Gly Gly Phe Gly Ala Ala Gly Gly Phe Gly
80 85 90

Gly Arg Gly Gly Gly Phe Gly Gly Gly Ser Gly Phe Gly Gly Gly
95 100 105

Ser Gly Phe Gly Gly Gly Ser Gly Phe Ser Gly Gly Gly Phe Gly
110 115 120

Gly Gly Gly Phe Gly Gly Gly Arg Phe Gly Gly Phe Gly Gly Pro
125 130 135

Gly Gly Val Gly Gly Leu Gly Gly Pro Gly Gly Phe Gly Pro Gly
140 145 150

Gly Tyr Pro Gly Gly Ile His Glu Val Ser Val Asn Gln Ser Leu
155 160 165

Leu Gln Pro Leu Asn Val Lys Val Asp Pro Glu Ile Gln Asn Val

-continued

```
                170                 175                 180

Lys Ala Gln Glu Arg Glu Gln Ile Lys Thr Leu Asn Asn Lys Phe
                185                 190                 195

Ala Ser Phe Ile Asp Lys Val Arg Phe Leu Glu Gln Gln Asn Gln
                200                 205                 210

Val Leu Gln Thr Lys Trp Glu Leu Leu Gln Gln Met Asn Val Gly
                215                 220                 225

Thr Arg Pro Ile Asn Leu Glu Pro Ile Phe Gln Gly Tyr Ile Asp
                230                 235                 240

Ser Leu Lys Arg Tyr Leu Asp Gly Leu Thr Ala Glu Arg Thr Ser
                245                 250                 255

Gln Asn Ser Glu Leu Asn Asn Met Gln Asp Leu Val Glu Asp Tyr
                260                 265                 270

Lys Lys Lys Tyr Glu Asp Glu Ile Asn Lys Arg Thr Ala Ala Glu
                275                 280                 285

Asn Asp Phe Val Thr Leu Lys Lys Asp Val Asp Asn Ala Tyr Met
                290                 295                 300

Ile Lys Val Glu Leu Gln Ser Lys Val Asp Leu Leu Asn Gln Glu
                305                 310                 315

Ile Glu Phe Leu Lys Val Leu Tyr Asp Ala Glu Ile Ser Gln Ile
                320                 325                 330

His Gln Ser Val Thr Asp Thr Asn Val Ile Leu Ser Met Asp Asn
                335                 340                 345

Ser Arg Asn Leu Asp Leu Asp Ser Ile Ile Ala Glu Val Lys Ala
                350                 355                 360

Gln Tyr Glu Glu Ile Ala Gln Arg Ser Lys Glu Glu Ala Glu Ala
                365                 370                 375

Leu Tyr His Ser Lys Tyr Glu Glu Leu Gln Val Thr Val Gly Arg
                380                 385                 390

His Gly Asp Ser Leu Lys Glu Ile Lys Ile Glu Ile Ser Glu Leu
                395                 400                 405

Asn Arg Val Ile Gln Arg Leu Gln Gly Glu Ile Ala His Val Lys
                410                 415                 420

Lys Gln Cys Lys Asn Val Gln Asp Ala Ile Ala Asp Ala Glu Gln
                425                 430                 435

Arg Gly Glu His Ala Leu Lys Asp Ala Arg Asn Lys Leu Asn Asp
                440                 445                 450

Leu Glu Glu Ala Leu Gln Gln Ala Lys Glu Asp Leu Ala Arg Leu
                455                 460                 465

Leu Arg Asp Tyr Gln Glu Leu Met Asn Val Lys Leu Ala Leu Asp
                470                 475                 480

Val Glu Ile Ala Thr Tyr Arg Lys Leu Leu Glu Gly Glu Glu Cys
                485                 490                 495

Arg Met Ser Gly Asp Leu Ser Ser Asn Val Thr Val Ser Val Thr
                500                 505                 510

Ser Ser Thr Ile Ser Ser Asn Val Ala Ser Lys Ala Ala Phe Gly
                515                 520                 525

Gly Ser Gly Gly Arg Gly Ser Ser Ser Gly Gly Gly Tyr Ser Ser
                530                 535                 540

Gly Ser Ser Ser Tyr Gly Ser Gly Gly Arg Gln Ser Gly Ser Arg
                545                 550                 555

Gly Gly Ser Gly Gly Gly Gly Ser Ile Ser Gly Gly Gly Tyr Gly
                560                 565                 570
```

-continued

Ser Gly Gly Gly Ser Gly Gly Arg Tyr Gly Ser Gly Gly Gly Ser
575 580 585

Lys Gly Gly Ser Ile Ser Gly Gly Gly Tyr Gly Ser Gly Gly Gly
590 595 600

Lys His Ser Ser Gly Gly Gly Ser Arg Gly Gly Ser Ser Ser Gly
605 610 615

Gly Gly Tyr Gly Ser Gly Gly Gly Gly Ser Ser Ser Val Lys Gly
620 625 630

Ser Ser Gly Glu Ala Phe Gly Ser Ser Val Thr Phe Ser Phe Arg
635 640 645

<210> SEQ ID NO 42
<211> LENGTH: 663
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 350650.1

<400> SEQUENCE: 42

ctgggccatg aaaagctccc tggagggaac cctggctgac acagaagctg gctacgtggc 60

tcagctgtca gaaattcaaa cgcagatcag tgccctggag gaggagatct gccagatctg 120

gggtgagact aaatgccaga acgcagagta caagcaattg ctggacatca agacacgcct 180

ggaggtggag atcgagacct accgccgcct gctcgatgga gagggaggtg gttctagttt 240

tgcagaattt ggtggtagaa actccaggat ctgtaaacat ggggatccca gggatctggg 300

tatctggtga ctcaagatct ggaagctgtt ctggtcaagg acgagattca agcaagacta 360

gagtgactaa gactatcgta gaggagttgg tggatggcaa ggttgtctcg tctcaagtca 420

gcagtatttc tgaggtgaaa gttaaataag gaacttccag atcaacaaaa gtgtctttca 480

aagaaaaaaa aatcaagaag gacacaagcg aagaaatggc atcaatctag gcatctttct 540

ggataatttc aggaaaagct tcagtccaga aatggatgac tagccaactt ttctgcatct 600

tcttatttcc tcattagaat gctcttgaaa tagctgaatt aacaactttg ctttaattgt 660

ttg 663

<210> SEQ ID NO 43
<211> LENGTH: 809
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 474630.24
<221> NAME/KEY: unsure
<222> LOCATION: 511
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 43

ccgggagctg gagacgggct cccctcgcag agcctacggc cttcccccgc ctggccctgc 60

tcggcccggc gccccccggc ggtgccaacg cggcccttcg ttgttcccaa tggctgcggc 120

tggaagttcg agcccctgct gggggaggag ctggacctgc ggcgcgtcac gtggcggctg 180

ccccggagc tcatcccgcg cctgtcggcc agcagcgggc gctcctccga cgccgaggcg 240

ccccacgggc ccccggacga cggcggcgcg ggcgggaagg gcggcagcct gccccgcagt 300

gcgacacccg ggcccccggg aggtgacagg ctcacccgcc gccccccgat ccgcgcccac 360

ccagcctcac tcgcgcctga gggccctggg gtgggcgtct gcgctgcctc gggggcccca 420

-continued

gtctcagcca ggcacgggcc ttggcggctg ggagcacagc tgctcagagg cagggcccag 480

tgccagggga cgcgtgaggc aggcgcttgg nccccttatgg tgcctgcctg gccaggggt 540

gcaaattcag aagtctgccc gggaagcgga ccctggcacc caagtagacc cctcaggggc 600

ctcaaaggac aggagggaag gcttggggat ctccccaggg cagagctgac tgcagacgca 660

gcaaaccccc gccactgcca gggtcagcag tgctcacacc gatagagtgg ccggccagag 720

gatatgggct gtggaagcct gggtggccct tgggctcctg ctaggacaga gggcctctgt 780

ccctagtggt ttgagggaaa ctggttgta 809

<210> SEQ ID NO 44
<211> LENGTH: 295
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 108089.1

<400> SEQUENCE: 44

gggaactagg tcttggccct ttctacagct tttctcctgc aaagggtcca gccttttcct 60

gctccccacg ttgtccttac ggctgtgtgg ggtagggcag ggtccacact ccttcccatc 120

cattttagag gaggaagctg gagtctggga agggatggga ttttcccagg gcaccctgtg 180

agtcacatgc cacttgagac aagggtctag agctccagca ttttccaagc tacaaatgta 240

tctgctgctc caagtgtccg ccagggtcgg cctcagagct ggcaggagtt cggtg 295

<210> SEQ ID NO 45
<211> LENGTH: 1744
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3346307CB1

<400> SEQUENCE: 45

ccaaggggga ggtgcgagcg tggacctggg acgggtctgg gcggctctcg gtggttggca 60

cgggttcgca cacccattca agcggcagga cgcacttgtc ttagcagttc tcgctgaccg 120

cgctagctgc ggcttctacg ctccggcact ctgagttcat cagcaaacgc cctggcgtct 180

gtcctcacca tgcctagcct ttgggaccgc ttctcgtcgt cgtccacctc ctcttcgccc 240

tcgtccttgc cccgaactcc caccccagat cggccgccgc gctcagcctg ggggtcggcg 300

acccgggagg aggggtttga ccgctccacg agcctggaga gctcggactg cgagtccctg 360

gacagcagca acagtggctt cgggccggag gaagacacgg cttacctgga tggggtgtcg 420

ttgcccgact tcgagctgct cagtgaccct gaggatgaac acttgtgtgc caacctgatg 480

cagctgctgc aggagagcct ggcccaggcg cggctgggct ctcgacgccc tgcgcgcctg 540

ctgatgccta gccagttggt aagccaggtg ggcaaagaac tactgcgcct ggcctacagc 600

gagccgtgcg gcctgcgggg ggcgctgctg gacgtctgcg tggagcaggg caagagctgc 660

cacagcgtgg gccagctggc actcgacccc agcctggtgc ccaccttcca gctgaccctc 720

gtgctgcgcc tggactcacg actctggccc aagatccagg ggctgtttag ctccgccaac 780

tctcccttcc tccctggctt cagccagtcc ctgacgctga gcactggctt ccgagtcatc 840

aagaagaagc tgtacagctc ggaacagctg ctcattgagg agtgttgaac ttcaacctga 900

gggggccgac agtgccctcc aagacagaga cgactgaact tttggggtgg agactagagg 960

caggagctga gggactgatt ccagtggttg gaaaactgag gcagccacct aaggtggagg 1020

-continued

tgggggaata gtgtttccca ggaagctcat tgagttgtgt gcgggtggct gtgcattggg 1080

gacacatacc cctcagtact gtagcatgaa acaaaggctt aggggccaac aaggcttcca 1140

gctggatgtg tgtgtagcat gtaccttatt atttttgtta ctgacagtta acagtggtgt 1200

gacatccaga gagcagctgg gctgctcccg ccccagcccg gcccagggtg aaggaagagg 1260

cacgtgctcc tcagagcagc cggagggagg ggggaggtcg gaggtcgtgg aggtggtttg 1320

tgtatcttac tggtctgaag ggaccaagtg tgtttgttgt ttgttttgta tcttgttttt 1380

ctgatcggag catcactact gacctgttgt aggcagctat cttacagacg catgaatgta 1440

agagtaggaa ggggtgggtg tcagggatca cttgggatct ttgacacttg aaaaattaca 1500

cctggcagct gcgtttaagc cttcccccat cgtgtactgc agagttgagc tggcagggga 1560

ggggctgaga gggtgggggc tggaacccct ccccgggagg agtgccatct gggtcttcca 1620

tctagaactg tttacatgaa gataagatac tcactgttca tgaatacact tgatgttcaa 1680

gtattaagac ctatgcaata ttttttactt ttctaataaa catgtttgtt aaaacaaaaa 1740

aaaa 1744

<210> SEQ ID NO 46
<211> LENGTH: 232
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3346307CD1

<400> SEQUENCE: 46

Met Pro Ser Leu Trp Asp Arg Phe Ser Ser Ser Ser Thr Ser Ser
1 5 10 15

Ser Pro Ser Ser Leu Pro Arg Thr Pro Thr Pro Asp Arg Pro Pro
20 25 30

Arg Ser Ala Trp Gly Ser Ala Thr Arg Glu Glu Gly Phe Asp Arg
35 40 45

Ser Thr Ser Leu Glu Ser Ser Asp Cys Glu Ser Leu Asp Ser Ser
50 55 60

Asn Ser Gly Phe Gly Pro Glu Glu Asp Thr Ala Tyr Leu Asp Gly
65 70 75

Val Ser Leu Pro Asp Phe Glu Leu Leu Ser Asp Pro Glu Asp Glu
80 85 90

His Leu Cys Ala Asn Leu Met Gln Leu Leu Gln Glu Ser Leu Ala
95 100 105

Gln Ala Arg Leu Gly Ser Arg Arg Pro Ala Arg Leu Leu Met Pro
110 115 120

Ser Gln Leu Val Ser Gln Val Gly Lys Glu Leu Leu Arg Leu Ala
125 130 135

Tyr Ser Glu Pro Cys Gly Leu Arg Gly Ala Leu Leu Asp Val Cys
140 145 150

Val Glu Gln Gly Lys Ser Cys His Ser Val Gly Gln Leu Ala Leu
155 160 165

Asp Pro Ser Leu Val Pro Thr Phe Gln Leu Thr Leu Val Leu Arg
170 175 180

Leu Asp Ser Arg Leu Trp Pro Lys Ile Gln Gly Leu Phe Ser Ser
185 190 195

Ala Asn Ser Pro Phe Leu Pro Gly Phe Ser Gln Ser Leu Thr Leu
200 205 210

-continued

Ser Thr Gly Phe Arg Val Ile Lys Lys Lys Leu Tyr Ser Ser Glu
215 220 225

Gln Leu Leu Ile Glu Glu Cys
230

<210> SEQ ID NO 47
<211> LENGTH: 897
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 200143.25

<400> SEQUENCE: 47

ccccagggca gggagcaggt tatgaccagg actaaggtcc cagagtcccc accctgaccc 60

ctccctgctg ttccagccgc tccctcatat ccacccctgc cccatctcct gactttggtc 120

acgctagcat cttctgctga tcctgaaatt gtaccagcgg caagatgtgg cctggaaggg 180

gactttaagt tctccacaac tgccagcaat ccttccacca ggcaaaacac atcatctaag 240

gaaaagaagt gaggtcggaa caccaacgca tcatctcact gcatggccct ggaggctctg 300

ccgtttaaag accccagaac cttccccatt caaggtcctc tcctgggcac aggagattgg 360

agaaagctcc tcccttaatt ccagggaccg agttccagcc catccaattc tccgtctcac 420

ctgaggctgc tgtggtcctg gtgaccccag ggagcaacct gccgcccatg gctggggagg 480

gggtgaagct gtctctttaa gagcaggaat ggagcccctg ggcctcaggg catctgactt 540

gttttctacc tgcccaggtt tgcttagggc gtggcagctt cggataaacg caggactccg 600

cctggcagcc cgatttctcc cggaacctct gctcagcctg gtgaaccaca caggtgagca 660

gctggggccc cttcctccaa gccctccttg tctctgcccc taaattagga agtatctacc 720

tgccccctga ccctgcccca tagaagcttt tatgttaaag cgcctaaaat cttgtgaaat 780

gcttttctgg agccaggaga taaacggaag tcccttcccc taatgtccct ttccccacca 840

ttctcctctc agggacttgt tgaaccagct gaggccagcg ctctgacatg cagaagg 897

<210> SEQ ID NO 48
<211> LENGTH: 1827
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 001929.1

<400> SEQUENCE: 48

ccttgacaat ctgtctgtcc gtctgcagct gcgtgactgt ctgtctctgc catgtctctc 60

tccccatgcc gggcccagag gggcttcagc gctcgctcag cctgttctgc tcgctcaagg 120

ggccgcagca ggggaggctt cagcagcagg ggcggcttca gcagcaggag ccttaattcc 180

tttggggggt gcctggaagg ctctcgtggg agtacctggg ggtcaggggg taggctgggg 240

gtgcggtttg gggagtggag tggtgggcct gggctctccc tgtgccctcc gggggggcatc 300

caagaagtga ccatcaacca gaatccgctg accccactga agattgagat cgatccccag 360

ttccaggtgg tgcggacgca ggagacccag gagatcagaa ccctcaacaa ccagtttgct 420

tccttcattg acaaggtgcg gttcctggag cagcagaaca aggtcctgga gacgaagtgg 480

catctgctgc agcaacaggg gttgagtggc agccagcagg gcctggagcc tgtctttgag 540

gcctgcctgg atcagctcag gaagcagctg gagcagctcc agggagaacg aggggctctg 600

-continued

gatgctgagt tgaaggcctg ccgggaccag gaggaggagt ataagtccaa gtatgaggag 660

gaggcccaca ggcgtgccac acttgagaac gactttgtgg tcctcaagaa ggatgtggat 720

ggggttttcc tgagcaagat ggagttggag ggcaagctgg aggctctgag agagtacctc 780

tacttcttga agcatctgaa tgaagaagag ctgggccagc tccagaccca ggccagcgac 840

acgtctgtgg tgctgtccat ggacaacaac cgctacctgg acttcagcag catcatcact 900

gaggtccgcg cccggtacga ggagatcgcc cggagcagca aggctgaggc tgaggccttg 960

taccagacca agtaccagga acttcaggtg tctgcccagc ttcatgggga caggatgcag 1020

gaaacgaaag tccagatctc tcagctacac caagagattc agaggctgca gagtcagact 1080

gagaacctca agaagcagaa cgccagcctg caggccgcca tcactgatgc tgagcagcgt 1140

ggggagctgg ccctcaagga cgctcaggcc aaggtggacg agctggaggc tgctctgagg 1200

atggccaagc agaacctggc ccggctgctg tgcgagtacc aggagctgac gagcacgaag 1260

ctttccctgg atgtggagat tgccacttac cgcaggctgc tggagggcga ggagtgcagg 1320

atgtctgggg agtgcaccag ccaggtcact atctcctcgg tgggaggcag cgctgtcatg 1380

tctggaggag ttggtggagg cttggggagc acttgtggac tcggtagtgg gaaaggcagc 1440

cctgggtcct gctgcaccag cattgtgact ggaggctcca acatcattct gggctctggg 1500

aaggaccctg ttttggattc ctgctctgtg tctggctcca gcgctggctc cagctgccac 1560

accatcctga agaagacagt tgagtcgagt ctgaagacat ccatcaccta ctgagcgacc 1620

cagcagccac ctccttcctg aacacatttg gcccactccc cccatcagcc ggctctgcaa 1680

ggccaactcc gtgtccgctg cccacagccc aagccagccc acagcggatg ctgcaaaaat 1740

caataaagtc tcccctcctg ctgttctgaa tgctctaagt gcttgcacac ctcacccagc 1800

aaaacaaaag ctgtgtgact ccccagc 1827

<210> SEQ ID NO 49
<211> LENGTH: 3936
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1088524.8
<221> NAME/KEY: unsure
<222> LOCATION: 2060-2170, 3796, 3799, 3816
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 49

taaacacagc tgcgatgacg aacccttca cgggaaggaa catgcgagcc cagaaaagtc 60

tctcctggtc ttgggatgga ggtcacacga agcctccgca aggcaaggac ttttgcggct 120

tctgcaacca agcgggtctt acccccggtc ctccgcgtct ccagtcctcg cacctggaac 180

cccaacgtcc ccgagagtcc ccgaatcccc gctcccaggc tacctaagag gatgagcggt 240

gctccgacgg ccggggcagc cctgatgctc tgcgccgcca ccgccgtgct actgagcgct 300

cagggcggac ccgtgcagtc caagtcgccg cgctttgcgt cctgggacga gatgaatgtc 360

ctggcgcacg gactcctgca gctcggccag gggctgcgcg aacacgcgga gcgcacccgc 420

agtcagctga gcgcgctgga gcggcgcctg agcgcgtgcg ggtccgcctg tcagggaacc 480

gaggggtcca ccgacctccc gttagcccct gagagccggg tggaccctga ggtccttcac 540

agcctgcaga cacaactcaa ggctcagaac agcaggatcc agcaactctt ccacaaggtg 600

gcccagcagc agcggcacct ggagaagcag cacctgcgaa ttcagcatct gcaaagccag 660

tttggcctcc tggaccacaa gcacctagac catgaggtgg ccaagcctgc ccgaagaaag 720

-continued

aggctgcccg agatggccca gccagttgac ccggctcaca atgtcagccg cctgcaccgg 780

ctgcccaggg attgccagga gctgttccag gttggggaga ggcagagtgg actatttgaa 840

atccagcctc aggggtctcc gccatttttg gtgaactgca agatgacctc agatggaggc 900

tggacagtaa ttcagaggcg ccacgatggc tcagtggact tcaaccggcc ctgggaagcc 960

tacaaggcgg ggtttgggga tccccacggc gagttctggc tgggtctgga gaaggtgcat 1020

agcatcaccg ggggaccgca acagccgcct ggccgtgcag ctgcgggact gggatggcaa 1080

cgccgagttg ctgcagttct ccgtgcacct gggtggcgag gacacggcct atagcctgca 1140

gctcactgca cccgtggccg gccagctggg cgccaccacc gtcccaccca gcggcctctc 1200

cgtacccttc tccacttggg accaggatca cgacctccgc agggacaaga actgcgccaa 1260

gagcctctct ggaggctggt ggtttggcac ctgcagccat tccaacctca acggccagta 1320

cttccgctcc atcccacagc agcggcagaa gcttaagaag ggaatcttct ggaagacctg 1380

gcggggccgc tactacccgc tgcaggccac caccatgttg atccagccca tggcagcaga 1440

ggcagcctcc tagcgtcctg gctgggcctg gtcccaggcc cacgaaagac ggtgactctt 1500

ggctctgccc gaggatgtgg ccgttccctg cctgggcagg ggctccaagg aggggccatc 1560

tggaaacttg tggacagaga agaagaccac gactggagaa gccccctttc tgagtgcagg 1620

ggggctgcat gcgttgcctc ctgagatcga ggctgcagga tatgctcaga ctctagaggc 1680

gtggaccaag gggcatggag cttcactcct tgctggccag ggagttgggg actcagaggg 1740

accacttggg gccagccaga ctggcctcaa tggcggactc agtcacattg actgacgggg 1800

accagggctt gtgtgggtcg agagcgccct catggtgctg gtgctgttgt gtgtaggtcc 1860

cctggggaca caagcaggcg ccaatggtat ctgggcggag ctcacagagt tcttggaata 1920

aaagcaacct cagaacactt tgttctttgt tcttgtttgt tttctttctt ttttttctct 1980

ttctttagtt cacagatcta gtaagttacc ctcagtttgt tttaaaaagt gaacaaagtc 2040

catgtaaaca tgttcccagn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2100

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2160

nnnnnnnnnn catctcgcaa gggtccatgg cttcattctt gaagtcagtg agaccaagaa 2220

ccccccaatt ccggacacag tgccactgca ctccagccca ggcaacagag cgagattctg 2280

tctggacgta gccccatttc tcttcccgga caggtcctct gatagtcggg taggttctca 2340

atcaagcctc tcattagtta tttggtctgt caatccattt cattcctgca gtcttccgcc 2400

ccgccctctt gagctcgccc ctgataggct ggcgcgtccg tcacttcaaa aaggtccgca 2460

ttccttccgc ctttctccag gacaccgagg gcgaggaggg tggtaccaag cggcgcccac 2520

cctcagagca ctacttccat ctctgattgg cttcgctggg tgcccgtcgc tactccactc 2580

gccgatcccg ccggaagcgc caggacaatg gggacccggg acgacgagta cgactaccta 2640

ttcaaagtgg tgctcatcgg ggactcaggc gtgggcaaga gcaacctgct gtcgcgcttc 2700

acccgcaacg agttcaacct ggagagcaag agcaccatcg gcgtggagtt cgccacccgc 2760

agcatccagg tggacggcaa gaccatcaag gcgcagatct gggacaccgc tggccaggag 2820

cgctaccgcg ccatcacctc cgcgtactac cgtggtgcag tgggcgccct gctggtgtac 2880

gacatcgcca agcacctgac ctatgagaac gtggagcgct ggctgaagga gctgcgggac 2940

cacgcagaca gcaacatcgt catcatgctg gtgggcaaca agagtgacct gcgccacctg 3000

cgggctgtgc ccactgacga ggcccgcgcc ttcgcagaaa agaacaactt gtccttcatc 3060

-continued

gagacctcag ccttggattc cactaacgta gaggaagcat tcaagaacat cctcacagag 3120

atctaccgca tcgtgtcaca gaaacagatc gcagaccgtg ctgcccacga cgagtccccg 3180

gggaacaacg tggtggacat cagcgtgccg cccaccacgg acggacagaa gcccaacaag 3240

ctgcagtgct gccagaacct gtgacccctg cgcctccacc cagcgtgcgt gcacgtcctc 3300

cgcccgtccc cgccacggta tcctctggcc cctccctgct gtccctctgt ggccggctcg 3360

ttccagccct cccagtgagc tctgcacggc cgggccgggg cccaggaagg acaggagcca 3420

gtgctacccc gtcctgcccg gggaaaagct agaagccccg gtttgctgca cccatgaaac 3480

tcgggtcccc acagcgtctt ggcggggtgg ggagggcggc aggatggacg gggctggcca 3540

gaggcgagga ggacgggcgg acggcgccgc cttctcccct tttccttggc cgactctagg 3600

gagcgattgc ctccctccct ctgtgaccgg gtggcccagc cagcccgtcg tccccaccca 3660

gaaccgtgct ctgggccaaa gcccgaagaa ccaggcagcg ggggccgggg caggcggacc 3720

ccccgggctc tcagcgccca cccgctcctc cgcacacagc agctcgcaca ggcctcccac 3780

tctgcctgtc cccctnctnt gtctcgtctc cccatntggt ctggaacctg tttgcaagtg 3840

aagcaatatc tccgtgtttt gtagtataca accgctcttg tagcctttgg tttgtgttaa 3900

tgtagagaaa ctcagattct ttatacactt ttgtaa 3936

<210> SEQ ID NO 50
<211> LENGTH: 1114
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 632664CB1

<400> SEQUENCE: 50

gccgcctctg ccgccgcgga cttcccgaac ctcttcagcc gcccggagcc gctcccggag 60

cccggccgta gaggctgcaa tcgcagccgg tgagcccgca gcccgcgccc cgagcccgcc 120

gccgcccttc gagggcgccc caggccgcgc catggtgaag gtgacgttca actccgctct 180

ggcccagaag gaggccaaga aggacgagcc caagagcggc gaggaggcgc tcatcatccc 240

ccccgacgcc gtcgcggtgg actgcaagga cccagatgat gtggtaccag ttggccaaag 300

aagagcctgg tgttggtgca tgtgctttgg actagcattt atgcttgcag gtgttattct 360

aggaggagca tacttgtaca aatattttgc acttcaacca gatgacgtgt actactgtgg 420

aataaagtac atcaaagatg atgtcatctt aaatgagccc tctgcagatg ccccagctgc 480

tctctaccag acaattgaag aaaatattaa aatctttgaa gaagaagaag ttgaatttat 540

cagtgtgcct gtcccagagt ttgcagatag tgatcctgcc aacattgttc atgactttaa 600

caagaaactt acagcctatt tagatcttaa cctggataag tgctatgtga tccctctgaa 660

cacttccatt gttatgccac ccagaaacct actggagtta cttattaaca tcaaggctgg 720

aacctatttg cctcagtcct atctgattca tgagcacatg gttattactg atcgcattga 780

aaacattgat cacctgggtt tctttattta tcgactgtgt catgacaagg aaacttacaa 840

actgcaacgc agagaaacta ttaaaggtat tcagaaacgt gaagccagca attgtttcgc 900

aattcggcat tttgaaaaca aatttgccgt ggaaacttta atttgttctt gaacagtcaa 960

gaaaaacatt attgaggaaa attaatatca cagcataacc ccacccttta cattttgtgc 1020

agtgattatt ttttaaagtc ttctttcatg taagtagcaa acagggcttt actatctttt 1080

catctcatta attcaattaa aaccattacc ttaa 1114

-continued

<210> SEQ ID NO 51
<211> LENGTH: 266
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 632664CD1

<400> SEQUENCE: 51

```
Met Val Lys Val Thr Phe Asn Ser Ala Leu Ala Gln Lys Glu Ala
 1               5                  10                  15

Lys Lys Asp Glu Pro Lys Ser Gly Glu Glu Ala Leu Ile Ile Pro
            20                  25                  30

Pro Asp Ala Val Ala Val Asp Cys Lys Asp Pro Asp Asp Val Val
        35                  40                  45

Pro Val Gly Gln Arg Arg Ala Trp Cys Trp Cys Met Cys Phe Gly
    50                  55                  60

Leu Ala Phe Met Leu Ala Gly Val Ile Leu Gly Gly Ala Tyr Leu
65                  70                  75

Tyr Lys Tyr Phe Ala Leu Gln Pro Asp Asp Val Tyr Tyr Cys Gly
                80                  85                  90

Ile Lys Tyr Ile Lys Asp Asp Val Ile Leu Asn Glu Pro Ser Ala
            95                  100                 105

Asp Ala Pro Ala Ala Leu Tyr Gln Thr Ile Glu Glu Asn Ile Lys
        110                 115                 120

Ile Phe Glu Glu Glu Glu Val Glu Phe Ile Ser Val Pro Val Pro
    125                 130                 135

Glu Phe Ala Asp Ser Asp Pro Ala Asn Ile Val His Asp Phe Asn
140                 145                 150

Lys Lys Leu Thr Ala Tyr Leu Asp Leu Asn Leu Asp Lys Cys Tyr
            155                 160                 165

Val Ile Pro Leu Asn Thr Ser Ile Val Met Pro Pro Arg Asn Leu
        170                 175                 180

Leu Glu Leu Leu Ile Asn Ile Lys Ala Gly Thr Tyr Leu Pro Gln
    185                 190                 195

Ser Tyr Leu Ile His Glu His Met Val Ile Thr Asp Arg Ile Glu
200                 205                 210

Asn Ile Asp His Leu Gly Phe Phe Ile Tyr Arg Leu Cys His Asp
            215                 220                 225

Lys Glu Thr Tyr Lys Leu Gln Arg Arg Glu Thr Ile Lys Gly Ile
        230                 235                 240

Gln Lys Arg Glu Ala Ser Asn Cys Phe Ala Ile Arg His Phe Glu
    245                 250                 255

Asn Lys Phe Ala Val Glu Thr Leu Ile Cys Ser
260                 265
```

<210> SEQ ID NO 52
<211> LENGTH: 1189
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 457372.17

<400> SEQUENCE: 52

```
acaggtgtga gccaccacac ccagcagttt ttttaaggtc acaaaatgac aagactagga     60

tttggaccca gttctgttcg actcaaaata gagtgcccta cacttatgtg tcatgctgca    120
```

-continued

tttggcaagt cacgtcactt ctttgaatct ccttttccct ctgcaaaaca gtaaccttat 180

ctagcctgca gacttcaaag gtggttatgg agatcaaatg aagtaaaatg ttttaaaaat 240

tgtacaatat ataccaataa aagctattgg ggaggtatat gtatgaacag gtagttggtt 300

tttctaccct gccacctcat aaagagtttg cagtggcacg tagaagggtt tatcttatta 360

tcacaaagct acccatttgc tggccatact gatacttggc acattaaact atcagagaaa 420

tatatgtggc tcctttacaa ctgtgtctag aagggtacat ttccaatcag agttcccagg 480

ttctgacttt ctcccattac atatttgtaa ttagtcatct ttgatactga ttcaaatttt 540

tgattaacat taattatata tatttacaag aatcttataa aaattaagat tttatttcac 600

ctcattttgc cctgtgagat agatggaaat agactatatt ctacccaggt taaaagtaca 660

gataatgaga caaaatgtca atagaacctg aaaaaagatt tttttagttg cctctagtct 720

ctgtttactt ggtatagata gtatgctgct tttttttctt ttttttaaaa tgtaactgct 780

gggttgtttt tttttcttg ttttttcttt ccctccagga tacaatgtct ctttgctata 840

tgaccttgaa aatcttccgg catccaagga ttccattgtg catcaagctg gcatgttgaa 900

gcgaaattgt tttgcctctg tctttgaaaa atacttccaa ttccaagaag agggcaagga 960

aggagagaac agggcagtta tccattatag ggatgatgag accatgtatg ttgagtctaa 1020

aaaggacaga gtcacagtag tcttcagcac agtgtttaag gatgacgacg atgtggtcat 1080

tggaaaggtg ttcatgcagg tatggagcag acatcttggg ggaaacccat gcatggcgac 1140

ttataccttt gcacccaaac ataccatgag cgtaggaaag agatctagc 1189

<210> SEQ ID NO 53
<211> LENGTH: 2539
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2993696CB1

<400> SEQUENCE: 53

ctcgagccgc aagacagcac agacagattg acctattggg gtgtttcgcg agtgtgagag 60

ggaagcgccg cggcctgtat ttctagacct gcccttcgcc tggttcgtgg cgccttgtga 120

ccccgggccc ctgccgcctg caagtcggaa attgcgctgt gctcctgtgc tacggcctgt 180

ggctggactg cctgctgctg cccaactggc tggcaagatg aagctctccc tggtggccgc 240

gatgctgctg ctgctcagcg cggcgcgggc cgaggaggag gacaagaagg aggacgtggg 300

cacggtggtc ggcatcgacc tggggaccac ctactcctgc gtcggcgtgt tcaagaacgg 360

ccgcgtggag atcatcgcca acgatcaggg caaccgcatc acgccgtcct atgtcgcctt 420

cactcctgaa ggggaacgtc tgattggcga tgccgccaag aaccagctca cctccaaccc 480

cgagaacacg gtctttgacg ccaagcggct catcggccgc acgtggaatg acccgtctgt 540

gcagcaggac atcaagttct tgccgttcaa ggtggttgaa aagaaaacta aaccatacat 600

tcaagttgat attggaggtg ggcaaacaaa gacatttgct cctgaagaaa tttctgccat 660

ggttctcact aaaatgaaag aaaccgctga ggcttatttg ggaaagaagg ttacccatgc 720

agttgttact gtaccagcct attttaatga tgcccaacgc caagcaacca aagacgctgg 780

aactattgct ggcctaaatg ttatgaggat catcaacgag cctacggcag ctgctattgc 840

ttatggcctg gataagaggg agggggagaa gaacatcctg gtgtttgacc tgggtggcgg 900

aaccttcgat gtgtctcttc tcaccattga caatggtgtc ttcgaagttg tggccactaa 960

-continued

```
tggagatact catctgggtg gagaagactt tgaccagcgt gtcatggaac acttcatcaa   1020

actgtacaaa aagaagacgg gcaaagatgt caggaaagac aatagagctg tgcagaaact   1080

ccggcgcgag gtagaaaagg ccaaacgggc cctgtcttct cagcatcaag caagaattga   1140

aattgagtcc ttctatgaag gagaagactt ttctgagacc ctgactcggg ccaaatttga   1200

agagctcaac atggatctgt tccggtctac tatgaagccc gtccagaaag tgttggaaga   1260

ttctgatttg aagaagtctg atattgatga aattgttctt gttggtggct cgactcgaat   1320

tccaaagatt cagcaactgg ttaaagagtt cttcaatggc aaggaaccat cccgtggcat   1380

aaacccagat gaagctgtag cgtatggtgc tgctgtccag gctggtgtgc tctctggtga   1440

tcaagataca ggtgacctgg tactgcttga tgtatgtccc cttacacttg gtattgaaac   1500

tgtgggaggt gtcatgacca aactgattcc aaggaacaca gtggtgccta ccaagaagtc   1560

tcagatcttt tctacagctt ctgataatca accaactgtt acaatcaagg tctatgaagg   1620

tgaaagaccc ctgacaaaag acaatcatct tctgggtaca tttgatctga ctggaattcc   1680

tcctgctcct cgtggggtcc cacagattga agtcaccttt gagatagatg tgaatggtat   1740

tcttcgagtg acagctgaag acaagggtac agggaacaaa aataagatca caatcaccaa   1800

tgaccagaat cgcctgacac ctgaagaaat cgaaaggatg gttaatgatg ctgagaagtt   1860

tgctgaggaa gacaaaaagc tcaaggagcg cattgatact agaaatgagt tggaaagcta   1920

tgcctattct ctaaagaatc agattggaga taaagaaaag ctgggaggta aactttcctc   1980

tgaagataag gagaccatgg aaaaagctgt agaagaaaag attgaatggc tggaaagcca   2040

ccaagatgct gacattgaag acttcaaagc taagaagaag gaactggaag aaattgttca   2100

accaattatc agcaaactct atggaagtgc aggccctccc ccaactggtg aagaggatac   2160

agcagaaaaa gatgagttgt agacactgat ctgctagtgc tgtaatattg taaatactgg   2220

actcaggaac ttttgttagg aaaaaattga aagaacttaa gtctcgaatg taattggaat   2280

cttcacctca gagtggagtt gaaactgcta tagcctaagc ggctgtttac tgcttttcat   2340

tagcagttgc tcacatgtct ttgggtgggg gggagaagaa gaattggcca tcttaaaaag   2400

cgggtaaaaa acctgggtta gggtgtgtgt tcaccttcaa aatgttctat ttaacaactg   2460

ggtcatgtgc atctggtgta ggaagttttt tctaccataa gtgacaccaa taaatgtttg   2520

ttatttacac tggtaagcg                                               2539
```

<210> SEQ ID NO 54
<211> LENGTH: 654
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2993696CD1

<400> SEQUENCE: 54

```
Met Lys Leu Ser Leu Val Ala Ala Met Leu Leu Leu Leu Ser Ala
  1               5                  10                  15

Ala Arg Ala Glu Glu Glu Asp Lys Lys Glu Asp Val Gly Thr Val
                20                  25                  30

Val Gly Ile Asp Leu Gly Thr Thr Tyr Ser Cys Val Gly Val Phe
                35                  40                  45

Lys Asn Gly Arg Val Glu Ile Ile Ala Asn Asp Gln Gly Asn Arg
                50                  55                  60

Ile Thr Pro Ser Tyr Val Ala Phe Thr Pro Glu Gly Glu Arg Leu
```

-continued

```
                65                  70                  75

Ile Gly Asp Ala Ala Lys Asn Gln Leu Thr Ser Asn Pro Glu Asn
                80                  85                  90

Thr Val Phe Asp Ala Lys Arg Leu Ile Gly Arg Thr Trp Asn Asp
                95                 100                 105

Pro Ser Val Gln Gln Asp Ile Lys Phe Leu Pro Phe Lys Val Val
               110                 115                 120

Glu Lys Lys Thr Lys Pro Tyr Ile Gln Val Asp Ile Gly Gly Gly
               125                 130                 135

Gln Thr Lys Thr Phe Ala Pro Glu Glu Ile Ser Ala Met Val Leu
               140                 145                 150

Thr Lys Met Lys Glu Thr Ala Glu Ala Tyr Leu Gly Lys Lys Val
               155                 160                 165

Thr His Ala Val Val Thr Val Pro Ala Tyr Phe Asn Asp Ala Gln
               170                 175                 180

Arg Gln Ala Thr Lys Asp Ala Gly Thr Ile Ala Gly Leu Asn Val
               185                 190                 195

Met Arg Ile Ile Asn Glu Pro Thr Ala Ala Ala Ile Ala Tyr Gly
               200                 205                 210

Leu Asp Lys Arg Glu Gly Glu Lys Asn Ile Leu Val Phe Asp Leu
               215                 220                 225

Gly Gly Gly Thr Phe Asp Val Ser Leu Leu Thr Ile Asp Asn Gly
               230                 235                 240

Val Phe Glu Val Val Ala Thr Asn Gly Asp Thr His Leu Gly Gly
               245                 250                 255

Glu Asp Phe Asp Gln Arg Val Met Glu His Phe Ile Lys Leu Tyr
               260                 265                 270

Lys Lys Lys Thr Gly Lys Asp Val Arg Lys Asp Asn Arg Ala Val
               275                 280                 285

Gln Lys Leu Arg Arg Glu Val Glu Lys Ala Lys Arg Ala Leu Ser
               290                 295                 300

Ser Gln His Gln Ala Arg Ile Glu Ile Glu Ser Phe Tyr Glu Gly
               305                 310                 315

Glu Asp Phe Ser Glu Thr Leu Thr Arg Ala Lys Phe Glu Glu Leu
               320                 325                 330

Asn Met Asp Leu Phe Arg Ser Thr Met Lys Pro Val Gln Lys Val
               335                 340                 345

Leu Glu Asp Ser Asp Leu Lys Lys Ser Asp Ile Asp Glu Ile Val
               350                 355                 360

Leu Val Gly Gly Ser Thr Arg Ile Pro Lys Ile Gln Gln Leu Val
               365                 370                 375

Lys Glu Phe Phe Asn Gly Lys Glu Pro Ser Arg Gly Ile Asn Pro
               380                 385                 390

Asp Glu Ala Val Ala Tyr Gly Ala Ala Val Gln Ala Gly Val Leu
               395                 400                 405

Ser Gly Asp Gln Asp Thr Gly Asp Leu Val Leu Leu Asp Val Cys
               410                 415                 420

Pro Leu Thr Leu Gly Ile Glu Thr Val Gly Gly Val Met Thr Lys
               425                 430                 435

Leu Ile Pro Arg Asn Thr Val Val Pro Thr Lys Lys Ser Gln Ile
               440                 445                 450

Phe Ser Thr Ala Ser Asp Asn Gln Pro Thr Val Thr Ile Lys Val
               455                 460                 465
```

-continued

```
Tyr Glu Gly Glu Arg Pro Leu Thr Lys Asp Asn His Leu Leu Gly
                470                 475                 480

Thr Phe Asp Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Val Pro
                485                 490                 495

Gln Ile Glu Val Thr Phe Glu Ile Asp Val Asn Gly Ile Leu Arg
                500                 505                 510

Val Thr Ala Glu Asp Lys Gly Thr Gly Asn Lys Asn Lys Ile Thr
                515                 520                 525

Ile Thr Asn Asp Gln Asn Arg Leu Thr Pro Glu Glu Ile Glu Arg
                530                 535                 540

Met Val Asn Asp Ala Glu Lys Phe Ala Glu Glu Asp Lys Lys Leu
                545                 550                 555

Lys Glu Arg Ile Asp Thr Arg Asn Glu Leu Glu Ser Tyr Ala Tyr
                560                 565                 570

Ser Leu Lys Asn Gln Ile Gly Asp Lys Glu Lys Leu Gly Gly Lys
                575                 580                 585

Leu Ser Ser Glu Asp Lys Glu Thr Met Glu Lys Ala Val Glu Glu
                590                 595                 600

Lys Ile Glu Trp Leu Glu Ser His Gln Asp Ala Asp Ile Glu Asp
                605                 610                 615

Phe Lys Ala Lys Lys Lys Glu Leu Glu Glu Ile Val Gln Pro Ile
                620                 625                 630

Ile Ser Lys Leu Tyr Gly Ser Ala Gly Pro Pro Pro Thr Gly Glu
                635                 640                 645

Glu Asp Thr Ala Glu Lys Asp Glu Leu
                650
```

<210> SEQ ID NO 55
<211> LENGTH: 5762
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 331106.6

<400> SEQUENCE: 55

```
gcgcgaccgt cccgggggtg gggccgggcg cagcggcgag aggaggcgaa ggtggctgcg     60

gtagcagcag cgcggcagcc tcgtgaccca gcccggagcg cagggcggcc gctgcaggtc    120

cccgctcccc tccccgtgcg tccgcccatg gccgccgccg ggcagctgtg cttgctctac    180

ctgtcggcgg ggctcctgtc ccggctcggc gcagccttca acttggacac tcgggaggac    240

aacgtgatcc ggaaatatgg agaccccggg agcctcttcg gcttctcgct ggccatgcac    300

tggcaactgc agcccgagga caagcggctg ttgctcgtgg gggccccgcg ggcagaagcg    360

cttccactgc agagagccaa cagaacggga gggctgtaca gctgcgacat caccgcccgg    420

gggccatgca cgcggatcga gtttgataac gatgctgacc ccacgtcaga aagcaaggaa    480

gatcagtgga tgggggtcac cgtccagagc caaggtccag ggggcaaggt cgtgacatgt    540

gctcaccgat atgaaaaaag gcagcatgtt aatacgaagc aggaatcccg agacatcttt    600

gggcggtgtt atgtcctgag tcagaatctc aggattgaag acgatatgga tgggggagat    660

tggagctttt gtgatgggcg attgagaggc catgagaaat ttggctcttg ccagcaaggt    720

gtagcagcta cttttactaa agactttcat tacattgtat ttggagcccc gggtacttat    780

aactggaaag ggattgttcg tgtagagcaa aagaataaca ctttttttga catgaacatc    840
```

-continued

tttgaagatg ggccttatga agttggtgga gagactgagc atgatgaaag tctcgttcct 900

gttcctgcta acagttactt aggtttttct ttggactcag ggaaaggtat tgtttctaaa 960

gatgagatca cttttgtatc tggtgctccc agagccaatc acagtggagc cgtggttttg 1020

ctgaagagag acatgaagtc tgcacatctc ctccctgagc acatattcga tggagaaggt 1080

ctggcctctt catttggcta tgatgtggcg gtggtggacc tcaacaagga tgggtggcaa 1140

gatatagtta ttggagcccc acagtatttt gatagagatg gagaagttgg aggtgcagtg 1200

tatgtctaca tgaaccagca aggcagatgg aataatgtga agccaattcg tcttaatgga 1260

accaaagatt ctatgtttgg cattgcagta aaaaatattg gagatattaa tcaagatggc 1320

tacccagata ttgcagttgg agctccgtat gatgacttgg gaaaggtttt tatctatcat 1380

ggatctgcaa atggaataaa taccaaacca acacaggttc tcaagggtat atcaccttat 1440

tttggatatt caattgctgg aaacatggac cttgatcgaa attcctaccc tgatgttgct 1500

gttggttccc tctcagattc agtaactatt ttcagatccc ggcctgtgat taatattcag 1560

aaaaccatca cagtaactcc taacagaatt gacctccgcc agaaaacagc gtgtggggcg 1620

cctagtggga tatgcctcca ggttaaatcc tgttttgaat atactgctaa ccccgctggt 1680

tataatcctt caatatcaat tgtgggcaca cttgaagctg aaaaagaaag aagaaaatct 1740

gggctatcct caagagttca gtttcgaaac caaggttctg agcccaaata tactcaagaa 1800

ctaactctga agaggcagaa acagaaagtg tgcatggagg aaaccctgtg gctacaggat 1860

aatatcagag ataaactgcg tcccattccc ataactgcct cagtggagat ccaagagcca 1920

agctctcgta ggcgagtgaa ttcacttcca gaagttcttc caattctgaa ttcagatgaa 1980

cccaagacag ctcatattga tgttcacttc ttaaaagagg gatgtggaga cgacaatgta 2040

tgtaacagca accttaaact agaatataaa ttttgcaccc gagaaggaaa tcaagacaaa 2100

ttttcttatt taccaattca aaaaggtgta ccagaactag ttctaaaaga tcagaaggat 2160

attgctttag aaataacagt gacaaacagc ccttccaacc caaggaatcc cacaaaagat 2220

ggcgatgacg cccatgaggc taaactgatt gcaacgtttc cagacacttt aacctattct 2280

gcatatagag aactgagggc tttccctgag aaacagttga gttgtgttgc caaccagaat 2340

ggctcgcaag ctgactgtga gctcggaaat ccttttaaaa gaaattcaaa tgtcactttt 2400

tatttggttt taagtacaac tgaagtcacc tttgacaccc cagatctgga tattaatctg 2460

aagttagaaa caacaagcaa tcaagataat ttggctccaa ttacagctaa agcaaaagtg 2520

gttattgaac tgcttttatc ggtctcggga gttgctaaac cttcccaggt gtattttgga 2580

ggtacagttg ttggcgagca agctatgaaa tctgaagatg aagtgggaag tttaatagag 2640

tatgaattca gggtaataaa cttaggtaaa cctcttacaa acctcggcac agcaaccttg 2700

aacattcagt ggccaaaaga aattagcaat gggaaatggt tgctttattt ggtgaaagta 2760

gaatccaaag gattggaaaa ggtaacttgt gagccacaaa aggagataaa ctccctgaac 2820

ctaacggagt ctcacaactc aagaaagaaa cgggaaatta ctgaaaaaca gatagatgat 2880

aacagaaaat tttctttatt tgctgaaaga aaataccaga ctcttaactg tagcgtgaac 2940

gtgaactgtg tgaacatcag atgcccgctg cgggggctgg acagcaaggc gtctcttatt 3000

ttgcgctcga ggttatggaa cagcacattt ctagaggaat attccaaact gaactacttg 3060

gacattctca tgcgagcctt cattgatgtg actgctgctg ccgaaaatat caggctgcca 3120

aatgcaggca ctcaggttcg agtgactgtg tttccctcaa agactgtagc tcagtattcg 3180

ggagtacctt ggtggatcat cctagtggct attctcgctg ggatcttgat gcttgcttta 3240

-continued

ttagtgttta tactatggaa gtgtggtttc ttcaagagaa ataagaaaga tcattatgat 3300

gccacatatc acaaggctga gatccatgct cagccatctg ataaagagag gcttacttct 3360

gatgcatagt attgatctac ttctgtaatt gtgtggattc tttaaacgct ctaggtacga 3420

tgacagtgtt ccccgatacc atgctgtaag gatccggaaa gaagagcgag agatcaaaga 3480

tgaaaagtat attgataacc ttgaaaaaaa acagtggatc acaaagtgga acagaaatga 3540

aagctactca tagcgggggc ctaaaaaaaa aaaaagcttc acagtaccca aactgctttt 3600

tccaactcag aaattcaatt tggatttaaa agcctgctca atccctgagg actgatttca 3660

gagtgactac acacagtacg aacctacagt tttaactgtg gatattgtta cgtagcctaa 3720

ggctcctgtt ttgcacagcc aaatttaaaa ctgttggaat ggatttttct ttaactgccg 3780

taatttaact ttctgggttg cctttgtttt tggcgtggct gacttacatc atgtgttggg 3840

gaagggcctg cccagttgca ctcaggtgac atcctccaga tagtgtagct gaggaggcac 3900

ctacactcac ctgcactaac agagtggccg tcctaacctc gggcctgctg cgcagacgtc 3960

catcacgtta gctgtcccac atcacaagac tatgccattg gggtagttgt gtttcaacgg 4020

aaagtgctgt cttaaactaa atgtgcaata gaaggtgatg ttgccatcct accgtctttt 4080

cctgtttcct agctgtgtga atacctgctc acgtcaaatg catacaagtt tcattctccc 4140

tttcactaaa aacacacagg tgcaacagac ttgaatgcta gttatactta tttgtatatg 4200

gtatttattt tttcttttct ttacaaacca ttttgttatt gactaacagg ccaaagagtc 4260

tccagtttac ccttcaggtt ggtttaatca atcagaatta gaattagagc atgggaggtc 4320

atcactttga cctaaattat ttactgcaaa aagaaaatct ttataaatgt accagagaga 4380

gttgttttaa taacttatct ataaactata acctctcctt catgacagcc tccaccccac 4440

aacccaaaag gtttaagaaa tagaattata actgtaaaga tgtttatttc aggcattgga 4500

tatttttac tttagaagcc tgcataatgt ttctggattt catactgtaa cattcaggaa 4560

ttcttggaga aaatgggttt attcactgaa ctctagtgcg gtttactcac tgctgcaaat 4620

actgtatatt caggacttga aagaaatggt gaatgcctat ggtggatcca aactgatcca 4680

gtataagact actgaatctg ctaccaaaac agttaatcag tgagtcgatg ttctattttt 4740

tgttttgttt cctcccctat ctgtattccc aaaaattact ttggggctaa tttaacaaga 4800

actttaaatt gtgttttaat tgtaaaaatg gcagggggtg gaattattac tctatacatt 4860

caacagagac tgaatagata tgaaagctga ttttttttaa ttaccatgct tcacaatgtt 4920

aagttatatg gggagcaaca gcaaacaggt gctaatttgt tttggatata gtataagcag 4980

tgtctgtgtt ttgaaagaat agaacacagt ttgtagtgcc actgttgttt tgggggggct 5040

tttttctttt cggaaatctt aaaccttaag atactaagga cgttgttttg gttgtacttt 5100

ggaattctta gtcacaaaat atattttgtt tacaaaaatt tctgtaaaac aggttataac 5160

agtgtttaaa gtctcagttt cttgcttggg gaacttgtgt ccctaatgtg tttagattgc 5220

tagattgcta aggagctgat actttgacag tgtttttaga cctgtgttac taaaaaaaag 5280

atgaatgtcc tgaaaagggt gttgggaggg tggttcaaca aagaaacaaa gatgttatgg 5340

tgtttagatt tatggttgtt aaaaatgtca tctcaagtca agtcactggt ctgtttgcat 5400

ttgatacatt tttgtactaa ctagcattgt aaaattattt catgattaga aattacctgt 5460

ggatatttgt ataaaagtgt gaaataaatt ttttataaaa gtgttcattg tttcgtaaca 5520

cagcattgta tatgtgaagc aaactctaaa attataaatg acaacctgaa ttatctattt 5580

-continued

catcaaacca aagttcagtg tttttatttt tggtgtctca tgtaatctca gatcagccaa 5640

agatactagt gccaaagcaa tgggattcgg ggtttttttc tgttttcgct ctatgtaggt 5700

gatcctcaag tctttcattt tccttcttta tgattaaaag aaacctacag gtatttaaca 5760

ac 5762

<210> SEQ ID NO 56
<211> LENGTH: 2471
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1256895CB1

<400> SEQUENCE: 56

ccgcgcgtcg cctgtcctcc gagccagtcg ctgacagccg cggcgccgcg agcttctcct 60

ctcctcacga ccgaggcaga gcagtcatta tggcgaacct tggctgctgg atgctggttc 120

tctttgtggc cacatggagt gacctgggcc tctgcaagaa gcgcccgaag cctggaggat 180

ggaacactgg gggcagccga tacccggggc agggcagccc tggaggcaac cgctacccac 240

ctcagggcgg tggtggctgg gggcagcctc atggtggtgg ctgggggcag cctcatggtg 300

gtggctgggg gcagccccat ggtggtggct ggggacagcc tcatggtggt ggctggggtc 360

aaggaggtgg cacccacagt cagtggaaca agccgagtaa gccaaaaacc aacatgaagc 420

acatggctgg tgctgcagca gctggggcag tggtgggggg ccttggcggc tacgtgctgg 480

gaagtgccat gagcaggccc atcatacatt tcggcagtga ctatgaggac cgttactatc 540

gtgaaaacat gcaccgttac cccaaccaag tgtactacag gcccatggat gagtacagca 600

accagaacaa ctttgtgcac gactgcgtca atatcacaat caagcagcac acggtcacca 660

caaccaccaa gggggagaac ttcaccgaga ccgacgttaa gatgatggag cgcgtggttg 720

agcagatgtg tatcacccag tacgagaggg aatctcaggc ctattaccag agaggatcga 780

gcatggtcct cttctcctct ccacctgtga tcctcctgat ctctttcctc atcttcctga 840

tagtgggatg aggaaggtct tcctgttttc accatctttc taatcttttt ccagcttgag 900

ggaggcggta tccacctgca gccctttttag tggtggtgtc tcactctttc ttctctcttt 960

gtcccggata ggctaatcaa taccccttggc actgatgggc actggaaaac atagagtaga 1020

cctgagatgc tggtcaagcc ccctttgatt gagttcatca tgagccgttg ctaatgccag 1080

gccagtaaaa gtataacagc aaataaccat tggttaatct ggacttattt ttggacttag 1140

tgcaacaggt tgaggctaaa acaaatctca gaacagtctg aaataccttt gcctggatac 1200

ctctggctcc ttcagcagct agagctcagt atactaatgc cctatcttag tagagatttc 1260

atagctattt agagatattt tccattttaa gaaaacccga caacatttct gccaggtttg 1320

ttaggaggcc acatgatact tattcaaaaa aatcctagag attcttagct cttgggatgc 1380

aggctcagcc cgctggagca tgagctctgt gtgtaccgag aactggggtg atgttttact 1440

tttcacagta tgggctacac agcagctgtt caacaagagt aaatattgtc acaacactga 1500

acctctggct agaggacata ttcacagtga acataactgt aacatatatg aaaggcttct 1560

gggacttgaa atcaaatgtt tgggaatggt gcccttggag gcaacctccc attttagatg 1620

tttaaaggac cctatatgtg gcattccttt ctttaaacta taggtaatta aggcagctga 1680

aaagtaaatt gccttctaga cactgaaggc aaatctcctt tgtccattta cctggaaacc 1740

agaatgattt tgacatacag gagagctgca gttgtgaaag caccatcatc atagaggatg 1800

-continued

atgtaattaa aaaatggtca gtgtgcaaag aaaagaactg cttgcatttc tttatttctg 1860

tctcataatt gtcaaaaacc agaattaggt caagttcata gtttctgtaa ttggcttttg 1920

aatcaaagaa tagggagaca atctaaaaaa tatcttaggt tggagatgac agaaatatga 1980

ttgatttgaa gtggaaaaag aaattctgtt aatgttaatt aaagtaaaat tattccctga 2040

attgtttgat attgtcacct agcagatatg tattactttt ctgcaatgtt attattggct 2100

tgcactttgt gagtattcta tgtaaaaata tatatgtata taaaatatat attgcatagg 2160

acagacttag gagttttgtt tagagcagtt aacatctgaa gtgtctaatg cattaacttt 2220

tgtaaggtac tgaatactta atatgtggga aacccttttg cgtggtcctt aggcttacaa 2280

tgtgcactga atcgtttcat gtaagaatcc aaagtggaca ccattaacag gtctttgaaa 2340

tatgcatgta ctttatattt tctatatttg taactttgca tgttcttgtt ttgttatata 2400

aaaaaattgt aaatgtttaa tatctgactg aaattaaacg agcgaagatg agcaccaaaa 2460

aaaaaaaaaa a 2471

<210> SEQ ID NO 57
<211> LENGTH: 253
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1256895CD1

<400> SEQUENCE: 57

Met Ala Asn Leu Gly Cys Trp Met Leu Val Leu Phe Val Ala Thr
1 5 10 15

Trp Ser Asp Leu Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
20 25 30

Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly
35 40 45

Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Gly Trp Gly Gln Pro
50 55 60

His Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln
65 70 75

Pro His Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly
80 85 90

Gln Gly Gly Gly Thr His Ser Gln Trp Asn Lys Pro Ser Lys Pro
95 100 105

Lys Thr Asn Met Lys His Met Ala Gly Ala Ala Ala Ala Gly Ala
110 115 120

Val Val Gly Gly Leu Gly Gly Tyr Val Leu Gly Ser Ala Met Ser
125 130 135

Arg Pro Ile Ile His Phe Gly Ser Asp Tyr Glu Asp Arg Tyr Tyr
140 145 150

Arg Glu Asn Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro
155 160 165

Met Asp Glu Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val
170 175 180

Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr Thr Lys Gly
185 190 195

Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg Val Val
200 205 210

Glu Gln Met Cys Ile Thr Gln Tyr Glu Arg Glu Ser Gln Ala Tyr
215 220 225

-continued

Tyr Gln Arg Gly Ser Ser Met Val Leu Phe Ser Ser Pro Pro Val
230 235 240

Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
245 250

<210> SEQ ID NO 58
<211> LENGTH: 5681
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 474630.29

<400> SEQUENCE: 58

cccgcgcccg ccctcggaca gtccctgctc gcccgcgcgc tgcagcccca tctcctagcg 60

gcagcccagg cgcggaggga gcgagtccgc cccgaggtag gtccaggacg ggcgcacagc 120

agcagccgag gctggccggg agagggagga agaggatggc agggccacgc cccagcccat 180

gggccaggct gctcctggca gccttgatca gcgtcagcct ctctgggacc ttggcaaacc 240

gctgcaagaa ggccccagtg aagagctgca cggagtgtgt ccgtgtggat aaggactgcg 300

cctactgcac agacgagatg ttcagggacc ggcgctgcaa cacccaggcg gagctgctgg 360

ccgcgggctg ccagcgggag agcatcgtgg tcatggagag cagcttccaa atcacagagg 420

agacccagat tgacaccacc ctgcggcgca gccagatgtc cccccaaggc ctgcgggtcc 480

gtctgcggcc cggtgaggag cggcattttg agctggaggt gtttgagcca ctggagagcc 540

ccgtggacct gtacatcctc atggacttct ccaactccat gtccgatgat ctggacaacc 600

tcaagaagat ggggcagaac ctggctcggg tcctgagcca gctcaccagc gactacacta 660

ttggatttgg caagtttgtg gacaaagtca gcgtcccgca gacggacatg aggcctgaga 720

agctgaagga gccctggccc aacagtgacc ccccccttctc cttcaagaac gtcatcagcc 780

tgacagaaga tgtggatgag ttccggaata aactgcaggg agagcggatc tcaggcaacc 840

tggatgctcc tgagggcggc ttcgatgcca tcctgcagac agctgtgtgc acgagggaca 900

ttggctggcg cccggacagc acccacctgc tggtcttctc caccgagtca gccttccact 960

atgaggctga tggcgccaac gtgctggctg gcatcatgag ccgcaacgat gaacggtgcc 1020

acctggacac cacgggcacc tacacccagt acaggacaca ggactacccg tcggtgccca 1080

ccctggtgcg cctgctcgcc aagcacaaca tcatccccat ctttgctgtc accaactact 1140

cctatagcta ctacgagaag cttcacacct atttccctgt ctcctcactg ggggtgctgc 1200

aggaggactc gtccaacatc gtggagctgc tggaggaggc cttcaatcgg atccgctcca 1260

acctggacat ccgggcccta gacagccccc gaggccttcg gacagaggtc acctccaaga 1320

tgttccagaa gacgaggact gggtcctttc acatccggcg gggggaagtg ggtatatacc 1380

aggtgcagct gcgggccctt gagcacgtgg atgggacgca cgtgtgccag ctgccggagg 1440

accagaaggg caacatccat ctgaaacctt ccttctccga cggcctcaag atggacgcgg 1500

gcatcatctg tgatgtgtgc acctgcgagc tgcaaaaaga ggtgcggtca gctcgctgca 1560

gcttcaacgg agacttcgtg tgcggacagt gtgtgtgcag cgagggctgg agtggccaga 1620

cctgcaactg ctccaccggc tctctgagtg acattcagcc ctgcctgcgg gagggcgagg 1680

acaagccgtg ctccggccgt ggggagtgcc agtgcgggca ctgtgtgtgc tacggcgaag 1740

gccgctacga gggtcagttc tgcgagtatg acaacttcca gtgtccccgc acttccgggt 1800

tcctctgcaa tgaccgagga cgctgctcca tgggccagtg tgtgtgtgag cctggttgga 1860

-continued

caggcccaag ctgtgactgt cccctcagca atgccacctg catcgacagc aatggggca 1920

tctgtaatgg acgtggccac tgtgagtgtg gccgctgcca ctgccaccag cagtcgctct 1980

acacggacac catctgcgag atcaactact cggcgatcca cccgggcctc tgcgaggacc 2040

tacgctcctg cgtgcagtgc caggcgtggg gcaccggcga gaagaagggg cgcacgtgtg 2100

aggaatgcaa cttcaaggtc aagatggtgg acgagcttaa gagagccgag gaggtggtgg 2160

tgcgctgctc cttccgggac gaggatgacg actgcaccta cagctacacc atggaaggtg 2220

acggcgcccc tgggcccaac agcactgtcc tggtgcacaa gaagaaggac tgccctccgg 2280

gctccttctg gtggctcatc cccctgctcc tcctcctcct gccgctcctg gccctgctac 2340

tgctgctatg ctggaagtac tgtgcctgct gcaaggcctg cctggcactt ctcccgtgct 2400

gcaaccgagg tcacatggtg ggctttaagg aagaccacta catgctgcgg gagaacctga 2460

tggcctctga ccacttggac acgcccatgc tgcgcagcgg gaacctcaag ggccgtgacg 2520

tggtccgctg gaaggtcacc aacaacatgc agcggcctgg ctttgccact catgccgcca 2580

gcatcaaccc cacagagctg gtgccctacg ggctgtcctt gcgcctggcc cgcctttgca 2640

ccgagaacct gctgaagcct gacactcggg agtgcgccca gctgcgccag gaggtggagg 2700

agaacctgaa cgaggtctac aggcagatct ccggtgtaca caagctccag cagaccaagt 2760

tccggcagca gcccaatgcc gggaaaaagc aagaccacac cattgtggac acagtgctga 2820

tggcgccccg ctcggccaag ccggccctgc tgaagcttac agagaagcag gtggaacaga 2880

gggccttcca cgacctcaag gtggcccccg gctactacac cctcactgca gaccaggacg 2940

cccggggcat ggtggagttc caggagggcg tggagctggt ggacgtacgg gtgcccctct 3000

ttatccggcc tgaggatgac gacgagaagc agctgctggt ggaggccatc gacgtgcccg 3060

caggcactgc caccctcggc cgccgcctgg taaacatcac catcatcaag gagcaagcca 3120

gagacgtggt gtcctttgag cagcctgagt tctcggtcag ccgcggggac caggtggccc 3180

gcatccctgt catccggcgt gtcctggacg gcgggaagtc ccaggtctcc taccgcacac 3240

aggatggcac cgcgcagggc aaccgggact acatccccgt ggagggtgag ctgctgttcc 3300

agcctgggga ggcctggaaa gagctgcagg tgaagctcct ggagctgcaa gaagttgact 3360

ccctcctgcg gggccgccag gtccgccgtt tccacgtcca gctcagcaac cctaagtttg 3420

gggcccacct gggccagccc cactccacca ccatcatcat cagggaccca gatgaactgg 3480

accggagctt cacgagtcag atgttgtcat cacagccacc ccctcacggc gacctgggcg 3540

ccccgcagaa ccccaatgct aaggccgctg ggtccaggaa gatccatttc aactggctgc 3600

ccccttctgg caagccaatg gggtacaggg taaagtactg gattcagggt gactccgaat 3660

ccgaagccca cctgctcgac agcaaggtgc cctcagtgga gctcaccaac ctgtacccgt 3720

attgcgacta tgagatgaag gtgtgcgcct acggggctca gggcgaggga ccctacagct 3780

ccctggtgtc ctgccgcacc caccaggaag tgcccagcga gccagggcgt ctggccttca 3840

atgtcgtctc ctccacggtg acccagctga gctgggctga gccggctgag accaacggtg 3900

agatcacagc ctacgaggtc tgctatggcc tggtcaacga tgacaaccga cctattgggc 3960

ccatgaagaa agtgctggtt gacaacccta agaaccggat gctgcttatt gagaaccttc 4020

gggagtccca gccctaccgc tacacggtga aggcgcgcaa cggggccggc tgggggcctg 4080

agcgggaggc catcatcaac ctggccaccc agcccaagag gcccatgtcc atccccatca 4140

tccctgacat ccctatcgtg gacgcccaga gcggggagga ctacgacagc ttccttatgt 4200

-continued

acagcgatga cgttctacgc tctccatcgg gcagccagag gcccagcgtc tccgatgaca 4260

ctgagcacct ggtgaatggc cggatggact ttgccttccc gggcagcacc aactccctgc 4320

acaggatgac cacgaccagt gctgctgcct atggcaccca cctgagccca cacgtgcccc 4380

accgcgtgct aagcacatcc tccaccctca cacgggacta caactcactg acccgctcag 4440

aacactcaca ctcgaccaca ctgccgaggg actactccac cctcacctcc gtctcctccc 4500

acgactctcg cctgactgct ggtgtgcccg acacgcccac ccgcctggtg ttctctgccc 4560

tggggcccac atctctcaga gtgagctggc aggagccgcg gtgcgagcgg ccgctgcagg 4620

gctacagtgt ggagtaccag ctgctgaacg gcggtgagct gcatcggctc aacatcccca 4680

accctgccca gacctcggtg gtggtggaag acctcctgcc caaccactcc tacgtgttcc 4740

gcgtgcgggc ccagagccag gaaggctggg gccgagagcg tgagggtgtc atcaccattg 4800

aatcccaggt gcacccgcag agcccactgt gtcccctgcc aggctccgcc ttcactttga 4860

gcactcccag tgccccaggc ccgctggtgt tcactgccct gagcccagac tcgctgcagc 4920

tgagctggga gcggccacgg aggcccaatg gggatatcgt cggctacctg gtgacctgtg 4980

agatggccca aggaggaggg ccagccaccg cattccgggt ggatggagac agccccgaga 5040

gccggctgac cgtgccgggc ctcagcgaga acgtgcccta caagttcaag gtgcaggcca 5100

ggaccactga gggcttcggg ccagagcgcg agggcatcat caccatagag tcccaggatg 5160

gaggaccctt cccgcagctg ggcagccgtg ccgggctctt ccagcacccg ctgcaaagcg 5220

agtacagcag catcaccacc acccacacca gcgccaccga gcccttccta gtggatgggc 5280

tgaccctggg ggcccagcac ctggaggcag gcggctccct cacccggcat gtgacccagg 5340

agtttgtgag ccggacactg accaccagcg gaacccttag cacccacatg gaccaacagt 5400

tcttccaaac ttgaccgcac cctgccccac ccccgccatg tcccactagg cgtcctcccg 5460

actcctctcc cggagcctcc tcagctactc catccttgca cccctggggg cccagcccac 5520

ccgcatgcac agagcagggg ctaggtgtct cctgggaggc atgaaggggg caaggtccgt 5580

cctctgtggg cccaaaccta tttgtaacca aagagctggg agcagcacaa ggacccagcc 5640

tttgttctgc acttaataaa tggttttgct actgctaaaa a 5681

<210> SEQ ID NO 59
<211> LENGTH: 1366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1256295.18

<400> SEQUENCE: 59

ctttgtcctc cagtggctgg taggcagtgg ctgggaggca gcggcccaat tagtgtcgtg 60

cggcccgtgg cgaggcgagg tccggggagc gagcgagcaa gcaaggcggg aggggtggcc 120

ggagctgcgg cggctggcac aggaggagga gcccgggcgg gcgaggggcg gccggagagc 180

gccagggcct gagctgccgg agcggcgcct gtgagtgagt gcagaaagca ggcgcccgcg 240

cgctagccgt ggcaggagca gcccgcacgc cgcgctctct ccctgggcga cctgcagttt 300

gcaatatgac tttggaggaa ttctcggctg gagagcagaa gaccgaaagg atggataagg 360

tgggggatgc cctggaggaa gtgctcagca aagccctgag tcagcgcacg atcactgtcg 420

gggtgtacga agcggccaag ctgctcaacg tcgaccccga taacgtggtg ttgtgcctgc 480

tggcggcgga cgaggacgac gacagagatg tggctctgca gatccacttc accctgatcc 540

-continued

aggcgttttg ctgcgagaac gacatcaaca tcctgcgcgt cagcaacccg ggccggctgg 600

cggagctcct gctcttggag accgacgctg gccccgcggc gagcgagggc gccgagcagc 660

ccccggacct gcactgcgtg ctggtgacga atccacattc atctcaatgg aaggatcctg 720

ccttaagtca acttatttgt ttttgccggg aaagtcgcta catggatcaa tgggttccag 780

tgattaatct ccctgaacgg tgatggcatc tgaatgaaaa taactgaacc aaattgcact 840

gaagtttttg aaataccttt gtagttactc aagcagttac tccctacact gatgcaagga 900

ttacagaaac tgatgccaag gggctgagtg agttcaacta catgttctgg gggcccggag 960

atagatgact ttgcagatgg aaagaggtga aaatgaagaa ggaagctgtg ttgaaacaga 1020

aaaataagtc aaaaggaaca aaaattacaa agaaccatgc aggaaggaaa actatgtatt 1080

aatttagaat ggttgagtta cattaaaata aaccaaatat gttaaagttt aagtgtgcag 1140

ccatagtttg ggtatttttg gtttatatgc cctcaagtaa aagaaaagcc gaaagggtta 1200

atcatatttg aaaaccatat tttattgtat tttgatgaga tattaaattc tcaaagtttt 1260

attataaatt ctactaagtt attttatgac atgaaaagtt atttatgcta taaatttttt 1320

gaaacacaat acctacaata aactggtatg aataattgca tcattt 1366

<210> SEQ ID NO 60
<211> LENGTH: 1432
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 444096.1

<400> SEQUENCE: 60

gacccatcag ggcttctgta aggctgagtg ggtcccatgc ctgaaaggag agccaggctg 60

agcctggcct gagtctccca tgtgtaacag gtacgaggat gaaatcaaca agcacactgc 120

tgcagagaac gagtttgtgg tgctcaagaa ggatgtggat gcagcataca tgggccggat 180

ggatctgcat ggcaaagtgg gcaccttgac ccaggagatt gacttcctgc agcaactcta 240

tgaaatggag ctgagccaag tgcagaccca cgtgtctaac accaatgtgg tgctgtccat 300

ggacaacaac cgcaacctgg acctggacag catcatcgcc gaggtcaagg cccagtatga 360

gctgattgcc cagaggagcc gggctgaggc cgaggcctgg taccagacca agtatgagga 420

gctgcaggtg actgctggga agcatgggga caacctgcgg gacaccaaga acgagattgc 480

tgagctcacc cgcactatcc agaggctgca gggggaggct gatgcagcca agaagcagtg 540

tcagcagctg cagacggcca ttgcggaacg cggagcagcg tggggagctg gcactcaagg 600

atgctcagaa gaagcttggg gatctggatg tggccctgca ccaggccaag gaggacctga 660

cacggctgct gcgtgactac caggagctga tgaatgtcaa gctggccctg gacgtggaga 720

ttgccaccta ccgcaagctt ctggagagcg aggagagcag gatgtctgga gaatgtccca 780

gtgcagtcag catttctgtg actggcaact ccaccactgt gtgcggaggt ggcgcaccag 840

ctttggaggt ggcatctccc tgggtgggag tgggggggcc accaagggtg gattcagcac 900

aaatgtgggc tatagcaccg tcaagggagg gccagtctct gcgggcacct ccatcctgcg 960

gaagaccact acggtcaaga cgtccagcca gaggtattag ctgctgagcc ctgcaaggcc 1020

ccctgcaatc atgtccctgc cctcctcacc ccacctctgc tgtcctttcc agtcacttct 1080

caggagcagg aacagccagg ggacctcaga cccagggtat tttcatacca gactatttgc 1140

atcttgggaa gcgctcaaat ctactcaggt tttctccttg gtcctgcagt aggatgggag 1200

-continued

ggaaggttaa agttgccagc ttgagtgatg tgcttgggtg acttgggggt gacctttga 1260

ccaccgagag gaggctgaat ttctcaagcc attaggagag agagaaattg ggagtggtcc 1320

ccaaagaccc ttcaacctcc ccagtccccc accagaccca ccctctccct gaatctaccc 1380

acatcccccc tccctgtctg tgtctcaata aatggtgcaa ctgcaaaaaa aa 1432

<210> SEQ ID NO 61
<211> LENGTH: 4559
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 008942.10

<400> SEQUENCE: 61

agcgggcggc gcgcacactg ctcgctgggc cgcggctccc gggtgtccca ggcccggccg 60

gtgcgcagag catggcgggt gcgggcccga agcggcgcgc gctagcggcg ccggcggccg 120

aggagaagga agaggcgcgg gagaagatgc tggccgccaa gagcgcggac ggctcggcgc 180

cggcaggcga gggcgagggc gtgaccctgc agcggaacat cacgctgctc aacggcgtgg 240

ccatcatcgt ggggaccatt atcggctcgg gcatcttcgt gacgcccacg ggcgtgctca 300

aggaggcagg ctcgccgggg ctggcgctgg tggtgtgggc cgcgtgcggc gtcttctcca 360

tcgtgggcgc gctctgctac gcggagctcg gcaccaccat ctccaaatcg ggcggcgact 420

acgcctacat gctggaggtc tacggctcgc tgcccgcctt cctcaagctc tggatcgagc 480

tgctcatcat ccggccttca tcgcagtaca tcgtggccct ggtcttcgcc acctacctgc 540

tcaagccgct cttccccacc tgcccggtgc ccgaggaggc agccaagctc gtggcctgcc 600

tgtgcgtgct gctgctcacg gccgtgaact gctacagcgt gaaggccgcc acccgggtcc 660

aggatgcctt tgccgccgcc aagctcctgg ccctggccct gatcatcctg ctgggcttcg 720

tccagatcgg gaagggtgat gtgtccaatc tagatcccaa cttctcattt gaaggcacca 780

aactggatgt ggggaacatt gtgctggcat tatacagcgg cctctttgcc tatggaggat 840

ggaattactt gaatttcgtc acagaggaaa tgatcaaccc ctacagaaac ctgcccctgg 900

ccatcatcat ctccctgccc atcgtgacgc tggtgtacgt gctgaccaac ctggcctact 960

tcaccaccct gtccaccgag cagatgctgt cgtccgaggc cgtggccgtg gacttcggga 1020

actatcacct gggcgtcatg tcctggatca tccccgtctt cgtgggcctg tcctgctttg 1080

gctccgtcaa tgggtccctg ttcacatcct ccaggctctt cttcgtgggg tcccgggaag 1140

gccacctgcc ctccatcctc tccatgatcc acccacagct cctcaccccc gtgccgtccc 1200

tcgtgttcac gtgtgtgatg acgctgctct acgccttctc caaggacatc ttctccgtca 1260

tcaacttctt cagcttcttc aactggctct gcgtggccct ggccatcatc ggcatgatct 1320

ggctgcgcca cagaaagcct gagcttgagc ggcccatcaa ggtgaacctg gccctgcctg 1380

tgttcttcat cctggcctgc ctcttcctga tcgccgtctc cttctggaag acacccgtgg 1440

agtgtggcat cggcttcacc atcatcctca gcgggctgcc cgtctacttc ttcggggtct 1500

ggtggaaaaa caagcccaag tggctcctcc agggcatctt ctccacgacc gtcctgtgtc 1560

agaagctcat gcaggtggtc ccccaggaga catagccagg aggccgagtg gctgccggag 1620

gagcatgcgc agaggccagt taaagtagat cacctcctcg aacccactcc ggttccccgc 1680

aacccacagc tcagctgccc atcccagtcc ctcgccgtcc ctcccaggtc gggcagtgga 1740

ggctgctgtg aaaactctgg tacgaatctc atccctcaac tgagggccag ggacccaggt 1800

-continued

gtgcctgtgc tcctgcccag gagcagcttt tggtctcctt gggccctttt tcccttccct 1860

cctttgttta cttatatata tatttttttt aaacttaaat tttgggtcaa cttgacacca 1920

ctaagatgat tttttaagga gctgggggaa ggcaggagcc ttcctttctc ctgccccaag 1980

ggcccagacc ctgggcaaac agagctactg agacttggaa cctcattgct accacagact 2040

tgcactgaag ccggacagct gcccagacac atgggcttgt gacattcgtg aaaaccaacc 2100

ctgtgggctt atgtctctgc cttagggttt gcagagtgga aactcagccg tagggtggca 2160

ctgggagggg gtgggggatc tgggcaaggt gggtgattcc tcccaggagg tgcttgaggc 2220

cccgatggac tcctgaccat aatcctagcc ccgagacacc atcctgagcc agggaacagc 2280

cccagggttg gggggtgccg gcatctcccc tagctcacca ggcctggcct ctgggcagtg 2340

tggcctcttg gctatttctg tgtccagttt tggaggctga gttctggttc atgcagacaa 2400

agccctgtcc ttcagtcttc tagaaacaga gacaagaaag gcagacacac cgcggccagg 2460

cacccatgtg ggcgcccacc ctgggctcca cacagcagtg tcccctgccc cagaggtcgc 2520

agctaccctc agcctccaat gcattggcct ctgtaccgcc cggcagcccc ttctggccgg 2580

tgctgggttc ccactcccgg cctaggcacc tccccgctct ccctgtcacg ctcatgtcct 2640

gtcctggtcc tgatgcccgt tgtctaggag acagagccaa gcactgctca cgtctctgcc 2700

gcctgcgttt ggaggcccct gggctctcac ccagtcccca cccgcctgca gagagggaac 2760

tagggcaccc cttgtttctg ttgttcccgt gaatttttt cgctatggga ggcagccgag 2820

gcctggccaa tgcggcccac tttcctgagc tgtcgctgcc tccatggcag cagccaagga 2880

cccccagaac aagaagaccc ccccgcagga tccctcctga gctcgggggg ctctgccttc 2940

tcagggcccc gggcttccct tctccccagc cagaggtgga gccaagtggt ccagcgtcac 3000

tccagtgctc agctgtggct ggaggagctg gcctgtggca cagccctgag tgtcccaagc 3060

cgggagccaa cgaagccgga cacggcttca ctgaccagcg gctgctcaag ccgcaagctc 3120

tcagcaagtg cccagtggag cctgccgccc ccacctgggc accgggaccc cctcaccatc 3180

cagtgggccc ggagaaacct gatgaacagt ttggggactc aggaccagat gtccgtctct 3240

cttgcttgag gaatgaagac ctttattcac ccctgccccg ttgcttcccg ctgcacatgg 3300

acagacttca cagcgtctgc tcataggacc tgcatccttc ctggggacga attccactcg 3360

tccaagggac agcccacggt ctggaggccg aggaccacca gcaggcaggt ggactgactg 3420

ttgggcaaga cctcttccct ctgggcctgt tctcttggct gcaaataagg acagcagctg 3480

gtgccccacc tgcctggtgc attgctgtgt gaatccagga ggcagtggac atcgtaggca 3540

gccacggccc cgggtccagg agaagtgctc cctggaggca cgcaccactg cttcccactg 3600

gggccggcgg ggcccacgca cgacgtcagc ctcttacctt cccgcctcgg ctaggggtcc 3660

tcgggatgcc gttctgttcc aacctcctgc tctgggacgt ggacatgcct caaggataca 3720

gggagccggc ggcctctcga cggcacgcac ttgcctgttg gctgctgcgg ctgtgggcga 3780

gcatgggggc tgccagcgtc tgttgtggaa agtagctgct agtgaaatgg ctggggccgc 3840

tggggtccgt cttcacactg cgcaggtctc ttctgggcgt ctgagctggg gtgggagctc 3900

ctccgcagaa ggttggtggg gggtccagtc tgtgatcctt ggtgctgtgt gccccactcc 3960

agcctgggga ccccacttca gaaggtaggg gccgtgtccc gcggtgctga ctgaggcctg 4020

cttccccctc cccctcctgc tgtgctggaa ttccacaggg accagggcca ccgcagggga 4080

ctgtctcaga agacttgatt tttccgtccc tttttctcca cactccactg acaaacgtcc 4140

ccagcggttt ccacttgtgg gcttcaggtg ttttcaagca caacccacca caacaagcaa 4200

-continued

gtgcattttc agtcgttgtg ctttttgtt ttgtgctaac gtcttactaa tttaaagatg 4260

ctgtcggcac catgtttatt tatttccagt ggtcatgctc agccttgctg ctctgcgtgg 4320

cgcaggtgcc atgcctgctc cctgtctgtg tcccagccac gcagggccat ccactgtgac 4380

gtcggccgac caggctggac accctctgcc gagtaatgac gtgtgtggct gggaccttct 4440

ttattctgtg ttaatggcta acctgttaca ctgggctggg ttgggtaggg tgttctggct 4500

tttttgtggg gtttttattt ttaaagaaac actcaatcat cctaaaaaaa aattaaaaa 4559

<210> SEQ ID NO 62
<211> LENGTH: 1756
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 008942.9

<400> SEQUENCE: 62

agtccccaca ccgcctgcag agagggaact agggcaccac cttgtttcat gttgttcccg 60

tgaatttttt tcagctatgg gaggcaaccg aggcactggc caaatgcagg cccaacattt 120

cactgagcat gtcagcatgc acatcacaat ggcaagcagc cagggaccca ccaagaacaa 180

gaagacccca gcaggatccc tcactgagca tcgggggggca tctgcacttc atcaggcacc 240

ccagggcatt caccattcat cacaccaagc acagaggtgg agcacaagtg gtccagcgtc 300

acatccaagt gctcagctgt ggctggagga gctggcctgt ggcacagcca ctgagtgtcc 360

acaagccagg gagcacaacg atagccagga cacaggcttc actgaccagc aggctgcatc 420

aagccagcaa gcatctcagc aagtgcacca gtggagcact gccagcaccc cagcactggg 480

cacacaggga ccccacatca ccagtccagt gggccacgga gaaacactga tgcccgttgt 540

ctaggagaca gagcacaagc actgctcacg tctctgccgc ctgcgtttgg aggcccctgg 600

gctctcaccc agtccccacc cgcctgcaga gagggaacta gggcacccct tgtttctgtt 660

gttcccgtga attttttttcg ctatgggagg cagccgaggc ctggccaatg cggcccactt 720

tcctgagctg tcgctgcctc catggcagca gccagggacc cccagaacaa gaagaccccg 780

caggatccct cctgagctcg gggggctctg ccttctcagg ccccgggctt cccttctccc 840

cagccagagg tggagccaag tggtccagcg tcactccagt gctcagctgt ggctggagga 900

gctggcctgt ggcacagccc tgagtgtccc aagccgggag ccaacgaagc cggacacggc 960

ttcactgacc agcggctgct caagccgcaa gctctcagca agtgcccagt ggagcctgcc 1020

gcccccgcct gggcaccggg acccccctcac catccagtgg gcccggagaa acctgatgaa 1080

cagtttgggg actcaggacc agatgtccgt ctctcttgct tgaggaatga agacctttat 1140

tcacccctgc cccgttgctt cccgctgcac atggacagac ttcacagcgt ctgctcatag 1200

gacctgcatc cttcctgggg acgaattcca ctcgtccaag ggacagccca cggtctggag 1260

gccgaggacc accagcaggc aggtggactg actgtgttgg gcaagacctc ttccctctgg 1320

gcctgttctc ttggctgcaa ataaggacag cagctggtgc cccacctgcc tggtgcattg 1380

ctgtgtgaat ccaggaggca gtggacatcg taggcagcca cggccccggg tccaggagaa 1440

gtgctccctg gaggcacgca ccactgcttc ccactggggc cggcggggcc cacgcacgac 1500

gtcagcctct taccttcccg cctcggctag gggtcctcgg gatgccgttc tgttccaacc 1560

tcctgctctg ggacgtggac atgcctcaac tgagggccag ggacccaggt gtgcctgtgc 1620

tcctgcccag gagcagcttt tggtctcctt gggccctttt tcccttccct cctttgttta 1680

-continued

cttatatata tatttttttt aaacttaaat tttgggtcaa cttgacacca ctaagatgat 1740

ttttaaggag ctgggg 1756

<210> SEQ ID NO 63
<211> LENGTH: 3304
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1252415.1
<221> NAME/KEY: unsure
<222> LOCATION: 3267, 3276, 3289-3290, 3297, 3299
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 63

gcggaactct gaggtgaggg tgtgcagctt ggtagggatt ggggtccctt ccggggccca 60

tcggcccctg gtggtgttaa tggcccttct ggcctacgcg cgtgtcatga accctggccg 120

agagggccgg ggctgaggcc ctcaggccga cccggactct tgggcgcggt ctcttgaggt 180

ggggccgggg tgagcagctg agtccgggtg ccccggggag gcccctctgg cccgatttcg 240

cagcgctgcc catcagcttc agcggaggcc tgattcctga ggtgctctga ctggaaggaa 300

cctccgagat cggagagtct tccctgtctc ctgttgatgc tcccattgca ctgataggta 360

aattgatccc tagagaagag gctagtctga gatatatagc gagtgaggaa aagaatcgga 420

atcatgatcc tggtgcctta gataaccagc cccagttctt cccgtgttgc tcggaacctc 480

tctaacttgg gatggtcttc cggtcggtgt tgccccgcag gctgctgcag cttaaaggcc 540

agcgctgcgt ggaacttttt tttttctctc ctcccaaatt gagccgtttg aaatgcctag 600

ggagttttta aaagaaaggc gggcacatcc ttgtatttac aggcagatat cctccctttc 660

ctcctcggct gctgctctta ctttgacaag ccaggctaac attgaaggtg gtccattatg 720

gctgacatgc aaaatctggt agaaagattg gagagggcag tgggccgcct ggaggcagta 780

tctcatacct ctgacatgca ccgtgggtat gcagacagtc cttcaaaagc aggagcagct 840

ccatatgtgc aggcatttga ctcgctgctt gctggtcctg tggcagagta cttgaagatc 900

agtaaagaga ttgggggaga cgtgcagaaa catgcggaga tggtccacac aggtttgaag 960

ttggagcgag ctctgttggt tacagcttct cagtgtcaac agccagcaga aaataagctt 1020

tccgatttgt tggcacccat ctcagagcag atcaaagaag tgataacctt tcgggagaag 1080

aaccgaggca gcaagttgtt taatcacctg tcagctgtca gcgaaagtat ccaggccctg 1140

ggctgggtgg ctatggctcc caagcctggc ccttatgtga aagaaatgaa tgatgccgcc 1200

atgttttata caaaccgagt cctcaaagag tacaaagatg tggataagaa gcatgtagac 1260

tgggtcaaag cttatttaag tatatggaca gagctgcagg cttacattaa ggagttccat 1320

accaccggac tggcctggag caaaacgggg cctgtggcaa aagaactgag cggactgcca 1380

tctggaccct ctgccggatc aggtcctcct ccccctccac caggcccccc tcctccccca 1440

gtctctacca gttcaggctc agatgagtct gcttcccgct cagcactgtt cgcgcagatt 1500

aatcaggggg agagcattac acatgccctg aaacatgtat ctgatgacat gaagactcac 1560

aagaaccctg ccctgaaggc tcagagtggt ccagtacgca gtggccccaa accattctct 1620

gcacctaaac cccaaaccag cccatccccc aaacgagcca caaagaagga gccagctgta 1680

cttgaactgg agggcaagaa gtggagagtg gaaaatcagg aaaatgtttc caacctggtg 1740

attgaggaca cagagctgaa acaggtggct tacatataca agtgtgtcaa cacgacattg 1800

-continued

caaatcaagg gcaaaattaa ctccattaca gtagataact gtaagaaact tggcctggta 1860

ttcgatgacg tggtgggcat tgtggagata atcaacagta aggatgtcaa agttcaggta 1920

atgggtaaag tgccaaccat atccatcaac aaaacagatg gctgccatgc ttacctgagc 1980

aagaattccc tggattgtga aatagtcagt gccaaatctt ccgagatgaa tgtcctcatt 2040

cctacagaag gcggtgactt taatgaattc ccagttcctg agcagttcaa gaccctatgg 2100

aacgggcaga agttggtcac cacagtgaca gaaattgctg gataagcgaa gtgccactgg 2160

gttctttgcc ctcccttcac accatgggat aaatctgtat caagacggtt cttttctaga 2220

tttcctctac ctttttgctc ttaaaactgc ttctctgctc tgagaagcac agctacctgc 2280

cttcactgaa atatacctca ggctgaaatt tggggtggga tagcaggtca gttgatcttc 2340

tgcaggaagg tgcagctttt ccatatcagc tcaaccacgc cgccagtcca ttcttaagga 2400

actgccgact aggactgatg atgcatttta gctttgagct tttgggggtt attctaccaa 2460

caaacagtcc attggaaaga aaacagtccc tggaattaac agatcagaat gttcacactg 2520

gttaatcttt ttttaacaat gagcatgaag gtagcagaag ctggtgtgtt tccagatggt 2580

tcttctaacc aaactaattt ttcactgttg acaagcgagg caagggttgc actggaccaa 2640

aggctgaggc ttggccatct agcattccat acaaaattgt ttcctataag cattcctttt 2700

attctctatt ctatcctggg tctgcctcaa ccgtgagata ggagagtctc tggtactagc 2760

tgctgtagca gtgcccttca tccagggcag ttaatggagt cttggaccct ttctttctct 2820

gggatccctg cccagcacct tcctatagag atgactttaa aaggaaaaaa aaaaaaaaaa 2880

caaacccaca tgatttcaag gagtctggca ttcctgaatc cttcttccct gccaggtgcc 2940

tgtcacctgt cttcactgcc tccttttccc tgtcatgctc atcagcttat ggcttctgtc 3000

taagcacctg aacagaggac tgaaacctcc actgcaggct ggttttaggt cttgaattat 3060

gtaagaatct tgcacagcac tgctaatgta aatttcagtt gtttttccct ctaggacaaa 3120

cacttaccaa aatatgcaac tttttttgg tgggaagaga gattgtcctg tgatttctac 3180

ccatttcctg aggcctgtgg aaataaacct ttatgtactt aaagttatac agaaaataga 3240

ataaagttaa taccaaactt gaaaaanaaa aaaaangggg ggccgccgnn tagtgancnc 3300

gtcg 3304

<210> SEQ ID NO 64
<211> LENGTH: 7231
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1399366.20
<221> NAME/KEY: unsure
<222> LOCATION: 5601, 5609, 7107
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 64

cccgagctgg cctgcgagtt cagggctcct gccgctctcc aggagcaacc tctactccgg 60

acgcacaggc attccccgcg cccctccagc cctcgccgcc ctcgccaccg ctcccggccg 120

ccgcgctccg gtacacacag gatccctgct gggcaccaac agctccacca tggggctggc 180

ctggggacta ggcgtcctgt tcctgatgca tgtgtgtggc accaaccgca ttccagagtc 240

tggcggagac aacagcgtgt ttgacatctt tgaactcacc ggggccgccc gcaaggggtc 300

tgggcgccga ctggtgaagg gccccgaccc ttccagccca gctttccgca tcgaggatgc 360

caacctgatc ccccctgtgc ctgatgacaa gttccaagac ctggtggatg ctgtgcgggc 420

-continued

agaaaagggt ttcctccttc tggcatccct gaggcagatg aagaagaccc ggggcacgct 480

gctggccctg gagcggaaag accactctgg ccaggtcttc agcgtggtgt ccaatggcaa 540

ggcgggcacc ctggacctca gcctgaccgt ccaaggaaag cagcacgtgg tgtctgtgga 600

agaagctctc ctggcaaccg gccagtggaa gagcatcacc ctgtttgtgc aggaagacag 660

ggcccagctg tacatcgact gtgaaaagat ggagaatgct gagttggacg tccccatcca 720

aagcgtcttc accagagacc tggccagcat cgccagactc cgcatcgcaa agggggcgt 780

caatgacaat ttccaggggg tgctgcagaa tgtgaggttt gtctttggaa ccacaccaga 840

agacatcctc aggaacaaag gctgctccag ctctaccagt gtcctcctca cccttgacaa 900

caacgtggtg aatggttcca gccctgccat ccgcactaac tacattggcc acaagacaaa 960

ggacttgcaa gccatctgcg gcatctcctg tgatgagctg tccagcatgg tcctggaact 1020

caggggcctg cgcaccattg tgaccacgct gcaggacagc atccgcaaag tgactgaaga 1080

gaacaaagag ttggccaatg agctgaggcg gcctccccta tgctatcaca acggagttca 1140

gtacagaaat aacgaggaat ggactgttga tagctgcact gagtgtcact gtcagaactc 1200

agttaccatc tgcaaaaagg tgtcctgccc catcatgccc tgctccaatg ccacagttcc 1260

tgatggagaa tgctgtcctc gctgttggcc cagcgactct gcggacgatg gctggtctcc 1320

atggtccgag tggacctcct gttctacgag ctgtggcaat ggaattcagc agcgcggccg 1380

ctcctgcgat acgctcaaca accgatgtga gggctcctcg gtccagacac ggacctgcca 1440

cattcaggag tgtgacaaga gatttaaaca ggatggtggc tggagccact ggtccccgtg 1500

gtcatcttgt tctgtgacat gtggtgatgg tgtgatcaca aggatccggc tctgcaactc 1560

tcccagcccc cagatgaacg ggaaaccctg tgaaggcgaa gcgcgggaga ccaaagcctg 1620

caagaaagac gcctgcccca tcaatggagg ctggggtcct tggtcaccat gggacatctg 1680

ttctgtcacc tgtggaggag gggtacagaa acgtagtcgt ctctgcaaca accccacacc 1740

ccagtttgga ggcaaggact gcgttggtga tgtaacagaa aaccagatct gcaacaagca 1800

ggactgtcca attgatggat gcctgtccaa tccctgcttt gccggcgtga agtgtactag 1860

ctaccctgat ggcagctgga aatgtggtgc ttgtcccccc ggttacagtg gaaatggcat 1920

ccagtgcaca gatgttgatg agtgcaaaga agtgcctgat gcctgcttca accacaatgg 1980

agagcaccgg tgtgagaaca cggaccccgg ctacaactgc ctgccctgcc ccccacgctt 2040

caccggctca cagcccttcg gccagggtgt cgaacatgcc acggccaaca aacaggtgtg 2100

caagccccgt aacccctgca cggatgggac ccacgactgc aacaagaacg ccaagtgcaa 2160

ctacctgggc cactatagcg accccatgta ccgctgcgag tgcaagcctg gctacgctgg 2220

caatggcatc atctgcgggg aggacacaga cctggatggc tggcccaatg agaacctggt 2280

gtgcgtggcc aatgcgactt accactgcaa aaaggataat tgccccaacc ttcccaactc 2340

agggcaggaa gactatgaca aggatggaat tggtgatgcc tgtgatgatg acgatgacaa 2400

tgataaaatt ccagatgaca gggacaactg tccattccat tacaacccag ctcagtatga 2460

ctatgacaga gatgatgtgg gagaccgctg tgacaactgt ccctacaacc acaacccaga 2520

tcaggcagac acagacaaca atggggaagg agacgcctgt gctgcagaca ttgatggaga 2580

cggtatcctc aatgaacggg acaactgcca gtacgtctac aatgtggacc agagagacac 2640

tgatatggat ggggttggag atcagtgtga caattgcccc ttggaacaca atccggatca 2700

gctggactct gactcagacc gcattggaga tacctgtgac aacaatcagg atattgatga 2760

-continued

agatggccac cagaacaatc tggacaactg tccctatgtg cccaatgcca accaggctga 2820

ccatgacaaa gatggcaagg gagatgcctg tgaccacgat gatgacaacg atggcattcc 2880

tgatgacaag gacaactgca gactcgtgcc caatcccgac cagaaggact ctgacggcga 2940

tggtcgaggt gatgcctgca aagatgattt tgaccatgac agtgtgccag acatcgatga 3000

catctgtcct gagaatgttg acatcagtga gaccgacttc cgccgattcc agatgattcc 3060

tctggacccc aaagggacat cccaaaatga ccctaactgg gttgtacgcc atcagggtaa 3120

agaactcgtc cagactgtca actgtgatcc tggactcgct gtaggttatg atgagtttaa 3180

tgctgtggac ttcagtggca ccttcttcat caacaccgaa agggacgatg actatgctgg 3240

atttgtcttt ggctaccagt ccagcagccg cttttatgtt gtgatgtgga agcaagtcac 3300

ccagtcctac tgggacacca accccacgag ggctcaggga tactcgggcc tttctgtgaa 3360

agttgtaaac tccaccacag ggcctggcga gcacctgcgg aacgccctgt ggcacacagg 3420

aaacacccct ggccaggtgc gcaccctgtg gcatgaccct cgtcacatag gctggaaaga 3480

tttcaccgcc tacagatggc gtctcagcca caggccaaag acgggtttca ttagagtggt 3540

gatgtatgaa gggaagaaaa tcatggctga ctcaggaccc atctatgata aaacctatgc 3600

tggtggtaga ctagggttgt ttgtcttctc tcaagaaatg gtgttcttct ctgacctgaa 3660

atacgaatgt agagatccct aatcatcaaa ttgttgattg aaagactgat cataaaccaa 3720

tgctggtatt gcaccttctg gaactatggg cttgagaaaa cccccaggat cacttctcct 3780

tggcttcctt cttttctgtg cttgcatcag tgtggactcc tagaacgtgc gacctgcctc 3840

aagaaaatgc agttttcaaa aacagactca gcattcagcc tccaatgaat aagacatctt 3900

ccaagcatat aaacaattgc tttggtttcc ttttgaaaaa gcatctactt gcttcagttg 3960

ggaaggtgcc cattccactc tgcctttgtc acagagcagg gtgctattgt gaggccatct 4020

ctgagcagtg gactcaaaag cattttcagg catgtcagag aagggaggac tcactagaat 4080

tagcaaacaa aaccaccctg acatcctcct tcaggaacac ggggagcaga ggccaaagca 4140

ctaaggggag ggcgcatacc cgagacgatt gtatgaagaa aatatggagg aactgttaca 4200

tgttcggtac taagtcattt tcaggggatt gaaagactat tgctggattt catgatgctg 4260

actggcgtta gctgattaac ccatgtaaat aggcacttaa atagaagcag gaaagggaga 4320

caaagactgg cttctggact tcctccctga tccccaccct tactcatcac ctgcagtggc 4380

cagaattagg gaatcagaat caaaccagtg taaggcagtg ctggctgcca ttgcctggtc 4440

acattgaaat tggtggcttc attctagatg tagcttgtgc agatgtagca ggaaaatagg 4500

aaaacctacc atctcagtga gcaccagctg cctcccaaag gaggggcagc cgtgcttata 4560

tttttatggt tacaatggca caaaattatt atcaacctaa ctaaaacatt ccttttctct 4620

tttttcctga attatcatgg agttttctaa ttctctcttt tggaatgtag attttttta 4680

aatgctttac gatgtaaaat atttattttt tacttattct ggaagatctg gctgaaggat 4740

tattcatgga acaggaagaa gcgtaaagac tatccatgtc atctttgttg agagtcttcg 4800

tgactgtaag attgtaaata cagattattt attaactctg ttctgcctgg aaatttaggc 4860

ttcatacgga aagtgtttga gagcaagtag ttgacattta tcagcaaatc tcttgcaaga 4920

acagcacaag gaaaatcagt ctaataagct gctctgcccc ttgtgctcag agtggatgtt 4980

atgggattct ttttttctct gttttatctt ttcaagtgga attagttggt tatccatttg 5040

caaatgtttt aaattgcaaa gaaagccatg aggtcttcaa tactgtttta ccccatccct 5100

tgtgcatatt tccagggaga aggaaagcat atacactttt ttctttcatt tttccaaaag 5160

-continued

agaaaaaaat gacaaaaggt gaaacttaca tacaaatatt acctcatttg ttgtgtgact 5220

gagtaaagaa tttttggatc aagcggaaag agtttaagtg tctaacaaac ttaaagctac 5280

tgtagtacct aaaaagtcag tgttgtacat agcataaaaa ctctgcagag aagtattccc 5340

aataaggaaa tagcattgaa atgttaaata caatttctga aagttatgtt ttttatctat 5400

catctggtat accattgctt tatttttata aattattttc tcattgccat tggaatagat 5460

atctcagatt gtgtagatat gctatttaaa taatttatca ggaaatactg cctgtagagt 5520

tagtatttct atttttatat aatgtttgca cactgaattg aagaattgtt ggtttttttct 5580

ttttttgtt ttgttttttt nttttttttnt ttttgctttt gacctcccat ttttactatt 5640

tgccaatacc tttttctagg aatgtgcttt tttttgtaca cattttatc cattttacat 5700

tctaaagcag tgtaagttgt atattactgt ttcttatgta caaggaacaa caataaatca 5760

tatggaaatt tatatttata cttactgtat ccatgcttat ttgttctcta ctggctttat 5820

gtcatgaagt atatgcgtaa ataccattca taaatcaata tagcatatac aaaaataaat 5880

tacagtaagt catagcaaca ttcacagttt gtatgtgatt gagaaagact gagttgctca 5940

ggcctaggct tagaatttgc tgcgtttgtg gaataaaaga acaaaatgat acattagcct 6000

gccatatcaa aaacatataa aagagaaatt atccctaagt caagggcccc cataagaata 6060

aaatttctta ttaaggtcat tagatgtcat tgaatccttt tcaaagtgca gtatgaaaac 6120

aaagggaaaa acactgaagc acacgcaact ctcacagcga cattttctga cccacgaatg 6180

atgccttggg tgggcaacac gattgcatgt tgtggagaca cttcggaagt aaatgtggat 6240

gagggaggag ctgtccttgc aatgttgagc caagcattac agatacctcc tcttgaagaa 6300

ggaataataa gtttaatcaa aaaagaagac taaaaaatgt aaaatttgga aggaatccat 6360

aaatgcgtgt gtgtctaaat acaaattatc atgtgaagaa aaggcccaag tgtaccaata 6420

agcagacctt gatttttgga tgggctaatt atgaatgtgg aatactgacc agttaatttc 6480

cagttttaat gaaaacagat caaagaagaa attttatgag taggttaaag gtctggcttt 6540

gaggtctatt aaacactaga aaggactggc tgggtgagat aaaatcttcc ttgttgattt 6600

tcactctcat tctataaata ctcatctttc tgagtagcca tgatcacata caaatgtaaa 6660

ttgccaaatc attttatagt accaaggtga agaagcagga actagaaagt gttgataata 6720

gctgtggagt taggaaaact gatgtgaagg aaataattct ttgaaatggc aaagaattaa 6780

ataccatcat tcattatcag aagagttcaa cgtttgaagt gctgggagat aattctaatt 6840

cattcttgga tagtgaagca aaactgattg aaaataccaa gataagacag aaaaagtgac 6900

tggaaagagg agcttttctt ccaggcatgt tccagtttca ccctaagact gaccttcaaa 6960

taatcaggtt gtactgaaat aaaggacttg ttaaaaatta aaattatgtc atcgagatga 7020

tagctttttt cctcctccaa cagtttattg tgcatgtgtt gtgggagagc tcgagtgaag 7080

agcaataaac tccaggtctt ataagantgt acatacaata aaggtggtgc cagcagtttt 7140

ttttttttcta aagagtcaca tgtagaaaag cctccagtat taagctcctg aattcattcc 7200

tataaataaa ttggctctct ctctcttcta t 7231

<210> SEQ ID NO 65
<211> LENGTH: 961
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3732868CB1

-continued

<221> NAME/KEY: unsure
<222> LOCATION: 19
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 65

ctggctctga ccgcgctgnc ctgggcccga gagcccagga ggcgtgtctc agagaaaaga 60

tataagcggc ccccggacgc taaagcggtg ccagcggcgg agtctccaac tgggagagct 120

gcagctgccg agaggaggag aacgctgagg tcggtcggac caacggacgc gctgaccgct 180

gccaactgca gctcgcgctg cctcctgctc gcgccgtgcc actaaggtca ctcccgcctc 240

cgagagccca gagccgagat ggaaacggtc caggagctga tccccctggc caaggagatg 300

atggcccaga agcgcaaggg gaagatggtg aagctgtacg tgctgggcag cgtgctggcc 360

ctcttcggcg tggtgctcgg cctgatggag actgtgtgca gccccttcac ggccgccaga 420

cgtctgcggg accaggaggc agccgtggcg gagctgcagg ccgccctgga gcgacaggct 480

ctccagaagc aagccctgca ggagaaaggc aagcagcagg acacggtcct cggcggccgg 540

gccctgtcca accggcagca cgcctcctag gaactgtggg agaccagcgg agtgggaggg 600

agacgcagta gacagagaca gaccgagaag gaagggagag acagaggggg cgcgcgcaca 660

ggagcctgac tccgctggga gagtgcagga gcacgtgctg ttttttattt ggacttaact 720

tcagagaaac cgctgacatc tagaactgac ctaccacaag catccaccaa aggagtttgg 780

gattgagttt tgctgctgtg cagcactgca ttgtcatgac atttccaaca ctgtgtgaat 840

tatctaaatg cgtctaccat tttgcactag ggaggaagga taaatgcttt ttatgttatt 900

attattaatt attacaatga ccaccatttt gcattttgaa ataaaaaact ttttatacca 960

t 961

<210> SEQ ID NO 66
<211> LENGTH: 103
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 3732868CD1

<400> SEQUENCE: 66

Met Glu Thr Val Gln Glu Leu Ile Pro Leu Ala Lys Glu Met Met
1 5 10 15

Ala Gln Lys Arg Lys Gly Lys Met Val Lys Leu Tyr Val Leu Gly
20 25 30

Ser Val Leu Ala Leu Phe Gly Val Val Leu Gly Leu Met Glu Thr
35 40 45

Val Cys Ser Pro Phe Thr Ala Ala Arg Arg Leu Arg Asp Gln Glu
50 55 60

Ala Ala Val Ala Glu Leu Gln Ala Ala Leu Glu Arg Gln Ala Leu
65 70 75

Gln Lys Gln Ala Leu Gln Glu Lys Gly Lys Gln Gln Asp Thr Val
80 85 90

Leu Gly Gly Arg Ala Leu Ser Asn Arg Gln His Ala Ser
95 100

<210> SEQ ID NO 67
<211> LENGTH: 2608
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature

-continued

<223> OTHER INFORMATION: Incyte ID No: 1137894.1

<400> SEQUENCE: 67

ttcagcgctc ccactctcgg ccgacacccc tgcatggcca accgttacac catggatctg 60

actgccatct acgaggtgag tccccgccgc acggcatccc cggtacctgc atgcctgagt 120

ccgagtcccc acctctctag cgccgcaaac tccagcccgg gacgcttgcc tcccttctcc 180

aactggggct ccctagcgcc gcgccctcca gcctggggcc cctgcctccc gctcagacca 240

gcttggtgat ttggaggtga aaatggaacc cgcgacaccc ggctcttcgc tcaaacatgg 300

gtggggcggc ccatgcaagt ggaaagtcgg agaacttttc tcagaccgag gctgcctgga 360

ggcggaagtg gcccccatac ctggctcacc cctagtcgtt gctgagggcg tggttttgcg 420

cggaggcgtc tctggggctg aagtctcagg gtgggggggat ccgacttctg tctctccagt 480

ccctgaccgt agagacagag aaccctaaaa ccgaagcaat ccggacttcc aggtcaactt 540

tgcccggttt ctccagttgt gaaactggag atcccgacgc gtgggtcata tccggggagg 600

acaagagacc caaaattggg aaacagtggt gcgccctgac ttcggggtcc ccctcttggt 660

ccagccgggg aagccgggat tcctgggtcc ctcgggataa ggcctcggtg gtgggtaaac 720

tcagaacctc caactctggg ttcctggcat ccggaaccca ggggtttctg cgggcgggtg 780

gggctcaggc ggggagccca caaaccggcc tggcaagctc tagttccctg cagctggggt 840

ggggcgtcgc cctgcatttt caggtgcctt aaccgaccca tttccgcaga gcctcctgtc 900

gctgagccct gacgtgcccg tgccatccga ccatggaggg actgagtcca gcccaggctg 960

gggctcctcg ggaccctgga gcctgagccc ctccgactcc agcccgtctg gggtcacctc 1020

ccgcctgcct ggccgctcca ccagcctagt ggagggccgc agctgtggct gggtgccccc 1080

acccccctggc ttcgcaccgc tggctccccg cctgggccct gagctgtcac cctcacccac 1140

ttcgcccact gcaacctcca ccacccccctc gcgctacaag actgagctat gtcggacctt 1200

ctcagagagt gggcgctgcc gctacggggc caagtgccag tttgcccatg gcctgggcga 1260

gctgcgccag gccaatcgcc accccaaata caagacggaa ctctgtcaca agttctacct 1320

ccagggccgc tgcccctacg gctctcgctg ccacttcatc cacaacccta gcgaagacct 1380

ggcggccccg ggccaccctc ctgtgcttcg ccagagcatc agcttctccg gcctgccctc 1440

tggccgccgg acctcaccac caccaccagg cctggccggc ccttccctgt cctccagctc 1500

cttctcgccc tccagctccc caccaccacc tggggacctt ccactgtcac cctctgcctt 1560

ctctgctgcc cctggcaccc ccctggctcg aagagacccc accccagtct gttgcccctc 1620

ctgccgaagg gccactccta tcagcgtctg ggggcccttg ggtggcctgg ttcggacccc 1680

ctctgtacag tccctgggat ccgaccctga tgaatatgcc agcagcggca gcagcctggg 1740

gggctctgac tctcccgtct tcgaggcggg agtttttgca ccaccccagc ccgtggcagc 1800

cccccggcga ctccccatct tcaatcgcat ctctgtttct gagtgacaaa gtgactgccc 1860

ggtcagatca gctggatctc agcggggagc cacgtctctt gcactgtggt ctctgcatgg 1920

accccagggc tgtggggact tgggggacag taatcaagta atccccttttt ccagaatgca 1980

ttaacccact cccctgacct cacgctgggg caggtcccca agtgtgcaag ctcagtattc 2040

atgatggtgg gggatggagt gtcttccgag gttcttgggg gaaaaaaaat tgtagcatat 2100

ttaagggagg caatgaaccc tctcccccac ctcttccctg cccaaatctg tctcctagaa 2160

tcttatgtgc tgtgaataat aggccttcac tgcccctcca gtttttatag acctgaggtt 2220

ccagtgtctc ctggtaactg gaacctctcc tgagggggaa tcctggtgct caaattaccc 2280

-continued

tccaaaagca agtagccaaa gccgttgcca aaccccaccc ataaatcaat gggcccttta 2340

tttatgacga ctttatttat tctaatatga ttttatagta tttatatata ttgggtcgtc 2400

tgcttccctt gtatttttct tccttttttt gtaatattga aaacgacgat ataattatta 2460

taagtagact ataatatatt tagtaatata tattattacc ttaaaagtct atttttgtgt 2520

tttgggcatt tttaaataaa caatctgagt gtgttcttcg tagaggaact cgattgagga 2580

ccagaggtcc tggacctcca aatacaac 2608

<210> SEQ ID NO 68
<211> LENGTH: 1527
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1418671CB1

<400> SEQUENCE: 68

gcttcctggg cgccgtgggc gcggactgcg cgggctgcgc gggtgccgag gagcgcgagg 60

cgcggggaag gcgcacctgg ggtggccctg gcgtgcgggc ggcgacatgg aggacggcgt 120

gctcaaggag ggcttcctgg tcaagagggg ccacattgtc cacaactgga aggcgcgatg 180

gttcatcctt cggcagaaca cgctggtgta ctacaagctt gaggggggtc ggagagtgac 240

ccctcccaag ggccggatcc tcctggatgg ctgcaccatc acctgcccct gcctggagta 300

tgaaaaccga ccgctcctca ttaagctgaa gactcaaaca tccacggagt acttcctgga 360

ggcctgttct cgagaggagc gggatgcctg ggcctttgag atcaccgggg ctattcatgc 420

agggcagccg gggaaggtcc agcagctgca cagcctgaga aactccttca agctgccccc 480

gcacatcagc ctgcatcgca ttgtggacaa gatgcacgat agcaacaccg gaatccgttc 540

aagccccaac atggagcagg gaagcaccta taaaaagacc ttcctcggct cctccctggt 600

ggactggctc atctccaaca gcttcacggc cagccgtctg gaggcggtga ccctggcctc 660

catgctcatg gaggagaact tcctcaggcc tgtgggtgtc cgaagcatgg gagccattcg 720

ctctggggat ctggccgagc agttcctgga tgactccaca gccctgtaca cttttgctga 780

gagctacaaa aagaagataa gccccaagga agaaattagc ctgagcactg tggagttaag 840

tggcacggtg gtgaaacaag gctacctggc caagcaggga cacaagagga aaaactggaa 900

ggtgcgtcgc tttgttctaa ggaaggatcc agctttcctg cattactatg acccttccaa 960

agaagagaac aggccagtgg gtgggttttc tcttcgtggt tcactcgtgt ctgctctgga 1020

agataatggc gttcccactg gggttaaagg gaatgtccag ggaaacctct tcaaagtgat 1080

tactaaggat gacacacact attacattca ggccagcagc aaggctgagc gagccgagtg 1140

gattgaagct atcaaaaagc taacatgaca aggacctgag ggaaccagga ttcctccctc 1200

ctaccagatg acacagacaa gagttcctgg agaatgggag tgttaagact tttgacttct 1260

ttgtaagttt tgtactgctt tggagagtga atgctgccaa gagttcctca gattacaaac 1320

agcagtggtg ccatttcctt ccccatcttc atgttacaaa cctggaaagg ctagaacagc 1380

cattaggcgt cagcatcttg acttttcccc agcatcacaa acagccattt cctcgggcac 1440

caaagtaggt tccctttgtt ggaacaatta cactggccat gccataatgt tgaataaaac 1500

tctcttctta tgaaaaaaaa aaaaaaa 1527

<210> SEQ ID NO 69
<211> LENGTH: 353

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1418671CD1

<400> SEQUENCE: 69

Met Glu Asp Gly Val Leu Lys Glu Gly Phe Leu Val Lys Arg Gly
1 5 10 15

His Ile Val His Asn Trp Lys Ala Arg Trp Phe Ile Leu Arg Gln
20 25 30

Asn Thr Leu Val Tyr Tyr Lys Leu Glu Gly Gly Arg Arg Val Thr
35 40 45

Pro Pro Lys Gly Arg Ile Leu Leu Asp Gly Cys Thr Ile Thr Cys
50 55 60

Pro Cys Leu Glu Tyr Glu Asn Arg Pro Leu Leu Ile Lys Leu Lys
65 70 75

Thr Gln Thr Ser Thr Glu Tyr Phe Leu Glu Ala Cys Ser Arg Glu
80 85 90

Glu Arg Asp Ala Trp Ala Phe Glu Ile Thr Gly Ala Ile His Ala
95 100 105

Gly Gln Pro Gly Lys Val Gln Gln Leu His Ser Leu Arg Asn Ser
110 115 120

Phe Lys Leu Pro Pro His Ile Ser Leu His Arg Ile Val Asp Lys
125 130 135

Met His Asp Ser Asn Thr Gly Ile Arg Ser Ser Pro Asn Met Glu
140 145 150

Gln Gly Ser Thr Tyr Lys Lys Thr Phe Leu Gly Ser Ser Leu Val
155 160 165

Asp Trp Leu Ile Ser Asn Ser Phe Thr Ala Ser Arg Leu Glu Ala
170 175 180

Val Thr Leu Ala Ser Met Leu Met Glu Glu Asn Phe Leu Arg Pro
185 190 195

Val Gly Val Arg Ser Met Gly Ala Ile Arg Ser Gly Asp Leu Ala
200 205 210

Glu Gln Phe Leu Asp Asp Ser Thr Ala Leu Tyr Thr Phe Ala Glu
215 220 225

Ser Tyr Lys Lys Lys Ile Ser Pro Lys Glu Glu Ile Ser Leu Ser
230 235 240

Thr Val Glu Leu Ser Gly Thr Val Val Lys Gln Gly Tyr Leu Ala
245 250 255

Lys Gln Gly His Lys Arg Lys Asn Trp Lys Val Arg Arg Phe Val
260 265 270

Leu Arg Lys Asp Pro Ala Phe Leu His Tyr Tyr Asp Pro Ser Lys
275 280 285

Glu Glu Asn Arg Pro Val Gly Gly Phe Ser Leu Arg Gly Ser Leu
290 295 300

Val Ser Ala Leu Glu Asp Asn Gly Val Pro Thr Gly Val Lys Gly
305 310 315

Asn Val Gln Gly Asn Leu Phe Lys Val Ile Thr Lys Asp Asp Thr
320 325 330

His Tyr Tyr Ile Gln Ala Ser Ser Lys Ala Glu Arg Ala Glu Trp
335 340 345

Ile Glu Ala Ile Lys Lys Leu Thr
350

-continued

<210> SEQ ID NO 70
<211> LENGTH: 5648
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 464689.64

<400> SEQUENCE: 70

ggtgtggtgt cggtgtcggc agcatccccg gcgccctgct gcggtcgccg cgagcctcgg 60

cctctgtctc ctccccctcc cgcccttacc tccacgcggg accgcccgcg ccagtcaact 120

cctcgcactt tgcccctgct tggcagcgga taaaaggggg ctgaggaaat accggacacg 180

gtcacccgtt gccagctcta gcctttaaat tcccggctcg gggacctcca cgcaccgcgg 240

ctagcgccga caaccagcta gcgtgcaagg cgccgcggct cagcgcgtac cggcgggctt 300

cgaaaccgca gtcctccggc gaccccgaac tccgctccgg agcctcagcc ccctggaaag 360

tgatcccggc atcggagagc caagatgccg gcccacttgc tgcaggacga tatctctagc 420

tcctatacca ccaccaccac cattacagcg cctccctcca ggggtcctgc agaatggagg 480

agataagttg gagacgatgc ccctctactt ggaagacgac attcgccctg atataaaaga 540

tgatatatat gaccccacct acaaggataa ggaaggccca agccccaagg ttgaatatgt 600

ctggagaaac atcatcctta tgtctctgct acacttggga gccctgtatg ggatcacttt 660

gattcctacc tgcaagttct acacctggct ttgggggtta ttctactatt ttgtcagtgc 720

cctgggcata acagcaggag ctcatcgtct gtggagccac cgctcttaca aagctcggct 780

gcccctacgg ctctttctga tcattgccaa cacaatggca ttccagaatg atgtctatga 840

atgggctcgt gaccaccgtg cccaccacaa gttttcagaa acacatgctg atcctcataa 900

ttcccgacgt ggctttttct tctctcacgt gggttggctg cttgtgcgca aacacccagc 960

tgtcaaagag aaggggagta cgctagactt gtctgaccta gaagctgaga aactggtgat 1020

gttccagagg aggtactaca aacctggctt gctgatgatg tgcttcatcc tgcccacgct 1080

tgtgccctgg tatttctggg gtgaaacttt tcaaaacagt gtgttcgttg ccactttctt 1140

gcgatatgct gtggtgctta atgccacctg gctggtgaac agtgctgccc acctcttcgg 1200

atatcgtcct tatgacaaga acattagccc ccgggagaat atcctggttt cacttggagc 1260

tgtgggtgag ggcttccaca actaccacca ctcctttccc tatgactact ctgccagtga 1320

gtaccgctgg cacatcaact tcaccacatt cttcattgat tgcatggccg ccctcggtct 1380

ggcctatgac cggaagaaag tctccaaggc cgccatcttg gccaggatta aaagaaccgg 1440

agatggaaac tacaagagtg gctgagtttg gggtccctca ggttcctttt tcaaaaacca 1500

gccaggcaga ggttttaatg tctgtttatt aactactgaa taatgctacc aggatgctaa 1560

agatgatgat gttaacccat tccagtacag tattctttta aaattcaaaa gtattgaaag 1620

ccaacaactc tgcctttatg atgctaagct gatattattt cttctcttat cctctctctc 1680

ttctaggccc attgtcctcc ttttcacttt attgctatcg ccctcctttc ccttattgcc 1740

tcccaggcaa gcagctggtc agtctttgct cagtgtccag cttccaaagc ctagacaacc 1800

tttctgtagc ctaaaacgaa tggtctttgc tccagataac tctctttcct tgagctgttg 1860

tgagctttga agtaggtggc ttgagctaga gataaaacag aatcttctgg gtagtcccct 1920

gttgattatc ttcagcccag gcttttgcta gatggaatgg aaaagcaact tcatttgaca 1980

caaagcttct aaagcaggta aattgtcggg ggagagagtt agcatgtatg aatgtaagga 2040

-continued

tgagggaagc gaagcaagag gaacctctcg ccatgatcag acatacagct gcctacctaa 2100

tgaggacttc aagccccacc acatagcatg cttcctttct ctcctggctc ggggtaaaaa 2160

gtggctgcgg tgtttggcaa tgctaattca atgccgcaac atatagttga ggccgaggat 2220

aaagaaagac attttaagtt tgtagtaaaa gtggtctctg ctggggaagg gtttcttttc 2280

ttttttcttt atcacaagga gatttcttag ttcatatatc aagaagtctt gaagttgggt 2340

gtttccagaa ttggtaaaaa cagcagctca tggaattttg agtattccat gagctgctca 2400

ttacagttct ttcctctttc tgctctgcca tcttcaggat attggttctt cccctcatag 2460

taataagatg gctgtggcat ttccaaacat ccaaaaaaag ggaaggattt aaggaggtga 2520

agtcgggtca aaaataaaat atatatacat atatacattg cttagaacgt taaactatta 2580

gagtatttcc cttccaaaga gggatgtttg gaaaaaactc tgaaggagag gaggaattag 2640

ttgggatgcc aatttcctct ccactgctgg acatgagatg gagaggctga gggacaggat 2700

ctataggcag cttctaagag cgaacttcac ataggaaggg atctgagaac acgttgccag 2760

gggcttgaga aggttactga gtgagttatt gggagtctta ataaaataaa ctagatatta 2820

ggtccattca ttaattagtt ccagtttctc cttgaaatga gtaaaaacta gaaggcttct 2880

ctccacagtg ttgtgcccct tcactcattt ttttttgagg agaaggggtg ctctgttaac 2940

atctagccta aagtatacaa ctgcctgggg ggcagggtta ggaatctctt cactaccctg 3000

attcttgatt cctggctcta ccctgtctgt ccctttttctt tgaccagatc tttctcttcc 3060

ctgaacgttt tcttctttcc ctggacaggc agcctccttt gtgtgtattc agaggcagtg 3120

atgacttgct gtccaggcag ctccctcctg cacacagaat gctcagggtc actgaaccac 3180

tgcttctctt ttgaaagtag agctagctgc cactttcacg tggcctccgc agtgtctcca 3240

cctacacccc tgtgctcccc tgccacactg atggctcaag acaaggctgg caaaccctcc 3300

cagaaacatc tctggcccag aaagcctctc tctccctccc tctctcatga ggcacagcca 3360

agccaagcgc tcatgttgag ccagtgggcc agccacagag caaaagaggg tttattttca 3420

gtcccctctc tctgggtcag aaccagaggg catgctgaat gccccctgct tacttggtga 3480

gggtgccccg cctgagtcag tgctctcagc tggcagtgca atgcttgtag aagtaggagg 3540

aaacagttct cactgggaag aagcaagggc aagaacccaa gtgcctcacc tcgaaaggag 3600

gccctgttcc ctggagtcag ggtgaactgc aaagctttgg ctgagacctg ggatttgaga 3660

taccacaaac cctgctgaac acagtgtctg ttcagcaaac taaccagcat tccctacagc 3720

ctagggcaga caatagtata gaagtctgga aaaaaacaaa aacagaattt gagaaccttg 3780

gaccactcct tgtccctgta gctcagtcat caaagcagaa gtcctggctt tgctctataa 3840

agaattggaa atggtacact acccaaacac tcagttcact tgttgagccc cagtgcctgg 3900

aagggaggaa ggccttttctt ctgtgttaat tgccgtagag gctacagggg ttagccctgg 3960

actaaaggca tccttgtctt ttgagctatt cacctcagta gaaaaggatc taagggaaga 4020

tcactgtagt ttagttctgt tgaccttgtg cacctacccc ttggaaatgt ctgctggtat 4080

ttctaattcc acaggtcatc agatgcctgc ttgataatat ataaacaata aaaacaactt 4140

tcacttcttc ctattgtaat cgtgtgccat ggatctgatc tgtaccatga ccctacataa 4200

ggctggatgg cacctcaggc tgagggcccc aatgtatgtg tggctgtggg tgtgggtggg 4260

agtgtgtctg ctgagtaagg aacacgattt tcaagattct aaagctcaat tcaagtgaca 4320

cattaatgat aaactcagat ctgatcaaga gtccggattt ctaacagtcc ttgctttggg 4380

-continued

ggggtgtgct gacaacttag ctcaggtgcc ttacatcttt tctaatcaca gtgttgcata 4440

tgagcctgcc ctcactccct ctgcagaatc cctttgcacc tgagacccta ctgaagtggc 4500

tggtagaaaa aggggcctga gtggaggatt atcagtatca cgatttgcag gattcccttc 4560

tgggcttcat tctggaaact tttgttaggg ctgcttttct taagtgccca catttgatgg 4620

agggtggaaa taatttgaat gtatttgatt tataagtttt ttttttttt ttgggttaaa 4680

agatggttgt agcatttaaa atggaaaatt ttctccttgg tttgctagta tcttgggtgt 4740

attctctgta agtgtagctc aaataggtca tcatgaaagg ttaaaaaagc gaggtggcca 4800

tgttatgctg gtggttaagg ccagggcctc tccaaccact gtgccactga cttgctgtgt 4860

gacctctggg caagtcactt aacgtataag gtgcctcagt tttccttctg ttaaaatggg 4920

gataataata ctgacctacc tcaaagggca gttttgaggc atgactaatg ctttttagaa 4980

agcattttgg gatccttcag cacaggaatt ctcaagacct gagtattttt tataatagga 5040

atgtccacca tgaacttgat acgtccgtgt gtcccagatg ctgtcattag tctatatggt 5100

tctccaagaa actgaatgaa tccattggag aagcggtgga taactagcca gacaaaattt 5160

gagaatacat aaacaacgca ttgccacgga aacatacaga ggatgccttt tctgtgattg 5220

ggtgggattt ttttcccttt ttatgtggga tatagtagtt acttgtgaca agaataattt 5280

tggaataatt tctattaata tcaactctga agctaattgt actaatctga gattgtggtg 5340

agcagtgacg atgaggagtt gtccagggac agagacgtat atgtgactac ccatactccc 5400

agaaacgcca gggatgaggg cgctacaggc ctcaggccct caggtactgt cagttgtccc 5460

atctgcatgg actggatact cagaggtaag taaaccaagc tgtatcttcc aggcttctgg 5520

tttctaaact tcactgaaag aattggatga gacaggatct tccccctcgg tgggattgga 5580

cacccctact cacagtcatg cctgggccct cacttattgc agatctgcct gtgaggggag 5640

aatgtgcc 5648

<210> SEQ ID NO 71
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 053959.1
<221> NAME/KEY: unsure
<222> LOCATION: 2, 13, 20, 32, 41, 47
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 71

gngaggcaat gancctctn ccccacctct tncctgccca natctgnctc ctagaa 56

<210> SEQ ID NO 72
<211> LENGTH: 580
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1384594.1

<400> SEQUENCE: 72

cttgggtgat ggggcacgga agagggttac aggcaaaggg accagcgttt ctaaactctt 60

ggagacacag tgaagaaggt tcatacctgg agtgccaagg ttactgtgtc tccagaaaca 120

catatggacc tcacaaagga cgagtgggga cttcttgatg aggctcagag actcctgtac 180

cttgaagtga tgctggagaa ctttgccctt gtagcctcac tgggttgtgg ccatggaaca 240

-continued

gaggatgaag agacaccttc tgaccagaat gtttactcta ggagtgtcac agtcaaaagg 300

caggttcatc caaaacagga gactccagtc ctgtggaaag tgtgtccaag tcctaaagat 360

aattttggat ctagctgaat ctcctagggc aggaaacata cttgggttcg ggagatgtac 420

aaacctggca caaggacaag aaggcttaac agtgcaaaga aaaaccttga taaggggcaa 480

tggacagagc ctcaaaaatg tggaagtgag gaccctagca tgtaagtcga tggaagccct 540

ttcgggaatt gggagggttt ggaaagggac cctccagacc 580

<210> SEQ ID NO 73
<211> LENGTH: 2572
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 021667CB1

<400> SEQUENCE: 73

gtgcgtaaca cacatcaaga cagaacctgt tgccattttc agccaccaga gtgaaacgac 60

tgcccctcct ccggccccga cccaggccct ccctgagttc accagtatat tcagctcaca 120

ccagaccgca gctccagagg tgaacaatat tttcatcaaa caagaacttc ctacaccaga 180

tcttcatctt tctgtcccta cccagcaggg ccacctgtac cagctactga atacaccgga 240

tctagatatg cccagttcta caaatcagac agcagcaatg gacactctta atgtttctat 300

gtcagctgcc atggcaggcc ttaacacaca cacctctgct gttccgcaga ctgcagtgaa 360

acaattccag ggcatgcccc cttgcacata cacaatgcca agtcagtttc ttccacaaca 420

ggccacttac tttccccccgt caccaccaag ctcagagcct ggaagtccag atagacaagc 480

agagatgctc cagaatttaa ccccacctcc atcctatgct gctacaattg cttctaaact 540

ggcaattcac aatccaaatt tacccaccac cctgccagtt aactcacaaa acatccaacc 600

tgtcagatac aatagaagga gtaaccccga tttggagaaa cgacgcatcc actactgcga 660

ttaccctggt tgcacaaaag tttataccaa gtcttctcat ttaaaagctc acctgaggac 720

tcacactggt gaaaagccat acaagtgtac ctgggaaggc tgcgactgga ggttcgcgcg 780

atcggatgag ctgacccgcc actaccggaa gcacacaggc gccaagccct tccagtgcgg 840

ggtgtgcaac cgcagcttct cgcgctctga ccacctggcc ctgcatatga agaggcacca 900

gaactgagca ctgcccgtgt gacccgttcc aggtcccctg ggctccctca aatgacagac 960

ctaactattc ctgtgtaaaa acaacaaaaa caaacaaaag caagaaaacc acaactaaaa 1020

ctggaaatgt atattttgta tatttgagaa aacagggaat acattgtatt aataccaaag 1080

tgtttggtca ttttaagaat ctggaatgct tgctgtaatg tatatggctt tactcaagca 1140

gatctcatct catgacaggc agccacgtct caacatgggt aaggggtggg ggtggagggg 1200

agtgtgtgca gcgtttttac ctaggcacca tcatttaatg tgacagtgtt cagtaaacaa 1260

atcagttggc aggcaccaga agaagaatgg attgtatgtc aagattttac ttggcattga 1320

gtagtttttt tcaatagtag gtaattcctt agagatacag tatacctggc aattcacaaa 1380

tagccattga acaaatgtgt gggtttttaa aaattatata catatatgag ttgcctatat 1440

ttgctattca aaattttgta aatatgcaaa tcagctttat aggtttatta caagtttttt 1500

aggattcttt tggggaagag tcataattct tttgaaaata accatgaata cacttacagt 1560

taggatttgt ggtaaggtac ctctcaacat taccaaaatc atttctttag agggaaggaa 1620

taatcattca aatgaacttt aaaaaagcaa atttcatgca ctgattaaaa taggattatt 1680

-continued

ttaaatacaa aaggcatttt atatgaatta taaactgaag agcttaaaga tagttacaaa 1740

atacaaaagt tcaacctctt acaataagct aaacgcaatg tcatttttaa aaagaaggac 1800

ttagggtgtc gttttcacat atgacaatgt tgcatttatg atgcagtttc aagtaccaaa 1860

acgttgaatt gatgatgcag ttttcatata tcgagatgtt cgctcgtgca gtactgttgg 1920

ttaaatgaca atttatgtgg attttgcatg taatacacag tgagacacag taattttatc 1980

taaattacag tgcagtttag ttaatctatt aatactgact cagtgtctgc ctttaaatat 2040

aaatgatatg ttgaaaactt aaggaagcaa atgctacata tatgcaatat aaaatagtaa 2100

tgtgatgctg atgctgttaa ccaaagggca gaataaataa gcaaaatgcc aaaaggggtc 2160

ttaattgaaa tgaaaattta attttgtttt taaaatattg tttatcttta tttattttgt 2220

ggtaatatag taagtttttt tagaagacaa ttttcataac ttgataaatt atagttttgt 2280

ttgttagaaa agttgctctt aaaagatgta aatagatgac aaacgatgta aataattttg 2340

taagaggctt caaaatgttt atacgtggaa acacacctac atgaaaagca gaaatcggtt 2400

gctgttttgc ttctttttcc ctcttatttt tgtattgtgg tcatttccta tgcaaataat 2460

ggagcaaaca gctgtatagt tgtagaattt tttgagagaa tgagatgttt atatattaac 2520

gacaattttt tttttggaaa ataaaaagtg cctaaaagac aaaaaaaaaa aa 2572

<210> SEQ ID NO 74
<211> LENGTH: 219
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 021667CD1

<400> SEQUENCE: 74

Met Pro Ser Ser Thr Asn Gln Thr Ala Ala Met Asp Thr Leu Asn
1 5 10 15

Val Ser Met Ser Ala Ala Met Ala Gly Leu Asn Thr His Thr Ser
20 25 30

Ala Val Pro Gln Thr Ala Val Lys Gln Phe Gln Gly Met Pro Pro
35 40 45

Cys Thr Tyr Thr Met Pro Ser Gln Phe Leu Pro Gln Gln Ala Thr
50 55 60

Tyr Phe Pro Pro Ser Pro Pro Ser Ser Glu Pro Gly Ser Pro Asp
65 70 75

Arg Gln Ala Glu Met Leu Gln Asn Leu Thr Pro Pro Pro Ser Tyr
80 85 90

Ala Ala Thr Ile Ala Ser Lys Leu Ala Ile His Asn Pro Asn Leu
95 100 105

Pro Thr Thr Leu Pro Val Asn Ser Gln Asn Ile Gln Pro Val Arg
110 115 120

Tyr Asn Arg Arg Ser Asn Pro Asp Leu Glu Lys Arg Arg Ile His
125 130 135

Tyr Cys Asp Tyr Pro Gly Cys Thr Lys Val Tyr Thr Lys Ser Ser
140 145 150

His Leu Lys Ala His Leu Arg Thr His Thr Gly Glu Lys Pro Tyr
155 160 165

Lys Cys Thr Trp Glu Gly Cys Asp Trp Arg Phe Ala Arg Ser Asp
170 175 180

Glu Leu Thr Arg His Tyr Arg Lys His Thr Gly Ala Lys Pro Phe
185 190 195

-continued

Gln Cys Gly Val Cys Asn Arg Ser Phe Ser Arg Ser Asp His Leu
200 205 210

Ala Leu His Met Lys Arg His Gln Asn
215

<210> SEQ ID NO 75
<211> LENGTH: 5325
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 224855.4
<221> NAME/KEY: unsure
<222> LOCATION: 1500-1699
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 75

acctcgcact ctcagtttca ccgctcgatc ttgggaccca ccgctgccct cagctccgag 60

tccagggcga gtgcagagca gagcgggcgg aggaccccgg gcgcgggcgc ggacggcacg 120

cggggcatga acctggaggg cggcggccga ggcggagagt tcggcatgag cgcggtgagc 180

tgcggcaacg ggaagctccg ccagtggctg atcgaccaga tcgacagcgg caagtacccc 240

gggctggtgt gggagaacga ggagaagagc atcttccgca tcccctggaa gcacgcgggc 300

aagcaggact acaaccgcga ggaggacgcc gcgctcttca aggcttgggc actgtttaaa 360

ggaaagttcc gagaaggcat cgacaagccg gaccctccca cctggaagac gcgcctgcgg 420

tgcgctttga acaagagcaa tgactttgag gaactggttg agcggagcca gctggacatc 480

tcagacccgt acaaagtgta caggattgtt cctgagggag ccaaaaaagg agccaagcag 540

ctcaccctgg aggacccgca gatgtccatg agccacccct acaccatgac aacgccttac 600

ccttcgctcc cagcccaggt tcacaactac atgatgccac ccctcgaccg aagctggagg 660

gactacgtcc cggatcagcc acacccggaa atcccgtacc aatgtcccat gacgtttgga 720

ccccgcggcc accactggca aggcccagct tgtgaaaatg gttgccaggt gacaggaacc 780

ttttatgctt gtgccccacc tgagtcccag gctcccggag tccccacaga gccaagcata 840

aggtctgccg aagccttggc gttctcagac tgccggctgc acatctgcct gtactaccgg 900

gaaatcctcg tgaaggagct gaccacgtcc agccccgagg gctgccggat ctcccatgga 960

catacgtatg acgccagcaa cctggaccag gtcctgttcc cctacccaga ggacaatggc 1020

cagaggaaaa acattgagaa gctgctgagc cacctggaga ggggcgtggt cctctggatg 1080

gcccccgacg ggctctatgc gaaaagactg tgccagagca ggatctactg ggacgggccc 1140

ctggcgctgt gcaacgaccg gcccaacaaa ctggagagag accagacctg caagctcttt 1200

gacacacagc agttcttgtc agagctgcaa gcgtttgctc accacggccg ctccctgcca 1260

agattccagg tgactctatg ctttggagag gagtttccag accctcagag gcaaagaaag 1320

ctcatcacag ctcacgtaga acctctgcta gccagacaac tatattattt tgctcaacaa 1380

aacagtggac atttcctgag gggctacgat ttaccagaac acatcagcaa tccagaagat 1440

taccacagat ctatccgcca ttcctctatt caagaatgaa aaatgtcaag atgagtgggn 1500

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1560

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1620

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1680

nnnnnnnnnn nnnnnnnnnc attgtaaata tttgacttta gtgaaagcgt ccaattgact 1740

-continued

gcgcctctta ctgttttgag gaactcagaa gtggagattt cagttcagcg gttgaggaga 1800

attgcggcga gacaagcatg gaaaatcagt gacatctgat tggcagatga gcttatttca 1860

aaaggaaggg tggctttgca ttttcttgtg ttctgtagac tgccatcatt gatgatcact 1920

gtgaaaattg accaagtgat gtgtttacat ttactgaaat gcgctcttta atttgttgta 1980

gattaggtct tgctggaaga cagagaaaac ttgcctttca gtattgacac tgactagagt 2040

gatgactgct tgtaggtatg tctgtgccat ttctcaggga agtaagatgt aaattgaaga 2100

agcctcacac gtaaaagaaa tgtattaatg tatgtaggag ctgcagttct tgtggaagac 2160

acttgctgag tgaaggaaat gaatctttga ctgaagccgt gcctgtagcc ttggggaggc 2220

ccatccccca cctgccagcg gtttcctggt gtgggtccct ctgccccacc ctccttccca 2280

ttggctttct ctccttggcc tttcctggaa gccagttagt aaacttccta ttttcttgag 2340

tcaaaaaaca tgagcgctac tcttggatgg gacatttttg tctgtcctac aatctagtaa 2400

tgtctaagta atggttaagt tttcttgttt ctgcatcttt ttgaccctca ttctttagag 2460

atgctaaaat tcttcgcata aagaagaaga aattaaggaa cataaatctt aatacttgaa 2520

ctgttgccct tctgtccaag tacttaacta tctgttccct tcctctgtgc cacgctcctc 2580

tgtttgtttg gctgtccagc gatcagccat ggcgacacta aaggaggagg agccggggac 2640

tcccaggctg gagagcactg ccaggaccca ccactggaag caggatggag ctgactacgg 2700

aactgcacac tcagtgggct gtttctgctt atttcatctg ttctatgctt cctcgtgcca 2760

attatagttt gacagggcct taaaattact tggctttttc caaatgcttc tatttataga 2820

atcccaaaga cctccacttg cttaagtata cctatcactt acatttttgt ggttttgaga 2880

aagtacagca gtagactggg gcgtcacctc caggccgttt ctcatactac aggatattta 2940

ctattactcc caggatcagc agaagattgc gtagctctca aatgtgtgtt cctgcttttc 3000

taatggatat tttaaattca ttcaacaagc acctagtaag tgcctgctgt atccctacat 3060

tacacagttc agcctttatc aagcttagtg agcagtgagc actgaaacat tatttttaa 3120

tgtttaaaaa gtttctaata ttaaagtcag aatattaata caattaatat taatattaac 3180

tacagaaaag acaaacagta gagaacagca aaaaaataaa aaggatctcc ttttttccca 3240

gcccaaattc tcctctctaa aagtgtccac aagaaggggt gtttattctt ccaacacatt 3300

tcacttttct gtaaatatac ataaacttaa aaagaaaacc tcatggagtc atcttgcaca 3360

cactttcatg cagtgctctt tgtagctaac agtgaagatt tacctcgttc tgctcagagg 3420

ccttgctgtg gagctccact gccatgtacc cagtagggtt tgacatttca ttagccatgc 3480

aacatggata tgtattgggc agcagactgt gtttcgtgaa ctgcagtgat gtatacatct 3540

tatagatgca aagtattttg gggtatatta tcctaaggga agataaagat gatattaaga 3600

actgctgttt cacggggccc ttacctgtga ccctctttgc tgaagaatat ttaaccccac 3660

acagcacttt caaagaagct gtcttggaag tctgtctcag gagcaccctg tcttcttaat 3720

tctccaagcg gatgctccat ttcaattgct ttgtgacttc ttcttctttg ttttttaaa 3780

tattatgctg ctttaacagt ggagctgaat tttctggaaa atgcttcttg gctggggcca 3840

ctacctcctt tcctatcttt acatctatgt gtatgttgac tttttaaaat tctgagtgat 3900

ccagggtatg acctagggaa tgaactagct atgaaatact cagggttagg aatcctagca 3960

cttgtctcag gactctgaaa aggaacggct tcctcattcc ttgtcttgat aaagtggaat 4020

tggcaaacta gaatttagtt tgtactcagt ggacagtgct gttgaagatt tgaggacttg 4080

ttaaagagca ctgggtcata tggaaaaaat gtatgtgtct cccaggtgca tttcttggtt 4140

-continued

tatgtcttgt tcttgagatt ttgtatattt aggaaaacct caagcagtaa ttaatatctc 4200

ctggaacact atagagaacc aagtgaccga ctcatttaca actgaaacct aggaagcccc 4260

tgagtcctga gcgaaaacag gagagttagt cgccctacag gaaacccagc tagactattg 4320

ggtatgaact aaaaagagac tgtgccatgg tgagaaaaat gtaaaatcct acagtggaat 4380

gagcagccct tacagtgttg ttaccaccaa gggcaggtag gtattagtgt ttgaaaaagc 4440

tggtctttga gcgagggcat aaatacagct agccccaggg gtggaacaac tctgggagtc 4500

ttgggtactc gcacctcttg gctttgttga tgctccgcca ggaaggccac ttgtgtgtgc 4560

gtgtcagtta ctttttttagt aacaattcag atccagtgta aacttccgtt cattgctctc 4620

cagtcacatg cccccacttc cccacaggtg aaagtttttc tgaaagtgtt gggattggtt 4680

aaggtcttta tttgtattac gtatctcccc aagtcctctg tggccagctg cgtctgtctg 4740

aatggtgcgt gaaggctctc agaccttaca caccattttg taagttatgt tttacatgcc 4800

ccgtttttga gactgatctc gatgcaggtg gatctccttg agatcctgat agcctgttac 4860

aggaatgaag taaaggtcag ttttttttgt attgattttc acagctttga ggaacatgca 4920

taagaaatgt agctgaagta gaggggcgt gagagaaggg ccaggccggc aggccaaccc 4980

tcctccaatg gaaattcccg tgttgcttca aactgagaca gatgggactt aacaggcaat 5040

ggggtccact tccccctctt cagcatcccc cgtaccccac tttctgctga aagaactgcc 5100

agcaggtagg accccagagg cccccaaatg aaagcttgaa tttcccctac tggctctgcg 5160

ttttgctgag atctgtagga aaggatgctt cacaaactga ggtagataat gctatgctgt 5220

cgttggtata catcatgaat ttttatgtaa attgctctgc aaagcaaatt gatatgtttg 5280

ataaatttat gtttttaggt aaataaaaac ttttaaaaag ttgtt 5325

<210> SEQ ID NO 76
<211> LENGTH: 2278
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1518310CB1

<400> SEQUENCE: 76

ggctcctctc cccgactcgg agcccctcgg cggcgcccgg cccaggaccc gcctaggagc 60

gcaggagccc cagcgcagag accccaacgc cgagaccccc gccccggccc cgccgcgctt 120

cctcccgacg cagagcaaac cgcccagagt agaagatgga ttggggcacg ctgcagacga 180

tcctgggggg tgtgaacaaa cactccacca gcattggaaa gatctggctc accgtcctct 240

tcatttttcg cattatgatc ctcgttgtgg ctgcaaagga ggtgtgggga gatgagcagg 300

ccgactttgt ctgcaacacc ctgcagccag gctgcaagaa cgtgtgctac gatcactact 360

tccccatctc ccacatccgg ctatgggccc tgcagctgat cttcgtgtcc acgccagcgc 420

tcctagtggc catgcacgtg gcctaccgga gacatgagaa gaagaggaag ttcatcaagg 480

gggagataaa gagtgaattt aaggacatcg aggagatcaa aacccagaag gtccgcatcg 540

aaggctccct gtggtggacc tacacaagca gcatcttctt ccgggtcatc ttcgaagccg 600

ccttcatgta cgtcttctat gtcatgtacg acggcttctc catgcagcgg ctggtgaagt 660

gcaacgcctg gccttgtccc aacactgtgg actgctttgt gtcccggccc acggagaaga 720

ctgtcttcac agtgttcatg attgcagtgt ctggaatttg catcctgctg aatgtcactg 780

aattgtgtta tttgctaatt agatattgtt ctgggaagtc aaaaaagcca gtttaacgca 840

-continued

ttgcccagtt gttagattaa gaaatagaca gcatgagagg gatgaggcaa cccgtgctca 900

gctgtcaagg ctcagtcgct agcatttccc aacacaaaga ttctgacctt aaatgcaacc 960

atttgaaacc cctgtaggcc tcaggtgaaa ctccagatgc cacaatggag ctctgctccc 1020

ctaaagcctc aaaacaaagg cctaattcta tgcctgtctt aattttcttt cacttaagtt 1080

agttccactg agaccccagg ctgttagggg ttattggtgt aaggtacttt catattttaa 1140

acagaggata tcggcatttg tttctttctc tgaggacaag agaaaaaagc caggttccac 1200

agaggacaca gagaaggttt gggtgtcctc ctggggttct ttttgccaac tttccccacg 1260

ttaaaggtga acattggttc tttcatttgc tttggaagtt ttaatctcta acagtggaca 1320

aagttaccag tgccttaaac tctgttacac tttttggaag tgaaaacttt gtagtatgat 1380

aggttatttt gatgtaaaga tgttctggat accattatat gttccccctg tttcagaggc 1440

tcagattgta atatgtaaat ggtatgtcat tcgctactat gatttaattt gaaatatggt 1500

cttttggtta tgaatacttt gcagcacagc tgagaggctg tctgttgtat tcattgtggt 1560

catagcacct aacaacattg tagcctcaat cgagtgagac agactagaag ttcctagtga 1620

tggcttatga tagcaaatgg cctcatgtca aatatttaga tgtaattttg tgtaagaaat 1680

acagactgga tgtaccacca actactacct gtaatgacag gcctgtccaa cacatctccc 1740

ttttccatga ctgtggtagc cagcatcgga aagaacgctg atttaaagag gtcgcttggg 1800

aattttattg acacagtacc atttaatggg gaggacaaaa tggggcaggg gagggagaag 1860

tttctgtcgt taaaaacaga tttggaaaga ctggactcta aattctgttg attaaagatg 1920

agctttgtct acttcaaaag tttgtttgct tacccccttca gcctccaatt ttttaagtga 1980

aaatataact aataacatgt gaaaagaata gaagctaagg tttagataaa tattgagcag 2040

atctatagga agattgaacc tgaatattgc cattatgctt gacatggttt ccaaaaaatg 2100

gtactccaca tacttcagtg agggtaagta ttttcctgtt gtcaagaata gcattgtaaa 2160

agcattttgt aataataaag aatagcttta atgatatgct tgtaactaaa ataattttgt 2220

aatgtatcaa atacatttaa aacattaaaa tataatctct atagtaacga acagaaaa 2278

<210> SEQ ID NO 77
<211> LENGTH: 226
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1518310CD1

<400> SEQUENCE: 77

Met Asp Trp Gly Thr Leu Gln Thr Ile Leu Gly Gly Val Asn Lys
1 5 10 15

His Ser Thr Ser Ile Gly Lys Ile Trp Leu Thr Val Leu Phe Ile
20 25 30

Phe Arg Ile Met Ile Leu Val Val Ala Ala Lys Glu Val Trp Gly
35 40 45

Asp Glu Gln Ala Asp Phe Val Cys Asn Thr Leu Gln Pro Gly Cys
50 55 60

Lys Asn Val Cys Tyr Asp His Tyr Phe Pro Ile Ser His Ile Arg
65 70 75

Leu Trp Ala Leu Gln Leu Ile Phe Val Ser Thr Pro Ala Leu Leu
80 85 90

Val Ala Met His Val Ala Tyr Arg Arg His Glu Lys Lys Arg Lys

-continued

```
                 95                  100                 105

Phe Ile Lys Gly Glu Ile Lys Ser Glu Phe Lys Asp Ile Glu Glu
                110                 115                 120

Ile Lys Thr Gln Lys Val Arg Ile Glu Gly Ser Leu Trp Trp Thr
                125                 130                 135

Tyr Thr Ser Ser Ile Phe Phe Arg Val Ile Phe Glu Ala Ala Phe
                140                 145                 150

Met Tyr Val Phe Tyr Val Met Tyr Asp Gly Phe Ser Met Gln Arg
                155                 160                 165

Leu Val Lys Cys Asn Ala Trp Pro Cys Pro Asn Thr Val Asp Cys
                170                 175                 180

Phe Val Ser Arg Pro Thr Glu Lys Thr Val Phe Thr Val Phe Met
                185                 190                 195

Ile Ala Val Ser Gly Ile Cys Ile Leu Leu Asn Val Thr Glu Leu
                200                 205                 210

Cys Tyr Leu Leu Ile Arg Tyr Cys Ser Gly Lys Ser Lys Lys Pro
                215                 220                 225

Val
```

<210> SEQ ID NO 78
<211> LENGTH: 445
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 098533.1
<221> NAME/KEY: unsure
<222> LOCATION: 406, 413
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 78

```
ggcaaggcca gtggctccgc cgctgggtcc gctgcccttt actttcagtc agcctggggc     60

ggtgtcctct cctacagaag tcctgagcgg ccttccacgt ggccggccct cgagtccgtc    120

cgccccgacc cttcgtagtc ccgaaaccgc ccccctggct aaggtctctt tcccccaggc    180

tgcttccttt ctccttgctt ttttcccacc ttttttgtta ctgaccaagg tgaatccttt    240

ccttaacaaa tcggcttaaa gcaagctaac tcagttacaa tacagtagaa ctgtacttaa    300

aaaaaaaaga aacgtgaatc taaccgttac gtcagaaaaa aaaatcttaa attagacgaa    360

tttcaaacag tgcttaacac atcgcagagc atttgcagtt atttgnatca cgnctttga    420

aacaccttta tgctgtaaat agagc                                         445
```

<210> SEQ ID NO 79
<211> LENGTH: 5227
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 410785.1
<221> NAME/KEY: unsure
<222> LOCATION: 4928, 4934, 4939, 4944, 4973, 4992
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 79

```
cacaagacct ggaattgaca ggactcccaa ctagtacaat gacagaagat aaggtcactg     60

ggaccctggt tttcactgtc atcactgctg tgctgggttc cttccagttt ggatatgaca    120

ttggtgtgat caatgcacct caacaggtaa taatatctca ctatagacat gttttgggtg    180

ttccactgga tgaccgaaaa gctatcaaca actatgttat caacagtaca gatgaactgc    240
```

-continued

ccacaatctc atactcaatg aacccaaaac caacccccttg ggctgaggaa gagactgtgg 300

cagctgctca actaatcacc atgctctggt ccctgtctgt atccagcttt gcagttggtg 360

gaatgactgc atcattcttt ggtgggtggc ttggggacac acttggaaga atcaaagcca 420

tgttagtagc aaacattctg tcattagttg gagctctctt gatggggttt tcaaaattgg 480

gaccatctca tatacttata attgctggaa gaagcatatc aggactatat tgtgggctaa 540

tttcaggcct ggttcctatg tatatcggtg aaattgctcc aaccgctctc aggggagcac 600

ttggcacttt tcatcagctg gccatcgtca cgggcattct tattagtcag attattggtc 660

ttgaatttat cttgggcaat tatgatctgt ggcacatctt gcttggcctg tctggtgtgc 720

gagccatcct tcagtctctg ctactctttt tctgtccaga aagccccaga tacctttaca 780

tcaagttaga tgaggaagtc aaagcaaaac aaagcttgaa aagactcaga ggatatgatg 840

atgtcaccaa agatattaat gaaatgagaa aagaaagaga agaagcatcg agtgagcaga 900

aagtctctat aattcagctc ttcaccaatt ccagctaccg acagcctatt ctagtggcac 960

tgatgctgca tgtggctcag caattttccg gaatcaatgg catttttac tactcaacca 1020

gcatttttca gacggctggt atcagcaaac ctgtttatgc aaccattgga gttggcgctg 1080

taaacatggt tttcactgct gtctctgtat tccttgtgga gaaggcaggg cgacgttctc 1140

tctttctaat tggaatgagt gggatgtttg tttgtgccat cttcatgtca gtgggacttg 1200

tgctgctgaa taagttctct tggactgagt tactgtgagc atgatagcca tcttcctctt 1260

tgtcagcttc tttgaaattg ggccaggccc gatcccctgg ttcatggtgg ctgagttttt 1320

cagtcaagga ccacgtcctg ctgctttagc aatagctgca ttcagcaatt ggacctgcaa 1380

tttcattgta gctctgtgtt tccagtacat tgcggacttc tgtggacctt atgtgttttt 1440

cctctttgct ggagtgctcc tggcctttac cctgtttaca ttttttaaag ttccagaaac 1500

caaaggaaag tcttttgagg aaattgctgc agaattccaa aagaagagtg gctcagccca 1560

caggccaaaa gctgctgtag aaatgaaatt cctaggagct acagagactg tgtaaaaaaa 1620

aaaccctgct ttttgacatg aacagaaaca ataagggaac cgtctgtttt taaatgatga 1680

ttccttgagc attttatatc cacatcttta agtattgttt tatttttatg tgctctcatc 1740

agaaatgtca tcaaatatta ccaaaaaagt atttttttaa gttagagaat atatttttga 1800

tggtaagact gtaattaagt aaaccaaaaa ggctagttta ttttgttaaa ctaaagggca 1860

ggtggttcta atatttttag ctctgttctt tataacaagg ttcttctaaa attgaagaga 1920

tttcaacata tcatttttt aacacataac tagaaacctg aggatgcaac aaatatttat 1980

atatttgaat atcattaaat tggaattttc ttacccatat atcttatgtt aaaggagata 2040

tggctagtgg caataagttc catgttaaaa tagacaactc ttccatttat tgcactcagc 2100

ttttttcttg agtactagaa tttgtatttt gcttaaaatt ttacttttgt tctgtatttt 2160

catgtggaat ggattataga gtatactaaa aaatgtctat agagaaaaac tttcattttt 2220

ggtaggctta tcaaaatctt tcagcactca gaaaagaaaa ccattttagt tcctttattt 2280

aatggccaaa tggtttttgc aagatttaac actaaaaagg tttcacctga tcatatagcg 2340

tgggttatca gttaacatta acatctatta taaaaccatg ttgattccct tctggtacaa 2400

tcctttgagt tatagtttgc tttgcttttt aattgaggac agcctggttt tcacatacac 2460

tcaaacatca tgagtcagac atttggtata ttacctcaat tcctaataag tttgatcaat 2520

ctaatgtaag aaaatttgaa gtaaaggatt gatcactttg ttaaaaatat tttctgaatt 2580

-continued

attatgtctc aaaataagtt gaaaaggtag ggtttgagga ttcctgagtg tgggcttctg 2640

aaacttcata aatgttcagc ttcagacttt tatcaaaatc cctatttaat tttcctggaa 2700

agactgattg ttttatggtg tgttcctaac ataaaataat cgtctccttt gacatttcct 2760

tctttgtctt agctgtatac agattctagc caaactattc tatggccatt actaacacgc 2820

attgtacact atctatctgc ctttacctac ataggcaaat tggaaataca cagatgatta 2880

aacagacttt agcttacagt caattttaca attatggaaa tatagttctg atgggtccca 2940

aaagcttagc agggtgctaa cgtatctcta ggctgttttc tccaccaact ggagcactga 3000

tcaatccttc ttatgtttgc tttaatgtgt attgaagaaa agcacttttt aaaaagtact 3060

ctttaagagt gaaataatta aaaaccactg aacatttgct ttgttttcta aagttgttca 3120

catatatgta atttagcagt ccaaagaaca agaaattgtt tcttttcagt gtgatttgtt 3180

tttcatttgg gccaatttgg gataaactat tttcacttgg gatttcagga tacagtcaaa 3240

ataagcttaa ataactcagg acatctttgt gctaaactgt gaactctgga caaaaataga 3300

gagtctctga atagggcagg agcaggaaaa tggctcctgg gtggctcttg tatgcttctt 3360

caggatgctg atggcctttg ggaagcccag tgtaaacaat gataaaggag cttaacactt 3420

ttataggtga tacatgtgat ttaatcaaat cactattcct gatctcattt actaacagaa 3480

taaagtggta aatatttaaa ttaaaaattc caaagaccac ttttaagtgc ttcttcacta 3540

ttttgactgg cccacaaaca ccagaaattc agaccctgaa gttttctgcc tcagagaaat 3600

ttaagtacct tatattgttc cccttctaca acttttttcct tgcagagata catgtgagtt 3660

gacaagaaac attaaaggga aataagaaga agctgataaa gctttatagg aggaccaaag 3720

aactagctta ctataataaa aaaattttaa gtcttcaagg gtatacatca taataaaaaa 3780

taaaattgac agtaattaat taaatttaat cccagggaaa ttagatgtga atttgaacac 3840

ctaactttcc atgtactctc tcatttttgt ggaagtgttt ctatactcta atgcctttac 3900

aaatgtgatt tttctcttag ctcgtttgaa gtatgagaat tagagttttt ggtctcgcat 3960

tcacctgcta catctaggat tgcccactgt catgactccc agggaaaagg tcctatctta 4020

gcttcctcct ccctactttc ctctacatgg tcagcactgt aatgtagcta agatatagta 4080

aggcattgct ccctcccccct acacttcaag gagttcacag tctaatgggg agttcaggaa 4140

ggccagagta ttaatatccc catctgtgtc ttttgccttc catgaacctg ggttttgagc 4200

cctctcttgt aaaatgggca cagtaatatt acctacctca gggagttgtg aggattaaac 4260

atgaagtgct aagcatagtg cctggtacaa agacagtact caataagtgc tacctaaaac 4320

tagtattcat agcaatactg ttaggataaa gaattatcat atatgagata gttccaaatt 4380

tttgtttttt taaaaaaaaa agagttttat aagttcaaga taatattttc ttacttcaaa 4440

gaaacaatct cacaacgagg gaatggtaag aatcaggaga gattactaac ctggcagagg 4500

agctatcaca atcacaaagg tggtttttcc agggcacggc tcatccatta cactccagat 4560

gtgctgaccc ctgccatttc cccaaatgtg ggaaacccaa ctgcacagtt tgtagtagtg 4620

ggtgactgtg ttcatgcgct cccctgaaaa caacaacaac aacaaagaat cagaagagat 4680

actaggctat ctaattccta aatccaaacc tgatatttct aagtaagatt ataagaattt 4740

ttattgcatt ttctgaattt gcttttgcat aagttatgtt atttttacag ggtctatatt 4800

actattattt cttagaataa tactaattat aaaacaaaat tctgtatatc acatttaaat 4860

gtaatttaat agaattataa tcacaagaca agaccaaact ttgtgtgata atcctcagta 4920

attgcganag gggnatatnc atgnaggcca gcatacatgc ataaactact tcntattgct 4980

-continued

aggctaattg tnccatatgt agcaaataca gcagttcagc aatatcttgt gcttacaggg 5040

tcctaagcag aggtgatgag tcaagtgtaa atatatatat atatttttt atttttcatg 5100

gcaattgtat attagtaacc tggggagaaa aggtttattg acaaccactc tgatccatct 5160

gctgctattt ttactgctaa tttggtgcac attaaaaaga atgatcatga aaagatatta 5220

ctttgag 5227

<210> SEQ ID NO 80
<211> LENGTH: 1199
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1089210.1

<400> SEQUENCE: 80

aaggaaacag gatctgctta gtgaaagaag tggcaagcaa tggatcccaa atatcagcgt 60

gtagagctaa atgatggtca cttcatgccc gtattgggat ttggcaccta tgcacctcca 120

gaggttccga ggaacagagc tgtggaggtc accaaattag caatagaagc tggcttccgc 180

catattgatt ctgcttattt atacaataat gaggagcagg ttggactggc catccgaagc 240

aagattgcag atggcagtgt gaagagagaa gacatattct acacttcaaa gctttggtgc 300

actttctttc aaccacagat ggtccaacca gccttggaaa gctcactgaa aaaactttaa 360

ctggactatg ttgacctcta tcttcttcat ttcccaatgg ctctcaagcc aggtgagacg 420

ccactaccaa aagatgaaaa tggaaaagta atattcgaca cagtggatct ctctgccaca 480

tgggaggtca tggagaagtg taaggatgca ggattggcca agtccatcgg ggtgtcaaac 540

ttcaactgca ggcagctgga gatgatcctc aacaagccag gactcaagta caagcctgtc 600

tgcaaccagg tagaatgtca tccttacctc aaccagagca aactgctgga tttctgcaag 660

tcaaaagaca ttgttctggt tgcccacagt gctctgggaa cccaacgaca taaactatgg 720

gtggacccaa actccccagt tcttttggag gacccagttc tttgtgcctt agcaaagaaa 780

cacaaacgaa ccccagccct gattgccctg cgctaccagc tgcagcgtgg ggttgtggtc 840

ctggccaaga gctacaatga gcagcggatc agagagaaca tccaggtttt tgaattccag 900

ttgacatcag agggatatga aagttctaga tggtctaaac agaaattatc gatatgttgt 960

catggatttt cttatggacc atcctgatta tccattttca gatgaatatt agcatagagg 1020

gtgttgcacg acatctagca gaaggccctg tgtgtggatg gtgatgcaga ggatgtctct 1080

atgctggtga ctggacacac ggcctctggt taaatccctc ccctcctgct tggcaacttc 1140

agctagctag atatatccat ggtccagaaa gcaaacataa taaattttta tcttgaagt 1199

<210> SEQ ID NO 81
<211> LENGTH: 807
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 333453.6
<221> NAME/KEY: unsure
<222> LOCATION: 32, 35, 166
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 81

gaacaagact ccgtcaaaaa aaaaaaaatt gnttnggaac ctggttctgg aatcggcttg 60

aatcattcca gcctttcata cttatagctg tgtggccttg ggcaacttac ttaactttat 120

-continued

ctataaaatg gggacaatag cttctcttcc tcatagcatg gttgtnagga ttagatgaag 180

ttctcagtgg gcattcctgt aagctctagg gagatgttag ctgttactaa tgtttggcac 240

catgacaaat gattagatgg aactttggag caattaataa tacaaattaa aataagggga 300

caaagccagc caaggagaaa agtaaaagat ccaagaatag gggcatataa tggctttatt 360

tttccttgag tctagtgtga ttctaacacc tgagtccaac cattcattat gtaggtccgt 420

atcctctcct gttcttttcc tctcatcctg ggtaccagac agaaggaaaa actgaaacaa 480

atgatgagtc ggctcccttt ctttccttcc atggtggcta tttaggtggc tgatttatga 540

agaacctgga tttcagggtg ttcctttcat cctggaacct ggtgaatacc ctgacttgtc 600

cttctgggat acagaagcag cgtacattgg atccatgcgg cctctgaaaa tggtaaaaat 660

gaaatccaaa tgtccttgtg gtgattcttt gtcagcttga cgtggtaatt cacagggtgt 720

gactttgaag caataaagct gacttttaag acacaaattt gtagtagatt ggacctattg 780

ctcaatacaa atcatggaaa gcataac 807

<210> SEQ ID NO 82
<211> LENGTH: 764
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 365070.1

<400> SEQUENCE: 82

acgaagcagc tgactgtgca tcacgcagtc acaatattgt ttttagggtg agggtggagg 60

actgtgtgtc cgtggattac tcctcctgct ggtggattgc agatgcatta ttaggtcata 120

ctggctagaa tgcagctttt ctcccaccat aacatgaaaa cagtgtaaga acatagggtg 180

ctttgtgcat agcccttctc tatgtaagca gccatggcag tcattaaaga gaaaggagta 240

gctttgacat taagctcccc agatccctgc tgctcatact tctggcaagg ggttcccctc 300

tctcatgcat gaacaggggc atccaaaata agaagctctc cattctgtgg tggggaaagc 360

ggagagggga gtgggtgaag ctgggaaagt aaaggcagca cgttacagaa ggaagaaagg 420

aagccagtaa ctgagggccc actgcctgcc cggccctggg ccaggccctc aacagaagcc 480

atctcattta agccctgcaa ccaatgagat gcacgtcatc attggctctt acagacaaga 540

aaactagact cagaggggct gagtccacat cccagacagc tcactgcaga cacaggtgga 600

gtggttccta caagacatcc agttttaaca acaaaagagt tattgaaatg catgggtaga 660

aattgaacca ggaaaatcag taaagtgatt gtaaaaaaga aggactagct tgcctggaga 720

tgatgtttct tgcttttgga aaaaaaaaaa aggtctctga aatt 764

<210> SEQ ID NO 83
<211> LENGTH: 1325
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 365070.3
<221> NAME/KEY: unsure
<222> LOCATION: 1242
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 83

gcgctgctgg cggccccggc ggccgggcgt gctgcctgca agatgtccgt gcgccgcggc 60

cggcggccgg cgcggccggg gacccgcctc tcctggctgc tgtgctgcag cgccctgctg 120

-continued

tccccggccg cgggctacgt gatcgtgagc tccgtgtctt gggccgtcac caacgaggtg 180

gacgaggagc tggacagcgc ctccactgag gaggctatgc ccgcgctgct agaggattcg 240

ggcagcatct ggcagcaaag cttccccgcc tctgcccaca aggaggacgc gcacctgcgg 300

ccccgggcgg gcgccgcccg ggccaggccg ccccccgcgc cacccgggat gttctcctac 360

cggcgcgagg gcggccagac ggccagtgcg cccccgggcc ctagactgcg cgccgccacc 420

gcccgctccc tggcccatgc cagcgtctgg ggctgcctgg ccaccgtgtc cacccacaag 480

aagatccaag gactgccatt tgggaactgc ctgcccgtca gtgatggccc cttcaacaat 540

agcactggga ttcctttctt ctacatgaca gccaaggacc ccgtggtggc tgatctgatg 600

aagaacccca tggcctcgct gatgctgcca gaatcagaag gggagttctg cagaaaaaac 660

atcgttgatc cggaagatcc ccgatgtgtc cagttaacgc tcactggcca gatgatcgca 720

gtgtctccag aagaagtaga atttgccaag caagccatgt tttcaaggca cccagggatg 780

aggaagtggc ctcgtcaata tgaatggttc tttatgaaga tgaggataga acatatctgg 840

cttcagaaat ggtatggagg cgcatccagt atttcaaggg aggaatattt caaagcagtt 900

cccagaaagg cctgatggag tgagaagaaa gtccttggtg tttgcactta aataaaaacc 960

ttttcagtga tgcagccaga cagctattga ccactgtctc tttgttgaag ggttcatagc 1020

agccctgcca tccctgcagc agaatgagag agggtgaaca gggaactcta tgctagattt 1080

gagattaaag tggtcatttg cagatctcca actcacacag atacttcacg tagatagtct 1140

ttattccatt gtattcaatc cagactcatc gattcagaaa tcatataata gctggtggtc 1200

aaaatgacat gttgagatca ttgttgtttc attgtttaag gnaaaaaaaa aatgcctgta 1260

cctacaatgt gattgctttg tattgtgaga gtatcttgtt gcttgctctg ccaaatgcag 1320

tcttg 1325

<210> SEQ ID NO 84
<211> LENGTH: 3663
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 413921.2

<400> SEQUENCE: 84

gtgcgctagg ctccggactc cgcggcgcag actggcacct cgcagtctcc ccaggtccgc 60

ccagcagccg cgcttcagcc agaatactgg gatcttcagt ggcaggagga gtaatcagaa 120

gacggagatg aattttaaca ctattttgga ggagattctt attaaaaggt cacagcagaa 180

aaagaagaca tcgcccttaa actacaaaga gagacttttt gtacttacaa agtccatgct 240

aacctactat gagggtcgag cagagaagaa atacagaaag gggtttattg atgtttcaaa 300

aatcaagtgt gtggaaatag tgaagaatga tgatggtgtc attccctgtc aaaataagta 360

tccatttcag gttgttcatg atgctaacac actttacatt tttgcaccta gtccacaaag 420

cagggacctg tgggtgaaga agttaaaaga agaaataaag aacaacaata atattatgat 480

taaatatcat cctaaattct ggacagatgg aagttatcag tgttgtagac aaactgaaaa 540

attagcaccc ggatgtgaaa aatacaatct ttttgagagc agtataagaa aagcactacc 600

tccagcacca gaaacaaaga agcgaaggcc tcccccacca attccactag aagaagaaga 660

taatagtgaa gaaatcgttg tagccatgta tgatttccaa gcagcagaag gacatgatct 720

cagattagag agaggccaag agtatctcat tttagaaaag aatgatgtgc attggtggag 780

-continued

agcaagagat aaatatggga atgaaggata tatcccaagt aattacgtaa cgggaaagaa 840

atcaaacaac ttagatcaat atgaatggta ttgcagaaat atgaatagaa gcaaggcaga 900

gcaactcctc cgcagtgaag ataaagaagg tggttttatg gtaagggatt ccagtcaacc 960

aggcttgtac acagtctccc tttataccaa gtttggagga gaaggttcat cgggttttag 1020

gcattatcat ataaaggaaa caacaacatc tccaaagaag tattacctag ctgaaaaaca 1080

tgcttttggc tccattcctg agattattga atatcataag cacaatgcag caggacttgt 1140

caccaggctt cggtacccag ttagtgtgaa agggaagaat gcacccacca ctgcaggatt 1200

cagctatgag aaatgggaga ttaacccttc agaactgacc tttatgaggg aattgggaag 1260

tggactgttt ggagtggtga ggcttggcaa atggcgagcc cagtacaaag tcgcaatcaa 1320

agctattcgg gaaggtgcaa tgtgcgagga ggactttata gaagaagcta aagtgatgat 1380

gaagctgaca cacccgaagt tagtgcagct ttatggtgtg tgcacccagc agaaaccaat 1440

atacattgtt actgagttca tggaaagggg ctgccttctg aatttcctcc gacagagaca 1500

aggtcatttc agtagagacg tactgctgag catgtgtcag gatgtgtgtg aagggatgga 1560

gtatctggag agaaacagct tcatccacag agatctggct gccagaaatt gtctagtaag 1620

tgaggcggga gttgtaaaag tatctgattt tggaatggcc aggtatgttc tggatgatca 1680

gtacacaagt tcttctggtg ctaagtttcc tgtgaagtgg tgtccacctg aagtgtttaa 1740

ttacagccgc ttcagcagca aatcagatgt ctggtcattt ggtgttttaa tgtgggaagt 1800

attcacggaa ggcagaatgc cttttgaaaa atacaccaat tatgaagtgg taaccatggt 1860

tactcgaggc caccgactct accagccgaa gttggcgtcc aactatgtgt atgaggtgat 1920

gctgagatgt tggcaggaga aaccagaggg aaggccttct ttcgaagatc tgctgcgcac 1980

aatagatgaa ctagttgaat gtgaagaaac ttttggaaga taagtgatgt gtgaccagtg 2040

gctcccagat tcccaagcac aaggaaggat gggcattttg tggcttttaa tttattgagc 2100

acttggacat gtagatcatt ttacttatac agtggaaaca cataaataat ttgcttctag 2160

accagcctct gtctagactt gcttctagac agaatctccc agagtgtgga aatgttgcct 2220

tagaaatggt gattaaaatc actcatttct attcattcct caggcacttg agtgacagtt 2280

gtttaccagg cactgtgtgt agccccaggg tttggccatt caggggtgca cacatgggac 2340

catgttagct gatgccagtt gaaggccagg gtatttggga aggggaaggg tattagagtc 2400

atgaccaagc aacccttctt tttccctttg acttctacag aaatctgggc ctgagacatt 2460

gtctacaatt gggttctaga tacatcagga acccatcttg gataaataaa tacctatctt 2520

ttgttttgaa aacatctcag ttttcaagac tgctcttagt attacatgaa caatatttgt 2580

atgctgtata tattgtaaat atatataata tataaagtta tatatttatg agaaacacga 2640

attgtctttt aattgaaact tttaatcctg tagtatagga gttcaccttc ttaggactag 2700

agactgtgcc ttatagctgt taattcattt ccccctgaac atcaaatatg cctgaagaga 2760

agaaagtcta gattcttcta tgagtaacgc cccctcctca ctcaggtaaa tgtgtctggg 2820

gatgcctgtc cagcttaacc acgtgcattt ggcctatgta atcctgccca tggtggccgc 2880

agctaatcag aatcagatgg aaaattaaac cgggtaatct acttctaagc cttaagaata 2940

ttccctggga cacagacact ataattggaa gtgctgagct ctggggcaga aggatcaggt 3000

gaccttcgca acaaagtttg cccccacctc acataggacc cggaagcagc ctgagctgtg 3060

gcggaggatc caggaagcta cggagagaag cagccagcat ggtgttccgt gcctcccgga 3120

-continued

cgtttttcag gaggcctggt tggacttggg ttcctggatg gtgggattgt tgtacagcct 3180

ctcaggagac cctgctgtca agactgtgtg tgtggatttc tcacccttag aagctctact 3240

aagacatcaa cggaattagg gccttccttt ttgccttgtg agcgccaagg aaaagaaact 3300

atctcggtca cgtgagcgcc agcgaaaaga aactgtatca gtcatccaga gaccgtttat 3360

tgcccaacac gttattcttg ctgttggtgg ggtaactagc cgaggaagac acagcgcctt 3420

cccttcagga gttgcgtctc ctctgcaggc cacgatggtc tgctctggag cattgggtga 3480

acacacaggc tggctgctct gggcagcgcc ttcactctga ccctggagaa ccatttcatt 3540

tcatcctggt cagtctagag tctgtgcacc aggcagtcca tccactgaag gctgtgttta 3600

ttcttttcct gtgcccctca taaatggaag aaagtaaact gcttatcccg agccttaaaa 3660

aaa 3663

<210> SEQ ID NO 85
<211> LENGTH: 1344
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 336615.1

<400> SEQUENCE: 85

ggaggaggag gcagctacgg tgataaagaa gagcaatcaa aagggcaaag ccaaaggaaa 60

aggcaaaaag aaagcgaagg aggagagggc cccgtctccc cccgtggagg tggacgaacc 120

ccgggagttt gtgctccggc ctgcccccca gggccgcacg gtgcgctgcc ggctgacccg 180

ggacaaaaag ggcatggatc gaggcatgta tccctcctac ttcctgcacc tggacacgga 240

gaagaaggtg ttcctcttgg ctggcaggaa acgaaaacgg agcaagacag ccaattacct 300

catctccatc gaccctacca atctgtcccg aggaggggag aatttcatcg ggaagctgag 360

gtccaacctc ctggggaacc gcttcacggt ctttgacaac gggcagaacc cacagcgtgg 420

gtacagcact aatgtggcaa gccttcggca ggagctggca gctgtgatct atgaaaccaa 480

cgtgctgggc ttccgtggcc cccggcgcat gaccgtcatc attcctggca tgagtgcgga 540

gaacgagagg gtccccatcc ggccccgaaa tgctagtgac ggcctgctgg tgcgctggca 600

gaacaagacg ctggagagcc tcatagaact gcacaacaag ccacctgtct ggaacgatga 660

cagtggctcc tacaccctca acttccaagg ccgggtcacc caggcctcag tcaagaactt 720

ccagattgtc cacgctgatg accccgacta tatcgtgctg cagttcggcc gcgtggcgga 780

ggacgccttc accctagact accggtaccc gctgtgcgcc ctgcaggcct tcgccatcgc 840

cctctccagt ttcgacggga agctggcctg cgagtgaccc cagcagcccc tcagcgcccc 900

cagagcccgt cagcgtgggg gaaaggattc agtggaggct ggcagggtcc ctccagcaaa 960

gctcccgcgg aaaactgctc ctgtgtcggg gctgacctct cactgcctct cggtgacctc 1020

cgtcctctcc ccagcctggc acaggccgag gcaggaggag cccggacggc gggtaggacg 1080

gagatgaaga acatctggag ttggagccgc acatctggtc tcggagctcg cctgcgccgc 1140

tgtgcccccc tcctccccgc gccccagtca cttcctgtcc gggagcagta gtcattgttg 1200

ttttaacctc ccctctcccc gggaccgcgc tagggctccg aggagctggg gcgggctagg 1260

aggagggggt aggtgatggg ggacgagggc caggcaccca catccccaat aaagccgcgt 1320

ccttgtgcaa aaaaaaaaaa aagg 1344

<210> SEQ ID NO 86

-continued

<211> LENGTH: 3156
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2733282CB1

<400> SEQUENCE: 86

gttcaggaag aaaccatctg catccatatt gaaaacctga cacaatgtat gcagcaggct 60

cagtgtgagt gaactggagg cttctctaca acatgaccca aaggagcatt gcaggtccta 120

tttgcaacct gaagtttgtg actctcctgg ttgccttaag ttcagaactc ccattcctgg 180

gagctggagt acagcttcaa gacaatgggt ataatggatt gctcattgca attaatcctc 240

aggtacctga gaatcagaac ctcatctcaa acattaagga aatgataact gaagcttcat 300

tttacctatt taatgctacc aagagaagag tatttttcag aaatataaag attttaatac 360

ctgccacatg gaaagctaat aataacagca aaataaaaca agaatcatat gaaaaggcaa 420

atgtcatagt gactgactgg tatggggcac atggagatga tccatacacc ctacaataca 480

gagggtgtgg aaaagaggga aaatacattc atttcacacc taatttccta ctgaatgata 540

acttaacagc tggctacgga tcacgaggcc gagtgtttgt ccatgaatgg gcccacctcc 600

gttggggtgt gttcgatgag tataacaatg acaaaccttt ctacataaat gggcaaaatc 660

aaattaaagt gacaaggtgt tcatctgaca tcacaggcat ttttgtgtgt gaaaaaggtc 720

cttgccccca agaaaactgt attattagta agctttttaa agaaggatgc acctttatct 780

acaatagcac ccaaaatgca actgcatcaa taatgttcat gcaaagttat ctctgtggtg 840

aaatttgtaa tgccagtacc cacaaccaag aagcaccaaa cctacagaac cagatgtgca 900

gcctcagaag tgcatgggat gtaatcacag actctgctga ctttcaccac agctttccca 960

tgaacgggac tgagcttcca cctcctccca cattctcgct tgtagaggct ggtgacaaag 1020

tggtctgttt agtgctggat gtgtccagca agatggcaga ggctgacaga ctccttcaac 1080

tacaacaagc cgcagaattt tatttgatgc agattgttga aattcatacc ttcgtgggca 1140

ttgccagttt cgacagcaaa ggagagatca gagcccagct acaccaaatt aacagcaatg 1200

atgatcgaaa gttgctggtt tcatatctgc ccaccactgt atcagctaaa acagacatca 1260

gcatttgttc agggcttaag aaaggatttg aggtggttga aaaactgaat ggaaaagctt 1320

atggctctgt gatgatatta gtgaccagcg gagatgataa gcttcttggc aattgcttac 1380

ccactgtgct cagcagtggt tcaacaattc actccattgc cctgggttca tctgcagccc 1440

caaatctgga ggaattatca cgtcttacag gaggtttaaa gttctttgtt ccagatatat 1500

caaactccaa tagcatgatt gatgctttca gtagaatttc ctctggaact ggagacattt 1560

tccagcaaca tattcagctt gaaagtacag gtgaaaatgt caaacctcac catcaattga 1620

aaaacacagt gactgtggat aatactgtgg gcaacgacac tatgtttcta gttacgtggc 1680

aggccagtgg tcctcctgag attatattat ttgatcctga tggacgaaaa tactacacaa 1740

ataattttat caccaatcta acttttcgga cagctagtct ttggattcca ggaacagcta 1800

agcctgggca ctggacttac accctgaaca atacccatca ttctctgcaa gccctgaaag 1860

tgacagtgac ctctcgcgcc tccaactcag ctgtgccccc agccactgtg gaagcctttg 1920

tggaaagaga cagcctccat tttcctcatc ctgtgatgat ttatgccaat gtgaaacagg 1980

gattttatcc cattcttaat gccactgtca ctgccacagt tgagccagag actggagatc 2040

ctgttacgct gagactcctt gatgatggag caggtgctga tgttataaaa aatgatggaa 2100

-continued

tttactcgag gtatttttc tcctttgctg caaatggtag atatagcttg aaagtgcatg 2160

tcaatcactc tcccagcata agcaccccag cccactctat tccagggagt catgctatgt 2220

atgtaccagg ttacacagca aacggtaata ttcagatgaa tgctccaagg aaatcagtag 2280

gcagaaatga ggaggagcga aagtggggct ttagccgagt cagctcagga ggctcctttt 2340

cagtgctggg agttccagct ggcccccacc ctgatgtgtt tccaccatgc aaaattattg 2400

acctggaagc tgtaaaagta gaagaggaat tgaccctatc ttggacagca cctggagaag 2460

actttgatca gggccaggct acaagctatg aaataagaat gagtaaaagt ctacagaata 2520

tccaagatga ctttaacaat gctattttag taaatacatc aaagcgaaat cctcagcaag 2580

ctggcatcag ggagatattt acgttctcac cccaaatttc cacgaatgga cctgaacatc 2640

agccaaatgg agaaacacat gaaagccaca gaatttatgt tgcaatacga gcaatggata 2700

ggaactcctt acagtctgct gtatctaaca ttgcccaggc gcctctgttt attcccccca 2760

attctgatcc tgtacctgcc agagattatc ttatattgaa aggagtttta acagcaatgg 2820

gtttgatagg aatcatttgc cttattatag ttgtgacaca tcatacttta agcaggaaaa 2880

agagagcaga caagaaagag aatggaacaa aattattata aataaatatc caaagtgtct 2940

tccttcttag atataagacc catggccttc gactacaaaa acatactaac aaagtcaaat 3000

taacatcaaa actgtattaa aatgcattga gtttttgtac aatacagata agatttttac 3060

atggtagatc aacaaattct ttttgggggt agattagaaa acccttacac tttggctatg 3120

aacaaataat aaaaattatt ctttaaaaaa aaaaaa 3156

<210> SEQ ID NO 87
<211> LENGTH: 942
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2733282CD1

<400> SEQUENCE: 87

Met Thr Gln Arg Ser Ile Ala Gly Pro Ile Cys Asn Leu Lys Phe
1 5 10 15

Val Thr Leu Leu Val Ala Leu Ser Ser Glu Leu Pro Phe Leu Gly
20 25 30

Ala Gly Val Gln Leu Gln Asp Asn Gly Tyr Asn Gly Leu Leu Ile
35 40 45

Ala Ile Asn Pro Gln Val Pro Glu Asn Gln Asn Leu Ile Ser Asn
50 55 60

Ile Lys Glu Met Ile Thr Glu Ala Ser Phe Tyr Leu Phe Asn Ala
65 70 75

Thr Lys Arg Arg Val Phe Phe Arg Asn Ile Lys Ile Leu Ile Pro
80 85 90

Ala Thr Trp Lys Ala Asn Asn Asn Ser Lys Ile Lys Gln Glu Ser
95 100 105

Tyr Glu Lys Ala Asn Val Ile Val Thr Asp Trp Tyr Gly Ala His
110 115 120

Gly Asp Asp Pro Tyr Thr Leu Gln Tyr Arg Gly Cys Gly Lys Glu
125 130 135

Gly Lys Tyr Ile His Phe Thr Pro Asn Phe Leu Leu Asn Asp Asn
140 145 150

Leu Thr Ala Gly Tyr Gly Ser Arg Gly Arg Val Phe Val His Glu
155 160 165

-continued

```
Trp Ala His Leu Arg Trp Gly Val Phe Asp Glu Tyr Asn Asn Asp
                170                 175                 180

Lys Pro Phe Tyr Ile Asn Gly Gln Asn Gln Ile Lys Val Thr Arg
                185                 190                 195

Cys Ser Ser Asp Ile Thr Gly Ile Phe Val Cys Glu Lys Gly Pro
                200                 205                 210

Cys Pro Gln Glu Asn Cys Ile Ile Ser Lys Leu Phe Lys Glu Gly
                215                 220                 225

Cys Thr Phe Ile Tyr Asn Ser Thr Gln Asn Ala Thr Ala Ser Ile
                230                 235                 240

Met Phe Met Gln Ser Tyr Leu Cys Gly Glu Ile Cys Asn Ala Ser
                245                 250                 255

Thr His Asn Gln Glu Ala Pro Asn Leu Gln Asn Gln Met Cys Ser
                260                 265                 270

Leu Arg Ser Ala Trp Asp Val Ile Thr Asp Ser Ala Asp Phe His
                275                 280                 285

His Ser Phe Pro Met Asn Gly Thr Glu Leu Pro Pro Pro Pro Thr
                290                 295                 300

Phe Ser Leu Val Glu Ala Gly Asp Lys Val Val Cys Leu Val Leu
                305                 310                 315

Asp Val Ser Ser Lys Met Ala Glu Ala Asp Arg Leu Leu Gln Leu
                320                 325                 330

Gln Gln Ala Ala Glu Phe Tyr Leu Met Gln Ile Val Glu Ile His
                335                 340                 345

Thr Phe Val Gly Ile Ala Ser Phe Asp Ser Lys Gly Glu Ile Arg
                350                 355                 360

Ala Gln Leu His Gln Ile Asn Ser Asn Asp Asp Arg Lys Leu Leu
                365                 370                 375

Val Ser Tyr Leu Pro Thr Thr Val Ser Ala Lys Thr Asp Ile Ser
                380                 385                 390

Ile Cys Ser Gly Leu Lys Lys Gly Phe Glu Val Val Glu Lys Leu
                395                 400                 405

Asn Gly Lys Ala Tyr Gly Ser Val Met Ile Leu Val Thr Ser Gly
                410                 415                 420

Asp Asp Lys Leu Leu Gly Asn Cys Leu Pro Thr Val Leu Ser Ser
                425                 430                 435

Gly Ser Thr Ile His Ser Ile Ala Leu Gly Ser Ser Ala Ala Pro
                440                 445                 450

Asn Leu Glu Glu Leu Ser Arg Leu Thr Gly Gly Leu Lys Phe Phe
                455                 460                 465

Val Pro Asp Ile Ser Asn Ser Asn Ser Met Ile Asp Ala Phe Ser
                470                 475                 480

Arg Ile Ser Ser Gly Thr Gly Asp Ile Phe Gln Gln His Ile Gln
                485                 490                 495

Leu Glu Ser Thr Gly Glu Asn Val Lys Pro His His Gln Leu Lys
                500                 505                 510

Asn Thr Val Thr Val Asp Asn Thr Val Gly Asn Asp Thr Met Phe
                515                 520                 525

Leu Val Thr Trp Gln Ala Ser Gly Pro Pro Glu Ile Ile Leu Phe
                530                 535                 540

Asp Pro Asp Gly Arg Lys Tyr Tyr Thr Asn Asn Phe Ile Thr Asn
                545                 550                 555
```

-continued

```
Leu Thr Phe Arg Thr Ala Ser Leu Trp Ile Pro Gly Thr Ala Lys
                560                 565                 570

Pro Gly His Trp Thr Tyr Thr Leu Asn Asn Thr His His Ser Leu
                575                 580                 585

Gln Ala Leu Lys Val Thr Val Thr Ser Arg Ala Ser Asn Ser Ala
                590                 595                 600

Val Pro Pro Ala Thr Val Glu Ala Phe Val Glu Arg Asp Ser Leu
                605                 610                 615

His Phe Pro His Pro Val Met Ile Tyr Ala Asn Val Lys Gln Gly
                620                 625                 630

Phe Tyr Pro Ile Leu Asn Ala Thr Val Thr Ala Thr Val Glu Pro
                635                 640                 645

Glu Thr Gly Asp Pro Val Thr Leu Arg Leu Leu Asp Asp Gly Ala
                650                 655                 660

Gly Ala Asp Val Ile Lys Asn Asp Gly Ile Tyr Ser Arg Tyr Phe
                665                 670                 675

Phe Ser Phe Ala Ala Asn Gly Arg Tyr Ser Leu Lys Val His Val
                680                 685                 690

Asn His Ser Pro Ser Ile Ser Thr Pro Ala His Ser Ile Pro Gly
                695                 700                 705

Ser His Ala Met Tyr Val Pro Gly Tyr Thr Ala Asn Gly Asn Ile
                710                 715                 720

Gln Met Asn Ala Pro Arg Lys Ser Val Gly Arg Asn Glu Glu Glu
                725                 730                 735

Arg Lys Trp Gly Phe Ser Arg Val Ser Ser Gly Gly Ser Phe Ser
                740                 745                 750

Val Leu Gly Val Pro Ala Gly Pro His Pro Asp Val Phe Pro Pro
                755                 760                 765

Cys Lys Ile Ile Asp Leu Glu Ala Val Lys Val Glu Glu Glu Leu
                770                 775                 780

Thr Leu Ser Trp Thr Ala Pro Gly Glu Asp Phe Asp Gln Gly Gln
                785                 790                 795

Ala Thr Ser Tyr Glu Ile Arg Met Ser Lys Ser Leu Gln Asn Ile
                800                 805                 810

Gln Asp Asp Phe Asn Asn Ala Ile Leu Val Asn Thr Ser Lys Arg
                815                 820                 825

Asn Pro Gln Gln Ala Gly Ile Arg Glu Ile Phe Thr Phe Ser Pro
                830                 835                 840

Gln Ile Ser Thr Asn Gly Pro Glu His Gln Pro Asn Gly Glu Thr
                845                 850                 855

His Glu Ser His Arg Ile Tyr Val Ala Ile Arg Ala Met Asp Arg
                860                 865                 870

Asn Ser Leu Gln Ser Ala Val Ser Asn Ile Ala Gln Ala Pro Leu
                875                 880                 885

Phe Ile Pro Pro Asn Ser Asp Pro Val Pro Ala Arg Asp Tyr Leu
                890                 895                 900

Ile Leu Lys Gly Val Leu Thr Ala Met Gly Leu Ile Gly Ile Ile
                905                 910                 915

Cys Leu Ile Ile Val Val Thr His His Thr Leu Ser Arg Lys Lys
                920                 925                 930

Arg Ala Asp Lys Lys Glu Asn Gly Thr Lys Leu Leu
                935                 940
```

-continued

<210> SEQ ID NO 88
<211> LENGTH: 1121
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 399161.1
<221> NAME/KEY: unsure
<222> LOCATION: 1070
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 88

caggcgggag caccgtgcct ggcccagatg gatttttaaa tatcacctgt tcatattgtt 60

taaaatagat acaactaaaa cagctttgag gcatacagga actctacaga taaggaggac 120

catttcataa tgataaaggg cttatctcac caagaaggca gtcacactta cgtttttatg 180

tatttgttga agagtcccaa tgtatttaaa gcaaaaataa gcaactacaa agagaaagat 240

acaaatccat gatcaaagtg aggaattttc acacacatcg tagtaactga tggaatgagt 300

caatgaaaaa ttagtgagga aatagaagat ttggacagca caacaaatgg cctaggagaa 360

catttagaat gttgccttcg atgcttaaga atacatattc ttttcaaaag aaaacccaga 420

acagcctggc aggagagata ccatcatcat gaaggtgatt ttcccagagc tgggcttatc 480

cattgcattc tggatgtgct gacgcctgtg gttttcccaa atgtgggaaa ctggactgca 540

taatttgtgg tagtgggggа ctatgttcgt gttctctcct ggtgtttaaa attaaaaaaa 600

aaaaaacttt attaaaggca cagaacatta ataaaaattg acaataaact gggctattaa 660

gtaaattgca acaatttcca gaggtttgaa atgatacaga gtatgttttc tgaccacagt 720

acagttaaac taggaatata acaaaaagat aactagggat atgtgtggat attgcatacc 780

tctaagtaac ccttgggatg agaaagaaat tacaatggaa attagaaaat atcttgaata 840

atgaaaatac aatatatgta agcttgtaga attcagctta ttaaatgcat attttagaaa 900

gaaggaaagg ctgaaaatca gtgagcaaag ccttccatct caagaaatag aaaaagaata 960

tagaaggaag gaattaatat ttttaaagaa gcactaattt acaagaataa ttaaatagaa 1020

aagaagttgt cattaggaag gatcaataaa gctagaagct tgttatttgn aaagacttgt 1080

aaatgtggta aatcacaagt aacgtacgta gatgaaaagg g 1121

<210> SEQ ID NO 89
<211> LENGTH: 721
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 339638.1
<221> NAME/KEY: unsure
<222> LOCATION: 266
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 89

gtggcccaca gcgaactaga gaaacaaaag gagagtcttt tacccccctgg agttatcgcc 60

atcagcaaac tgagagctgc ctctcttcct ctccctgccc tgtgtctgtc tccacctcct 120

tccctctcat ccttgctctt tccctttttct ctttatcccc cgccccctttt ctttctcttc 180

ctcctttctc ctcccaggga ccaaagggag aagggagagc cgagaaagtg gccctgccat 240

cccctactgg aataaccgcc gccgcngccc catcactggt ggccacatcc cttctaattt 300

gtagtggtgg gtttctttcc ttgaagagca gggtactttt aaacagatag aggtaatggg 360

aggattaata ttcataggta agtccaaacg gaaaatgttt agcttcctta caccaaaggt 420

-continued

ctgctgtgtc tgagattaca ctaagttcaa gcaacatcat gtcagtgaag aagccattag 480

ctgcaggaac acactgagaa gtgagggagc ctgtctacca gaaggaaatg gagctaggat 540

ctttgcaaac tgctgagtag agaggagagg acgagtaaat gagacagacg gaaaagagct 600

ggaagagaga gactccttta tggcacattt ttatcctgag atttccaagc attttatata 660

tattgcatgg taaagaggaa ttgaaatagc caaaagaaat gaactaaaat gaaaagggag 720

g 721

<210> SEQ ID NO 90
<211> LENGTH: 538
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 697785CB1

<400> SEQUENCE: 90

cccacgcgtc cggtggagtc ttctgacagc tggtgcgcct gcccgggaac atcctcctgg 60

actcaatcat ggcttgtggt ctggtcgcca gcaacctgaa tctcaaacct ggagagtgcc 120

ttcgagtgcg aggcgaggtg gctcctgacg ctaagagctt cgtgctgaac ctgggcaaag 180

acagcaacaa cctgtgcctg cacttcaacc ctcgcttcaa cgcccacggc gacgccaaca 240

ccatcgtgtg caacagcaag gacggcgggg cctgggggac cgagcagcgg gaggctgtct 300

ttcccttcca gcctggaagt gttgcagagg tgtgcatcac cttcgaccag gccaacctga 360

ccgtcaagct gccagatgga tacgaattca agttccccaa ccgcctcaac ctggaggcca 420

tcaactacat ggcagctgac ggtgacttca agatcaaatg tgtggccttt gactgaaatc 480

agccagccca tggcccccaa taaaggcagc tgcctctgct ccctctgaaa aaaaaaaa 538

<210> SEQ ID NO 91
<211> LENGTH: 135
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 697785CD1

<400> SEQUENCE: 91

Met Ala Cys Gly Leu Val Ala Ser Asn Leu Asn Leu Lys Pro Gly
1 5 10 15

Glu Cys Leu Arg Val Arg Gly Glu Val Ala Pro Asp Ala Lys Ser
20 25 30

Phe Val Leu Asn Leu Gly Lys Asp Ser Asn Asn Leu Cys Leu His
35 40 45

Phe Asn Pro Arg Phe Asn Ala His Gly Asp Ala Asn Thr Ile Val
50 55 60

Cys Asn Ser Lys Asp Gly Gly Ala Trp Gly Thr Glu Gln Arg Glu
65 70 75

Ala Val Phe Pro Phe Gln Pro Gly Ser Val Ala Glu Val Cys Ile
80 85 90

Thr Phe Asp Gln Ala Asn Leu Thr Val Lys Leu Pro Asp Gly Tyr
95 100 105

Glu Phe Lys Phe Pro Asn Arg Leu Asn Leu Glu Ala Ile Asn Tyr
110 115 120

Met Ala Ala Asp Gly Asp Phe Lys Ile Lys Cys Val Ala Phe Asp
125 130 135

-continued

<210> SEQ ID NO 92
<211> LENGTH: 866
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 399785.1
<221> NAME/KEY: unsure
<222> LOCATION: 18
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 92

acgagacgag cacccgtngg gggctggagc accccgcgcg ctcccctggc gagagggagg 60

gtcgtggctc ggcccctgct cagacaaagg ctgggaggcg ggagacatgc acttcccctt 120

ccttttcagc caggcgcgcg ctgataccag gcccacgtca gctatttttg gagcctttta 180

cacgacagct ggaggagcgt ccttttttaat tttccccttt tgtttggccg cccccacccc 240

caccccttcg ccttcatcgc tgcacttgag gctccatcct ggggcctctc cttgacttga 300

cctgccttgg caggcacatg ccctccctgc ctggctcact cgccgcagag acctggcagc 360

ccgcgcaaaa tgtcactttg cggaatcgtt cccacggctt ctgggtaccc ttagttccct 420

gcttagggag ggaagacagt agtcgggtcg taataagcaa gacttagccc gagcctccgt 480

tgccaacgca ggctgccttg cttggcgtgt gggcatcggc ctgccccctc accctggcta 540

cccaacacag ctacaaaagg cagggaacaa tgtaggtccc ttggccctgc ctaatgcctg 600

ttgccatgga aacccctatc ctaatctggc caggagcccc ttgcagtgag ccaggagagt 660

gaggaagagg ggatggggcc cgctggcctg aacctggcca gaggaggtaa tggttaaccg 720

gattgtggga gcagctgact agagccgggg gggtagggag gcttgggccc cagtcctacc 780

ttccctgcca aggagaaagg ggcatgtctg cttttgtacc tctgggaatc tacctcaggg 840

atctgcccaa caactcccag gttcca 866

<210> SEQ ID NO 93
<211> LENGTH: 1274
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 002455.1

<400> SEQUENCE: 93

gcggccgcca gcttgcaaag ccgaagtctg gccgcgctct tcgactcgct gcgccacgtc 60

cccgggggtg ccgagccggc ggggggtgag tggtctgcgc cggcggccgc gctaggaggt 120

gcgggcactt gggggcgccg ggaaggggaa cttggcagcc ccgcgggggc cacgggcgat 180

cccaggggcc aggaaggtcc cgctgcgggc acgcaatctg cctccgtcct tcttcacgga 240

gccgtcccgg gcaggcggcg gcgggtgtgg cccgtcgggg ccggacgtga gcttgggcga 300

cctggagaag ggcgcggagg ccgtggagtt ctttgagctg ctggggcccg actacggcgc 360

cggcacggag gcggcagtct tgcttgccgc cgagcctctc gacgtgttcc ccgccggagc 420

ctccgtactg cggggacccc cggagctgga gcccggcctc tttgagccgc cgccggcagt 480

ggtgggaaac ctactgtacc ccgagccctg gagcgtcccg ggctgctccc cgaccaaaaa 540

gagccccctg actgcccccc gcggcggctt gaccttgaac gagcccttga gccccctgta 600

ccccgccgct gcggattctc ccggcgggga ggacgggcgg ggccatttgg cctctttcgc 660

ccccttcttt ccagactgcg ccctgccccc gacgccgccg ccccatcagg tgtcctacga 720

-continued

ttacagcgcg ggctacagcc gcaccgccta ttccagcctt tggagatccg acggggtttg 780

ggaaggggcg ccgggggagg agggggcgca ccgggactga cttcgaggca cgcttccctt 840

cattagagac ggctgtggag agcgccgcgc ctccgtgggt ttctcctaaa tctgaagaac 900

gatgggaaaa tgcacgtgga gatgaaacca gatttttaaa aattcaatta ataaaagcaa 960

ycttcagaaaa aagagatgaa gacgagttgg ggattgttta atcacaacct caagtgttaa 1020

aacaaaaaca aacaaacacg tttgtaggtt cttactggac cagaggagtc aagaaaccaa 1080

gatggtttgg ggtatggggt ggggacggca aaaggggtaa gagctggctt ctgtagccac 1140

ctgtcccttc tatttttcag cgaaggtcag tgtatttagt gtaattaccc cttctaaaca 1200

gtgtcctagt ccctcccttc cctctccttg agtgcatttt gaattaaagc ctatattgaa 1260

aaaaaaaaaa aagg 1274

<210> SEQ ID NO 94
<211> LENGTH: 924
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1382920.38

<400> SEQUENCE: 94

atctagaact accgagagtc gtcggggttt cctgcttcaa cagtgcttgg acggaacccg 60

gcgctcgttc cccaccccgg ccggccgccc atagccagcc ctccgtcacc tcttcaccgc 120

accctcggac tgccccaagg cccccgccgc cgctccagcg ccgcgcagcc accgccgccg 180

ccgcctcctt tccttagtcg ccgccatgac gaccgcgtcc acctgcgcag gtgccgccag 240

aactaccacc aggactcaga ggccgccatc aaccgccaga tcaacctgga gctctacgcc 300

tcctacgttt acctgtccat gtcttactac tttgaccgcg atgatgtggc tttgaagaac 360

tttgccaaat actttcttca ccaatctcat gaggagaggg aacatgctga gaaactgatg 420

aagctgcaga accaacgagg tggccgaatc ttccttcagg atatcaagaa accagactgt 480

gatgactggg agagcgggct gaatgcaatg gagtgtgcat tacatttgga aaaaaatgtg 540

aatcagtcac tactggaact gcacaaactg gccactgaca aaaatgaccc ccatttgtgt 600

gacttcattg agacacatta cctgaatgag caggtgaaag ccatcaaaga attgggtgac 660

cacgtgacca acttgcgcaa gatgggagcg cccgaatctg gcttggcgga atatctcttt 720

gacaagcaca ccctgggaga cagtgataat gaaagctaag cctcgggcta atttccccat 780

agccgtgggg tgactttcct ggtcaccaag gcagtgcatg catgttgggg tttcctttac 840

cttttctata agttgtacca aaacatccac ttaagttctt tgatttgtac cattccttca 900

aataaagaaa tttggtaccc aaaa 924

<210> SEQ ID NO 95
<211> LENGTH: 634
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 334749.1

<400> SEQUENCE: 95

gacgcccatc aatgaacaaa caagattccc actgtcccat ctcctatcca gtgaaacaca 60

gccaacttga taatttgtgc agggaaagac tctgtttagc ttataccttg aacctaaggg 120

aaattaaatt gcacattttc tgttcctggc taatcttctg aataatgtac tgaacacagt 180

-continued

aggagttaag aattaaaaat acctgtctgc agtttcagaa acaatcacac acaaaatatt 240

tgtttatttc cagactgatg aaagactgaa tttttggtct catgtattta ctgtattgtt 300

tcatatattt atctatatgc tttggctgta ttaacttgtt gaaatagttt gtggttcttt 360

atatttagct tttataaata attgaaaatc taatgaatgc ttacttaata accaatctaa 420

actggggact tcaaacatag ggagtcaagt aatctggttg tgtaataaat aagcaagttg 480

ttatctttca ggctgagggc atatcaacca agctaaaaga cgtgtgtgta ttaaaaaaaa 540

aaaaaagtct accaaaccac catatgatat ccaaggttaa ctatatagga ggtctaataa 600

cattcagaag gtgctagatg aatataccaa aaac 634

<210> SEQ ID NO 96
<211> LENGTH: 579
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 041764.1

<400> SEQUENCE: 96

gaaaaaccat ataatggagg aaggccttgc cccaaactgg accatgtcaa ccaggcacag 60

gtgtatgagg ttgtcccatg ccacagtgac tgcaaccagt acctatgggt cacagagccc 120

tggagcatct gcaaggtgac ctttgtgaat atgcgggaga actgtggaga gggcgtgcaa 180

acccgaaaag tgagatgcat gcagaataca gcagatggcc cttctgaaca tgtagaggat 240

tacctctgtg acccagaaga gatgcccctg ggctctagag tgtgcaaatt accatgccct 300

gaggactgtg tgatatctga atggggtcca tggacccaat gtgttttgcc ttgcaatcaa 360

agcagtttcc ggcaaaggtc agctgatccc atcagacaac cagctgatga aggaagatct 420

tgccctaatg ctgttgagaa agaaccctgt aacctgaaca aaaactgcta ccactatgat 480

tataatgtaa cagactggag tacatgtcag ctgagtgaga aggcagtttg tggaaatgga 540

ataaaaacaa ggatgttgga ttgtgttcga agtgatggc 579

<210> SEQ ID NO 97
<211> LENGTH: 10432
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2700132CB1

<400> SEQUENCE: 97

tggttcgaca agtggccttg cgggccggat cgtcccagtg gaagagttgt aaatttgctt 60

ctggccttcc cctacggatt atacctggcc ttcccctacg gattatactc aacttactgt 120

ttagaaaatg tggcccacga gacgcctggt tactatcaaa aggagcgggg tcgacggtcc 180

ccactttccc ctgagcctca gcacctgctt gtttggaagg ggtattgaat gtgacatccg 240

tatccagctt cctgttgtgt caaaacaaca ttgcaaaatt gaaatccatg agcaggaggc 300

aatattacat aatttcagtt ccacaaatcc aacacaagta aatgggtctg ttattgatga 360

gcctgtacgg ctaaaacatg gagatgtaat aactattatt gatcgttcct tcaggtatga 420

aaatgaaagt cttcagagtg gaaggaagtc aactgaattt ccaagaaaaa tacgtgaaca 480

ggagccagca cgtcgtgtct caagatctag cttctcttct gaccctgatg agaaagctca 540

agattccaag gcctattcaa aaatcactga aggaaaagtt tcaggaaatc ctcaggtaca 600

-continued

tatcaagaat gtcaaagaag acagtaccgc agatgactca aaagacagtg ttgctcaggg 660

aacaactaat gttcattcct cagaacatgc tggacgtaat ggcagaaatg cagctgatcc 720

catttctggg gattttaaag aaatttccag cgttaaatta gtgagccgtt atggagaatt 780

gaagtctgtt cccactacac aatgtcttga caatagcaaa aaaaatgaat ctccctttg 840

gaagctttat gagtcagtga agaaagagtt ggatgtaaaa tcacaaaaag aaaatgtcct 900

acagtattgt agaaaatctg gattacaaac tgattacgca acagagaaag aaagtgctga 960

ytggtttacag ggggagaccc aactgttggt ctcgcgtaag tcaagaccaa aatctggtgg 1020

gagcggccac gctgtggcag agcctgcttc acctgaacaa gagcttgacc agaacaaggg 1080

gaagggaaga gacgtggagt ctgttcagac tcccagcaag gctgtgggcg ccagctttcc 1140

tctctatgag ccggctaaaa tgaagacccc tgtacaatat tcacagcaac aaaattctcc 1200

acaaaaacat aagaacaaag acctgtatac tactggtaga agagaatctg tgaatctggg 1260

taaaagtgaa ggcttcaagg ctggtgataa aactcttact cccaggaagc tttcaactag 1320

aaatcgaaca ccagctaaag ttgaagatgc agctgactct gccactaagc cagaaaatct 1380

ctcttccaaa accagaggaa gtattcctac agatgtggaa gttctgccta cggaaactga 1440

aattcacaat gagccatttt taactctgtg gctcactcaa gttgagagga agatccaaaa 1500

ggattccctc agcaagcctg agaaattggg cactacagct ggacagatgt gctctgggtt 1560

acctggtctt agttcagttg atatcaacaa ctttggtgat tccattaatg agagtgaggg 1620

aataccttg aaaagaaggc gtgtgtcctt tggtgggcac ctaagacctg aactatttga 1680

tgaaaacttg cctcctaata cgcctctcaa aaggggagaa gccccaacca aaagaaagtc 1740

tctggtaatg cacactccac ctgtcctgaa gaaaatcatc aaggaacagc ctcaaccatc 1800

aggaaaacaa gagtcaggtt cagaaatcca tgtggaagtg aaggcacaaa gcttggttat 1860

aagccctcca gctcctagtc ctaggaaaac tccagttgcc agtgatcaac gccgtaggtc 1920

ctgcaaaaca gcccctgctt ccagcagcaa atctcagaca gaggttccta agagaggagg 1980

agaaagagtg gcaacctgcc ttcaaaagag agtgtctatc agccgaagtc aacatgatat 2040

tttacagatg atatgttcca aaagaagaag tggtgcttcg gaagcaaatc tgattgttgc 2100

aaaatcatgg gcagatgtag taaaacttgg tgcaaaacaa acacaaacta aagtcataaa 2160

acatggtcct caaaggtcaa tgaacaaaag gcaaagaaga cctgctactc caaagaagcc 2220

tgtgggcgaa gttcacagtc aatttagtac aggccacgca aactctcctt gtaccataat 2280

aatagggaaa gctcatactg aaaaagtaca tgtgcctgct cgaccctaca gagtgctcaa 2340

caacttcatt tccaaccaaa aaatggactt taaggaagat ctttcaggaa tagctgaaat 2400

gttcaagacc ccagtgaagg agcaaccgca gttgacaagc acatgtcaca tcgctatttc 2460

aaattcagag aatttgcttg gaaaacagtt tcaaggaact gattcaggag aagaacctct 2520

gctccccacc tcagagagtt ttggaggaaa tgtgttcttc agtgcacaga atgcagcaaa 2580

acagccatct gataaatgct ctgcaagccc tcccttaaga cggcagtgta ttagagaaaa 2640

tggaaacgta gcaaaaacgc ccaggaacac ctacaaaatg acttctctgg agacaaaaac 2700

ttcagatact gagacagagc cttcaaaaac agtatccact gtaaacaggt caggaaggtc 2760

tacagagttc aggaatatac agaagctacc tgtggaaagt aagagtgaag aaacaaatac 2820

agaaattgtt gagtgcatcc taaaaagagg tcagaaggca acactactac aacaaaggag 2880

agaaggagag atgaaggaaa tagaaagacc ttttgagaca tataaggaaa atattgaatt 2940

aaaagaaaac gatgaaaaga tgaaagcaat gaagagatca agaacttggg ggcagaaatg 3000

-continued

tgcaccaatg tctgacctga cagacctcaa gagcttgcct gatacagaac tcatgaaaga 3060

cacggcacgt ggccagaatc tcctccaaac ccaagatcat gccaaggcac caaagagtga 3120

gaaaggcaaa atcactaaaa tgccctgcca gtcattacaa ccagaaccaa taaacacccc 3180

aacacacaca aaacaacagt tgaaggcatc cctggggaaa gtaggtgtga aagaagagct 3240

cctagcagtc ggcaagttca cacggacgtc aggggagacc acgcacacgc acagagagcc 3300

agcaggagat ggcaagagca tcagaacgtt taaggagtct ccaaagcaga tcctggaccc 3360

agcagcccgt gtaactggaa tgaagaagtg gccaagaacg cctaaggaag aggcccagtc 3420

actagaagac ctggctggct tcaaagagct cttccagaca ccaggtccct ctgaggaatc 3480

aatgactgat gagaaaacta ccaaaatagc ctgcaaatct ccaccaccag aatcagtgga 3540

cactccaaca agcacaaagc aatggcctaa gagaagtctc aggaaagcag atgtagagga 3600

agaattctta gcactcagga aactaacacc atcagcaggg aaagccatgc ttacgcccaa 3660

accagcagga ggtgatgaga aagacattaa agcatttatg ggaactccag tgcagaaact 3720

ggacctggca ggaactttac ctggcagcaa aagacagcta cagactccta aggaaaaggc 3780

ccaggctcta gaagacctgg ctggctttaa agagctcttc cagactcctg gtcacaccga 3840

ggaattagtg gctgctggta aaaccactaa aataccctgc gactctccac agtcagaccc 3900

agtggacacc ccaacaagca caaagcaacg acccaagaga agtatcagga aagcagatgt 3960

agagggagaa ctcttagcgt gcaggaatct aatgccatca gcaggcaaag ccatgcacac 4020

gcctaaacca tcagtaggtg aagagaaaga catcatcata tttgtgggaa ctccagtgca 4080

gaaactggac ctgacagaga acttaaccgg cagcaagaga cggccacaaa ctcctaagga 4140

agaggcccag gctctggaag acctgactgg ctttaaagag ctcttccaga cccctggtca 4200

tactgaagaa gcagtggctg ctggcaaaac tactaaaatg ccctgcgaat cttctccacc 4260

agaatcagca gacaccccaa caagcacaag aaggcagccc aagacacctt tggagaaaag 4320

ggacgtacag aaggagctct cagccctgaa gaagctcaca cagacatcag gggaaaccac 4380

acacacagat aaagtaccag gaggtgagga taaaagcatc aacgcgttta gggaaactgc 4440

aaaacagaaa ctggacccag cagcaagtgt aactggtagc aagaggcacc caaaaactaa 4500

ggaaaaggcc caacccctag aagacctggc tggctggaaa gagctcttcc agacaccagt 4560

atgcactgac aagcccacga ctcacgagaa aactaccaaa atagcctgca gatcacaacc 4620

agacccagtg gacacaccaa caagctccaa gccacagtcc aagagaagtc tcaggaaagt 4680

ggacgtagaa gaagaattct tcgcactcag gaaacgaaca ccatcagcag gcaaagccat 4740

gcacacaccc aaaccagcag taagtggtga gaaaaacatc tacgcattta tgggaactcc 4800

agtgcagaaa ctggacctga cagagaactt aactggcagc aagagacggc tacaaactcc 4860

taaggaaaag gcccaggctc tagaagacct ggctggcttt aaagagctct tccagacacg 4920

aggtcacact gaggaatcaa tgactaacga taaaactgcc aaagtagcct gcaaatcttc 4980

acaaccagac ctagacaaaa acccagcaag ctccaagcga cggctcaaga catccctggg 5040

gaaagtgggc gtgaaagaag agctcctagc agttggcaag ctcacacaga catcaggaga 5100

gactacacac acacacacag agccaacagg agatggtaag agcatgaaag catttatgga 5160

gtctccaaag cagatcttag actcagcagc aagtctaact ggcagcaaga ggcagctgag 5220

aactcctaag ggaaagtctg aagtccctga agacctggcc ggcttcatcg agctcttcca 5280

gacaccaagt cacactaagg aatcaatgac taatgaaaaa actaccaaag tatcctacag 5340

-continued

agcttcacag ccagacctag tggacacccc aacaagctcc aagccacagc ccaagagaag 5400

tctcaggaaa gcagacactg aagaagaatt tttagcattt aggaaacaaa cgccatcagc 5460

aggcaaagcc atgcacacac ccaaaccagc agtaggtgaa gagaaagaca tcaacacgtt 5520

tttgggaact ccagtgcaga aactggacca gccaggaaat ttacctggca gcaatagacg 5580

gctacaaact cgtaaggaaa aggcccaggc tctagaagaa ctgactggct tcagagagct 5640

tttccagaca ccatgcactg ataaccccac gactgatgag aaaactacca aaaaaatact 5700

ctgcaaatct ccgcaatcag acccagcgga caccccaaca aacacaaagc aacggcccaa 5760

gagaagcctc aagaaagcag acgtagagga agaattttta gcattcagga aactaacacc 5820

atcagcaggc aaagccatgc acacgcctaa agcagcagta ggtgaagaga aagacatcaa 5880

cacatttgtg gggactccag tggagaaact ggacctgcta ggaaatttac ctggcagcaa 5940

gagacggcca caaactccta aagaaaaggc caaggctcta gaagatctgg ctggcttcaa 6000

agagctcttc cagacaccag gtcacactga ggaatcaatg accgatgaca aaatcacaga 6060

agtatcctgc aaatctccac aaccagaccc agtcaaaacc ccaacaagct ccaagcaacg 6120

actcaagata tccttgggga aagtaggtgt gaaagaagag gtcctaccag tcggcaagct 6180

cacacagacg tcagggaaga ccacacagac acacagagag acagcaggag atggaaagag 6240

catcaaagcg tttaaggaat ctgcaaagca gatgctggac ccagcaaact atggaactgg 6300

gatggagagg tggccaagaa cacctaagga agaggcccaa tcactagaag acctggccgg 6360

cttcaaagag ctcttccaga caccagacca cactgaggaa tcaacaactg atgacaaaac 6420

taccaaaata gcctgcaaat ctccaccacc agaatcaatg gacactccaa caagcacaag 6480

gaggcggccc aaaacacctt tggggaaaag ggatatagtg gaagagctct cagccctgaa 6540

gcagctcaca cagaccacac acacagacaa agtaccagga gatgaggata aaggcatcaa 6600

cgtgttcagg gaaactgcaa aacagaaact ggacccagca gcaagtgtaa ctggtagcaa 6660

gaggcagcca agaactccta agggaaaagc ccaaccccta gaagacttgg ctggcttgaa 6720

agagctcttc cagacaccaa tatgcactga caagcccacg actcatgaga aaactaccaa 6780

aatagcctgc agatctccac aaccagaccc agtgggtacc ccaacaatct tcaagccaca 6840

gtccaagaga agtctcagga aagcagacgt agaggaagaa tccttagcac tcaggaaacg 6900

aacaccatca gtagggaaag ctatggacac acccaaacca gcaggaggtg atgagaaaga 6960

catgaaagca tttatgggaa ctccagtgca gaaattggac ctgccaggaa atttacctgg 7020

cagcaaaaga tggccacaaa ctcctaagga aaaggcccag gctctagaag acctggctgg 7080

cttcaaagag ctcttccaga caccaggcac tgacaagccc acgactgatg agaaaactac 7140

caaaatagcc tgcaaatctc cacaaccaga cccagtggac accccagcaa gcacaaagca 7200

acggcccaag agaaacctca ggaaagcaga cgtagaggaa gaatttttag cactcaggaa 7260

acgaacacca tcagcaggca aagccatgga cacaccaaaa ccagcagtaa gtgatgagaa 7320

aaatatcaac acatttgtgg aaactccagt gcagaaactg gacctgctag gaaatttacc 7380

tggcagcaag agacagccac agactcctaa ggaaaaggct gaggctctag aggacctggt 7440

tggcttcaaa gaactcttcc agacaccagg tcacactgag gaatcaatga ctgatgacaa 7500

aatcacagaa gtatcctgta aatctccaca gccagagtca ttcaaaacct caagaagctc 7560

caagcaaagg ctcaagatac ccctggtgaa agtggacatg aaagaagagc ccctagcagt 7620

cagcaagctc acacggacat caggggagac tacgcaaaca cacacagagc caacaggaga 7680

tagtaagagc atcaaagcgt ttaaggagtc tccaaagcag atcctggacc cagcagcaag 7740

-continued

tgtaactggt agcaggaggc agctgagaac tcgtaaggaa aaggcccgtg ctctagaaga 7800

cctggttgac ttcaaagagc tcttctcagc accaggtcac actgaagagt caatgactat 7860

tgacaaaaac acaaaaattc cctgcaaatc tcccccacca gaactaacag acactgccac 7920

gagcacaaag agatgcccca agacacgtct caggaaagaa gtaaaagagg agctctcagc 7980

agttgagagg ctcacgcaaa catcagggca aagcacacac acacacaaag aaccagcaag 8040

cggtgatgag ggcatcaaag tattgaagca acgtgcaaag aagaaaccaa acccagtaga 8100

agaggaaccc agcaggagaa ggccaagagc acctaaggaa aaggcccaac ccctggaaga 8160

cctggccggc ttcacagagc tctctgaaac atcaggtcac actcaggaat cactgactgc 8220

tggcaaagcc actaaaatac cctgcgaatc tcccccacta gaagtggtag acaccacagc 8280

aagcacaaag aggcatctca ggacacgtgt gcagaaggta caagtaaaag aagagccttc 8340

agcagtcaag ttcacacaaa catcagggga aaccacggat gcagacaaag aaccagcagg 8400

tgaagataaa ggcatcaaag cattgaagga atctgcaaaa cagacaccgg ctccagcagc 8460

aagtgtaact ggcagcagga gacggccaag agcacccagg gaaagtgccc aagccataga 8520

agacctagct ggcttcaaag acccagcagc aggtcacact gaagaatcaa tgactgatga 8580

caaaaccact aaaataccct gcaaatcatc accagaacta gaagacaccg caacaagctc 8640

aaagagacgg cccaggacac gtgcccagaa agtagaagtg aaggaggagc tgttagcagt 8700

tggcaagctc acacaaacct caggggagac cacgcacacc gacaaagagc cggtaggtga 8760

gggcaaaggc acgaaagcat ttaagcaacc tgcaaagcgg aagctggacg cagaagatgt 8820

aattggcagc aggagacagc caagagcacc taaggaaaag gcccaacccc tggaagatct 8880

ggccagcttc caagagctct ctcaaacacc aggccacact gaggaactgg caaatggtgc 8940

tgctgatagc tttacaagcg ctccaaagca aacacctgac agtggaaaac ctctaaaaat 9000

atccagaaga gttcttcggg cccctaaagt agaacccgtg ggagacgtgg taagcaccag 9060

agaccctgta aaatcacaaa gcaaaagcaa cacttccctg cccccactgc ccttcaagag 9120

gggaggtggc aaagatggaa gcgtcacggg aaccaagagg ctgcgctgca tgccagcacc 9180

agaggaaatt gtggaggagc tgccagccag caagaagcag agggttgctc ccagggcaag 9240

aggcaaatca tccgaacccg tggtcatcat gaagagaagt ttgaggactt ctgcaaaaag 9300

aattgaacct gcggaagagc tgaacagcaa cgacatgaaa accaacaaag aggaacacaa 9360

attacaagac tcagtccctg aaaataaggg aatatccctg cgctccagac gccaaaataa 9420

gactgaggca gaacagcaaa taactgaggt ctttgtatta gcagaaagaa tagaaataaa 9480

cagaaatgaa aagaagccca tgaagacctc cccagagatg gacattcaga atccagatga 9540

tggagcccgg aaacccatac ctagagacaa agtcactgag aacaaaaggt gcttgaggtc 9600

tgctagacag aatgagagct cccagcctaa ggtggcagag gagagcggag ggcagaagag 9660

tgcgaaggtt ctcatgcaga atcagaaagg gaaaggagaa gcaggaaatt cagactccat 9720

gtgcctgaga tcaagaaaga caaaaagcca gcctgcagca agcactttgg agagcaaatc 9780

tgtgcagaga gtaacgcgga gtgtcaagag gtgtgcagaa aatccaaaga aggctgagga 9840

caatgtgtgt gtcaagaaaa taagaaccag aagtcatagg gacagtgaag atatttgaca 9900

gaaaaatcga actgggaaaa atataataaa gttagttttg tgataagttc tagtgcagtt 9960

tttgtcataa attacaagtg aattctgtaa gtaaggctgt cagtctgctt aagggaagaa 10020

aactttggat ttgctgggtc tgaatcggct tcataaactc cactgggagc actgctgggc 10080

-continued

tcctggactg agaatagttg aacaccgggg gctttgtgaa ggagtctggg ccaaggtttg 10140

ccctcagctt tgcagaatga agccttgagg tctgtcacca cccacagcca ccctacagca 10200

gccttaactg tgacacttgc cacactgtgt cgtcgtttgt ttgcctatgt cctccagggc 10260

acggtggcag gaacaactat cctcgtctgt cccaacactg agcaggcact cggtaaacac 10320

gaatgaatgg atgagcgcac ggatgaatgg agcttacaga tctgtctttc caatggccgg 10380

ggggatttgg tccccaaatt aaggctattg gacatctgca caggacagtc ta 10432

<210> SEQ ID NO 98
<211> LENGTH: 3256
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 2700132CD1

<400> SEQUENCE: 98

Met Trp Pro Thr Arg Arg Leu Val Thr Ile Lys Arg Ser Gly Val
1 5 10 15

Asp Gly Pro His Phe Pro Leu Ser Leu Ser Thr Cys Leu Phe Gly
20 25 30

Arg Gly Ile Glu Cys Asp Ile Arg Ile Gln Leu Pro Val Val Ser
35 40 45

Lys Gln His Cys Lys Ile Glu Ile His Glu Gln Glu Ala Ile Leu
50 55 60

His Asn Phe Ser Ser Thr Asn Pro Thr Gln Val Asn Gly Ser Val
65 70 75

Ile Asp Glu Pro Val Arg Leu Lys His Gly Asp Val Ile Thr Ile
80 85 90

Ile Asp Arg Ser Phe Arg Tyr Glu Asn Glu Ser Leu Gln Ser Gly
95 100 105

Arg Lys Ser Thr Glu Phe Pro Arg Lys Ile Arg Glu Gln Glu Pro
110 115 120

Ala Arg Arg Val Ser Arg Ser Ser Phe Ser Ser Asp Pro Asp Glu
125 130 135

Lys Ala Gln Asp Ser Lys Ala Tyr Ser Lys Ile Thr Glu Gly Lys
140 145 150

Val Ser Gly Asn Pro Gln Val His Ile Lys Asn Val Lys Glu Asp
155 160 165

Ser Thr Ala Asp Asp Ser Lys Asp Ser Val Ala Gln Gly Thr Thr
170 175 180

Asn Val His Ser Ser Glu His Ala Gly Arg Asn Gly Arg Asn Ala
185 190 195

Ala Asp Pro Ile Ser Gly Asp Phe Lys Glu Ile Ser Ser Val Lys
200 205 210

Leu Val Ser Arg Tyr Gly Glu Leu Lys Ser Val Pro Thr Thr Gln
215 220 225

Cys Leu Asp Asn Ser Lys Lys Asn Glu Ser Pro Phe Trp Lys Leu
230 235 240

Tyr Glu Ser Val Lys Lys Glu Leu Asp Val Lys Ser Gln Lys Glu
245 250 255

Asn Val Leu Gln Tyr Cys Arg Lys Ser Gly Leu Gln Thr Asp Tyr
260 265 270

Ala Thr Glu Lys Glu Ser Ala Asp Gly Leu Gln Gly Glu Thr Gln
275 280 285

-continued

```
Leu Leu Val Ser Arg Lys Ser Arg Pro Lys Ser Gly Gly Ser Gly
                290                 295                 300

His Ala Val Ala Glu Pro Ala Ser Pro Glu Gln Glu Leu Asp Gln
                305                 310                 315

Asn Lys Gly Lys Gly Arg Asp Val Glu Ser Val Gln Thr Pro Ser
                320                 325                 330

Lys Ala Val Gly Ala Ser Phe Pro Leu Tyr Glu Pro Ala Lys Met
                335                 340                 345

Lys Thr Pro Val Gln Tyr Ser Gln Gln Gln Asn Ser Pro Gln Lys
                350                 355                 360

His Lys Asn Lys Asp Leu Tyr Thr Thr Gly Arg Arg Glu Ser Val
                365                 370                 375

Asn Leu Gly Lys Ser Glu Gly Phe Lys Ala Gly Asp Lys Thr Leu
                380                 385                 390

Thr Pro Arg Lys Leu Ser Thr Arg Asn Arg Thr Pro Ala Lys Val
                395                 400                 405

Glu Asp Ala Ala Asp Ser Ala Thr Lys Pro Glu Asn Leu Ser Ser
                410                 415                 420

Lys Thr Arg Gly Ser Ile Pro Thr Asp Val Glu Val Leu Pro Thr
                425                 430                 435

Glu Thr Glu Ile His Asn Glu Pro Phe Leu Thr Leu Trp Leu Thr
                440                 445                 450

Gln Val Glu Arg Lys Ile Gln Lys Asp Ser Leu Ser Lys Pro Glu
                455                 460                 465

Lys Leu Gly Thr Thr Ala Gly Gln Met Cys Ser Gly Leu Pro Gly
                470                 475                 480

Leu Ser Ser Val Asp Ile Asn Asn Phe Gly Asp Ser Ile Asn Glu
                485                 490                 495

Ser Glu Gly Ile Pro Leu Lys Arg Arg Arg Val Ser Phe Gly Gly
                500                 505                 510

His Leu Arg Pro Glu Leu Phe Asp Glu Asn Leu Pro Pro Asn Thr
                515                 520                 525

Pro Leu Lys Arg Gly Glu Ala Pro Thr Lys Arg Lys Ser Leu Val
                530                 535                 540

Met His Thr Pro Pro Val Leu Lys Lys Ile Ile Lys Glu Gln Pro
                545                 550                 555

Gln Pro Ser Gly Lys Gln Glu Ser Gly Ser Glu Ile His Val Glu
                560                 565                 570

Val Lys Ala Gln Ser Leu Val Ile Ser Pro Pro Ala Pro Ser Pro
                575                 580                 585

Arg Lys Thr Pro Val Ala Ser Asp Gln Arg Arg Arg Ser Cys Lys
                590                 595                 600

Thr Ala Pro Ala Ser Ser Ser Lys Ser Gln Thr Glu Val Pro Lys
                605                 610                 615

Arg Gly Gly Glu Arg Val Ala Thr Cys Leu Gln Lys Arg Val Ser
                620                 625                 630

Ile Ser Arg Ser Gln His Asp Ile Leu Gln Met Ile Cys Ser Lys
                635                 640                 645

Arg Arg Ser Gly Ala Ser Glu Ala Asn Leu Ile Val Ala Lys Ser
                650                 655                 660

Trp Ala Asp Val Val Lys Leu Gly Ala Lys Gln Thr Gln Thr Lys
                665                 670                 675
```

-continued

Val Ile Lys His Gly Pro Gln Arg Ser Met Asn Lys Arg Gln Arg
680 685 690

Arg Pro Ala Thr Pro Lys Lys Pro Val Gly Glu Val His Ser Gln
695 700 705

Phe Ser Thr Gly His Ala Asn Ser Pro Cys Thr Ile Ile Ile Gly
710 715 720

Lys Ala His Thr Glu Lys Val His Val Pro Ala Arg Pro Tyr Arg
725 730 735

Val Leu Asn Asn Phe Ile Ser Asn Gln Lys Met Asp Phe Lys Glu
740 745 750

Asp Leu Ser Gly Ile Ala Glu Met Phe Lys Thr Pro Val Lys Glu
755 760 765

Gln Pro Gln Leu Thr Ser Thr Cys His Ile Ala Ile Ser Asn Ser
770 775 780

Glu Asn Leu Leu Gly Lys Gln Phe Gln Gly Thr Asp Ser Gly Glu
785 790 795

Glu Pro Leu Leu Pro Thr Ser Glu Ser Phe Gly Gly Asn Val Phe
800 805 810

Phe Ser Ala Gln Asn Ala Ala Lys Gln Pro Ser Asp Lys Cys Ser
815 820 825

Ala Ser Pro Pro Leu Arg Arg Gln Cys Ile Arg Glu Asn Gly Asn
830 835 840

Val Ala Lys Thr Pro Arg Asn Thr Tyr Lys Met Thr Ser Leu Glu
845 850 855

Thr Lys Thr Ser Asp Thr Glu Thr Glu Pro Ser Lys Thr Val Ser
860 865 870

Thr Val Asn Arg Ser Gly Arg Ser Thr Glu Phe Arg Asn Ile Gln
875 880 885

Lys Leu Pro Val Glu Ser Lys Ser Glu Glu Thr Asn Thr Glu Ile
890 895 900

Val Glu Cys Ile Leu Lys Arg Gly Gln Lys Ala Thr Leu Leu Gln
905 910 915

Gln Arg Arg Glu Gly Glu Met Lys Glu Ile Glu Arg Pro Phe Glu
920 925 930

Thr Tyr Lys Glu Asn Ile Glu Leu Lys Glu Asn Asp Glu Lys Met
935 940 945

Lys Ala Met Lys Arg Ser Arg Thr Trp Gly Gln Lys Cys Ala Pro
950 955 960

Met Ser Asp Leu Thr Asp Leu Lys Ser Leu Pro Asp Thr Glu Leu
965 970 975

Met Lys Asp Thr Ala Arg Gly Gln Asn Leu Leu Gln Thr Gln Asp
980 985 990

His Ala Lys Ala Pro Lys Ser Glu Lys Gly Lys Ile Thr Lys Met
995 1000 1005

Pro Cys Gln Ser Leu Gln Pro Glu Pro Ile Asn Thr Pro Thr His
1010 1015 1020

Thr Lys Gln Gln Leu Lys Ala Ser Leu Gly Lys Val Gly Val Lys
1025 1030 1035

Glu Glu Leu Leu Ala Val Gly Lys Phe Thr Arg Thr Ser Gly Glu
1040 1045 1050

Thr Thr His Thr His Arg Glu Pro Ala Gly Asp Gly Lys Ser Ile
1055 1060 1065

Arg Thr Phe Lys Glu Ser Pro Lys Gln Ile Leu Asp Pro Ala Ala

-continued

```
                1070                1075                1080

Arg Val Thr Gly Met Lys Lys Trp Pro Arg Thr Pro Lys Glu Glu
                1085                1090                1095

Ala Gln Ser Leu Glu Asp Leu Ala Gly Phe Lys Glu Leu Phe Gln
                1100                1105                1110

Thr Pro Gly Pro Ser Glu Glu Ser Met Thr Asp Glu Lys Thr Thr
                1115                1120                1125

Lys Ile Ala Cys Lys Ser Pro Pro Pro Glu Ser Val Asp Thr Pro
                1130                1135                1140

Thr Ser Thr Lys Gln Trp Pro Lys Arg Ser Leu Arg Lys Ala Asp
                1145                1150                1155

Val Glu Glu Glu Phe Leu Ala Leu Arg Lys Leu Thr Pro Ser Ala
                1160                1165                1170

Gly Lys Ala Met Leu Thr Pro Lys Pro Ala Gly Gly Asp Glu Lys
                1175                1180                1185

Asp Ile Lys Ala Phe Met Gly Thr Pro Val Gln Lys Leu Asp Leu
                1190                1195                1200

Ala Gly Thr Leu Pro Gly Ser Lys Arg Gln Leu Gln Thr Pro Lys
                1205                1210                1215

Glu Lys Ala Gln Ala Leu Glu Asp Leu Ala Gly Phe Lys Glu Leu
                1220                1225                1230

Phe Gln Thr Pro Gly His Thr Glu Glu Leu Val Ala Ala Gly Lys
                1235                1240                1245

Thr Thr Lys Ile Pro Cys Asp Ser Pro Gln Ser Asp Pro Val Asp
                1250                1255                1260

Thr Pro Thr Ser Thr Lys Gln Arg Pro Lys Arg Ser Ile Arg Lys
                1265                1270                1275

Ala Asp Val Glu Gly Glu Leu Leu Ala Cys Arg Asn Leu Met Pro
                1280                1285                1290

Ser Ala Gly Lys Ala Met His Thr Pro Lys Pro Ser Val Gly Glu
                1295                1300                1305

Glu Lys Asp Ile Ile Ile Phe Val Gly Thr Pro Val Gln Lys Leu
                1310                1315                1320

Asp Leu Thr Glu Asn Leu Thr Gly Ser Lys Arg Arg Pro Gln Thr
                1325                1330                1335

Pro Lys Glu Glu Ala Gln Ala Leu Glu Asp Leu Thr Gly Phe Lys
                1340                1345                1350

Glu Leu Phe Gln Thr Pro Gly His Thr Glu Glu Ala Val Ala Ala
                1355                1360                1365

Gly Lys Thr Thr Lys Met Pro Cys Glu Ser Ser Pro Pro Glu Ser
                1370                1375                1380

Ala Asp Thr Pro Thr Ser Thr Arg Arg Gln Pro Lys Thr Pro Leu
                1385                1390                1395

Glu Lys Arg Asp Val Gln Lys Glu Leu Ser Ala Leu Lys Lys Leu
                1400                1405                1410

Thr Gln Thr Ser Gly Glu Thr Thr His Thr Asp Lys Val Pro Gly
                1415                1420                1425

Gly Glu Asp Lys Ser Ile Asn Ala Phe Arg Glu Thr Ala Lys Gln
                1430                1435                1440

Lys Leu Asp Pro Ala Ala Ser Val Thr Gly Ser Lys Arg His Pro
                1445                1450                1455

Lys Thr Lys Glu Lys Ala Gln Pro Leu Glu Asp Leu Ala Gly Trp
                1460                1465                1470
```

-continued

```
Lys Glu Leu Phe Gln Thr Pro Val Cys Thr Asp Lys Pro Thr Thr
                1475                1480                1485

His Glu Lys Thr Thr Lys Ile Ala Cys Arg Ser Gln Pro Asp Pro
                1490                1495                1500

Val Asp Thr Pro Thr Ser Ser Lys Pro Gln Ser Lys Arg Ser Leu
                1505                1510                1515

Arg Lys Val Asp Val Glu Glu Glu Phe Phe Ala Leu Arg Lys Arg
                1520                1525                1530

Thr Pro Ser Ala Gly Lys Ala Met His Thr Pro Lys Pro Ala Val
                1535                1540                1545

Ser Gly Glu Lys Asn Ile Tyr Ala Phe Met Gly Thr Pro Val Gln
                1550                1555                1560

Lys Leu Asp Leu Thr Glu Asn Leu Thr Gly Ser Lys Arg Arg Leu
                1565                1570                1575

Gln Thr Pro Lys Glu Lys Ala Gln Ala Leu Glu Asp Leu Ala Gly
                1580                1585                1590

Phe Lys Glu Leu Phe Gln Thr Arg Gly His Thr Glu Glu Ser Met
                1595                1600                1605

Thr Asn Asp Lys Thr Ala Lys Val Ala Cys Lys Ser Ser Gln Pro
                1610                1615                1620

Asp Leu Asp Lys Asn Pro Ala Ser Ser Lys Arg Arg Leu Lys Thr
                1625                1630                1635

Ser Leu Gly Lys Val Gly Val Lys Glu Glu Leu Leu Ala Val Gly
                1640                1645                1650

Lys Leu Thr Gln Thr Ser Gly Glu Thr Thr His Thr His Thr Glu
                1655                1660                1665

Pro Thr Gly Asp Gly Lys Ser Met Lys Ala Phe Met Glu Ser Pro
                1670                1675                1680

Lys Gln Ile Leu Asp Ser Ala Ala Ser Leu Thr Gly Ser Lys Arg
                1685                1690                1695

Gln Leu Arg Thr Pro Lys Gly Lys Ser Glu Val Pro Glu Asp Leu
                1700                1705                1710

Ala Gly Phe Ile Glu Leu Phe Gln Thr Pro Ser His Thr Lys Glu
                1715                1720                1725

Ser Met Thr Asn Glu Lys Thr Thr Lys Val Ser Tyr Arg Ala Ser
                1730                1735                1740

Gln Pro Asp Leu Val Asp Thr Pro Thr Ser Ser Lys Pro Gln Pro
                1745                1750                1755

Lys Arg Ser Leu Arg Lys Ala Asp Thr Glu Glu Glu Phe Leu Ala
                1760                1765                1770

Phe Arg Lys Gln Thr Pro Ser Ala Gly Lys Ala Met His Thr Pro
                1775                1780                1785

Lys Pro Ala Val Gly Glu Glu Lys Asp Ile Asn Thr Phe Leu Gly
                1790                1795                1800

Thr Pro Val Gln Lys Leu Asp Gln Pro Gly Asn Leu Pro Gly Ser
                1805                1810                1815

Asn Arg Arg Leu Gln Thr Arg Lys Glu Lys Ala Gln Ala Leu Glu
                1820                1825                1830

Glu Leu Thr Gly Phe Arg Glu Leu Phe Gln Thr Pro Cys Thr Asp
                1835                1840                1845

Asn Pro Thr Thr Asp Glu Lys Thr Thr Lys Lys Ile Leu Cys Lys
                1850                1855                1860
```

-continued

```
Ser Pro Gln Ser Asp Pro Ala Asp Thr Pro Thr Asn Thr Lys Gln
                1865                1870                1875

Arg Pro Lys Arg Ser Leu Lys Lys Ala Asp Val Glu Glu Glu Phe
                1880                1885                1890

Leu Ala Phe Arg Lys Leu Thr Pro Ser Ala Gly Lys Ala Met His
                1895                1900                1905

Thr Pro Lys Ala Ala Val Gly Glu Glu Lys Asp Ile Asn Thr Phe
                1910                1915                1920

Val Gly Thr Pro Val Glu Lys Leu Asp Leu Leu Gly Asn Leu Pro
                1925                1930                1935

Gly Ser Lys Arg Arg Pro Gln Thr Pro Lys Glu Lys Ala Lys Ala
                1940                1945                1950

Leu Glu Asp Leu Ala Gly Phe Lys Glu Leu Phe Gln Thr Pro Gly
                1955                1960                1965

His Thr Glu Glu Ser Met Thr Asp Asp Lys Ile Thr Glu Val Ser
                1970                1975                1980

Cys Lys Ser Pro Gln Pro Asp Pro Val Lys Thr Pro Thr Ser Ser
                1985                1990                1995

Lys Gln Arg Leu Lys Ile Ser Leu Gly Lys Val Gly Val Lys Glu
                2000                2005                2010

Glu Val Leu Pro Val Gly Lys Leu Thr Gln Thr Ser Gly Lys Thr
                2015                2020                2025

Thr Gln Thr His Arg Glu Thr Ala Gly Asp Gly Lys Ser Ile Lys
                2030                2035                2040

Ala Phe Lys Glu Ser Ala Lys Gln Met Leu Asp Pro Ala Asn Tyr
                2045                2050                2055

Gly Thr Gly Met Glu Arg Trp Pro Arg Thr Pro Lys Glu Glu Ala
                2060                2065                2070

Gln Ser Leu Glu Asp Leu Ala Gly Phe Lys Glu Leu Phe Gln Thr
                2075                2080                2085

Pro Asp His Thr Glu Glu Ser Thr Thr Asp Asp Lys Thr Thr Lys
                2090                2095                2100

Ile Ala Cys Lys Ser Pro Pro Pro Glu Ser Met Asp Thr Pro Thr
                2105                2110                2115

Ser Thr Arg Arg Arg Pro Lys Thr Pro Leu Gly Lys Arg Asp Ile
                2120                2125                2130

Val Glu Glu Leu Ser Ala Leu Lys Gln Leu Thr Gln Thr Thr His
                2135                2140                2145

Thr Asp Lys Val Pro Gly Asp Glu Asp Lys Gly Ile Asn Val Phe
                2150                2155                2160

Arg Glu Thr Ala Lys Gln Lys Leu Asp Pro Ala Ala Ser Val Thr
                2165                2170                2175

Gly Ser Lys Arg Gln Pro Arg Thr Pro Lys Gly Lys Ala Gln Pro
                2180                2185                2190

Leu Glu Asp Leu Ala Gly Leu Lys Glu Leu Phe Gln Thr Pro Ile
                2195                2200                2205

Cys Thr Asp Lys Pro Thr Thr His Glu Lys Thr Thr Lys Ile Ala
                2210                2215                2220

Cys Arg Ser Pro Gln Pro Asp Pro Val Gly Thr Pro Thr Ile Phe
                2225                2230                2235

Lys Pro Gln Ser Lys Arg Ser Leu Arg Lys Ala Asp Val Glu Glu
                2240                2245                2250

Glu Ser Leu Ala Leu Arg Lys Arg Thr Pro Ser Val Gly Lys Ala
```

-continued

```
                2255                2260                2265

Met Asp Thr Pro Lys Pro Ala Gly Gly Asp Glu Lys Asp Met Lys
                2270                2275                2280

Ala Phe Met Gly Thr Pro Val Gln Lys Leu Asp Leu Pro Gly Asn
                2285                2290                2295

Leu Pro Gly Ser Lys Arg Trp Pro Gln Thr Pro Lys Glu Lys Ala
                2300                2305                2310

Gln Ala Leu Glu Asp Leu Ala Gly Phe Lys Glu Leu Phe Gln Thr
                2315                2320                2325

Pro Gly Thr Asp Lys Pro Thr Thr Asp Glu Lys Thr Thr Lys Ile
                2330                2335                2340

Ala Cys Lys Ser Pro Gln Pro Asp Pro Val Asp Thr Pro Ala Ser
                2345                2350                2355

Thr Lys Gln Arg Pro Lys Arg Asn Leu Arg Lys Ala Asp Val Glu
                2360                2365                2370

Glu Glu Phe Leu Ala Leu Arg Lys Arg Thr Pro Ser Ala Gly Lys
                2375                2380                2385

Ala Met Asp Thr Pro Lys Pro Ala Val Ser Asp Glu Lys Asn Ile
                2390                2395                2400

Asn Thr Phe Val Glu Thr Pro Val Gln Lys Leu Asp Leu Leu Gly
                2405                2410                2415

Asn Leu Pro Gly Ser Lys Arg Gln Pro Gln Thr Pro Lys Glu Lys
                2420                2425                2430

Ala Glu Ala Leu Glu Asp Leu Val Gly Phe Lys Glu Leu Phe Gln
                2435                2440                2445

Thr Pro Gly His Thr Glu Glu Ser Met Thr Asp Asp Lys Ile Thr
                2450                2455                2460

Glu Val Ser Cys Lys Ser Pro Gln Pro Glu Ser Phe Lys Thr Ser
                2465                2470                2475

Arg Ser Ser Lys Gln Arg Leu Lys Ile Pro Leu Val Lys Val Asp
                2480                2485                2490

Met Lys Glu Glu Pro Leu Ala Val Ser Lys Leu Thr Arg Thr Ser
                2495                2500                2505

Gly Glu Thr Thr Gln Thr His Thr Glu Pro Thr Gly Asp Ser Lys
                2510                2515                2520

Ser Ile Lys Ala Phe Lys Glu Ser Pro Lys Gln Ile Leu Asp Pro
                2525                2530                2535

Ala Ala Ser Val Thr Gly Ser Arg Arg Gln Leu Arg Thr Arg Lys
                2540                2545                2550

Glu Lys Ala Arg Ala Leu Glu Asp Leu Val Asp Phe Lys Glu Leu
                2555                2560                2565

Phe Ser Ala Pro Gly His Thr Glu Glu Ser Met Thr Ile Asp Lys
                2570                2575                2580

Asn Thr Lys Ile Pro Cys Lys Ser Pro Pro Pro Glu Leu Thr Asp
                2585                2590                2595

Thr Ala Thr Ser Thr Lys Arg Cys Pro Lys Thr Arg Leu Arg Lys
                2600                2605                2610

Glu Val Lys Glu Glu Leu Ser Ala Val Glu Arg Leu Thr Gln Thr
                2615                2620                2625

Ser Gly Gln Ser Thr His Thr His Lys Glu Pro Ala Ser Gly Asp
                2630                2635                2640

Glu Gly Ile Lys Val Leu Lys Gln Arg Ala Lys Lys Lys Pro Asn
                2645                2650                2655
```

-continued

```
Pro Val Glu Glu Glu Pro Ser Arg Arg Arg Pro Arg Ala Pro Lys
               2660                2665                2670

Glu Lys Ala Gln Pro Leu Glu Asp Leu Ala Gly Phe Thr Glu Leu
               2675                2680                2685

Ser Glu Thr Ser Gly His Thr Gln Glu Ser Leu Thr Ala Gly Lys
               2690                2695                2700

Ala Thr Lys Ile Pro Cys Glu Ser Pro Pro Leu Glu Val Val Asp
               2705                2710                2715

Thr Thr Ala Ser Thr Lys Arg His Leu Arg Thr Arg Val Gln Lys
               2720                2725                2730

Val Gln Val Lys Glu Glu Pro Ser Ala Val Lys Phe Thr Gln Thr
               2735                2740                2745

Ser Gly Glu Thr Thr Asp Ala Asp Lys Glu Pro Ala Gly Glu Asp
               2750                2755                2760

Lys Gly Ile Lys Ala Leu Lys Glu Ser Ala Lys Gln Thr Pro Ala
               2765                2770                2775

Pro Ala Ala Ser Val Thr Gly Ser Arg Arg Arg Pro Arg Ala Pro
               2780                2785                2790

Arg Glu Ser Ala Gln Ala Ile Glu Asp Leu Ala Gly Phe Lys Asp
               2795                2800                2805

Pro Ala Ala Gly His Thr Glu Glu Ser Met Thr Asp Asp Lys Thr
               2810                2815                2820

Thr Lys Ile Pro Cys Lys Ser Ser Pro Glu Leu Glu Asp Thr Ala
               2825                2830                2835

Thr Ser Ser Lys Arg Arg Pro Arg Thr Arg Ala Gln Lys Val Glu
               2840                2845                2850

Val Lys Glu Glu Leu Leu Ala Val Gly Lys Leu Thr Gln Thr Ser
               2855                2860                2865

Gly Glu Thr Thr His Thr Asp Lys Glu Pro Val Gly Glu Gly Lys
               2870                2875                2880

Gly Thr Lys Ala Phe Lys Gln Pro Ala Lys Arg Lys Leu Asp Ala
               2885                2890                2895

Glu Asp Val Ile Gly Ser Arg Arg Gln Pro Arg Ala Pro Lys Glu
               2900                2905                2910

Lys Ala Gln Pro Leu Glu Asp Leu Ala Ser Phe Gln Glu Leu Ser
               2915                2920                2925

Gln Thr Pro Gly His Thr Glu Glu Leu Ala Asn Gly Ala Ala Asp
               2930                2935                2940

Ser Phe Thr Ser Ala Pro Lys Gln Thr Pro Asp Ser Gly Lys Pro
               2945                2950                2955

Leu Lys Ile Ser Arg Arg Val Leu Arg Ala Pro Lys Val Glu Pro
               2960                2965                2970

Val Gly Asp Val Val Ser Thr Arg Asp Pro Val Lys Ser Gln Ser
               2975                2980                2985

Lys Ser Asn Thr Ser Leu Pro Pro Leu Pro Phe Lys Arg Gly Gly
               2990                2995                3000

Gly Lys Asp Gly Ser Val Thr Gly Thr Lys Arg Leu Arg Cys Met
               3005                3010                3015

Pro Ala Pro Glu Glu Ile Val Glu Glu Leu Pro Ala Ser Lys Lys
               3020                3025                3030

Gln Arg Val Ala Pro Arg Ala Arg Gly Lys Ser Ser Glu Pro Val
               3035                3040                3045
```

-continued

Val Ile Met Lys Arg Ser Leu Arg Thr Ser Ala Lys Arg Ile Glu
3050 3055 3060

Pro Ala Glu Glu Leu Asn Ser Asn Asp Met Lys Thr Asn Lys Glu
3065 3070 3075

Glu His Lys Leu Gln Asp Ser Val Pro Glu Asn Lys Gly Ile Ser
3080 3085 3090

Leu Arg Ser Arg Arg Gln Asn Lys Thr Glu Ala Glu Gln Gln Ile
3095 3100 3105

Thr Glu Val Phe Val Leu Ala Glu Arg Ile Glu Ile Asn Arg Asn
3110 3115 3120

Glu Lys Lys Pro Met Lys Thr Ser Pro Glu Met Asp Ile Gln Asn
3125 3130 3135

Pro Asp Asp Gly Ala Arg Lys Pro Ile Pro Arg Asp Lys Val Thr
3140 3145 3150

Glu Asn Lys Arg Cys Leu Arg Ser Ala Arg Gln Asn Glu Ser Ser
3155 3160 3165

Gln Pro Lys Val Ala Glu Glu Ser Gly Gly Gln Lys Ser Ala Lys
3170 3175 3180

Val Leu Met Gln Asn Gln Lys Gly Lys Gly Glu Ala Gly Asn Ser
3185 3190 3195

Asp Ser Met Cys Leu Arg Ser Arg Lys Thr Lys Ser Gln Pro Ala
3200 3205 3210

Ala Ser Thr Leu Glu Ser Lys Ser Val Gln Arg Val Thr Arg Ser
3215 3220 3225

Val Lys Arg Cys Ala Glu Asn Pro Lys Lys Ala Glu Asp Asn Val
3230 3235 3240

Cys Val Lys Lys Ile Arg Thr Arg Ser His Arg Asp Ser Glu Asp
3245 3250 3255

Ile

<210> SEQ ID NO 99
<211> LENGTH: 826
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 211881.1

<400> SEQUENCE: 99

cttaaaacct gacatccttc atgttagcta acctttataa tctctttgga tgtagtaaat 60

ttttagtatt ttttagattg aatttgtatc atatttgcta gcaaattgag tataaagagt 120

agcatatttt tactacagat gtattatttt aactaacaaa ggcatattat acatttttt 180

catatataaa ctttggaata ggattttaca gtaacttaag ttttttattt ctacccatgt 240

gtcaaagttt tatgctaaat tctgaataga atagttgtaa ctcccactct gggtatttta 300

tttattttaa acagttctag tattgtttcc tgtgaatttt ttccagggat tgctactttc 360

tgcactattc attagaccaa gagcatttca ccaaatactt aaaacttaaa aatttttaaa 420

cttttccaaa tttgattaaa aggataacat attctaaagg tattcaatat ttttacttat 480

ctctgaaaaa cttaatcaca taaaagcata cattttacac atacagctct ctccatcttc 540

cacaatagat taagacataa aacataacca gtatttttga aaagccccct taactggcat 600

gcttcttact gaaattatca taaaaggttc gtatgagaaa ggattccaga atatccctta 660

attgtgttgt agcttatgca tttctattta ttttatacat tatttaattc atgtgagtta 720

-continued

cttacctggc agggaagata tgatcaccaa ggtgcctttc acattcattg cactctggat 780

gtgctgaccc ctgcaatttc cccaaatggg ggaagctcaa ctgcat 826

<210> SEQ ID NO 100
<211> LENGTH: 1498
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 409895.2

<400> SEQUENCE: 100

agctaatgtg ttacattaga atcacctcgg ggaggccctg ggtgcccttc tcagccctcc 60

ctccggaggc tgctgaagcc cagcaaagcc ggagtcagag aacaatgtcc gcctgagggc 120

agggctgggc tgggctggcc ttctggccct atctgctccg tgcccaaccc agcgccccgc 180

acagtcggag ctttgtaaat acgaggtgac tgtctgccta caaactttgt aaacatcact 240

tgaaatggcc gcagggtatt gcgacatggc cataccacta tttgtttgct attgaatttg 300

tacttccctg ccttactttt gctattgcaa accatgctgt cactaaggtc ttcatgcaca 360

cagttgtgtc ttggtcagat gatatgtttc taccaatttt aattgtgttt ctttccacct 420

gggacacaca gctctctggg ccccagggct gggtcatcag cacaccctgc tgctgctgtt 480

cagatctgca tcctggtccc gcttggtccc acagtgagaa cgctttgcta tcacatgggc 540

aggctctgag agccctgccg gcctggcctt ctcaaagaag acctgagagc ttgggaccca 600

agcagagagg aagaacaggg ctcagggtgc ttgctccatg ctcgctccac acctggggct 660

caaccctggc tttccccggc tccctgtgtg acttcagggc aggtcccttg ggccctctgg 720

gccttatcat cttcatctgt aacagggcga tgcctctgcc gtgtctggtg gtgttgagga 780

gttcctgttt gtgtaagcag ctagttcagt gccagcacga gatgggaggc ccatgaagtt 840

agcagtgcac aaaaaataga gcaaagactg gatgcatttc ctgagaacaa ccatcactgt 900

aaagcacttt acaaatccaa agacaacccc cggcaaaaac tcaaaatgaa actccctctc 960

gcagagcaca attccaattc gctctaaaaa cattacaagt tagttcatgt catgccagat 1020

agctgaaggc agctcacaag ttcttaaggc caggaatgcc atgtgtctgc tatgcacagc 1080

tggccctggc cctgagcctg aatgacagca aaggtgacgc agatgtgggt gccctgctcc 1140

tgcccagcag cagtgcttgg tggaggctga ggccctgcac aggcaccctc actgctgacc 1200

ttgagcctct ctctcctcta gagtggaaaa gacaaggatg ccgtggataa attgctcaag 1260

gacctggacg ccaatggaga tgcccaggtg gacttcagtg agttcatcgt gttcgtggct 1320

gcaatcacgt ctgcctgtca caagtacttt gagaaggcag gactcaaatg atgccctgga 1380

gatgtcacag attcctggca gagccatggt cccaggcttc ccaaaagtgt ttgttggcaa 1440

ttattcccct aggctgagcc tgctcatgta cctctgatta ataaatgctt atgaaatg 1498

<210> SEQ ID NO 101
<211> LENGTH: 860
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1422432CB1
<221> NAME/KEY: unsure
<222> LOCATION: 205
<223> OTHER INFORMATION: a, t, c, g, or other

<400> SEQUENCE: 101

-continued

agagcaaaga ctggatgcat ttcctgagaa caaccatcac tgtaaagcac tttacaaatc 60

caaagacaac ccccggcaaa aactcaaaat gaaactccct ctcgcagagc acaattccaa 120

ttcgctctaa aaacattaca agttagttca tgtcatgcca gatagctgaa ggcagctcac 180

aagttcttaa ggccaggaat gccangtgtc tgctatgcac agctggccct ggccctgagc 240

ctgaatgaca gcaaaggtga cgcagatgtg ggtgccctgc tcctgcccag cagcagtgct 300

tggtggaggc tgaggccctg cacaggcacc ctcactgctg accttgagcc tctctcctct 360

ctcaagaggc tgccagtggg acattttctc ggccctgcca gcccccagga ggaaggtggg 420

tctgaatcta gcaccatgac ggaactagag acagccatgg gcatgatcat agacgtcttt 480

tcccgatatt cgggcagcga gggcagcacg cagaccctga ccaaggggga gctcaaggtg 540

ctgatggaga aggagctacc aggcttcctg cagagtggaa aagacaagga tgccgtggat 600

aaattgctca aggacctgga cgccaatgga gatgcccagg tggacttcag tgagttcatc 660

gtgttcgtgg ctgcaatcac gtctgcctgt cacaagtact ttgagaaggc aggactcaaa 720

tgatgccctg gagatgtcac agattcctgg cagagccatg gtcccaggct tcccaaaagt 780

gtttgttggc aattattccc ctaggctgag cctgctcatg tacctctgat taataaatgc 840

ttatgaaatg aaaaaaaaaa 860

<210> SEQ ID NO 102
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Incyte ID No: 1422432CD1

<400> SEQUENCE: 102

Met Thr Glu Leu Glu Thr Ala Met Gly Met Ile Ile Asp Val Phe
1 5 10 15

Ser Arg Tyr Ser Gly Ser Glu Gly Ser Thr Gln Thr Leu Thr Lys
20 25 30

Gly Glu Leu Lys Val Leu Met Glu Lys Glu Leu Pro Gly Phe Leu
35 40 45

Gln Ser Gly Lys Asp Lys Asp Ala Val Asp Lys Leu Leu Lys Asp
50 55 60

Leu Asp Ala Asn Gly Asp Ala Gln Val Asp Phe Ser Glu Phe Ile
65 70 75

Val Phe Val Ala Ala Ile Thr Ser Ala Cys His Lys Tyr Phe Glu
80 85 90

Lys Ala Gly Leu Lys
95

What is claimed is:

1. A combination comprising a plurality of cDNAs that are differentially expressed in prostate cancer, wherein the plurality of cDNAs consist of SEQ ID NOs:1–3, 5, 6, 8, 10–15, 17–19, 21, 23–28, 30, 32, 34–36, 38, 40, 42–45, 47–50, 52, 53, 55, 56, 58–65, 67, 68, 70–73, 75, 76, 78–86, 88–90, 92–97, 99–101 or a plurality of cDNAs consisting of the complements thereof.

2. The combination of claim **1**, wherein each of the cDNAs is differentially regulated between non-metastatic and metastatic prostate cancer, consisting of SEQ ID NOs:1–3, 5, 6, 8, 10–15, 17–19, 21, 23–28, 30, 32, 34–36, 38, 40, 42–45, 47–50, 52, 53, 55, 56, 58–65, 67, 68, 70–73, 75.

3. The combination of claim **1**, wherein each of the cDNAs is differentially regulated between prostate cancer and normal prostate, consisting of SEQ ID NOs:76, 78–86, 88–90, 92–97, 99–101.

4. The combination of claim **1**, wherein the cDNAs are immobilized on a substrate.

5. A high throughput method for detecting differential expression of one or more cDNAs in a sample containing nucleic acids, the method comprising:

(a) hybridizing the substrate of claim **4** with nucleic acids of the sample, thereby forming one or more hybridization complexes;

(b) detecting the hybridization complexes; and

(c) comparing the hybridization complexes with those of a standard, wherein differences between the standard and sample hybridization complexes indicate differential expression of cDNAs in the sample.

6. The method of claim **5**, wherein the nucleic acids of the sample are amplified prior to hybridization.

7. The method of claim **5**, wherein the sample is from a subject with prostate cancer and comparison with a standard defines an early, mid, or late stage of that disease.

8. A high throughput method of screening a plurality of molecules or compounds to identify a ligand which specifically binds a cDNA, the method comprising:

(a) combining the composition of claim **1** with the plurality of molecules or compounds under conditions to allow specific binding; and

(b) detecting specific binding between each cDNA and at least one molecule or compound, thereby identifying a ligand that specifically binds to each cDNA.

9. The method of claim **8** wherein the plurality of molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, transcription factors, repressors, and regulatory proteins.

* * * * *